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ABSTRACT 
 
Diabetic Foot Ulcers are a common precursor to the development of infection and amputations. 
A breach in the protective skin barrier represents a portal of entry for invading microorganisms, 
where infective episodes frequently pursue. Three key areas that may augment clinical care are 
one. understanding what microorganisms are present in Diabetic Foot Ulcers, two. 
differentiating if microorganisms are planktonic microbial cells or slow growing microbial 
biofilms and three. treating Diabetic Foot Ulcers complicated by microorganisms with effective 
topical agents.  
 
As part of this thesis, 16S rDNA next generation sequencing was utilised to profile the 
microbiota of infected Diabetic Foot Ulcers (DFUs). Clinical / laboratory data and treatment 
outcomes were collected and correlated against microbiota data. Thirty-nine patients with 
infected DFUs were recruited over twelve-months. Shorter duration DFUs (<six weeks) all had 
one dominant bacterial species (n= five of five, 100%, p <⋅001), S. aureus in three cases and S. 
agalactiae in two. Longer duration DFUs (≥six weeks) were diversely polymicrobial (p = .01) 
with an average of 63 (range 19-125) bacterial species. Severe Diabetic Foot Infections (DFIs) 
had complex microbiota’s and were distinctly dissimilar to less severe infections (p = .02), 
characterised by the presence of low frequency microorganisms.  
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Our results confirm that short DFUs have a simpler microbiota’s consisting of pyogenic cocci 
but chronic DFUs have a highly polymicrobial microbiota. The duration of a DFU may be 
useful as a guide to directing antimicrobial therapy. 
 
Secondly, we utilised Scanning electron microscopy (SEM) and Fluorescent in situ 
Hybridisation (FISH) techniques to determine if DFUs were complicated by sessile, slow 
growing bacteria referred to as biofilms. 65 DFU specimens were obtained from subjects with  
infected chronic ulcers. Of the 65 DFU specimens evaluated by microscopy, all were 
characterized as containing biofilm (100%, p < .001). Molecular analyses of DFU specimens 
revealed diverse polymicrobial communities. No clinical visual cues were identified in aiding 
clinicians identify wound biofilm. Microscopy visualization when combined with molecular 
approaches, confirms biofilms are ubiquitous in DFUs and a paradigm shift of managing these 
complicated wounds needs to consider anti-biofilm strategies. 
 
Lastly, the effectiveness of various topical antimicrobials commonly used in woundcare were 
tested in two separate studies by employing in vitro models, ex vivo porcine skin explant 
models and in vivo human studies.  In the first study, 17 participants with chronic non-healing 
DFUs due to suspected biofilm involvement were recruited to receive one-week application of 
Cadexomer Iodine ointment. Real-time qPCR was used to determine the microbial load with 
11 participants exhibiting one-two Log10 reductions in microbial load after treatment, in 
comparison to six patients who experienced <one log10 reduction (p =.04). Scanning electron 
microscopy (SEM) and/or fluorescent in situ hybridisation (FISH) confirmed the presence or 
absence of biofilm in all 17 participants. 16S rDNA next generation sequencing provided useful 
insights that these wounds support complex polymicrobial communities and demonstrated that 
Cadexomer Iodine had a broad level of antimicrobial activity in reducing both facultative 
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anaerobes such as Staphylococcus spp., Serratia spp., aerobes including Pseudomonas spp., 
and obligate anaerobes including Clostridiales family XI.  
 
In the second study, a range of topical antimicrobial wound solutions were tested under three 
different conditions; (in vitro) 4 % w/v melaleuca oil, polyhexamethylene biguanide, 
chlorhexidine, povidone iodine and hypochlorous acid were tested at short duration exposure 
times for 15-minutes against three-day mature biofilms of S. aureus and P. aeruginosa. (ex 
vivo) Hypochlorous acid was tested in a porcine skin explant model with twelve cycles of ten-
minute exposure, over 24 hours, against three-day mature P. aeruginosa biofilms. (in vivo) 4 
% w/v Melaleuca Oil was applied for 15-minutes exposure, daily, for seven days, in ten patients 
with chronic non-healing Diabetic Foot Ulcers (DFUs) complicated by biofilm. 
 
In vitro assessment demonstrated variable efficacy in reducing biofilms ranging between 0.5 
log10 reductions to full eradication. Repeated instillation of hypochlorous acid in a porcine 
model achieved < one log10 reduction (0.77 log10, p < 0.1). Application of 4 % w/v melaleuca 
oil in vivo, resulted in no change to the total microbial load of DFUs complicated by biofilm 
(median log10 microbial load pre-treatment = 4.9 log10 versus 4.8 log10 (p = .43). 
 
In conclusion, to the best of our knowledge, the in vivo human studies testing the performances 
of topical antimicrobials represents the first in vivo evidence employing a range of molecular 
and microscopy techniques. These demonstrate the ability of Cadexomer Iodine (sustained 
release over 48-72 hours) to reduce the microbial load of chronic non-healing DFUs 
complicated by biofilm. In contrast, short durations of exposure to topical antimicrobial wound 
solutions commonly utilised by clinicians are ineffective against microbial biofilms, 
particularly when used in vivo.  
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SETTING THE SCENE 
 
Diabetic foot ulceration (DFU) is a significant complication of diabetes and is associated with 
increased morbidity, mortality and increased health care expenditure. There are many facets to 
diabetic foot disease that contribute to the development of a DFU, in particular the “triad” of 
factors - peripheral neuropathy, peripheral vascular disease and trauma 1. The pathway to 
amputation following a foot ulcer is a complex array of intertwining pathways with infection 
playing a key role. In a person with diabetes, foot ulceration leaves a physical break in the 
protective barrier of the skin. Invading microorganisms may colonize the wound, in which a 
impaired immune response is common in a person with diabetes. This may predispose an 
ulceration to further microbial invasion and replication, resulting in damage to host tissues and 
an inflammatory response that is characterized as clinical infection 2. In a person with diabetes 
over 90% of infections are the primary pathway to lower extremity amputation, thus the 
significance of developing a foot infection in a person with diabetes is evident 3.  
 
In a significant proportion of people with diabetic foot infection (DFI) the severity is enough 
to cause hospitalisation. Recent data by Malone and colleagues (2014) 4 indicated that infection 
was the primary cause of admission in 82% of patients with diabetes on a vascular surgery 
ward. It is perhaps not surprising then that the economic burden of managing infection in people 
with diabetes has been reported at an average of $17,879 per hospital separation 5. 
 
The importance of managing DFI is underpinned by the requirement to identify the pathogen 
so as to direct antimicrobial therapy. Traditionally, wound cultures have been utilised to 
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identify planktonic pathogenic microorganisms, in addition to looking at their density through 
qualitative and quantitative measures 6. The limitation of this method is that culture-dependent 
techniques select for species that flourish under the typical conditions of the diagnostic 
microbiology laboratory, and this may not necessarily reflect the most abundant or clinically 
important microorganisms in DFI 7.  Molecular DNA-based techniques that are culture-
independent have identified the limitations of traditional cultivation-based methods when 
examining the wound microbiota. Amplification and sequence analysis of 16S rDNA, a highly-
conserved gene present in all prokaryotes (bacteria) but not eukaryotes (humans), has revealed 
a vastly more complex array of bacterial communities in chronic wounds 8-10. 
 
Additionally, research into the role of microorganisms in causing DFI has identified contrasting 
evidence suggesting that changes in management paradigms are required 11. The roles of single 
free-floating microorganisms (planktonic) that are responsible for acute infections and readily 
identified through cultivation-based approaches differ vastly from multi-species sessile 
microorganisms typically not found by the same cultivation methods. The role of these sessile 
microbes and their significance in causing persistent infections in chronic wounds has only 
recently been appreciated 8. Data from scanning electron microscopy of biopsies from chronic 
wounds have identified that 60% to 90% of specimens contained biofilm structures, in 
comparison to only 6% of biopsies from acute wounds 12-13. 
 
Overall, limited evidence is available from both molecular and microscopy techniques to 
identify which microorganisms might be of importance in infected DFUs. A vast diversity of 
microorganisms from clinically uninfected DFUs has been found, extending the view of the 
diabetic foot microbiota. There remains, however, a large gap in knowledge regarding the 
specific roles of all of the microorganisms detected in infected DFUs and their relevance to 
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clinical care. Importantly, few studies have attempted to explore the relationship between 
infected DFUs and the presence of biofilm phenotypes through combinations of molecular and 
microscopy methods.  
 
“Gentleman: It is the microbes who will have the last word” 
- Louis Pasteur 
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THESIS  OVERVIEW 
 
Chapters 1 and 2 of this thesis provides an overview of the literature, highlighting the 
contributions of diabetes as a comorbidity and how it converges to create unique circumstances 
that increase the risk of infection and amputation. The bacteriology of DFI through culture-
dependent techniques heavily implicate aerobic Gram-positive cocci as the predominant 
pathogens of infection. This sets the scene to discuss the relevance of genomic approaches, 
such as 16S rDNA sequencing which possess the ability to provide an extended view of the 
microorganisms that colonise infected DFUs. The microbiota of diabetic foot infections and 
role of biofilms in DFUs remains poorly understood. Understanding the microbial load, 
diversity and phenotypic state of microorganisms, and how they interact and or converge to 
bring about infection or wound chronicity in DFUs would be highly adventitious for targeted 
clinical therapeutics.  
 
In chapter 3, 16S rDNA next generation sequencing was employed to profile the microbiota of 
infected tissues from the feet in people with diabetes. The primary aim of this study was to 
explore microbial communities, community structure and presence of likely pathogens from a 
molecular perspective, and how this extended view (if any) correlates to clinical parameters 
and treatment outcomes. This is imperative to determine if directed antimicrobial therapy based 
on conventional microbiological cultures are relevant based on genomic analysis.  
 
The primary findings from thirty-nine patients with infected DFUs identify the duration of a 
DFU prior to the development of a new infective episode may be useful as a guide to directing 
antimicrobial therapy. The results confirm that shorter duration DFUs (<six weeks) have a 
  5 
simpler microbiota consisting of one dominant bacterial species that are typically pyogenic 
cocci (Staphylococcus aureus, Streptococcus agalactiae). Conversely, longer duration DFUs 
(≥six weeks) are diversely polymicrobial with an average of 63 (range 19-125) bacterial 
species. Nineteen patients (49%) during the study period experienced antimicrobial treatment 
failure, but no overall differences exist in the microbiota of patients who fail therapy and those 
who experience treatment success (p = 0.2). Despite an extended view afforded by DNA 
sequencing, current guidance materials available to clinicians managing DFIs that are 
predominantly based on culture-dependent data are still clinically relevant and useful for 
treating most DFIs  
 
In chapter 4, the primary aim was to identify the presence of biofilms in non-healing or infected 
DFUs. The secondary aims were to identify the accuracy of clinical cues to detect the presence 
of wound biofilm, as debate surrounds whether or not wound biofilms are visible to the naked 
eye. Accurate clinical indicators of biofilm presence in chronic wounds may aid clinicians in 
initiating appropriate biofilm-based treatment regimens.  
 
Scanning electron microscopy (SEM) and peptide nucleic acid fluorescent in situ hybridisation 
(PNA-FISH) were employed to directly visualise microbial cells to assess the spatial 
organisation of microorganisms on a wound surface, and to observe any constituents of biofilm 
architecture such as EPS. Of 65 DFUs sampled, the presence of densely aggregated colonies 
(both mono and multi-species) of bacteria often surrounded by an extracellular matrix in tissue 
biopsies was identified in 100% of our samples. The use of binomial probabilities identified 
that visual cues are not better than chance alone in detecting wound biofilm, with visual cues 
(the presence of a gelatinous material on the wound bed, the rapid reformation of gelatinous 
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material after debridement, the presence of slough, and signs of pyocyanin) being absent in 
>50% of cases, indicating their presence is no better than chance alone.  
 
Chapter 5 details the performance of Cadexomer iodine against microbial populations from 
chronic non-healing diabetic foot ulcers (DFUs) complicated by biofilm in vivo. Seventeen 
patients with chronic non-healing DFUs with suspected biofilm involvement were treated every 
two days for one week with Cadexomer Iodine. Tissue punch biopsies were obtained pre-and-
post-treatment, with samples being subjected to molecular, microscopy and zymography 
methods. Microscopy confirmed the presence of dense biofilm in all patients with the 
application of Cadexomer Iodine being able to reduce the total microbial load by 1-2 Logs10 
(p = .04), in addition to statistical reductions in wound proteases (MMP-9 – p = .03). 
 
Analysis of the microbiota pre-and-post treatment indicate that DFUs support complex 
polymicrobial communities. Molecular methods demonstrate that Cadexomer Iodine has a 
broad level of antimicrobial activity in reducing facultative anaerobic microorganisms; 
Staphylococcus spp., Serratia spp., aerobic; Pseudomonas spp., and obligate anaerobes; 
Clostridiales family XI.   
 
In five patients, no reduction in microbial load was noted with the use of Cadexomer Iodine. 
Molecular analysis was used to investigate these failed responses to therapy. Many unidentified 
and uncultivable microorganisms exist in DFUs. These often fluctuate from low frequency taxa 
pre-treatment to more dominant taxa post-treatment. The presence of “uncommon” 
microorganisms existing in polymicrobial biofilms may explain why some wounds are tolerant 
to treatment and why previously low numbers of these microbes increase when community 
disruption creates a nutrient availability or mutual advantage 14. 
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In chapter 6, an in vitro to in vivo evaluation of topical antimicrobial solutions based on a 
hypothesis that short exposure times are in-effective against microbial biofilms was performed. 
In vitro assessment demonstrated a variable efficacy of antimicrobial wound solutions in 
reducing biofilms at 15-minute exposures (0.5 log10 reductions to full eradication), with 
effectiveness increasing with increased exposure. Repeated exposure of hypochlorous acid in 
an ex vivo porcine skin explant model achieved < 1 log10 reduction (0.77 log10, p = .1), and 
application of 4 % w/v melaleuca oil in vivo, resulted in no change to the total microbial load 
of DFUs complicated by biofilm (median log10 microbial load pre-treatment = 4.9 log10 
versus 4.8 log10 (p = .43).  
 
A correlation between the poor performance of SBMO in vitro against P. aeruginosa and S. 
aureus was also seen in vivo. The relative abundances of P. aeruginosa and S. aureus post-
treatment increased in most of the samples where it was detected.  At the same time, low 
frequency taxa microorganisms contributing <1% relative abundance typically decreased.  In 
these select cases, the total microbial loads pre-and-post treatment remained static. This 
suggests that more dominant species such as Staphylococcus spp. or Pseudomonas spp., were 
not affected by the topical wash, and benefitted from the increased nutrient availability14 caused 
by disruption to the microbial community.  
 
This raises an important question about the use of topical antimicrobials and their appropriate 
testing in in vivo conditions using molecular and microscopy techniques. Situations may arise 
where clinicians use products that result in perturbations to the complex microflora seen within 
chronic wounds, and this may lead to microbial dysbiosis. Of particular significance is the 
reduction in microbial diversity, secondary to selective actions of an antimicrobial, which may 
directly contribute to pathogen selection and persistence 15. This was observed in patients in 
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this study where increases in known pathogens of infection (Staphylococcus aureus and P. 
aeruginosa) occurred following treatment.  
 
Chapter 7, reviews the literature on current testing methods in determining the effectiveness of 
treatment strategies to manage biofilm. The chapter presents a discussion point that covers 
many of the underlying themes presented in chapters 5 and 6. Typically, biofilms show 
remarkable tolerance to many forms of treatments and the host immune response. This has led 
to vast increase in research to identify new (and to test current) anti-biofilm strategies that 
demonstrate effectiveness against these tolerant phenotypes. Unfortunately, a standardized 
methodological approach of biofilm models has not been adopted leading to a disparity 
between testing conditions. This has made it almost impossible to compare data across multiple 
laboratories, leaving large gaps in the evidence. 
 
Furthermore, many biofilm models testing anti-biofilm strategies aimed at the medical arena 
have not considered the matter of relevance to an intended application. This may explain why 
some in vitro models based on methodological designs that do not consider relevance to an 
intended application fail when applied in vivo at the clinical level. This is exemplified in chapter 
6, where the effectiveness of topical antimicrobial solutions tested at clinically relevant 
exposure times demonstrate poor effectiveness.  
 
Chapter 8 summarises this thesis, it links chapters and presents potential future works in the 
area. As a collective group of works, the chapters of this thesis present a detailed exploration 
of managing a person with diabetes who has developed a DFU complicated by microorganisms. 
To identify the microorganisms that colonise and or infect tissue, 16S rDNA next generation 
sequencing was utilised to explore the microbiota of DFUs. Next, microscopy and molecular 
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techniques were utilised to better understand the phenotypic nature of microbes involved in 
DFUs. This identified that biofilms were ubiquitous in both infected and chronic wounds. 
Management of DFUs include many wound therapies such as topical antimicrobials, yet there 
is a lack of clinical evidence for effectiveness against biofilms. Varying topical antimicrobials 
were tested in vitro, ex vivo porcine skin explant model and in human in vivo clinical trials. 
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CHAPTER 1  
1.1 FOOT INFECTION IN PEOPLE WITH DIABETES 
(APPENDIX 1) MALONE, M. (2017) THE MICROBIOTA OF DIABETIC FOOT 
ULCERS AND THE ROLE OF BIOFILMS IN KON, K., & RAI, M., THE 
MICROBIOLOGY OF SKIN, SOFT TISSUE, BONE AND JOINT INFECTIONS 
(PP. 41-56). LONDON, UK, ACADEMIC PRESS, ELSEVIER. 
Candidate contribution: 
 Worked as the sole author for this book chapter 
 Wrote the manuscript in full using information from thesis chapters 1 and 2 
 Reviewed and amended all required changes and proofs 
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The most common pathway leading to a foot infection in a person with diabetes is through a 
physical break in the protective barrier of the skin, in the form of a DFU 16. Once the skin is 
breached, a diabetic foot ulcer exposes the underlying soft tissues to potential bacterial 
colonisation with infection arising if certain conditions favour bacterial replication. Further 
contiguous extension to deeper structures may ensue scenarios where failure in controlling the 
spread of infection leads to extensive damage of host tissue and bone and this in part maybe 
driven by several aspects of altered immunologic function 17. Of particular focus is the 
reduction in polymorphonuclear leukocyte response to bacterial infection and the role of 
hyperglycaemia all being reviewed 18. This scenario optimizes the pathway to lower extremity 
amputation in a person with diabetes. 
 
Bacteria that contaminate and colonize wounds likely originate from the surrounding skin flora 
but other sources include the environment and endogenous mucous membranes such as the 
gastrointestinal tract or nares 6. One reason for this is that DFUs present an ideal environment 
for harbouring microorganisms since they offer a warm, moist, nutritive home, especially if 
devitalized tissue is present in the wound bed 6. The longer a wound remains open the greater 
the chances of a more diverse and abundant bacterial colonization; with the type, depth, 
location, level of perfusion and the efficacy of the host immune response dictating the niche of 
colonizing bacteria 10,6.  
 
Bacterial colonisation of wounds versus infection is an area that must be greatly appreciated 
by treating clinicians so that the appropriate use of antimicrobials and adjunct therapies can be 
delivered effectively. Whilst all wounds contain bacteria, colonisation refers to a specific 
scenario where bacteria are presently multiplying but the sum of their actions are not enough 
to elicit an immune response 6. Infection and specifically DFI, has been described when 
  12 
bacterial organisms proliferate within a wound (that is infra-malleolar) and in the course of 
doing so, cause substantial tissue damage that induces a host response accompanied by 
inflammation that is clinical infection 2. For this reason the diagnosis of DFI has been promoted 
by expert groups as a ‘clinical diagnosis’ using greater than two clinical signs of infection; 
inflammation, erythema, local tenderness or pain, warmth and purulent discharge 2.  
 
In some people with diabetes the overt clinical signs of infection are diminished or absent, and 
this may be due to the failure to exhibit an inflammatory response 19 with reports identifying  
that people with diabetes and infected chronic wounds express erythema less frequently than 
people without diabetes 20. This has led to a clinical perspective that some chronic DFUs may 
have ‘secondary signs’ of infection that include but are not limited to malodour, delayed wound 
closure and poor quality wound bed tissue 19,21.  
 
The fine line between colonisation and infection can be clinically challenging and some 
clinicians have adopted more quantitative measures to differentiate potential ‘healthy’ 
colonization from pathogenic infection by relying on the density of bacteria present per gram 
of tissue. Greater than 105 colony forming units (cfu) of bacteria per gram of tissue has been 
widely used as a key indicator of potential ‘bioburden’ as the causative factor associated with 
delayed wound healing. This numerical indicator is based largely on early evidence from 
various wound aetiologies 22 and further incorporated by others 23, yet controversy persists over 
whether a burden of >105 cfu of bacteria per gram of tissue is required to cause wound 
infection.  
 
Kingsley (2003) 24 proposed a wound infection continuum model that placed an emphasis on 
the progression from colonization of bacteria within a wound through to infection. An 
  13 
important component of the wound continuum model is the concept of “critical colonization” 
that refers to the multiplication of organisms within a wound without invasion or interfering 
with wound healing. Whilst the concept of critical colonization is still the center of much debate 
it is often used by clinicians to explain delayed wound healing in the absence of any overt 
clinical signs of infection and other wound delaying variables. This concept ‘if true’ may be of 
importance for clinicians as chronic wounds with critical colonization may benefit from local 
and or topical treatments such as antimicrobial wound dressings and wound debridement, rather 
than systemic management with the use of antibiotics, however no quantifiable data exists to 
prove or disprove this theory.  
 
Figure 1.1The Infection continuum theory 22. Adapted version for use in this thesis. 
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Sampling methods to detect pathogens of infected tissues 
In order to guide antimicrobial therapy in the treatment of infected DFUs, clinicians must 
identify potential pathogens of infection using appropriate sampling techniques which are sent 
for conventional culture. In DFUs, wound cultures must be obtained following the removal of 
non-viable, devitalized tissue (either by debridement or curettage) after cleansing. The 
Infectious Disease Society of America (IDSA) diabetic foot guidelines and the International 
Working Group on the Diabetic Foot (IWGDF) diabetic foot infection committee, currently 
propose that tissue samples (either by curettage or biopsy) are the preferred method of 
collection for identifying potential bacterial pathogens from infected DFUs as they yield the 
most accurate results 2,25. This is based on each expert group performing systematic reviews of 
the literature that identifies high-level evidence from large cohorts, that concordance between 
superficial swabs and tissue biopsy is low to average (range of concordance 41% - 78%) when 
assessed through conventional culture 2,25-28.  
 
Conversely, some research groups have published small cohort studies identifying swabs and 
tissue yield similar results when exploring the microbiota of chronic wounds using either/or 
conventional culture and 16S rDNA sequencing 10,26,29-33. However, there still remains scant 
data within the literature which have directly compared concordance between tissue and swab 
samples when employing solely DNA based methods from large cohorts.  Debate still exists 
whether swab samples are equal to or superior then tissue for sampling wound microbiota.  
 
This is exemplified in studies employing molecular techniques where biopsies from superficial 
and deep tissues of infected DFUs identified pathogens of infection resided in deeper tissues 
34-36. The pathogens of infection situated within deeper tissues were aerobes, along with 
fastidious anaerobes that were more frequently under recognized from superficial cultures. 
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Similarly, Frank et al (2014) found poor concordance (52%) between swabs and tissue 
specimens using16S rDNA sequencing. In only six of the 15 overlapping samples, there were 
high correlations between swab and biopsy samples (r = .98–1.00), while in the remaining nine 
of these 15 samples there were low correlations (r = .04 to .53) 37. 
 
Advantages and disadvantages of swabs versus tissue 
The major advantage for a clinician or researcher selecting a swab sampling technique is its 
ease of use. Whilst this technique from a clinical perspective is not promoted as the preferred 
sampling method for DFI, it is one of the most widely employed because of its ease of use.  In 
this sampling method, a cotton or nylon swab is pressed firmly against the wound tissue, in the 
center of the wound, with the aim to express tissue fluid (containing microbes) from deep tissue 
layers. The technique is referred to as the Levine technique 26. An alternate technique is where 
the swab traces a ten-point Z-pattern without pressure on the entire wound bed without 
touching the wound edge 26. Because taking a wound swab requires little in the way of training, 
obtaining culture specimens through swabs is preferred by many clinicians who lack the 
expertise to perform a biopsy or obtain tissue specimens. Conversely,  this too means that 
performing a swab is less invasive for patients, does not require any local anesthesia as some 
biopsies may require and the technique can sample a larger wound surface area 38. 
 
Previous studies 13,29,39-41 have highlighted the potential importance of macro-spatial variation 
or the biogeography of how microorganisms organise themselves within wounded tissue. 
Sprockett et al (2015) reported the difference in biogeography of a wound when comparing 
tissue to swab, in a case report of a single patient 29. Some of the differences identified were 
the bacterial load was significantly higher in samples from the wound centre than the wound 
edge (p = .04), yet the load at different wound depths was not significantly different. 
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Fazli et al (2009) looked at the distribution of S. aureus and P. aeruginosa in five chronic 
wounds using PNA-FISH with confocal microscopy 41. The analysis showed that the S. 
aureus aggregates were located close to the wound surface, whereas the P. 
aeruginosa aggregates were located deeper in the wound bed (p < .0001). 
 
Price et al (2011) performed a cross-sectional study on the macro-scale spatial variation in 
chronic wound microbiota in twelve patients. Curettage samples of tissue were obtained from 
the leading edge of the wound; the opposing leading edge; and/or the centre of the wound. 
While substantial macro-scale spatial variation was observed among the wounds, bacterial 
communities at different sites within individual wounds were similar than those in different 
wounds (p = 0.001). These results support the prevalent opinion that controlling for sample site 
may improve the quality of wound microbiota studies; however, the significant similarity in 
bacterial communities from different sites within individual wounds indicates that studies 
failing to control for sampling site should not be disregarded based solely on this criterion. 
 
In summary, the evidence for obtaining tissue specimens over wound swabs when processing 
samples by conventional culture is clear. It is less clear when applying this to molecular 
techniques such as 16S rDNA sequencing. From scant reports within the literature it seems that 
the use of swabs maybe equal to obtaining tissue specimens when exploring the microbiota of 
wounds using for 16S rDNA sequencing. There are advantages and disadvantages to both 
methods, but ultimately larger cohort studies are required to confirm this. Macro-spatial 
variation is an interesting variable which could impact the overall picture of the microbiota of 
wounds. It seems plausible that relying on a single site for sampling such as a biopsy, may 
increase the chances of sampling error and that and obtaining samples from multiple sites of 
the wound may improve detection.  
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Bacteriology of Diabetic Foot Infections 
The importance in managing DFIs is underpinned by the requirement to identify any pathogen/s 
of infection so that antimicrobial therapy can be directed. Traditional culture-dependent 
methods have been utilised to identify planktonic organisms subjected to controlled laboratory 
conditions. The limitations of such are that culture-dependent methods select for species that 
flourish under the controlled conditions of the diagnostic microbiology laboratory and this may 
not necessarily reflect the most abundant or clinically important organisms in DFIs 10.  
 
Current culture-dependent studies on the bacteriology of DFIs have widely reported the 
involvement of aerobic Gram-positive cocci, mainly Staphylococcus spp., and Streptococcus 
spp., as being the most common aetiological agents that infect DFUs 42,43. The spotlight has 
centred on the well-known pathogen S. aureus and its role in DFI has been well reported 16,42-
45. In two large culture-dependent studies on the bacteriology of infected DFUs 42,43 samples 
from over 1,266 patients indicated the predominant pathogens of infection as being 
Staphylococcus aureus and Streptococcus spp., with Enterococcus spp., and Corynebacterium 
spp., also playing prominent roles. In both studies, anaerobes were generally reported as being 
of low abundance with one of the studies identifying the ratio of aerobe to anaerobe isolates 
being approximately 7:1 43 and the other study identifying the overall percentage of anaerobe 
isolates in only 28% of samples 42.  
 
Complicating the picture of DFI is a reduced immune-mediated response (which can be present 
in people with diabetes), whereby the potential involvement of low virulence colonizers of 
devitalized tissue or bone such as coagulase-negative Staphylococci and Corynebacterium spp. 
may assume a more pathogenic role 46.  Additionally, whilst it is generally regarded that DFUs 
of short duration presenting with acute infection are monomicrobial 16, chronic infected DFUs 
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seem to harbour a much more complex polymicrobial flora including Pseudomonas spp., 
Enterococcus spp., Enterobacteriaceae family, and other obligate anaerobes 42,43,47,48.  
 
1.2. HUMAN SKIN  
1.2.1. THE SKIN IS OUR FIRST LINE OF DEFENCE AGAINST INVADING 
MICROORGANISMS. 
 
Human skin is involved in an array of processes that include but are not limited to forming an 
outer protective shell that acts as a barrier to external threats. In addition to that of a barrier, 
the skin plays an integral role as an immunological interface that modulates the residing 
microorganisms that constitute the skin flora 49 who for the most part reside as non-pathogenic 
permanent residents (commensal flora). The fine balance between the host and microbe is 
essential for the propagation of mutual benefits (symbiosis and or commensalism) and this may 
afford protection against invasion from more pathogenic bacteria. One such example of this 
beneficial relationship is the proposed presence of the commensal bacterium S. epidermidis 
and its ability to inhibit the known pathogen S. aureus 50. 
 
The epidermis forms the outermost layer of the skin and keratinocytes (KCs) constitute the 
predominant cells providing an essential first line of innate immunity 51-52. Specific receptors 
present within KCs known as pattern recognition receptors (PRRs) are stimulated by 
pathogenic organisms intent on invading the epidermis via surface associated molecular 
structures 53. Examples of PRRs are the Toll-like receptors (TLRs) that detect pathogen-
associated molecular patterns (PAMPs) such as the lipopolysaccharide (LPS) of Gram-negative 
bacteria or the peptidoglycan (PGN) of Gram-positive bacteria 54. Our current understanding 
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of the mechanisms of action of TLRs is the vital role they play in the induction of antimicrobial 
responses, with a myriad of TLRs being reported in the literature, each with their own unique 
function 54.  A study by Jugeau et al (2005) demonstrated that P. acnes induced expression  of 
TLR-2 and TLR-4 by KCs in addition to MMP-9, a known pro-inflammatory protease 55.  TLR-
2 has also been identified as crucial for the pro-inflammatory signalling pathway activating 
NF-kB through the myeloid differentiation protein MyD88 54.  
 
The epidermis perpetuates other defence mechanisms in response to invading pathogens such 
as the process of KC up-regulation and expression of endogenous antimicrobial peptides 
(AMPs) in response to inflammatory stimuli. Over 20 AMPs have been reported on human 
skin 56 where they pose a formidable broad-spectrum antimicrobial activity, however typically 
they can be sub-divided into two families; β-defensins (hBD) 57 and cathelicidins 58.   
 
Cathelicidin has been purported to be an important regulator of new born babies’ microbiota 
through its over-abundance in newborns where it has been shown to significantly inhibit the 
growth of S. epidermidis 59, whilst hBD exhibits a broad range of antimicrobial activity against 
Group A Streptococci, S. aureus, E. coli and  P. aeruginosa 60. In a study by Percoco et al 
(2013) 61 utilising real time qPCR, human epidermal cells exposed to the bacterial stimuli of S. 
epidermidis and P. fluorescens resulted in the increased transcription of the genes that encode 
for AMPs (hBD) in tandem with increased expression of pro-inflammatory cytokines 
interleukin (IL)-1α and (IL)-1-β, as well as IL-6. 
 
Specifically, the role of KCs as regulatory orchestrators of cutaneous inflammation and 
immunity through cytokine and chemokine activity is noteworthy. Even more so is the inherent 
ability to mobilise a defensive strike against invading pathogens while abstaining in the 
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presence of ‘friendly fire’. In some instances, this friendly fire or commensal enterprise can be 
of benefit. One recent study has identified the mutual benefit of S. epidermidis and the phenol-
soluble modulins that it produces, which can selectively inhibit the more pathogenic S. aureus 
and even co-operate with host AMPs to improve bactericidal activity 62. Expanding this concept 
has been the recent body of work suggesting commensal microorganisms may have a role in 
modulating the innate immune response through ‘cross-talking’. Lai et al (2010) reported on 
the inhibition of TLR-2 and TLR-3 through a mediated cross-talk mechanism driven by 
lipoteichoic acid production by S. epidermidis 60. The same group also identified the ability of 
S. epidermidis to incite KCs expression of AMPs through the TLR-2 pathway.  
 
Taken collectively, the evidence above presents the extensive role that KCs, the epidermis and 
microorganisms play in the innate immune response. Several teams have observed the links 
between KCs and the innate response to microbial recognition and have postulated cross talking 
between the innate pathways, microorganisms and KCs. Considering this, the role of the 
epidermis as an adjuvant is distinguishable and of importance. The loss of this function would 
clearly pose a risk of infection to a person with diabetes.  
 
1.2.2. THE HUMAN MICROBIOME PROJECT 
 
Within the last decade, groups of researchers have actively investigated the role and impact of 
microorganisms on human health and disease through the human microbiome project. This 
project involves the identification of all known microbes residing on and in the human host, 
including; bacterial, viral, fungal and archaea. The human microbiome project is a consortium 
of nearly 80 universities and scientific institutions who have mapped the microbial makeup of 
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the human body using molecular approaches and in doing so, created reference databases that 
have provided a foundation to accelerate infectious disease research 63.  
 
Gao et al (2007) 64 employed PCR-based DNA sequencing to survey the skin microbiota of the 
volar forearm in 6 healthy subjects. Actinobacteria, Firmicutes and Proteobacteria contributed 
to 95% of sequences. Similarly Grice and colleagues (2008) 7 examined the diversity of the 
microbiota of human skin identifying Proteobacteria (59%) as the dominant bacterial Phylum. 
Utilising amplification and sequence analysis of 16S rDNA, Grice and colleagues (2008) 7 
obtained skin samples (swab, scrape and tissue biopsy) from five healthy volunteer’s arms and 
grouped the DNA sequences into operational taxonomic units (OTUs). In the context of 
molecular methods OTUs are clusters of single DNA sequences grouped together based on 
their similarity to other sequences in the community and used to define microorganisms to 
species or genera level. The most abundant OTUs belonged to the genus Pseudomonas spp., a 
member of the Proteobacteria Phylum followed by Janthinobacterium spp. Other OTUs 
identified belonged to the phyla of Actinobacterium (28%), Firmicutes (12%) and 
Bacteroidetes Phyla (9.7%).  
 
With the advent of the human microbiome project and the evolution of culture independent 
methods employing molecular techniques, researchers have now identified the majority of all 
microorganisms residing on healthy adults. In contrast, environmental microbiologists estimate 
less than 2% of all bacteria are known via cultivation based approaches 65. 
 
Human skin is more than an external barrier, it is composed of unique microbial communities 
that vary depending on anatomical location. The skin microbiota may house core 
microorganisms that constitute a steady state of symbiosis 66. If the skin barrier is disrupted, 
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such as occurs in DFUs, symbiosis may shift to parasitic invasion, especially if the host may 
already be immunocompromised. It is therefore quintessential to understand what 
microorganisms reside on intact healthy skin and to understand their potential for causing 
human disease. 
1.2.3 IS NATIVE SKIN FLORA DIFFERENT IN PEOPLE WITH DIABETES VERSUS 
NON-DIABETIC  
 
Bacteria that contaminate and colonize wounds likely originate from the surrounding skin flora 
but other sources include the environment and endogenous mucous membranes such as the 
gastrointestinal tract or nares 6. There is evidence that the native skin flora in the feet of people 
with diabetes are different than those of non-diabetics. Using 16s rDNA sequencing, Redel et 
al (2013) compared intact skin in the feet of people with and without diabetes (healthy control).  
In the feet of people with diabetes, intact skin demonstrated increased populations of S. aureus 
with reduced quantities of other staphylococci genera. Bacterial diversity when compared to 
healthy controls was also greater in the feet of people with diabetes 67. 
 
Oates et al (2013) employed PCR-denaturing gradient gel electrophoresis (DGGE) in 
conjunction with DNA sequencing to compare intact (healthy) skin in the feet of 26 people 
with diabetes. In skin samples, the most prevalent genera were Staphylococcus spp. followed 
by the class Bacilli 68. Similarly, Gardiner et al (2017) 32 used 16S rDNA sequencing to also 
compare the microbiota of intact (healthy) skin in the feet of persons with diabetes versus non-
diabetics (controls). In the feet of people with diabetes the skin was significantly less diverse 
than non-diabetics and the community composition was also significantly different between 
the two. Despite the differences in community composition the most abundant taxa from both 
groups were similar. Both groups were dominated by the genera Staphylococcus spp., 
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Acinetobacter spp., and Corynebacterium spp 32. The above data may help to support a notion 
that diabetes-specific alterations in normal/native flora predispose diabetic patients to greater 
exposures of colonization by specific species, such as the highly virulent S. aureus. This also 
supports existing data that indicate many of the aforementioned microorganisms as common 
pathogens of DFI. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  24 
1.3 16S RDNA NEXT GENERATION SEQUENCING  
(APPENDIX 2) MALONE, M., GOSBELL, I. B., DICKSON, H. G., VICKERY, 
K., ESPEDIDO, B. A., AND JENSEN S. O. CAN MOLECULAR DNA-BASED 
TECHNIQUES UNRAVEL THE TRUTH ABOUT DIABETIC FOOT 
INFECTIONS? DIABETES METABOLISM RESEARCH AND REVIEWS 2017. 
33: E2834.DOI: 10.1002/DMRR.2834. 
Candidate contribution: 
 Worked as primary author for publication 
 Wrote the manuscript in full using information from thesis chapters 1 and 2 
 Designed and produced Table 1 and Figure 1 
 Reviewed and amended all required changes from co-author contributions 
 Submitted the manuscript as primary author
  25 
 
1.3.1. INTRODUCTION 
 
Diabetic foot infections (DFI) are a common complication when breaks in the 
protective barrier of the skin occur in people with diabetes allowing easy entry of 
bacteria. A diabetic foot ulceration (DFU) that becomes infected is a major causal 
pathway to lower extremity amputation and the identification of causative pathogens 
and any accomplices is vital in directing antimicrobial therapy. Historically, clinicians 
have relied upon culture-dependent techniques that are now widely acknowledged as 
both being both selective for microorganisms that thrive under the physiological and 
nutritional constraints of the microbiology laboratory, and that grossly underestimates 
the microbial diversity of a sample.  
 
The amplification and sequence analysis of 16S rDNA gene has revealed a vast 
diversity of microorganisms in DFIs extending the view of the diabetic foot microbiota. 
The interpretation of these additional findings and their relevance to clinical care 
remains largely unexplored. The advancement of molecular methods that are culture-
independent and employ DNA sequencing technology represent a potential “game 
changer”.  One advancement with the potential to provide a greater understanding of 
infection is the role of metagenomics and its shotgun approach to surveying whole-
community genomic DNA from within a sample (whole genome shotgun sequencing, 
WGS) 69,70.  
 
In this respect “whole genome shotgun sequencing” affords the possibility to 
characterize not only the microbial diversity within a DFI (i.e., “which microorganisms 
  26 
are present”) but the biological functions of the community such as virulence and 
pathogenicity (i.e., “what are the microorganisms capable of doing”) 71. This review 
will focus on interpreting the current scientific evidence that is available about new 
molecular techniques for exploration of the microbiota of infected and uninfected 
DFUs, exploring the potential of these new technologies and postulating how they 
could translate to improved clinical care. 
 
1.3.2. CULTURE-DEPENDENT DFU BACTERIOLOGY 
 
The importance in managing DFIs is underpinned by the requirement to identify any 
pathogen so that antimicrobial therapy can be directed. Traditional culture-dependent 
methods have been utilised to identify planktonic organisms subjected to controlled 
laboratory conditions. Many bacteria that can be grown in the laboratory are only a 
small fraction of the total diversity that exists in nature. Importantly, bacterial species 
can exist in a viable but non-culturable state 72. The limitations of this are that culture-
dependent methods select for species that flourish under the conventional culture 
methods utilised in the routine diagnostic microbiology laboratory, and this may not 
necessarily reflect the most abundant or clinically important organisms in DFIs 7. This 
could lead to an underestimation of total viable cells within a clinical sample posing an 
increased risk to the patient. 
 
The majority of studies exploring the bacteriology of DFIs have utilised conventional 
culture methods. These have widely reported the involvement of aerobic Gram-positive 
cocci, with S. aureus and Streptococcus spp., being the most common aetiological 
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microorganisms that acutely infect DFUs (Table 1.1) 42,43. The spotlight has centred on 
the well-known pathogen S. aureus and its role in DFI has been well reported 25,42. 
 
In two large culture-dependent studies on the bacteriology of infected DFUs samples 
from over 1,266 patients indicated the predominant pathogens being S. aureus and 
Streptococcus spp., with Enterococci spp., and Corynebacterium spp., also playing 
prominent roles 42,43. In both studies, anaerobes were generally reported as being of low 
abundance with one of the studies identifying the ratio of aerobe to anaerobe isolates 
being approximately 7:1 43 and the other study identifying anaerobe isolates in only 
28% of samples 42. In DFI, patients may also exhibit reduced immune-mediated 
responses, where the potential involvement of low virulence colonizers of devitalized 
tissue or bone, such as coagulase-negative staphylococci and Corynebacterium spp., 
may assume a more pathogenic role 46.  Additionally, while DFUs of short duration 
presenting with acute infection are generally monomicrobial 16, chronic infected DFUs 
seem to harbour a much more complex polymicrobial flora including Pseudomonas 
spp., Enterococcus spp., Enterobacteriaceae family., and other obligate anaerobes 
42,46,47.  
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Table 1.1 Bacteriology of culture-dependent and independent studies of infected DFU 
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1.3.3. CURRENT STUDIES EMPLOYING MOLECULAR TECHNIQUES FOR 
DIABETIC FOOT INFECTIONS AND CHRONIC WOUNDS 
 
The advent of molecular DNA based techniques that are culture-independent have 
identified limitations of traditional culture-dependent methods, acknowledging their 
capacity to identify a limited number of known cultivable bacteria (less than 1%) 7. 
DNA-based techniques, supported by ever-growing gene reference libraries, allow for 
the characterization of microbial communities or microbiota’s that encompass the sum 
of all microorganisms residing on and within the host - bacterial, fungal and viral 73.  
 
Characterizing the microbiota of infected and uninfected DFUs using molecular 
methods is growing with increasing publications occurring year on year 8-10,74. 
Composite evidence by authors employing molecular techniques also exist for chronic 
wounds, where studies have pooled multiple wound aetiologies to provide an overview 
of the chronic wound microbiota 75-78. Most chronic wound microbiota studies to date 
have employed pyrosequencing centred approaches that amplify and sequence the 
small subunit ribosomal RNA (16S rRNA) gene, a highly-conserved gene present in all 
prokaryotic DNA (bacteria) but not eukaryotes (humans). This has revealed a vastly 
more complex array of bacterial communities than those identified by traditional 
culture-dependent methods.  
 
16S rDNA is an ideal target for bacterial DNA analysis given that it possesses nine 
hypervariable regions that have considerable sequence diversity between bacterial taxa 
79. The hypervariable regions are bordered by stretches of sequences that are highly 
conserved between bacteria, ideal for designing universal and species-specific primers 
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to amplify the hypervariable regions by PCR 80. The workflows required to generate 
data on microbiota studies that include chronic wounds are depicted in Figure 1.2 
 
Figure 1.2 An overview of a common PCR and MPS-based workflow employed 
for microbiota research into chronic wounds 
 
 
 
 
The first report in the literature on the microbiota of DFUs was undertaken by Dowd et 
al (2008a) reporting on ten chronic DFUs using multiple genomic approaches that 
included; partial ribosomal amplification and pyrosequencing (PRAPS), full ribosomal 
amplification, cloning and Sanger sequencing (FRACS), density gel electrophoresis 
(DGGE) and Sanger sequencing (PRADS) 8. Identification of species was undertaken 
using operational taxonomic units (OTUs), these are clusters of single DNA sequences 
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grouped together based on their similarity and used to define microorganisms to a 
species or genus level.  
 
DNA reads from each wound were compiled to create a pooled DNA data set from 
multiple DFUs. Facultative and strict anaerobic Gram-positive cocci formed most 
sequences with genus level identification highlighting the predominance of 
Staphylococcus spp., (PRAPS = 10874 of 36508 sequences, 30%, FRACS = 70 of 178 
sequences, 39%) in addition to Peptoniphilus spp., Anaerococcus spp., 
Rhodopseudomonas spp., Enterococcus spp., Veillonella spp., Bacterioides spp., and 
Finegoldia spp., each contributing to greater than 5% of the microbial diversity.  
 
The second study to explore DFU microbiota was undertaken by Dowd et al (2008b) 
who employed bacterial tag-encoded FLX amplicon pyrosequencing (bTEFAP) to 
sample 40 chronic infected DFUs from a range of locations on the foot and ankle 9. 
Dowd et al (2008b) hypothesized that a single major pathogen would be associated 
with all wounds therefore DNA reads for each DFU were reported individually and not 
pooled. This allowed the compilation of community profiles for each DFU including 
the accurate identification of the number of samples each genus was detected, and the 
average percentage each genus contributed to its positive sample.  
 
Results identified each DFU contained a rich diversity of microorganisms with 
Corynebacterium spp., (30 of 40 DFUs, avg. abundance = 14.4%), Bacteroides spp., 
(25 of 40 DFUs, avg. abundance = 24.2%), Peptoniphilus spp., (25 of 40 DFUs, avg 
abundance = 13.6%), Fingoldia spp., (23 of 40 DFUs, avg. abundance = 6.7%) 
Anaerococcus spp., (22 of 40 DFUs, avg. abundance = 7.7%) and Streptococcus spp., 
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(21 of 40, avg. abundance = 36.5%) being present in all samples. Surprisingly, 
Staphylococcus spp., was only present in 13 of 40 (avg. abundance = 8.3%) DFUs 
compared to a previous study by the same authors that identified Staphylococcus spp., 
as the major bacterial genus in 10 infected DFUs 8. 
 
 The location of ulcers originating from multiple sites of the foot and ankle may have 
increased the heterogeneity observed between samples in the latter study. Some DFUs 
may have been purely ischemic or neuroischemic in origin, increasing the likelihood 
for the presence of devitalized, hypoxic tissue and selection towards low-virulent 
colonizers and anaerobic microorganisms.  
 
No single genus of bacteria was present in all 40 DFUs and this led Dowd et al (2008b) 
to hypothesize the microbiota of DFUs (and chronic wounds) is dominated by multiple 
species which cooperate in a biofilm; a concept Dowd et al ‘coin’ as functionally 
equivalent pathogroups. This centers on genotypically distinct bacteria working 
cooperatively to induce pathogenesis similar to that observed from a known single 
pathogen, such as S. aureus; however, there are currently limited data available to 
support this. 
 
Gardner et al (2013) 10 profiled the microbiotata  of 52 individuals with non-infected 
DFUs using 16S rDNA sequence analysis and were the first to restrict the sampling of 
patients to a homogenous sample of DFUs (neuropathic DFUs only). The group 
proposed that previous studies within the area were restricted by heterogeneous 
sampling (e.g., pooled samples of differing chronic wounds and of all three DFU 
aetiology types (neuropathic, ischemic and neuroischemic) and, as such, these 
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pathophysiologically distinct lesions likely harbour their own unique 
microenvironments and thus microbiota 8,9. 
 
In characterizing the microbiota of 52 non-infected DFUs, a total of 13 Phylum were 
reported from 300,660 DNA sequences with the majority being classified into 
Firmicutes (67%), Actinobacteria (14%), Proteobacteria (9.8%), Bacteroidetes (7.3%) 
and Fusobacteria (1.4%). Staphylococcus spp., was identified as the most common and 
abundant genus in 49 of 52 DFU samples (DNA sequences = 88,995 of 300,660, 
abundance = 29.6%). At a species-level the majority of sequences belonged to the 
common pathogen S. aureus (S. aureus sequences = 85,880 of 88,995, 96.5%), an 
unsurprising finding considering the highly documented role of this microorganism in 
diabetes related foot infection 2.  
 
Further analysis of microbial diversity in 52 DFUs reported on average 30 OTUs per 
DFU (range 7 – 64) in comparison to culture-dependent analysis that detected on 
average 4 isolates per DFU (p < .0001). Comparisons of the relative bacterial 
abundances within each DFU using culture-dependent analysis identified the 
overestimation in the abundance of Staphylococcus spp., (.47 vs. .32, p < .0001) and 
underestimation of anaerobes (.11 vs. .18, p = .0063) in comparison to 16S rDNA 
sequence analysis. 
 
By culture, anaerobes were identified as the predominant organisms in only 6 of 52 
DFUs (12%) a finding consistent with the known limitations of culture-dependent 
methods, particularly in the identification of slow-growing, fastidious anaerobic 
organisms 10. In contrast, 16S rDNA sequence analysis identified twice this amount (12 
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DFUs, 23%); this is of importance at a clinical level where the role of anaerobes in DFI 
and wounds is often underestimated. Their significance as highly virulent pathogens, 
detrimental to the wound environment 6, or as pathogens of DFI 47 is only becoming 
appreciated through advances in new molecular techniques that are culture-
independent. 
 
Gardner et al (2013) also depicted bacterial community structure using a statistical 
approach of Euclidean distances to determine how similar DFU attributes were to the 
indicators of wound bioburden (microbial load, diversity and presence of pathogens). 
The partitioning of data identified three clusters in which Gardener et al (2013) referred 
to as EUC1, EUC2, and EUC3. EUC1 contained significantly greater OTU richness (p 
= .006), diversity (p = .02) and bacterial load (p = .02), whereas EUC2 contained a 
greater abundance of Staphylococcus spp., and lower abundance of anaerobes (p = 
.0003) and EUC3 contained the highest abundance of Streptococcus spp., (p = .0002).  
 
Euclidean clusters were also mapped against clinical markers that included HbA1c, 
mean tissue oxygenation, ulcer duration, ulcer depth, ulcer surface area and necrotic 
tissue. EUC1 containing greater OTU richness, diversity and bacterial load, were 
associated with DFUs of longer duration (p = .02) and increased ulcer depth (p = .01). 
EUC1 also contained a greater abundance of anaerobes (p = .01) and Proteobacteria (p 
= .005), a likely association with wound longevity and deeper tissue involvement. EUC 
2 and EUC 3 had the highest proportions of both Staphylococcus spp., and 
Streptococcus spp., with laboratory markers from these participants recording the 
highest levels of glycosylated haemoglobin (HbA1c %) (Median EUC 2 HbA1c = 9.2% 
versus median EUC 3 HbA1c = 9.4%).  
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Assumptions on infections in people with diabetes have repeatedly associated 
Staphylococcus spp., and Streptococcus spp., as major pathogens, noting higher 
colonisation rates in those with sub-optimal glycaemic control 6,81,82. A plethora of 
studies have also identified that hyperglycaemia causes immunosuppression, and a 
reduction in glucose by a variety of means reverses immune function deficits 83-85. 
However, no evidence exists identifying direct links between hyperglycaemia, infection 
and potential deficits in the immune response to specific microorganisms 2,86.  
 
Gardner et al (2013) invested a significant proportion of their analysis on undertaking 
a statistical approach to partitioning DFUs into meaningful clusters based on their 
associations to the three dimensions of bioburden (i.e., microbial load, microbial 
diversity, presence of pathogens). Interpretation and validation of cluster analysis 
occurred through a silhouette score (SI), a method used to report the graphical 
representation of how similar one cluster is in comparison to other clusters. An average 
SI score of .42 was reported by Gardner et al (2013), but a SI score of less than < .5 
signifies only modest support for the proposed cluster algorithms 87,88. Other 
researchers such as Wu et al (2011) 89, who explored gut microbial enterotypes  using 
molecular approaches, recommended using a high SI threshold (≥ .75) for validating 
clusters.  
 
The statistical significance of partitioning 52 DFUs into similar clusters given the 
moderate SI score should be aired on the side of caution as a low SI score suggests that 
clustering could be due to chance. Further studies aiming to increase cluster validity 
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through higher SI scores may be required in supporting the partitioning of DFU 
microbiota to clinical indicators like those observed by Gardner et al (2013).  
 
Wolcott et al (2015) retrospectively reported 910 non-infected DFUs using 16S rDNA 
sequencing and currently represents the largest body of evidence surveying the 
microbiota of DFUs 90. Wound samples were collected from superficial debridement 
material obtained from the wound bed and relative abundances were calculated from 
species-level OTUs constituting >10% of all DNA reads per sample. Given the large 
sample size from multiple wound aetiologies, individual wound microbiotas were not 
reported, and DNA sequences were pooled. Of 910 DFUs the most abundant Phyla 
were Firmicutes (64%) followed by Proteobacteria (26%), Actinobacteria (9.6%) and 
Bacteroidetes (1%). Staphylococcus spp., (31%) was the most abundant OTU with S. 
aureus (48%) and S. epidermidis (35%) predominating at the species-level.  
 
Smith et al (2016) 74 sampled 20 new and recurrent DFUs using superficial swab 
cultures and analysed the data through 16S rDNA sequencing. They hypothesized that 
distinct differences would exist between the microbiota of new ulcer versus those that 
were recurrent. Herein lies one of the major methodological flaws of this study, of 
which there are several. Smith et al (2016) fail to define what a recurrent ulcer is. 
Logically one would assume recurrent ulcers are healed wounds that due to factors such 
as peripheral neuropathy and altered foot architecture, eventually at a time point re-
ulcerate. But these are then classified as new ulcers as the skin barrier was intact prior 
to re-ulceration. Therefore, there is no real difference between the two cohorts 
examined.  
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This point is proven as the study identified that new ulcers were predominated by 
Peptoniphilus spp., (6 samples), Staphylococcus spp., (5 samples), Anaerococcus spp., 
(5 samples) and Corynebacterium spp., (4 samples). Recurrent ulcers had similar 
microorganisms; Corynebacterium spp., (5 samples), Peptoniphilus spp., (4 samples) 
and Anaerococcus spp., (4 samples). Further analysis of both alpha and beta diversity 
(dominance, diversity, principal coordinates analysis) identified no differences in the 
microbiota of either wound. 
 
Another drawback of the study is the poorly presented data which makes comparison 
to other studies difficult. The primary table of results that identify genera through 16S 
rDNA sequencing are not presented as rank abundance, instead the authors name genera 
alphabetically and omit reference to the relative abundance of microorganisms 
identified. This severely restricts the ability to decipher community structure and 
determine who the major or minor players are in these wounds and if any differences 
existed between groups. 
 
The omission of data pertaining to the infection status or chronicity of wounds is further 
limiting. Given that most DFUs will be colonized by microorganisms on injury, this 
does not necessarily translate to microbial pathogenesis. If DFUs are appropriately 
managed through standard care (i.e. offloading and woundcare) and if the host response 
controls colonization, these DFUs are likely to heal 91. Had the authors compared the 
microbiota of new wounds that healed in the study groups to wounds that failed to heal, 
then this would have been novel to the literature and may have increased our 
understanding of the wound microbiota. 
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The major defining features linking all the above studies are that samples were obtained 
at singular time points. This does not allow for the temporal analysis of wounds 
sampled longitudinally which may identify shifts in community structure or diversity 
that may lead to impaired healing or clinical infection. Importantly monitoring temporal 
shifts may allow for model prediction of wounds which heal, remain chronic or become 
infected. Recently three studies have employed these methods to explore DFUs 92,30,31.  
 
Loesche et al (2017) 31 examined 100 participants with neuropathic DFUs, obtaining 
bi-weekly superficial swab cultures over 26 week follow up period. Staphylococcus 
spp., Streptococcus spp., Corynebacterium spp., and Anaerococcus spp., were the most 
abundant genera in DFUs. Previously this group had used using partitioning around 
medoids 10, to identify specific clusters of microbiota from DFUs with similar traits. In 
the new temporal study, the authors utilised Dirichlet multinominal mixture (DMM) 
model-based approach to cluster longitudinal DFU samples in 4 groups or community 
types (CT). CT1 and CT2 were highly heterogeneous with no dominant taxa, CT3 were 
characterized as having high relative abundance of Streptococcus spp., and CT4 DFUs 
had high relative abundances of S. aureus.  
 
The community type clusters allowed further analysis against longitudinal samples, 
where transitions or shifts of the microbiota were apparent. Wounds that healed faster 
(<12 weeks) experienced greater transition frequencies than wounds which took longer 
to heal (>12 weeks) (p < .0001), of which these wounds were dominated by CT1 and 
CT2. CT3 and CT4 experienced stability with minimal transitions and these wounds 
took longer to heal. The authors proposed therefore that their findings suggest 
community stability reflects a delayed healing phenotype.  
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From the same 100 patient sample, Kalan et al (2017) 31 employed high through-put 
sequencing to profile the fungal mycobiome using the internal transcribed spacer 
(ITS1) region. They identified that up to 80% of the 100 DFUs contained fungi, with 
the entire dataset represented by two phyla; Ascomycota and Basidiomycota. The most 
abundant species were Cladosporidium herbarum, Candida albicans and Trichosporon 
spp. The authors additionally correlated clinical data against fungal mycobiome and 
identified increased relative abundance of fungi after antibiotic therapy and increased 
fungal diversity in DFUs with poor perfusion. Kalan’s study further tried to correlate 
the fungal mycobiome with clinical outcomes but identified no significant correlations. 
Explanations as to lack of clinical correlation with outcomes were provided in an open 
letter by Malone & Dickson (2017) (Appendix 3)   
  
Kalan et al (2016) report only on the ITS1 sequences (18S rDNA) and do not include 
bacterial or archaeal sequences (16S rDNA) paying reference to the composite relative 
abundances of each group. In doing so, the clinical relevance of fungi in chronic 
wounds becomes lost. This is because, without identifying all the microorganisms 
within a wound (bacterial, fungal, archaeal), one cannot determine the overall microbial 
load for fungi or what their relative abundances are in relation to those of other 
microorganisms. This allows us to understand whether a microorganism is a dominant, 
major, or minor player. Therefore, no assumptions can be made on the community 
structure, and the “mycobiome” becomes clinically uninterpretable. 
 
The data presented by Kalan et al (2016) are difficult to interpret within the context of 
clinical management. They report the sampling of chronic wounds undertaken using 
the Levine technique with a swab. This culture method has been the subject of great 
  40 
debate in the diabetic foot arena, with opinions still divided. Some expert groups 
promote tissue biopsy as the most appropriate sampling method for identifying 
pathogens of infection and for exploring both the microbiota and the role of biofilms 
93.25 
 
A previous study from the authors’ group suggests good concordance between culture-
independent swab samples (DNA sequencing) and tissue samples 26. However, the use 
of swab samples from superficial tissue makes it difficult to ascertain whether any fungi 
identified merely resided on wound surfaces as colonizers or whether the fungi were 
invasive and involved deeper tissue (this may suggest a more pathogenic involvement). 
Tipton et al (2017) 73 obtained DFU samples from three-time points in 167 subjects 
from a previously reported sample dataset 90,92.  Community stability was quantified as 
the percentage of genera/species observed at each time point that were still present at 
subsequent time points. Dirichlet multinominal mixture (DMM) model-based approach 
was used in a similar fashion to Loesche et al (2017) 31, to cluster wound communities 
into community types. The most prevalent species identified as common and major 
contributors (>1% to >10%) in DFUs were S. aureus, P. aeruginosa, S. haemolyticus, 
C. straiatum, S. epidermidis and F. magna which accounted for 41% of total 
microorganisms.  
 
When combining samples longitudinally, a trend was observed between time points 
where low frequency taxa (<1%) later contributed to DFU microbiota at higher relative 
abundance levels (>10%) in 20% of DFUs. Community types determined through 
DMM did not identify any clear pattern of clusters with the exception of clusters that 
were highly variable akin to those identified by Loesche et al (2017) 31 of CT1 and 
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CT2. This variability is likely due to the data by Tipton et al being affected by treatment 
variables that patients received, such as the use of antibiotics, or by the time between 
sample intervals which was around 3 months (significantly longer than Loesche et al 
(2017) who performed sampling bi-weekly. 
 
The prospect of understanding changing shifts in the microbiota of wounds that may 
enable predictive modelling is compelling and would likely significantly impact patient 
care and therapeutics. There are some potential limitations that may restrict its ability 
to be used on a generalised scale. Firstly, analyzing single samples from >100 people 
that are pooled together, by itself introduces large heterogeneity into the dataset. This 
may skew the data and cloud highly relevant pictures that would otherwise be visible 
at the individual wound level. When combing multiple samples from patients, this may 
further complicate the heterogeneity of samples. Other variables which may skew data 
and introduce error are sampling methods and macro-spatial variation 13. Loesche et al 
(2017) 31 utilised superficial swabs which can capture the full area of a wound surface 
when using the Z technique or the central wound area when using the Levine technique. 
However, expert groups suggest that superficial swabs are not appropriate for depicting 
the full array of microorganisms residing in a wound 2,25.  
 
Tissue samples are promoted as the preferred detection methods, yet many tissue punch 
biopsies or debridement material may only capture a specific area of the wound and 
thus miss areas of microbes that contribute to the microbiota 41. These factors may add 
to the sampling error of data and restrict the generalisation of modelling or the 
interpretation of data from large cohorts. Lastly, what the two temporal analysis studies 
fail to achieve is to capture patients where the microbiota of wounds transition to a 
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clinical infection status and or those wounds that receive therapy but fail. This would 
present valuable data in being able to identify patterns which suggests shifts towards 
causing a host immune response that is characterized as clinical infection or those at 
risk of failing therapy.  
 
In review of the studies employing amplification and sequence analysis of 16S rDNA 
to characterize the microorganisms involved in DFI, few have sampled participants 
with overt clinical signs of infection. It is generally regarded that clinically uninfected 
wounds should not be treated with antimicrobials and therefore should not be cultured 
2,94. The clinical relevance of culturing uninfected and or chronic DFUs to characterize 
the microbiota is therefore a matter of debate. In patients with diabetes presenting with 
overt clinical signs of infection, the decision to obtain a culture from a wound to identify 
a pathogen of infection is clinically justified. It has been well addressed in the literature 
however, that many patients with diabetes, often do not display overt clinical signs of 
infection in the presence of a non-healing DFU 19.  
 
Some clinical researchers have proposed under these circumstances to utilize secondary 
signs and symptoms (i.e., malodor, increased exudate, poor quality tissue) to diagnose 
infections, that may be more pertinent to guiding clinicians facing wounds that are non-
healing in the presence of standard care 2.  Therefore, obtaining samples to examine the 
microbiota of patients with ‘masked’ signs of infection in DFUs that are non-healing 
despite standard care, may prove greatly beneficial.  
 
With the exception of Gardner et al (2013) 10 who restricted sampling to a homogenous 
group of DFUs (neuropathic), all other microbiota studies have included the sampling 
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of different DFU etiologies. The extent to which community diversity is affected 
through variances in wound etiologies is currently the focus of debate. It is generally 
accepted that DFUs of ischemic origin may contain a wound bed environment of 
devitalized, slough tissue. This may perpetuate very different bacteria to healthy 
vascularized tissue common in neuropathic DFUs 2,16,95  . Further studies comparing 
each DFU etiology individually may clarify this matter. 
 
Lastly, it has been cited in the literature that certain aerobic species are often 
overestimated as the primary pathogens in DFI 42,43. When comparing the evidence on 
the bacteriology of DFIs through both culture-dependent and -independent approaches, 
both corroborate S. aureus as being the predominant pathogen colonizing DFUs. In 
tandem with this, reports have also suggested that the abundance and role of anaerobes 
are greatly underestimated 10,76. The significance however at a clinical level, of 
identifying additional “hidden” anaerobes that often form part of a polymicrobial 
infection are yet undefined. Many antimicrobial agents commonly used in the treatment 
of DFIs have a broad-spectrum of activity to cover most anaerobes 96. Furthermore, no 
published studies are available reporting improved clinical outcomes when adding 
additional anti-anaerobic directed therapy to concurrent regimes.  
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1.3.4. APPLYING METAGENOMICS TO DFI – COULD THIS BE A ‘GAME 
CHANGER’ IN DEFINING “WHICH MICROORGANISMS ARE PRESENT, 
WHAT ARE THEY CAPABLE OF DOING AND “WHO DID IT” 
 
Advancements in molecular technologies have seen the emergence of next generation 
DNA sequencing platforms (NGS) that greatly increase the throughput of sequencing 
large amounts of DNA. This significantly reduces the cost to analyse clinical samples 
and makes NGS platforms widely applicable to use in clinical practice 97. In tandem 
with advancements in NGS platforms, has been the output of increasingly larger and 
more complex data sets. Bioinformatics programs and software packages to cater for 
this have therefore become an essential tool to complement MPS platforms. Open-
source software such as QIIME 98 and Mothur 99 for example, have been widely used 
in microbiome research for their ability to construct details on three areas of importance 
to clinicians dealing with chronic wounds: the microbial load, the microbial diversity 
and the presence of pathogens 38. 
 
Unlike the targeted amplification and sequence analysis of 16S rDNA through PCR, 
whole genome shotgun sequencing (WGS) (metagenomics) employs a complement of 
molecular technologies and techniques to sequence DNA extracted directly from a 
sample. For example, DNA can be sheared into small fragments and independently 
sequenced in a technique commonly referred to as whole genome shotgun sequencing 
(WGS). This approach produces sizeable data sets requiring the alignment of DNA 
reads to known genes through open-access reference databases, such as NCBI GenBank 
100. When combined, these ever-growing gene reference libraries enable the analysis of 
varying components of microbial ecology and their functions.  
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Applying metagenomics to DFI may allow for an extended picture of which 
microorganisms are there. What are they capable of doing and “who” did it? 
Additionally, metagenomics could provide information on how we should direct 
therapy.  Metagenomics identifies all genomic DNA including bacteria, fungi, archaea 
and viruses (microbiota) allowing for greater taxonomic (species level) resolution. In 
addition to DNA sequences involving the taxonomically informative genes (such as 
16S rDNA), other genes of interest maybe identified through metagenomics such as 
protein coding sequences from which the biological functions of the microbe can be 
inferred e.g., pathogenicity (pathogenicity islands), virulence, antibiotic susceptibility 
101 or metabolic pathways 102.  
 
These protein sequences are identified through databases containing resources required 
for understanding high-level functions and utilities of biological systems, including 
known proteins for microbial cells (Kyoto Encyclopedia of Genes and Genomes – Kegg 
and MG-RAST). Metagenomics is however limited in its capacity to provide 
information on the actual metabolic activity of a microbial community, as it cannot 
differentiate between expressed and non-expressed genes 103.  
 
To circumvent this limitation, metagenomic methods have combined newer sub-
disciplines that utilize mass spectrometry in combination with molecular approaches. 
Transcriptomics and proteomics can identify expressed biological signatures such as 
RNA-based regulation or proteins, respectively, that control metabolic activities in 
microbial communities 104,105. In this respect, combining metagenomics with 
transcriptome or proteome analysis may afford the possibility to characterize not only 
the microbial diversity within a DFI (i.e., “which microorganisms are present”) but the 
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functional potential i.e., “which microorganisms are present and what are they capable 
of doing and who did it” 102.  
 
Thus, it would be highly desirable to determine which microbes are the potential 
“assailants”, “co-conspirators” and “bystanders”; this would allow for targeted 
antimicrobial therapy. One study exemplifying the combined use of 16S rDNA 
sequencing with proteomic analysis was by Lassek et al (2015) 106 who elucidated 
pathogen-protein expressions of catheter-biofilm associated urinary tracts infections.  
Both P. aeruginosa and M. morganii were identified as the predominant 
microorganisms through WGS community analysis. Proteomic analysis then revealed 
several interesting findings at a functional level which implicated P. aeruginosa as the 
primary driving pathogen and identified that it up-regulated proteins involved in the 
degradation of red blood cells, the siderophore systems for iron acquisition (i.e. 
bacterial growth), biofilm formation, antibiotic resistance and in pathogenicity. 
Currently, no studies employing 16S rDNA sequencing in combination with 
transcriptome, proteome or metabolome data have been undertaken for DFI. 
 
1.3.5. LIMITATIONS OF DIFFERENT MOLECULAR TECHNOLOGIES AND 
TECHNIQUES 
 
PCR amplification of DNA fragments requires the use of primers to bind to a specific 
region of the 16S rDNA enough to produce a PCR product. The use of some universal 
primers may not be broad enough to detect the bacteria that often cause polymicrobial 
infections in chronic DFUs 2. In this respect the microbiota may be overrepresented by 
certain taxa due to primer bias 101. Although the hypervariable regions of the 16S rDNA 
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are highly diverse, this variation is reduced between closely related taxa. Thus, some 
workflows that use a single gene assay (through 16S rDNA gene sequencing analysis) 
as the sole sequencing method for community profiling may lead to inconclusive results 
with closely related taxa 64 or an inability to classify taxa to species level 75. This 
limitation can be somewhat partially offset using multiple primer sets (multiplexing 
PCR) to amplify different hypervariable regions. Lastly, current DNA-based methods 
are unable to distinguish between live or dead bacteria, amplifying all DNA regardless.   
 
Metagenomics also possess inherent limitations; in particular, the gargantuan and 
complex data sets it produces with some MPS platforms generating up to 600 Gb of 
sequence data when performing sequencing runs 107. Furthermore, both human-host 
DNA and microbial DNA are sequenced with approximately 90% of DNA from a 
sample being human.101 Therefore obtaining adequate coverage of microbial DNA 
requires deep sequencing (i.e., large data sets) with removal of human DNA sequences 
via computational resources. Currently, no studies employing metagenomics with or 
without transcriptome or proteome analysis have been used to determine both microbial 
diversity and functional potential of samples from patients with DFI. High costs and 
computational requirements to analyse the complex data may account for this. 
 
1.3.6. SUMMARY 
 
Amplification and sequence analysis of 16S rDNA for profiling the microbiota of 
infected and non-infected DFUs have already provided insights for the medical 
community by identifying that many more bacteria are present in DFUs than the 
corresponding view from culture-dependent methods 10. Despite the wealth of 
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knowledge gained from molecular microbiology, the use of 16S rDNA based 
approaches have not been routinely employed in frontline clinical microbiology 
services for the identification of pathogens of wound infection. This limited uptake has 
been attributed to the low throughput and relatively high sample sequencing costs using 
PCR-based platforms. This may account for why it has been primarily confined as a 
researcher’s tool for characterizing the microbial profile of various infective 
pathologies in human health and disease. 
 
Whilst the progress and application of current DNA sequencing continues to rapidly 
evolve, thus far we have only been enlightened with a broader view of “which 
microorganisms are there” while the interpretation and any clinical implications of 
additional bacteria within samples remains unclear. The potential of molecular methods 
that employ metagenomics, transcriptomics, proteomics and metabolomics, represent a 
potential future ‘game changer’ to improving clinical care in people with DFI. Their 
usage may help to reveal the full extent of DFI; “which microorganisms are present, 
what are they capable of doing and which microorganism/s are responsible.
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CHAPTER 2  
 2.1. MICROBIAL BIOFILMS  
 
Bacteria are often viewed as being single cells that rapidly multiply when in exponential 
growth and are susceptible to antibiotics if not inherently resistant. Antimicrobial 
resistance and multi-drug resistance are an increasing problem across the globe and are 
a current hot topic subject to much debate 108. Most clinicians involved in the treatment 
of wounds will utilize susceptibility patterns they receive from the clinical 
microbiology laboratory, as a guide to determine which antibiotic(s) a patient requires 
27.  
 
These decisions are often aided by international consensus guidelines, which are 
sufficient when managing acute infections 2,25. However, in cases of chronic infection, 
such as those seen for implantable medical devices, pulmonary infections of cystic 
fibrosis patients and chronic non-healing wounds, these guidelines may be inadequate 
109. Why is this? How can we explain the quick resolution of infective symptoms using 
antimicrobials in patients with acute wounds 110, in comparison to the prolonged 
response often noted in non-healing chronic wounds 111?  
 
The answer is both complicated but also rather simple. Bacteria can exist in two (maybe 
more?) phenotypic different growth forms, that being single fast-growing cells i.e. the 
planktonic form, and the second as aggregated communities of slow growing cells in a 
biofilm form. All classical microbiology and development of antimicrobials have been 
solely based on planktonic paradigms, through methods developed in the early 1800’s. 
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These methods are considerably easier to grow bacteria, through shaken cultures or by 
spreading on an agar plate, and it is how bacteria presumably exist during acute 
infections.  
 
These methods are still widely accepted as gold standard for depicting the pathogens of 
acute infections. The picture for chronic infections is completely the opposite. In this 
case, a substantial amount of the bacteria resides in biofilms, where they are surrounded 
by a dense matrix of polysaccharides, free bacterial DNA and proteins that tightly 
attaches the biofilm community to themselves and structures and protects them from 
being engulfed and killed by neutrophils and macrophages 112.  In addition, many of the 
bacteria are not rapidly multiplying or metabolising, which causes the bacteria to 
become tolerant. This is because almost all antibiotics only work on metabolically 
active bacteria via their numerous bacterial targets 113,114.  
 
Biofilms are frequently defined based on in vitro observations 115. Classic definitions 
often describe biofilms as bacteria attached to surfaces, encapsulated in a self-produced 
extracellular matrix and tolerant to antimicrobials 116,117. In addition, biofilm 
development is often described as a three to five stage scenario, beginning with single 
cells attaching to a surface, maturation of the biofilm and lastly dispersal of bacteria 
from the biofilm 118,119. However, in vitro observations based on flow cell models 
utilizing glass surfaces, and fresh oxygenated culture media continuously flowing over 
the bacterium, differ greatly from the conditions within chronic wound infections 120. 
Here, the bacteria are not exposed to a continuous flow of fresh media and are not 
attached to a glass surface (They adhere to human cells). In vivo chronic wound 
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biofilms are also often encapsulated in matrix that includes host material making 
dispersal a problematic event 121.  
 
Therefore, using in vitro observations to define, diagnose and treat biofilms in chronic 
infections, may provide a misguided impression 122. Commonalities between in vitro 
and in vivo evidence that we can be more abreast to in providing a definition of a biofilm 
are; the aggregation of bacteria, some sort of matrix that is not restricted to self-
produced since it can also be of host origin, and the tolerance and protection against 
most antimicrobials and the host defense. There are, however, commonalities between 
in vitro and in vivo evidence that can help in providing a definition of a biofilm 93. These 
include: 
• Aggregation of bacteria 
• Some sort of matrix that is not restricted to self-produce as it can also be of host 
origin 
• Extreme tolerance and protection against most antimicrobial agents and the host 
defence. 
 
How do biofilm communities differ from planktonic bacteria? 
Planktonic bacteria are single cells that are usually fast growing and are commonly  
observed in acute infections 123. During acute infections bacteria are of the planktonic 
phenotype, since they are susceptible to antimicrobial agents with targeted treatments 
causing an abrupt resolution of symptoms. 
 
In vivo evidence has suggested biofilm phenotypes differ markedly in both their 
physiology and activity when compared with planktonic cells 120. The bacteria are 
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aggregated and difficult to treat, if not impossible, somehow evading host defences 93. 
Often the bacteria are embedded in a matrix which can be produced by the bacteria or 
is of host origin. The exact composition of EPS varies according to the microorganism’s 
present, but generally comprise polysaccharides, proteins, glycolipids and extracellular 
DNA 124-126. Microelectrode studies have further identified anoxic regions within a 
biofilm, resulting in lower bacterial cell metabolic activity 127-129. This contributes in 
part to the inherent resilience of biofilms to antimicrobial treatments. 
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Abstract 
Evidence supporting the presence of biofilms in chronic non-healing wounds is 
continuing to advance. A large proportion of what we have learnt about biofilms and 
how they may contribute to the chronicity of wounds are derived from in vitro model 
and in vivo animal data. However, human chronic wound studies are under-represented 
with most studies having low sample sizes. For this reason, we sought to ascertain the 
prevalence of biofilms in human chronic wounds by undertaking a systematic review 
and meta-analysis.  
 
Only studies that used rigorous methods for sample collection (biopsy or curettage) and 
visualization of biofilm consistent with recent guidelines (light microscopy, scanning 
or transmission electron microscopy) with or without molecular methods were 
included. Our initial search identified 554 studies from the literature databases 
(Cochrane Library, Embase, Med-line). After removal of duplicates, and those not 
meeting the requirements of inclusion, 9 studies involving 185 chronic wounds met the 
inclusion criteria. Between-study heterogeneity was high (Q test p = .022, I2 = 55%) so 
a random-effects meta-analysis model was utilised. Pooled visual prevalence of 
biofilms in chronic wounds was 78.2% (p = .002, CI 61.6 – 89). The results of our meta-
analysis support our clinical assumptions that biofilms are ubiquitous in human chronic 
non-healing wounds. 
 
2.2.1. INTRODUCTION 
 
During most of the history and development of microbiology, the general understanding 
of the role microbes play in human health and disease has been that they exist as 
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planktonic or free-floating single cell organisms. Seminal works by Louis Pasteur and 
Robert Koch in the mid to late 1800s paved the way in the field of microbiology and 
laboratories still use the 150-year old methods developed by these pioneers.  These 
techniques postulate that microbial cells act in a planktonic state, that is, they disperse 
in a liquid environment.  
 
However, emerging evidence from the previous century, based on microbial studies of 
aquatic environments and dental plaque provided insights that microorganisms have a 
natural tendency to associate surfaces, preferring a sessile lifestyle 130,131. This early 
work, which focussed predominantly on environmental samples, later provided a 
platform for the contemporary medical models that we have come to understand as 
“microbial biofilms”. Unlike their planktonic counterparts, biofilm phenotypes have 
been defined as structured consortiums of aggregated microbial cells, surrounded by a 
polymer matrix, that adhere to natural surfaces or to themselves 132.  
 
The concept of biofilms in human health and disease is now universally accepted in 
tuberculosis 133, periodontal disease and dental caries 134, cystic fibrosis 135-137, in-
dwelling medical device infections 138, otitis media and other upper respiratory 
infections 139,140, and chronic wounds 12,90,141. So highly attuned are researchers to the 
wide involvement of biofilm associated infections across the spectrum of human health 
and disease, the United States Department of Defence for example, has recognized the 
significance of biofilms as being problematic in wound healing, and has prioritized 
research in this area 142.  
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Unlike some commensal sessile microbial communities, microorganisms residing 
within a non-healing chronic wound in the biofilm phenotype may promote a hyper- 
inflammatory response as a persisting adverse pathology, much to the detriment of the 
host 8,143,144. Recent observations have also provided alternative insights into how 
bacterial biofilms in chronic wounds may promote chronicity. Using oxygen 
microsensors and transcriptomics (examining microbial metabolic activities), James 
and colleagues identified steep oxygen gradients within in situ biofilms and induced 
oxygen-stress responses from bacteria 129.  
 
Once established, biofilms often become highly tolerant to standard treatment and 
removal/eradication paradigms, yielding several hallmark features that distinguish 
biofilm phenotypes from their planktonic counterparts. The most notable of these is a 
remarkable tolerance to antimicrobial agents 145, disinfectants and host immune 
defenses 146,147. 
 
Whilst non-healing chronic wounds represent an umbrella terminology for a range of 
pathologies, biofilms have been cited across all related etiologies including;- venous 
leg ulcers (VLU’s) 148, pressure Injuries (PI) 143,149 and diabetic foot ulcers (DFUs) 12. 
Collectively these chronic wounds contribute to significant morbidity, mortality and 
increased healthcare expenditure. Importantly, the continuing rise in antimicrobial 
resistance has placed a greater emphasis on correctly diagnosing and managing biofilm 
associated infections in non-healing chronic wounds. This will require a shift in 
treatment paradigms to more multifaceted biofilm-based approaches given the 
resilience of biofilms in responding to planktonic-based treatments.  
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As the presence of biofilms across the spectrum of chronic wounds has significant 
implications both medically and economically, clear and concise information is 
required to help guide healthcare professionals managing these recalcitrant causes of 
delayed healing. Over the last decade an increasing body of evidence from in vitro 
models and animal 150,151 and human studies has identified the capacity of wound 
isolates to grow as biofilms, and for chronic non-healing wound samples to harbour 
biofilm. This has been driven largely by advancements in molecular microbiology and 
microscopy technology and techniques applicable to the study of bacterial populations 
in situ. This has allowed authors to implicate biofilms as the cause of non-healing 
chronic wounds and in the development of associated clinical infections.  
 
There is a plethora of in vitro model and in vivo animal data supporting the presence of 
biofilms in non-healing chronic wounds 152-155. A recent review of the scientific 
literature for the presence of biofilms in chronic wounds has eloquently explored the 
models utilised156. However, human chronic wound studies are under-represented with 
most studies having low sample sizes. For this reason, we proposed to ascertain the 
prevalence of biofilms recognised in human chronic wounds by systematically 
reviewing the literature from published in vivo human chronic wound studies to 
increase sample size and power to provide a meta-analysis. 
 
2.2.2. METHODS 
Search strategy  
An electronic search of the literature was performed to identify published studies on 
the broad area of biofilms in chronic wounds with the primary aim to ascertain the 
percentage of chronic wound samples that contain biofilm. A systematic review of the 
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Cochrane Library, Embase, Med-line (PubMed) databases was conducted between 
January 2008 and December 2015 using the following search term “biofilm” [all fields] 
AND “chronic wounds”. A secondary search was also undertaken using ‘biofilm” with 
supplementary keyword filters; OR “diabetic foot ulcers” OR “venous leg ulcers” OR 
“pressure ulcers” OR “decubitus ulcers” OR “non-healing surgical wounds”, OR 
“visualization”, OR “scanning electron microscopy” OR “fluorescent in situ 
hybridization”, OR “16S rRNA”.  Only articles limited to English language were 
included. The search was limited to prospective clinical studies, case reports, case series 
and published conference abstracts. The systematic review was conducted in 
accordance with the PRISMA guidelines (Figure 2.1) 157. 
 
Figure 2.1 PRISMA flow diagram of literature search. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Database article sources 
(N = 554) 
Medline = 368 
Cochrane library = 4 
Embase = 182 
Title and abstract screened 
(N= 452) 
Duplicates removed 
(N = 102) 
Failed to meet study inclusion criteria 
(N= 443) 
 
Full text articles assessed 
(N= 9) 
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Data extraction 
Two investigators (MM and TB) independently reviewed titles and abstracts of all articles to 
establish their eligibility based on predefined criteria. All eligible article references were 
tabled, and their abstracts obtained for review. Articles meeting the eligibility criteria were 
hand-searched for additional studies.  For the meta-analysis, we extracted the following 
domains or variables from the articles that included, date of study publication (2008 – 2015), 
prevalence rates (number of confirmed tissue samples over the total number of samples 
screened), sample size and study design. 
 
Study eligibility  
Articles publishing data on in vivo human chronic wounds, in participants over the age of 18 
were included. Chronic wound aetiologies included in the search were diabetic foot ulcers 
(DFUs), venous leg ulcers (VLUs), pressure injuries/ulcers (PI/PUs) and non-healing surgical 
wounds (NHSW). Individual searches of the methodology section from each paper were 
undertaken and universal definitions of a chronic wound or phrases denoting the chronicity of 
participant wounds such as “non-healing”, “delayed healing” and or “chronic” were used to 
ensure eligibility.  
 
Only articles detailing the presence of biofilms and bacteria in general through microscopy 
with or without combined molecular methods were included for review. In line with recent 
guidelines93 the following visualization techniques were deemed appropriate for the 
confirmation of biofilm presence; scanning electron microscopy (SEM), transmission electron 
microscopy (TEM), confocal laser scanning microscopy (CLSM), conventional and peptide 
nucleic acid - fluorescent in situ hybridisation (PNA-FISH) and microscopy with or without 
staining methods. Articles diagnosing biofilm presence by clinical observation were excluded. 
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Additionally, to meet inclusion, articles must have cited optimal collection methods for the 
sampling of chronic wounds with tissue biopsy, curettage or debridement material being 
regarded as the preferred sampling method. Swab cultures of the wound bed were excluded for 
being inadequate for biofilm identification, given the inability to detect between planktonic 
and biofilm phenotype93. 
 
Statistical analysis 
Data from studies were extracted as raw numbers using the number of samples with confirmed 
biofilm over the total number of samples obtained. Data were analysed using comprehensive 
meta-analysis software (Biostat Inc., New Jersey, United States). Pooled prevalence estimate 
rates, weighted averages and 95 % confidence intervals (CIs) were undertaken using fixed-
effects meta-analysis. Forest plots were reported for inconsistencies in effect sizes and their 
confidence intervals. Between-study variance or heterogeneity in estimates was modelled using 
Cochran’s Q and the I2 statistic. Where Cochran’s Q value was reported with p-values < 0.10 
and I2 values exceeded >50%, a random-effects model was used 158. 
 
2.2.3. RESULTS 
 
The search identified 554 studies from the literature databases. After removal of duplicates, 
exclusion and the screening of 452 titles and abstracts, eight studies involving 185 chronic 
wounds met the inclusion criteria (Figure 2.1). The numbers of each respective chronic wound 
were; DFUs (n = 33), VLUs (n = 67), PI (n = 26), NHSW (n = 28), Unspecified chronic wounds 
(n = 31). Eight articles were from prospective cohort studies with the remaining one study 
being case reports / series (Table 2.1). Primary authors were contacted for data from two studies 
to clarify the number of positive biofilm samples 159,160. As expected, between-study 
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heterogeneity was high (Q test P< 0.022, I2 = 55%). To address this, a random-effects model 
was utilised with pooled prevalence rates reported.  
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Table 2.1 Descriptions of included studies utilising microscopy approaches to visualise wound biofilm. Scanning Electron Microscopy (SEM), 
Light microscopy (LM), partial nucleic acid fluorescent in situ hybridisation (PNA-FISH), confocal laser scanning microscopy (CLSM), denaturing 
gradient gel electrophoresis (DGGE), amplification and sequence analysis of the 16S rRNA gene (16S rDNA), diabetic foot ulcer (DFU), venous 
leg ulcer (VLU), pressure ulcer (PU), non-healing surgical wounds (NHSW).
Author/s Study design Number of participants Visualisation methods 
with or without molecular 
Chronic wound aetiologies No of samples with 
confirmed biofilm 
(%) 
James et al (2008) 12 Prospective study 
case vs control 
 
66 Light microscopy, SEM 
16S rDNA with DGGE 
13 DFUs, 21 PUs 
8 VLUs, 24 NHSW 
30 out of 50 
(60%) 
Kirketerp-Moller (2008) 13 Prospective cohort 
study 
22 PNA-FISH, CLSM 
 
Un-specified chronic wounds 13 of 22 
(60%) 
 
Fazli et al (2009) 161 
 
Prospective cohort 
study 
 
9 PNA-FISH, CLSM 10 VLUs 10 of 10 
(100%) 
 
Thomsen et al (2009) 39 
 
Prospective cohort 
study 
Sub analysis  
 
2 
PNA-FISH, 16S rDNA 2 VLUs 2 of 2 
(100%) 
 
Han et al (2011) 78 
 
Prospective cohort 
study 
 
15 PNA-FISH, CLSM 
16S rDNA 
4 DFUs, 5 PUs, 2 VLUs 
4 NHSW 
9 of 15 
(60%) 
Neut et al (2011) 162 Case report 2 CLSM 2 DFUs 2 of 2 
(100%) 
 
Oates et al (2014) 163 
 
Prospective cohort 
study 
Sub analysis 
4 FISH, SEM, 
 
4 DFUs 4 of 4 
(100%) 
 
Martinez-Velasco et al (2014) 159 
 
Prospective cohort 
study 
conference abstract 
 
 
20 
 
SEM, LM 
 
Un-specified chronic wounds 
20 of 20 
(100%) 
 
Honorato-Sampaio et al (2014) 160 
 
Prospective cohort 
study 
 
45 
 
TEM 
 
45 VLUs 
45 of 45 
(100%) 
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Prevalence of biofilms in chronic wounds 
The pooled prevalence of biofilms in chronic wounds was 78.2% (p =  .002, CI 61.6 – 89) 
(Table 3). Biofilm prevalence varied greatly over all studies, however the percentage(s) of 
positive biofilm samples was no lower than 60% noted in three studies 12,13,78, with all 
remaining studies identifying 100% biofilm prevalence 159-164. Given the relatively small 
sample size and the co-variable of 4 different chronic wound aetiologies, inferences regarding 
whether biofilms were more prevalent in one chronic wound were not possible. 
 
Table 2.2 Random–effects model of nine chronic wound biofilm studies. 
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2.3.4. DISCUSSION 
 
Early landmark publications providing evidence for the presence of biofilms in chronic wounds 
have provided guidance for clinicians and researchers alike 12,13,141. These studies identified 
that biofilms were present in 60% of non-healing chronic wounds. Since then, studies 
employing combined molecular and microscopy methods to directly visualise biofilms have 
gathered pace. 
 
This systematic review and meta-analysis is the first to collate all available in vivo studies 
pertaining to the identification of biofilms from non-healing human chronic wounds. In doing 
so, our meta-analysis results suggest that biofilms are prevalent in all these wounds. Pooled 
prevalence rates identify that 78% of non-healing chronic wounds harbour biofilms, with 
prevalence rates varying between 60% and 100%. We propose therefore, that biofilms are 
ubiquitous in nearly all non-healing chronic wounds and the disparity in prevalence rates 
maybe a reflection in study design and methodological limitations. For example, we argue that 
heterogeneous distribution of microorganisms within wounds may allow for variability in 
sampling, increasing the likelihood of returning negative or inconclusive samples.  
 
Three previous studies 13,39,40 have highlighted the heterogeneous spatial distribution of wound 
microbiota through sampling multiple areas of the wound bed, identifying vast shifts in 
community diversity. This suggests relying on a single site for sampling may reduce the 
chances of visualizing biofilm. Obtaining samples from multiple sites of the wound may 
improve the detection of biofilm. However, this is often not feasible at a clinical level and is 
reflected in many studies that employ tissue collection methods. 
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When combining the results of our systematic review and meta-analysis with the plethora of in 
vitro models and in vivo animal studies it seems highly likely that biofilms are ubiquitous in 
non-healing human chronic wounds. It is important therefore, that clinicians appreciate the 
distinct differences of biofilm phenotypes to their planktonic counterparts, the challenges in 
eradicating and removing biofilm from a wound. A paradigm shift to a biofilm based wound 
care approach should be adopted. 
 
2.3. SIGNIFICANCE OF MICROBIAL BIOFILMS IN CHRONIC WOUNDS 
2.3.1. CLINICAL SIGNS AND SYMPTOMS OF BIOFILMS IN CHRONIC WOUNDS 
 
Current methods to visualise biofilm from tissue samples have been confined primarily to use 
by researchers of high-powered microscopes (scanning electron microscopy – SEM) or in 
combination with molecular DNA sequencing techniques that utilise fluorescent probes to 
determine the presence or absence and location of bacteria (Confocal laser scanning 
microscopy - CLSM). Given then, biofilms are microscopic by nature; this has led to a 
grumbling argument over whether biofilms can be visually observed by clinicians.  
 
Under certain circumstances, biofilms when left to thrive may show evidence at a macroscopic 
level, with one example being oral plaque 134. The picture however is less clear for chronic 
wounds. Some clinicians have used rhetoric to promote what they believe are “clinical cues” 
of biofilm presence, through naked eye observations not based on scientific rigour 165-168. Such 
signs have included a shiny, translucent, slime layer on the non-healing wound surface, the 
presence of slough or fibrin, and gelatinous material that reforms quickly following removal in 
contrast to slough and other devitalised tissue, or fibrin that often takes longer to reform.  
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Assumptions to suggest biofilm involvement in non-healing chronic wounds or associated 
infection have used observations on the characteristics of disease progression. These have 
included contrasting symptomology, where acute infections instigated by planktonic 
microorganisms exhibit rapid onset symptoms. In contrast, biofilm related infections have been 
acknowledged for their lower acuity and longevity, often persisting with transient symptoms 
for months or even years 169.  
 
Observations of patients receiving oral antimicrobial therapy for biofilm-associated chronic 
infection have highlighted periods of quiescence, that alternate with acute exacerbations once 
antimicrobials are discontinued 170,171. Once antimicrobial therapy ceases, the biofilm serves as 
a nidus for recurrence of infection with acute exacerbations again manifesting 145. The transient 
suppression of microbial cells demonstrates the tolerance of biofilms to antimicrobials and 
standard treatment regimens. The suppression of infective symptoms may occur through 
bactericidal action against planktonic microbes shed from the biofilm, or action against the 
most superficial of biofilm cells 172. Failure to eradicate dormant microorganisms within the 
deeper stratum of biofilm, have also been suggested as a mechanism for reconstitution 172.  
 
Presently, there is no gold standard diagnostic test to define the presence of wound biofilm and 
there exist no quantifiable biomarkers. This may pose significant implications at a clinical 
level, where the inability to distinguish between planktonic or biofilm-based pathogenicity may 
lead to ineffective treatment. 
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2.3.2. HOW DO BIOFILMS IMPEDE WOUND HEALING? 
 
The exact mechanisms of biofilm impairment on the healing processes of wounds remain 
ambiguous. Existing data suggest a chronic wound is kept in either a severe inflammatory state, 
or subject to localized low oxygen tensions. The pathways behind this are not clear, but several 
systemic and local factors may contribute to the occurrence and maintenance of the wound 
chronicity. 
2.3.3. BIOFILMS MAY SUSTAIN HYPER-INFLAMMATION 
 
In a review article, Wolcott et al (2008) 144 present a detailed hypothesis summarising that once 
a biofilm community becomes established, their stubbornness and often failure to many 
treatments propagates hyper-inflammation. Specifically, they propose that a biofilm “hijacks 
the host immune response” through various general non-specific pathways to create a hyper-
inflammatory state within the chronic wound.  
 
Wolcott et al (2008) hypothesise that biofilm phenotype bacteria produce proteases that inhibit 
and destroy extracellular matrix. In addition, the chronic wound environment also possess host 
derived proteases. Together this may over-fill a chronic wound with a proteolytic mix of 
proteases, elastases and gelatinases (these are commonly referred to as matrix 
metalloproteinases - MMPs). In parallel, biofilm adherence to the wound bed may also 
potentially inhibit the release of the natural suppressor of MMPs – tissue inhibitors of MMPs 
(TIMPS). This scenario may therefore sustain a perpetual state of hyper-inflammation. 
Another mechanism to sustain a hyper-inflammatory state proposed by Wolcott et al (2008) is 
the manipulation of neutrophil function. The over-abundance of neutrophils within chronic 
wounds is well documented 173,174. A profound neutrophil response is both normal and required 
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for bacterial eradication following disruption to the skin barrier, however excessive neutrophils 
are detrimental to wound healing 173,174. Wolcott et al (2008) suggest neutrophils are over-
expressed through biofilm stimulation of IL-8, the chemo-attractant cytokine acting on 
neutrophils 175. No in vivo data on human chronic wounds exist to support this hypothesis.  
 
Wolcott et al (2008) also put forward the potential of biofilms to ‘bait’ the immune system 
through releasing planktonic microorganisms. Thus, biofilm survival is maintained through 
planktonic seeds released so they can bait the immune system through the PAMP recognition 
pathways, inducing an inflammatory response and nutrient pathway. The resulting exudate and 
its nutrients could then be utilised for biofilm growth. Wolcott et al (2008) also suggests an 
increased role for anaerobic microorganisms who may play a key role in biofilms sustaining a 
hyper-inflammatory host response, by releasing lipopolysaccharide, a potent inflammatory 
inducer. In an animal model on cystic fibrosis patients, biofilm forming P. aeruginosa were 
shown to undergo lipopolysaccharide modifications that induced greater inflammatory 
responses in mice 176. No human in vivo data exist to support this theory for chronic wounds. 
 
2.3.4. BIOFILMS MAY CONTRIBUTE TO LOCALIZED AREAS OF LOW OXYGEN 
TENSION WITHIN A WOUND. 
 
Early microelectrode studies of aerobic in vitro biofilm models found discrete areas within  
biofilm that had significant oxygen depletion 177. These suggested areas of biofilm, housed 
micro-niches favouring differing microorganisms, and may explain how the presence of 
anaerobes in mixed-species biofilms, exist, contribute and cooperate with aerobic neighbours.  
Further studies employing microelectrodes with CLSM have identified micro-domains with 
different biochemical environments including alterations in pH and oxygen 178. Recent data by 
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James et al (2016) 129 has provided further evidence to support a concept of a localized low 
oxygen tensions contributing to wound chronicity. Using oxygen microsensors and 
transcriptomics (examining microbial metabolic activities) to study in situ biofilms, James and 
colleagues identified steep oxygen gradients and induced oxygen-limitation stress responses 
from bacteria. James et al (2016) identified through transcriptomics, that inferred metabolic 
activities of the biofilm and the recruitment of cells that consume oxygen for host defensive 
processes, were the primary pathways of oxygen depletion. Taken collectively, this data 
supports the concept of a biofilm establishing and maintaining localized low oxygen tensions 
in a wound could potentially contribute to wound chronicity. 
 
2.3.5. THE EFFECT OF BIOFILMS ON THE HOST-MICROBE INTERACTION AND 
HOW THEY MAY IMPEDE WOUND HEALING. 
 
Data on the interactions of the host - biofilm phenotype have been primarily undertaken using 
single species biofilm models of S. aureus and P. aeruginosa. In vitro data presented by 
Tankersley et al (2014) 179, has revealed S. aureus biofilms may have a direct impact on human 
epithelial keratinocytes. The effects of S. aureus biofilms and planktonic S. aureus, on gene 
expression and up-regulation of inflammatory cytokines by human keratinocytes, were 
explored. S. aureus biofilm induced significant alterations in gene expression from human 
keratinocytes in comparison to planktonic S. aureus. Forty-two inflammatory associated genes 
were over-expressed, including IL-8, IL-6 and Nitric Oxide (p = .05). Keratinocytes have 
several key roles in wound healing, and the ability to induce numerous cellular pathways makes 
them important as both the first line of defence and in the re-epithelialization of wounds 180. If 
a biofilm can induce an effect to cause up-regulation of pro-inflammatory cytokines capable of 
degrading the extracellular matrix of wounds, this may directly impact re-epithelialisation 181. 
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Schierle et al (2009) 182 used an in vivo mouse model to examine S. aureus biofilm involvement 
in preventing wound healing. Full-thickness excisional punch wounds were made into six adult 
male C57B16/J mice and inoculated with S. aureus (strain CFS101), with six controls free from 
inoculation. Biofilm formation was determined post 3 days using microscopy and fluorescent 
stains. All six inoculated mice demonstrated gross evidence of biofilm formation. This 
correlated to a delay in re-epithelialization at day 9 of wounding, in comparison to control mice 
where all wounds healed (Epidermal gap: S. aureus = 2.4 vs. 0.5mm, p = 0.01).  
 
Gurjala et al (2011) 183 developed a novel in vivo animal model to assess the effects of S. aureus 
biofilms on wound healing. Full thickness dermal punch wounds on the back of New Zealand 
white rabbit’s ears, were inoculated with S. aureus (strain UAMS -1). Biofilm presence was 
confirmed using SEM and CLSM. Biopsy samples identified biofilm growth was associated 
with reduced granulation tissue formation and delayed epithelial migration.  
 
In a P. aeruginosa biofilm model, Zhao et al (2013) 184 inoculated five db/db mice with a 
biofilm producing wild type strain of P. aeruginosa (PAO1). Four mice were left un-inoculated 
as controls and monitored for 28 days. At day 28, PAO1 inoculated mice experienced a 
significant delay in wound healing with no mouse healing. In comparison, all the control mice 
had healed within the study time frame. Histological analysis showed extensive inflammatory 
cell infiltration, tissue necrosis and epidermal hyperplasia adjacent to challenged wounds- all 
indicators of an inflammatory non-healing wound. 
 
Fazli et al (2011) 161 analysed the cellular inflammatory response of tissue obtained from five 
CVLU samples with confirmed P. aeruginosa biofilm, and five CVLU samples containing 
confirmed S. aureus biofilm. Staining methods using haematoxylin and eosin revealed that 
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PMNs were abundant around biofilms but failed to infiltrate the EPS. In comparison to S. 
aureus biofilm samples, P. aeruginosa biofilms had significantly greater PMN accumulation 
(range 57-96 cells per image vs 18-50 cells per image, p < .0001). This may suggest that the 
presence of a P. aeruginosa biofilm can increase the cellular inflammatory response through 
in situ neutrophil accumulation. Alternatively, Jensen et al  (2006) 185 have identified the 
capability of P. aeruginosa biofilms to rapidly kill PMNs through the production of 
rhamnolipid.  Rhamnolipid, is regulated via quorum sensing communication and its production 
by the biofilm phenotype of P. aeruginosa may serve as a PMN protective force field. 
 
Marano et al (2015) 186 identified that migration and proliferation of human epidermal 
keratinocytes were decreased by derivatives from biofilms of P. aeruginosa and S. 
aureus.  Employing proteomic analysis, Marano et al (2015) mapped S. aureus activity to a 
protein, while P. aeruginosa activity was due to a small molecule. The several proteins 
revealed through proteomic analysis had putative links to delayed wound healing. These 
included alpha hemolysin, alcohol dehydrogenase, fructose-bisphosphate aldolase, lactate 
dehydrogenase and epidermal cell differentiation inhibitor. 
 
In vitro models and in vivo animal studies of both S. aureus and P. aeruginosa biofilms and 
their secretions, identify potential mechanisms of impeding wound healing. Data suggests that 
both microorganisms possess several complex and potential pathways for inducing wound 
chronicity. S. aureus in a biofilm mode of growth may play a role in altering the up-regulation 
of pro-inflammatory cytokines through human keratinocytes. Conversely, the sustained in situ 
necrosis by microbial cells could explain both the constant influx of PMNs into chronic wounds 
containing P. aeruginosa, in addition to the resulting localised releases of proteolytic enzymes 
that are pro-inflammatory 144.  
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Wolcott et al (2016) 187 undertook a study design in order to ascertain if microbiota removed 
from a chronic human wound could actively produce a new chronic wound in an animal model. 
In short, the authors attempted to prove Koch’s postulates and show that chronic wound 
microbiota is fully capable of propagating on new host tissues and is a cause of delayed healing. 
To prove this concept, Wolcott obtained wound bed material via debridement and transferred 
this onto wounded Swiss Webster mice. Three mice were used as controls. 16S rDNA 
sequencing was performed on sections of human wound debridement material to identify the 
residing microbiota. 
 
After four days, control mice failed to develop any measurable microbiota as identified through 
16S rDNA sequencing. In contrast, mice inoculated with human tissue developed clinical signs 
of wound chronicity. The symptoms included the development of excessive slough, exudate 
and slow progression of wound closure. 16S rDNA sequencing also revealed 93% of the 
measurable bacterial load identified identified in the mouse model were from the human tissue 
debridement samples. Furthermore, the wound microbiota was not significantly altered through 
the process of sampling, re-inoculation into a secondary host tissue, and final re-isolation.  
 
2.3.6. EXTRACELLULAR POLYMERIC SUBSTANCE (EPS) IS A THREE-
DIMENSIONAL FORCE FIELD THAT ENCLOSES SESSILE BACTERIA. 
 
Costerton and Irvin (1981) 188 first described a process by which bacterial cells produced a 
‘slime’ like substance they termed ‘glycocalyx’, and proposed it provided additional benefits 
to microorganisms in a sessile phenotype. The glycocalyx was defined as being a composition 
of polysaccharides that accounted for over 90% of a biofilm, with less than 10% being bacterial 
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in composition 124. The terminology of glycocalyx, was redefined in later years to extracellular 
polymeric substance (EPS) 189,190, as it became clear that bacterial glycocalyx were more than 
just polysaccharides. EPS were characterized as biopolymers, composed of proteins, nucleic 
acids, lipids and humic substances, enabling the immobilization and cohesion of bacterial cells 
in close proximity 124 (Figure 2.2). 
 
Figure 2.2 Scanning electron microscope of a diabetic foot ulcer identifies bacteria in 
aggregates (purple) with the production of EPS (white). 
 
 
 
The EPS or matrix represents the immediate environment for microbial cells in a biofilm 124,191, 
producing its own microenvironment by affecting porosity, density, water content, charge, and 
sorption properties. The exact function, structure and physiochemical interactions of EPS have 
not been fully depicted owing to the inherent difficulty in analysing EPS in situ 191. The 
diversity of residing microorganisms and environmental influences, likely contribute to the 
final architecture of the EPS, the quantity of EPS production, and its function 126,192. In some 
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ways, the term biofilm is a misnomer, as it conjures up thoughts of being a one-dimensional 
monolayer of slime. In stark contrast, a biofilm is a complex, heterogeneous three-dimensional 
structure containing dense pockets of bacterial micro-colonies (either monomicrobial or 
polymicrobial) 117,188,193-196. 
 
In vitro models utilizing CLSM with computational programs have depicted biofilm 
morphology and architecture 197. Certain biofilms present as flat structures, whilst some take 
on mushroom appearances containing channels to funnel nutrients, water and waste products 
177. For example, the most widely documented evidence for EPS production is based on in vitro 
mucoid strains of P. aeruginosa. Its production of alginate has profound impacts on biofilm 
architecture where it can induce a more heterogeneous structure when compared to non-mucoid 
strains that develop flat homogenous biofilms 198,199. In tandem, a down regulation of the 
flagellum of P. aeruginosa occurs, suggesting it halts mobility to become a productive biofilm 
stabiliser 200.  
 
Several functions of EPS have also been elucidated.  As a hydrated biopolymer, the EPS 
interacts with the environment. Through its sorption properties it can sequester substances from 
the surroundings, thus providing nutrients for microbial cells 201.  The EPS creates the ideal 
environment to allow for enhanced cell-cell communication and synergism 124. The benefits of 
microorganisms remaining in close proximity under biofilm conditions are ideal for promoting 
higher horizontal gene transfer 202. This creates a pantry of mobile genetic elements and 
plasmids that may promote stable social interactions, fitness and survival of usually more 
vulnerable microorganisms to environmental stresses 202,203. Perhaps the most discussed 
function of the EPS has been its role as protective shield against biocides, antimicrobials and 
the host immune response. This will be explored later in this chapter. 
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2.4. BIOFILM LIFE CYCLE: FROM ATTACHMENT TO DISPERSAL  
2.4.1.  BACTERIAL ADHESION 
 
The selectiveness of microorganisms in natural environments to attach to a surface or to each 
other (Figure 2.3) is so pervasive, that it advocates a strong selective advantage to those 
choosing a more sessile and social lifestyle 193,204. Microbial adhesion initiates when 
microorganisms move into close proximity of a surface (usually <1nm) 205. Attachment is 
governed by numerous variables that include, the composition of the surface, the environmental 
milieu, the bacterial species, available gene products, and communication of microorganisms 
via quorum sensing 205. In some environments, an intermediary step prior to primary adhesion 
may result surface conditioning. This process involves the alteration of a substrate, through 
physiochemical interactions to improve adhesion conditions 206,207. 
 
Figure 2.3 A tissue biopsy of a diabetic foot ulcer identifies bacterial cell-cell 
adhesion and cell-surface (collagen) attachment. 
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Adhesion of microorganisms to a surface is a sequential process initiated through primary 
adhesion. When a microorganism approaches a surface (or another microbe), a range of 
mechanical forces (including van der Waals, electrostatic, hydrodynamic and hydrophobic) 
and or specific molecular anchors aid adhesion (i.e. Adhesin, ligand, EPS) 208-210. Initially, 
microbial docking in primary adhesion is undertaken through a reversible bond allowing 
detachment should conditions be unfavourable 211. 
 
Examples of microbial anchors to aid adhesion include lipopolysaccharide (LPS) found on the 
outer membranes of Gram-negative bacteria 209. Gram-negative microorganisms with defects 
in LPS show reduced adhesion capabilities 212. Pilus or fimbri are hair-like nano-structures 
found on Gram-negative bacteria. Their involvement in adhesion and biofilm formation has 
identified type IV pili, hosting specific binding receptors to target molecules in human hosts 
213.  
 
Microbes also host a repertoire of adhesion molecules to target adhesion to human tissue or 
other abiotic surfaces, such as in-dwelling medical devices. S. epidermidis and S. aureus 
possess microbial surface components recognizing adhesive matrix molecules. These 
molecules bind to proteins such as fibrinogen, fibronectin or collagen 214. Additionally, 
Staphylococcus spp., have non-covalent bound surface proteins known as autolysins, that have 
strong affinities for both plastic surfaces and binding receptors of human tissue 215.  
 
The secondary phase of adhesion involves the permanent anchoring of microorganisms to a 
surface and is governed by global anchors such as EPS 208. During permanent attachment, 
planktonic microorganisms may preferentially seek microorganisms of the same species that 
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have already established themselves in a sessile lifestyle. Planktonic microorganisms may also 
seek to adhere to different species, where benefits of synergism maybe exploited. Data by 
Leung et al (1996) 216 identified the synergistic effects of both Gram-positive and Gram-
negative biofilm microorganisms on plastic stents, and found that colonisation of Escherichia 
coli facilitated the subsequent attachment of Enterococcus spp. Ultimately, the outcome of 
adhesion, whether to a surface or microbe to microbe, is the formation of aggregates and the 
promotion of differential gene expression for biofilm phenotype.  
 
2.4.2.  BIOFILM MATURATION; SHAPING THE MICROBIAL CITY. 
 
Once planktonic microorganisms alter their behaviour through attachment and micro-colony 
formation to progress into mature biofilms, the residing microorganisms, their interaction with 
one another, and environmental pressures largely control the maturation process 217. This social 
interaction between microorganisms is both an area that has divided researchers, and spawned 
an entirely unique area of research termed “sociomicrobiology” 218. The importance of bacterial 
cooperation versus competition is highly relevant to biofilm mode of growth. Changes to 
respiratory rate, oxygen consumption, motility and the synthesis of EPS, shape the living 
structure and composition of a biofilm 65.  
 
In mixed species biofilms, bacterial aggregation and microcolonies do not seem to form by 
random chance. Instead biofilms form communities with similar requirements and vested 
interests and settle in microenvironments where survival is possible through the power of 
cooperation 65,219-221.  Kreft (2004) 222 illustrated the concept of altruism in biofilms using 
computational modelling to identify fast growth – low yield strains or “selfish individuals” 
would often outcompete slow growth – high yield strains. When the model introduced single 
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cell lineage of sloth growth –high yield strains, the out-competing of “cheaters” was possible. 
Kreft (2004) concluded this was through the promotion of altruism, a fundamental requirement 
for biofilm formation. 
 
The specific mechanisms involved in social interaction and the molecular pathways on how 
microorganisms interact are referred to as cell-to-cell signalling, and in particular ‘quorum 
sensing - QS’. QS is a mechanism in which microbial cells communicate, by releasing small 
signal molecules that diffuse freely across the cell membrane 223. The QS system is based on 
cell density and requires a sufficient microbial population to produce an abundant 
concentration or ‘quorum’. When attained, a quorum of signalling molecules triggers 
differential gene expression and behavioural traits that only occur whilst growing within a 
social community 218,224.  
 
The increased synthesis of signalling molecules creates a positive feedback loop hence QS 
molecules have been termed autoinducers. Autoinducers are generally divided into three 
classes; the lux-type system in Gram-negative bacteria that utilise acyl-homoserine lactones 
(AHL) for species specific communication 225, autoinducing peptides (AIP) used by Gram- 
positive bacteria 226, and the luxS encoded autoinducer 2 (AI-2) enabling cross species 
communication between both Gram-negative and Gram-positive bacteria 227. 
 
Gram-negative bacteria produce a unique AHL or a unique combination of AHLs (if it 
possesses more than one LuxI-type protein). As a result, only members of the same species 
recognize and respond to it. P. aeruginosa is the most widely reported AHL producing bacteria, 
with several of its virulence traits controlled by AHL, including rhamnolipid up-regulation. 
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Additionally, several other aspects of biofilm life have been linked with the AHL-QS system 
of P. aeruginosa including biofilm diversity, architecture, resistance and dispersal 228-230. 
 
Gram-positive bacteria also use intercellular communication through the AIP mechanism. 
However, it is vastly more complex than its Gram-negative counterparts and requires greater 
depletion of energy resources 231. The most widely reported of these systems is S. aureus and 
its encoder, accessory gene regulator (agr). This QS molecule is responsible for the production 
of a wide array of virulence factors 232,233, and has been cited for its role in biofilm maturation 
234.  
 
The role however of QS systems in biofilm development has been predominantly examined 
under planktonic cultures 235-238. Data has indicated that QS modulates numerous microbial 
pathways, including the regulation of virulence factors, adhesion molecules 239 and swarming 
motility 235. Davies et al (1998) 229 were amongst the first to hypothesise that cell-cell signalling 
could be involved in P. aeruginosa biofilm maturation. Davis et al (1998) identified that a P. 
aeruginosa mutant strain lacking QS production had a significantly thinner EPS (20%) that 
was more vulnerable to biofilm disruption through the application of a detergent.  
 
Yarwood et al (2004) 234 studied the contribution of agr expression to biofilm development. 
Under certain conditions agr expression enhanced biofilm formation, conversely in other 
conditions agr expression had no effect on biofilm formation or seemed to impair biofilm 
growth. Tan et al (2015) identified that the absence of the agr function in methicillin sensitive 
S. aureus led to biofilms that were greater in density and more resistant to antibiotics 240. Vuong 
et al (2004) 241 studied S. epidermidis mutant strains defunct of agr production, and found the 
absence of agr promoted biofilm development of in-dwelling medical devices. This data 
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suggests the mechanisms involved in QS and biofilm formation in Gram-positive bacteria 
differ in complexity, operating through numerous pathways. The use of QS inhibitors as part 
of anti-biofilm strategies for Gram-positive microorganisms may  potentially promote biofilm 
formation 242. 
 
The above QS systems refer predominantly to species-specific communication. The auto-
inducer peptide (AI-2) has been described as a universal language allowing intra-species 
communication 227,243. MacNab et al (2003) 244 highlighted the potential of intra-species 
communication through their in vitro model on polystyrene surfaces. Two mutant strains of P. 
gingivalis and S. gordonii missing the Lux-S gene required for AI-2 synthesis were compared 
to wild strains with intact Lux-S synthesis. In the absence of AI-2 mixed biofilm formation 
was not possible, unlike wild type strain microorganism that formed mixed species biofilm.  
 
Despite the plethora of studies over the last three decades that have pursued the involvement 
of cell-to-cell signalling and its role in bacterial infections or biofilm formation, there has been 
little in the way of translational development of medicines, medical devices or other quorum 
sensing therapeutics that have made their way into commercial use for human health and 
disease. In fact, despite of the focus on QS, little is still known about its activity in human 
infections 245. 
 
2.4.3.  BIOFILM DISPERSAL: TO BOLDLY GO WHERE NO MICROORGANISM HAS 
GONE BEFORE 
 
Within the biofilm life-cycle there is a point when over-population, crowding, or a lack of 
nutrients occurs 246. There will also be microbes  who transit to and from a biofilm in an attempt 
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to explore and colonize new niches 247. The process of biofilm dispersion encapsulates the 
reversion from a sessile phenotype to a planktonic cell.  
 
Biofilm dispersal can occur through passive processes such as erosion, a physical sloughing 
event (i.e. tooth brushing) or fluid shear 117. Alternatively, biofilm dispersal may arise due to 
active mechanistic events triggered by the microbial biofilm themselves in response to 
environmental changes. These may include nutrient starvation, toxic by-products, 
pharmaceutical/medical device related treatments such as antimicrobial stress or unfavourable 
oxygen levels 121.  
 
Boyd and Chakrabarty (1994) 248 investigated the role of alginate lyase in cell dispersion in P. 
aeruginosa biofilms. The production of alginate lyase in a mutant strain resulted in the 
disruption of EPS and increased microbial dispersal. Allison et al (1998) 228 also identified the 
production of two-exopolysaccharide lyase enzymes that degrade P. fluorescens biofilm and 
thus promotes microbial.microbial dispersion. In S. epidermidis, Coulon et al (2012) 247 
identified a link between a reduction in nutrient availability and a reduced production of 
polysaccharide intercellular adhesion (PIA). PIA is an important component in cellular 
aggregation, and under nutrient starvation conditions, Coulon et al (2012) found that significant 
reductions in PIA were associated with rapid biofilm dispersal. 
 
2.4.4.  BIOFILM TOLERANCE  
 
Antimicrobial therapies based on the routine microbiology laboratories reporting of the 
bacterial species in question’s susceptibility to a disc diffusion test 249, target rapidly 
multiplying planktonic microorganisms with high efficacy. Unfortunately, when these 
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therapies are employed against biofilm phenotype microorganisms that differ markedly in both 
their physiology250 and activity 251, they typically fail to eradicate the problem (chronic 
infection). Indeed, a plethora of in vitro biofilm models have elucidated that bacterial biofilms 
can withstand antimicrobial concentrations 100 to 1000 times higher than that of planktonic 
counterparts 145,172,252-254. Both resistance 255,256 and tolerance 257-259 of biofilms have been 
reported synonymously in defining their ability to withstand much higher concentrations of 
antimicrobials (both topical, oral and intravenous), antiseptics and disinfectants, but they infer 
two very different mechanisms.  
 
Individual bacteria can promote resistance through mobile genetic elements such as plasmids 
or transposons allowing horizontal gene transfer 260, or by target mutations, modifying enzymes 
or efflux pumps 261. These familiar mechanisms by which individual planktonic 
microorganisms can resist the increased concentrations of antimicrobials do not seem to 
explain the enhanced protection afforded to bacteria in biofilm phenotype. Instead, an enhanced 
tolerance and ability of biofilms to survive concentrations 100 to 1000 greater then planktonic 
microorganisms have been directed towards mechanisms induced by their phenotypic state 262. 
In vitro data has identified that when biofilm microorganisms revert back to a planktonic state, 
their susceptibility to antimicrobials also increases 263,264. 
 
Despite the wealth of research undertaken to identify biofilm resistance and or tolerance to 
antimicrobials no single causative mechanism has been identified. Instead it has been suggested 
that a likely combination of factors contributes to biofilm tolerance 145,258,265. The protective 
mechanisms of biofilm microorganisms to many forms of chemical and biological attack have 
yielded several areas of interest including but not limited to; slow or incomplete permeation of 
antimicrobials through extracellular polymeric substance (EPS), altered microenvironment and 
 
 
 83 
niches within biofilms promoting slow growth rates and adaptive stress response, efflux pumps, 
and the role of “persisters”. 
 
2.4.4.1.  SLOW OR INCOMPLETE PERMEATION OF ANTIMICROBIALS THROUGH 
BIOFILMS 
 
One focus on the ability for biofilms to withstand significantly greater concentrations of 
antimicrobials has singled out the protective force field of the EPS. The process of permeation 
that acts synergistically with enzymatic deactivation and the polyionic nature of EPS. The 
available literature suggests that the type of antibiotic precipitates the ability to penetrate EPS, 
and it simply seems that some antibiotics have a greater ability to penetrate biofilms and act 
against their targets, in comparison to some antibiotics that encounter difficulties.  
 
In support of this, some researchers have explored the surface charge omitted by EPS as a 
mechanism that may lead to binding and/or deactivation of an antibiotic 172. Most studies have 
centred on P. aeruginosa, and its alginate polymer that produces a negative charge that can 
bind and sequester positively charged antibiotics such as gentamicin 266. Ciprofloxacin 
however, being uncharged, maybe less affected by alginate 267. The ability of the quinolones 
(ciprofloxacin, ofloxacin), lipopeptides (daptomycin) and polypeptides (colistin) to rapidly 
penetrate biofilm and kill microbial cells at therapeutic dose levels, demonstrates the ability of 
some antibiotics to be effective against medically relevant biofilms 172,253,257,268. 
 
Anderl et al (2000) 267 tested the penetration of ampicillin against a β-lactamase-positive K. 
pneumonaie wild type strain in vitro, revealing ampicillin deactivated quicker than it could 
diffuse through the EPS. Similarly, this has been identified in aminoglycoside antibiotics tested 
on β-lactamase-positive P. aeruginosa biofilms in vitro 269. Additional data provided from 
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Singh et al (2010) 270 on S. aureus and S. epidermidis biofilms, have further identified reduced 
penetration of oxacillin, cefotaxime (β-lactams) and vancomycin (a glycopeptide) through in 
vitro biofilm models. Taken collectively, it seems negatively charged polymers of both K. 
pneumonaie and P. aeruginosa are effective in protecting microbial cells from positively 
charged agents through limiting their diffusion via binding 271. 
 
2.4.4.2.  ALTERED MICROENVIRONMENT AND NICHES WITHIN BIOFILMS 
 
Advancements in technologies and techniques applicable to the study of in vitro biofilms in 
situ have allowed researchers to explore the interior of biofilms identifying niche areas of 
oxygen and nutrient depletion and altered pH levels. Microelectrode analysis of biofilm 
structures have identified that oxygen is depleted at the substratum layers of biofilms and in 
the centre of microcolonies 129,172,272.  Utilising methods such as microinjection of fluorescent 
dyes and quantitative analysis using confocal laser microscopy, de Beer et al (1994) explored 
local diffusion gradients developed in biofilms, identifying anoxic and acidic zones in the 
interior of biofilms 177.  
These varied microenvironments can contribute to both nutrient limitations that promote 
limited stationary-phase physiology 273 and or effects to antimicrobial action. Antimicrobials 
are predominantly effective against rapidly growing microbial cells with some antibiotics such 
as penicillin and ampicillin requiring an absolute condition of microbial growth 258. Walters et 
al (2003) 172 exemplified this when they tested the effects of tobramycin and ciprofloxacin 
against P. aeruginosa biofilms in vitro. Both antibiotics penetrated the biofilm but failed to 
effectively kill the bacteria, with antibiotic-affected cells being located exclusively near the air 
interface where most metabolically active cells are located. Altered metabolism and a reduced 
drug efficacy promoted by environmental niches and stresses therefore, undoubtedly contribute 
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to biofilm tolerance. Newer generation antibiotics such as daptomyocin and colistin can kill 
non-dividing biofilm cells as shown in vitro 253,274.  
 
2.4.4.3.  EFFLUX PUMPS 
 
Efflux pumps expressed by planktonic microorganisms remove toxic substances such as 
antimicrobials, and their actions and roles in Gram-negative bacteria multi drug resistance are 
well documented 275 . Presently, little is known about the phenotypic changes that occur during 
the transition from the planktonic to the biofilm mode of growth but the role of efflux pumps 
in biofilm tolerance to antimicrobials has emerged as an area of interest.  Whilst limited, current 
evidence indicates that efflux pumps are highly active in bacterial biofilms, making them 
attractive targets for potential anti-biofilm measures 276,277.  
  
 
2.4.4.4.  PERSISTER CELLS IN MICROBIAL BIOFILMS. AN ANSWER TO THE RIDDLE 
OF BIOFILM TOLERANCE? 
 
Biofilm show enhanced tolerance to many forms of antimicrobials, antiseptics and 
disinfectants, as outlined by their ability to withstand 100 – 1000 times the minimum lethal 
dose. This would suggest that biofilm cells harbour the capability to switch on multidrug 
resistance mechanisms that they only express during biofilm growth. If this were true, then 
mutants expressing the same resistance would have been seen in rapidly multiplying planktonic 
cultures. This has not been the case, and has therefore led to the riddle of how a biofilm can be 
resistant to killing by many antimicrobials in the absence of specific resistance mechanisms 
278. 
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An answer to this riddle has been proposed in the form of “persister” cells. Brooun et al (2000) 
257 discussed the role of persister cells when they explored the dose-response of P. aeruginosa 
biofilms in vitro to ofloxacin and ciprofloxacin. Following exposure, a 3-log10 to 4-log10 
reduction of bulk biofilm cells was achievable through therapeutic levels. However, following 
this initial log reduction, further increasing concentrations of antimicrobials were ineffective 
at eradicating surviving microbial cells.  
 
From this simple observation of seemingly “invulnerable” cells, Lewis et al (2001) presented 
a rationale for persisters being responsible for biofilm tolerance to antimicrobials 257. There are 
now numerous review articles that have outlined a rationale to further support the role of 
persisters in biofilm tolerance 145,258,265,278, and a few commonalities from across the literature 
is discussed below.  
 
Initially identified in rapidly growing planktonic populations 279, and later in microbial biofilms 
257,280, persister cells seem to exist as phenotypic variants of normal cells within a population 
and not as mutants. In fact, experiments have shown that perister populations when re-
inoculated, produce a bulk of sensitive cells in addition to new tolerant cells 279-281. While 
persisters are not unique to biofilms, the mere fact that biofilms are significantly more tolerant 
then planktonic microorganisms suggest that biofilms may produce more persisters 281-283. 
Evidence to support this hypothesis is presented by data showing that persister formation is 
growth dependent and inversely related to metabolic activity 259. Given that key elements to 
biofilm life are slow growth and reduced metabolic profiles, it seems plausible that biofilms 
promote persister formation.  
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One of the conundrums of biofilm resistance has been the inability to explain how biofilms are 
tolerant to treatments but lack specific multidrug resistance mechanisms. If persisters do not 
confer conventional multi drug resistance afforded to planktonic microorganisms, how do they 
potentially resist treatment? One explanation has been that persister cells decrease their 
metabolic profiles and enter a dormant state, thus reducing functional targets for the action of 
cidal antimicrobials 284. In this respect, persister cells interfere with the lethal action of cidal 
antimicrobials by shutting down their target functions such as peptidoglycan synthesis 281, 
ribosomal synthesis and DNA replication 278. Evidence supporting this has emerged from 
studies of E. coli where researchers have identified the toxin/antitoxin module hip A gene could 
shut down cellular functions in persister cells 281. 
 
The role of peristers in biofilm tolerance to antimicrobials are still poorly defined. Their 
contribution to the recalcitrance of biofilms to treatment however, may explain in part a 
common clinical symptom noted in chronic biofilm-associated infections, relapse of infection. 
The use of antimicrobials against microorganisms will reduce the bulk of cells in the population 
or eradicate them completely. In acute infections caused by planktonic microorganisms, any 
remaining persisters are likely to be exposed to the host immune system, which “mop up” the 
remaining persisters.  
 
Herein lies a problem for the host challenged by biofilm and compounded in those patients 
who are immunocompromised. The use of antimicrobials may desiccate the bulk of biofilm 
and planktonic cells. Clinically, this may be represented by improvements in visual symptoms 
of infection. Following the discontinuation of antimicrobial therapy, the remaining persisters 
sheltered from the host immune response through the EPS reform the biofilm that acts as a 
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nidus for shedding planktonic microorganisms, and an acute infective flair may ensue 
156,258,278,285. 
2.5. ANTIMICROBIALS AND OTHER AGENTS USED IN WOUNDCARE AS 
ANTI-BIOFILM STRATEGIES 
 
Topical antimicrobials or antiseptic wound dressings are commonly used by clinicians to target 
biofilms associated with chronic non-healing wounds. The use of topical antimicrobial or 
antiseptic solutions to decontaminate wounds has been around for millennia, but the use of 
such agents with specific context to managing wound biofilm has increased significantly in 
recent years. This has largely been, in part, due to the marketing campaigns of many companies 
who have claimed their topical solution has anti-biofilm properties. The action and 
effectiveness of agents as bactericidal or bacteriostatic agents in targeting biofilm-phenotype 
bacteria are based solely on in vitro and animal models. To the best of our knowledge, this 
thesis is the first to perform an in vivo human wound study that explores the effects of 
antimicrobial agents against wound biofilm, and explore effectiveness using 16S rDNA 
sequencing and microscopy methods. 
 
When critiquing the evidence to substantiate anti-biofilm claims, there are large gaps in the 
available literature. This is discussed in in section 2.6 and Chapter 7. There is limited in vitro 
and in vivo evidence (using standardized biofilm models) of the performance of antimicrobial 
solutions marketed and used for the sole purpose of wound-care agents. More traditional 
antiseptics such as Chlorhexidine and Povidone Iodine, though, have been tested against a 
multitude of human and animal wound related biofilms 286-288 and oral biofilms 289-291. This 
data has reported that both antiseptics are effective in vitro and in animal models and will only 
be discussed further where directly applicable to wound-care related usage.  
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2.5.1 TOPICAL ANTIMICROBIAL DRESSINGS / AGENTS 
 
Ionic silver has been widely studied as a topical antimicrobial treatment used by clinicians to 
cater for a wide array of wound aetiologies complicated by high levels of planktonic 
microorganisms. The emergence of biofilms as a concept in delayed wound healing and as 
contributors to infection has seen a concomitant application to studying the effects of ionic 
silver on biofilm phenotypes. Early reports for the use of ionic silver in S. epidermidis biofilms 
suggested that low concentrations of silver ions were unable to eradicate mature biofilms (0.05 
ppm of silver) 292.   
 
Bjarnsholt et al (2007) 293 tested the performance of multiple ionic silver dressings against 
four-day-old P. aeruginosa biofilms in vitro.  Biofilms were exposed to 10 ppm of silver 
sulfadiazine and complete eradication at this concentration was noted. Following this, exposure 
of biofilm to three commonly used ionic silver wound dressings (varying degrees of ionic silver 
concentration - a. 0.033 ppm, b. 2.2 ppm, c. 0.93 ppm) found no effect on biofilm disruption. 
Non-healing chronic wounds may often create excessive exudate (both primarily linked to 
biofilms and or due to other systemic factors) that contain chloride ions. These are known to 
inactivate ionic silver through forming insoluble compounds of silver chloride 294. For this 
reason, Bjarnsholt et al (2007) concluded that both higher concentrations of ionic silver and 
the mode of delivery were important factors in wound dressings likely to affect biofilm.  
 
Percival et al (2008) 295 used a sustained release ionic silver dressing (AQUACEL® Ag, 
Convatec inc, US) containing 1 ppm to assess the in vitro effects against biofilms of P. 
aeruginosa, S. aureus, E. cloacae and a mixed species biofilm. A 24-hour biofilm model was 
subjected to the sustained release silver dressing and LIVE/DEAD staining was used to confirm 
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the presence of live or dead cells. Within 24 to 48 hours’ post application to all biofilm models, 
a 90% and 100% kill rate of sessile bacteria were noted. A major limitation of this study was 
the absence of incorporating any nutritional or media flow in the biofilm model to mimic 
wound exudate. The absence of media would create a bias environment by restricting exposure 
of ionic silver to chloride binding allowing higher concentrations of ionic silver then those 
expected in a wound.  
 
Hill et al (2010) 294 tested the effectiveness of various topical antimicrobial wound dressings 
in vitro on mature S. aureus and P. aeruginosa biofilms in a constant depth film fermenter. 
This methodology attempted to replicate the presence of exudate in chronic wounds by partially 
soaking the dressings in a controlled amount of protein rich media. This media was replaced 
daily for up to seven-days and the authors proposed this was a more accurate reflection of a 
real wound environment. In total, six silver dressings were tested on mixed species biofilms 
and the results indicated that exposure to the silver dressings over three and seven-days had no 
effects on biofilm disruption. Hill et al (2010) concluded that protein rich media likely reduced 
the bioavailability of ionic silver. In the same experiment, Hill et al (2010), tested Iodine based 
products (PVP-I, Acelity and Cadexomer Iodine®, Smith and Nephew). In contrast to the poor 
results noted against silver wound dressings, both Iodine based antimicrobials eradicated S. 
aureus and P. aeruginosa biofilms at three and seven-days exposure. 
 
Kostenko et al (2010) 296 tested the performance of five different silver dressings over a seven-
day period against bacterial biofilms of P. aeruginosa, MRSA and E. coli. Additionally, the 
silver dressings and bacterial biofilms were transferred into fresh media daily to represent a 
continual exposure to fresh wound exudate. The results identified all the silver dressings were 
unable to decrease the number of sessile cells within a 24-hour period (p < .05). Nanocrystalline 
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silver yielded the greatest log reductions (4 log10 - 5 log10) and maintained the reduction over 
the seven-day period. The remaining silver dressings also reduced sessile cell numbers over 
the first 24-hours (2 log10 - 3.5 log10), but after 24 hours their actions rapidly deteriorated and 
biofilm re-growth was observed.  
 
Phillips et al (2015) 297 used an ex vivo porcine skin explant model on mature three-day P. 
aeruginosa PA01 biofilms, to test multiple topical antimicrobial agents commonly used in 
woundcare; Cadexomer Iodine, PVP-I,  silver, PHMB, honey and alginates. Dressings were 
exposed for 24 and 72-hour continuous exposure and the bacterial cell viability was determined 
using cfu. Only Cadexomer Iodine could fully eradicate P. aeruginosa PA01 biofilms at both 
24 and 72-hours exposure. Nanocrystalline silver dressings could reduce cfu by >2 log10 at 24 
and 72-hours, but all other dressings were unable to achieve a log reduction >1 log10. 
 
Fitzgerald et al (2017) 298 evaluated the performance of Cadexomer Iodine, Povidone Iodine, 
ionic silver and PHMB against 48- hour S. aureus and P. aeruginosa biofilms in a multi 
experimental design incorporating; an in vitro colony biofilm model, colony drip-flow biofilm 
model, MRSA colony wound biofilm model and a mouse wound biofilm model. Bacterial cell 
viability was determined by cfu. 24-hours exposure to Cadexomer Iodine resulted in full 
eradication of S. aureus and P. aeruginosa biofilms in the colony biofilm model. In 
comparison, other dressings were only able to achieve <2 log10 reduction.  
 
In the colony drip-flow biofilm model, exposure of Cadexomer Iodine for 24-hours resulted in 
a >5 log10 reduction against both S. aureus and P. aeruginosa biofilms, whilst the other 
dressings were not able to achieve >0.7 log10 reductions. Similarly, in the MRSA colony wound 
biofilm model Cadexomer Iodine achieved >7 log10 reductions in comparison to other 
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dressings who could not achieve >1 log10 reductions. Lastly, in a mouse MRSA wound biofilm 
model the application of Cadexomer Iodine for a 48-hour exposure resulted in >4 log10 
reduction in comparison to other treatments (0.7 - 1.6 log10 reduction).  
 
Hoekstra et al (2017) 299 evaluated the performance of 10% PVP-I ointment (at concentrations 
3.3%, 10% and 33% and 100%) and silver nanocrystalline in a CDC biofilm reactor against 
48-hour mixed biofilms of P. aeruginosa and mixed biofilms of MRSA and C albicans. 
Following exposure of the agents to P. aeruginosa biofilms for 24-hours, bacterial cell viability 
(cfu/mL) identified that 10% PVP-I (all concentrations) eradicated biofilms (>5 log10 
reduction), whereas silver nanocrystalline reduced biofilms by 2 log10. Against mixed species 
biofilms, 24-hour exposures both 10% PVP-I (100% concentration) and silver nanocrystalline 
resulted in full eradication of biofilms (>5 log10 reduction). 10% PVP-I tested at reduced 
concentrations (3.3% and 33%) identified variable results against mixed species biofilms only 
achieving a <2 log10 reduction. One of the major strengths of the study were to test PVP-I at 
differing concentrations to account for the presence of wound fluid. This is because the effects 
of wound fluid cause dilution or they inactivate agents.  
 
Using a colony drip-flow biofilm reactor, Bourdillion et al (2017) 300 evaluated the 
performance of ionic silver dressings, nanocrystalline silver dressings and Cadexomer Iodine, 
against 24 and 72-hour P. aeruginosa biofilms. Against 24-hour biofilms PROMOGRAN 
PRISMA™ (oxidised regenerative cellulose with 0.02 ppm of silver) and ionic silver reduced 
P. aeruginosa biofilms by 0.2 log10, but Cadexomer Iodine was not tested. After 72-hour 
PROMOGRAN PRISMA™ performed better than all the other dressings by reducing 24-hour 
P. aeruginosa biofilms by 1.49 log10 (p = 0.01), whilst Cadexomer Iodine were only able to 
reduce P. aeruginosa biofilms by 0.8 log10.  These results are surprising given the previous 
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evidence for the performance of Cadexomer Iodine against mature biofilms both in vitro and 
in animal models. Furthermore, PROMOGRAN PRISMA™ contains only 0.02 ppm of silver, 
the lowest concentration of silver bioavailability in any wound product, yet it could achieve 
log reductions greater than wound dressings containing 100 – 1000 times the silver 
concentrations and perform better then Cadexomer Iodine.  
 
Given the results conflict with many other published data, the authors fail to discuss the 
relevance of their findings in the relation to past data. No attempts were made to discuss or 
explain the poor performance of Cadexomer Iodine and why this contrasts with many other in 
vitro and animal data. The authors also fail to explain the results of log reductions in an 
appropriate context to what is an effective log reduction for an in vitro test yet make the claim 
that PROMOGRAN PRISMA™ was the only dressing to significantly reduce biofilm 
populations.  
 
However, when interpreting these results, the starting amount of 24-hour P. aeruginosa 
biofilms pre-treatment were 6.73 log10 and post-treatment following PROMOGRAN 
PRISMA™ was 6.47 log10. This is only a 0.2 log10 reduction which indicates a poor effect. 
The performance of PROMOGRAN PRISMA™ against 72-hour P. aeruginosa biofilms 
identified a 1.49 log10 reduction from a starting amount of 9.30 log10, therefore leaving 7.5 
log10 of biofilm bacteria. In this context, the performance of PROMOGRAN PRISMA™ 
remains poor. 
2.5.2 TOPICAL ANTIMICROBIAL / ANTISEPTIC SOLUTIONS USED IN WOUNDCARE 
 
Of the available in vitro data on topical antimicrobial solutions, Sauer et al (2009) 301 present 
a study testing the performance of super-oxidised solution (Microdacyn™) using a continuous 
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flow tube reactor on mature six-day P. aeruginosa PA01. Super-oxidised solution of varying 
concentrations of the active ingredient hypochlorous acid/sodium hypochlorite (80 ppm, 125 
ppm, 200ppm), were tested under flow against P. aeruginosa PA01 biofilms. Outcome 
measures for bacterial cell viability were cfu and LIVE/DEAD stain reported at 5-minute 
intervals for up to 60 minutes’ total exposure. The highest concentration of SOS (200 ppm) 
used for a 60-minute exposure resulted in > 3 log10 reduction in cfu and a 12.7-fold reduction 
in biomass.  
 
The above findings on the performance of SOS would seem to suggest its effectiveness in vitro 
against P. aeruginosa PA01 biofilms, and the evidence from this paper is used for promotion 
by a medical device company manufacturing SOS. The problem with the above results, 
however, is that they lack clinical relevance and applicability for use in wounds. Firstly, the 
tube flow reactor is an experimental model designed to look at either disinfection of hospital-
based equipment and or catheter-based biofilm models. Secondly, the outcomes reported for 
60 minutes do not reflect a clinically relevant time for the use in wound-care, of which a typical 
exposure time would last for a maximum of 15 minutes (as promoted for intended usage by 
medical device companies).  
 
When the data is re-analysed at these clinically relevant exposure times, a different story begins 
to appear. The performance of SOS (200 ppm) at 10-minute and 15-minute exposure is 0.65 
log10 and 1 log10 respectively, which is significantly less than the >3 log10 observed at 60-
minute exposure time. Thirdly, the concentration which exhibited the greatest effects of SOS 
was 200ppm, and this represents the industrial strength used for disinfection purposes. The 
concentration of SOS used in wound solutions is 65-80 ppm, a concentration for which no data 
are available. 
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Davis et al (2017) 302 tested the effectiveness of three topical antimicrobial wound solutions 
(Polyhexamethylene biguanide, PHMB - Prontosan, 60 ppm hypochlorous acid/sodium 
hypochlorite – Microdaycn, Octenilin dihydrochloride - Octenilin) against immature 24-
hour MRSA (ATCC 33593) biofilms in a porcine wound model. Each porcine wound was 
irrigated twice daily for six days’ total with the antimicrobial solutions, and bacterial cell 
viability was determined by cfu/g on days three and six from baseline initial biofilms counts 
of 7.42 log10 cfu/g. 
 
 Treatment with PHMB reduced biofilms by 1.67 log10 at day three and 3.08 log10 reduction 
at day six. Treatment with Octenilin reduced biofilms by 0.76 log10 at day three and 2.56 
log10 at day six. Treatment with hypochlorous acid/sodium hypochlorite increased the cfu/g 
after three days of treatment by 0.24 log10 (pre-treatment = 7.42 log10 cfu/g vs post-treatment 
3 days = 7.66 log10 cfu/g), but after six days of treatment a reduction of 0.67 log10 was noted. 
The authors conclude that PHMB performed better and was superior to other antimicrobial 
wound solutions for use against wound biofilm. While this statement attempts to paint a 
positive light for specific antimicrobial solutions, the performance in reducing biofilms is 
questionable. None of the solutions could achieve >3 log10 reduction against immature 
biofilms of 24 hours following treatments of up to six days. However, the results are not 
surprising given the extremely short exposure times of the solutions which were used as 
irrigations (exposure of seconds) as this exposure time is likely inadequate 303. 
 
2.5.3 OTHER MEDICAL DEVICES USED FOR WOUND BIOFILM TREATMENT 
 Negative pressure wound therapy (NPWT) is utilised by clinicians to improve wound healing 
in several clinical pathologies. In the diabetic foot, it is commonly employed post-operatively 
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to augment debridement or surgical procedures by enhancing angiogenesis and granulation 
tissue formation 304, but may also be employed for use in chronic wounds to promote wound 
healing 305. As its title suggests, its primary mode of action is providing a topical negative 
pressure to the wound interface via a special dressing system consisting of a permeable foam 
(some foams dressings can have impregnated silver) and tube system which encloses and seals 
the wound. Ngo et al (2012) 306 hypothesised that the action of NPWT would likely lead to an 
alteration to biofilm architecture. 
  
P. aeruginosa (ATCC 25619) biofilms were grown under shear in a CDC biofilm reactor on 
polycarbonate discs for 24-hours and then transported to an in vitro wound model.  The wound 
model incorporated bacteriological agar to mimic a wound surface allowing the biofilm-
containing polycarbonate discs to embed. A nutrient in-flow system provided continuous flow 
of 1% TSB and the polycarbonate discs were sealed with 1) control no NPWT, 2) NPWT with 
foam and 3) NPWT with silver impregnated foam. Outcomes measures were assessed at day 
one application and day seven using cfu and LIVE/DEAD stain with CLSM to determine 
bacterial cell viability, average biofilm thickness and average and maximal diffusion distances.  
 
Following a seven-day application of topical negative pressure, there was no significant 
reduction in cfu between control and those receiving topical negative pressure with foam 
(control = 1.18 x 107 vs NPWT and foam = 1.19 x 107). NPWT with foam, however, altered 
biofilm characteristics, decreasing the average thickness of biofilms, and the average and 
maximal diffusion distances (p = 0.001). When biofilm coupons were challenged with NPWT 
and silver foam, there was a significant reduction in viable bacteria in one day by 3 log10 and 
by day seven no viable bacteria were present (p = .002). The authors suggest the alteration to 
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biofilm architecture by topical negative pressure provides an enhanced synergy with topical 
silver to provide a greater effect against P. aeruginosa biofilms. 
 
Phillips et al (2013) 307 used an ex vivo porcine skin explant model to test the performance of 
antimicrobial solutions under negative pressure wound therapy with instillation (NPWTi) 
against mature P. aeruginosa PA01 biofilms. NPWTi was applied for six cycles over 24-hours 
with each 4-hour cycle consisting of 30 seconds of instillation followed by ten minutes of dwell 
and four hours of continuous negative pressure at 125 mm Hg. The solutions tested were 1% 
PVP-I, 10% PVP-I, PHMB and chlorhexidine gluconate, and these were compared to untreated 
coupons and coupons receiving NPWT alone. Control coupons bacterial loads were 7 log10 
with NPWT alone reducing bacterial load <1 log10. Instillation with 10% PVP-I resulted in 
the largest reductions to bacterial loads (5 log10), followed by PHMB (4 log10), chlorhexidine 
gluconate (3 log10) and 1% PVP-I (2 log10). This data provides support to the concept raised 
by Ngo et al (2012), suggesting that the effects of NPWT to biofilm architecture in vitro may 
also occur when employed against tissue (in the form of porcine skin). To date, no trials in vivo 
on human subjects have been undertaken to evaluate the potential synergy gained from NPWT. 
 
2.5.4 WOUND DEBRIDEMENT 
 
Wound debridement using a scalpel blade or curettage has long been regarded as the gold 
standard practice for managing chronic DFUs without ischemia by removal of devitalised 
tissue and thus bacteria 308. A single report on sharp debridement has identified positive effects 
on mature biofilm 309. Findings from this clinical case series on three chronic VLUs 
complicated by P. aeruginosa biofilms, identified sharp debridement resulted in a 4 log10 
reduction in biofilm bacteria, but biofilms reconstituted within 24 hours. Interestingly at 24 
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hours’ post debridement, biofilm susceptibility to gentamicin increased. A nine-fold reduction 
in antibiotic concentration was required to induce biofilm disruption in comparison to a control 
biofilm. Correlating this finding clinically, explains the potential mechanism of sharp 
debridement to physically disrupt and remove parts of a biofilm, forcing it to reconstitute itself 
with younger cells that are more susceptible to antimicrobial attack. The authors proclaim that 
debridement opens a therapeutic window when antimicrobial treatments may be more 
successful.  
 
In some patients in whom sharp debridement is not possible (i.e. wound ischemia, wound pain), 
treatments are often augmented with agents that are chemical or biological and that can aid in 
providing autolytic debridement. Yang et al (2017) 310 explored the effectiveness of a surfactant 
based poloxamer gel (autolytic debriding agent) in reducing mature P. aeruginosa PA01 
biofilms in an ex vivo porcine skin explant model. The gel was placed on wounds daily and 
gently wiped and re-applied to mimic what would occur at a dressing change. Following three 
days of treatment observed bacterial cell viability (cfu counts) identified a total 
reduction/eradication of P. aeruginosa PA01 biofilms (p = .02). 
 
 
Wilkinson et al (2015) 311 tested the effectiveness of two mechanical polymer fiber debriding 
devices (Debrimitt™ and Debrisoft™) against mature P. aeruginosa and S. aureus biofilms in 
a porcine skin explant model. Mechanical debridement using Polymer fiber pads were 
compared against sterile gauze using a mechanical brush simulator to control; levels of force, 
direction of debridement, duration of debridement.  Biofilm removal was determined using a 
surface viability assay, bacterial counts (CFU), histological assessment, and scanning electron 
microscopy (SEM). 
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The results identified that the polymer fibre pads significantly reduced viable P. aeruginosa 
biofilm surface coverage compared to control biofilms that underwent no debridement 
(Debrimitt™ p = .003 and Debrisoft™ p = .001). No significant difference was found between 
the gauze dressing and control P. aeruginosa biofilms. Post-debridement on S. aureus noted a 
reduction in the biofilm surface coverage but this was not statistically significant.  
 
Bacterial viability counts (CFU) against P. aeruginosa biofilms identified that both 
Debrimitt™ and Debrisoft™ treatment appeared effective, resulting in a 6 log10 reduction (p 
< 0.001), and 5 log10 reduction (p < .001) respectively.  S. aureus viability was also 
significantly reduced (7 log10 reduction, p < .001) following debridement with both Polymer 
fibre pads. By contrast, treatment with a gauze dressing led to a 5 log10 reduction in S. aureus 
(p < .001).  
 
Both SEM and confocal microscopy further identified that treatment with Polymer fiber pads 
significantly altered biofilm architecture of both P. aeruginosa and S. aureus biofilms, but 
sterile gauze did not.  In particular, a substantial proportion of the bacteria and EPS were 
removed using Polymer fibre pads. Using a porcine skin explant model, the data suggest that 
Polymer fibre pads help remove both EPS and wound bacteria, thus reduce viable biofilms of 
S. aureus and P. aeruginosa from porcine tissue. The positive results noted here warrant further 
exploration from in vivo human trial. This would significantly enhance the clinical care of 
many patients with chronic non-healing wounds, because many woundcare clinicians are 
unable to perform sharp debridement (either through lack of competency or due to professional 
constraints) 11.  
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Abstract  
We used 16S rDNA next generation sequencing to profile the microbiota of infected Diabetic 
Foot Ulcers (DFUs). The microbiome was correlated to clinical parameters and treatment 
outcomes to determine if directed antimicrobial therapy based on conventional microbiological 
cultures are relevant based on genomic analysis. Patients ≥18 years presenting with a new 
Diabetic Foot Infection (DFI) who had not received topical or oral antimicrobials in the two 
weeks prior to presentation, were eligible for enrolment. Tissue punch biopsies were obtained 
from infected DFUs for analysis.  
 
Demographics, clinical and laboratory data were collected and correlated against microbiome 
data. Thirty-nine patients with infected DFUs were recruited over twelve-months. Shorter 
duration DFUs (<six weeks) all had one dominant bacterial species (n = 5 of 5, 100%, p < 
⋅001), S. aureus in three cases and S. agalactiae in two. Longer duration DFUs (≥six weeks) 
were diversely polymicrobial (p = ⋅01) with an average of 63 (range 19-125) bacterial species. 
Severe DFIs had complex microbiotas and were distinctly dissimilar to less severe infections 
(p = ⋅02), characterised by the presence of low frequency microorganisms.  
 
Nineteen patients (49%) during the study period experienced antimicrobial treatment failure, 
but no overall differences existed in the microbiota of patients who failed therapy and those 
who experienced treatment success (p = .2). Our results confirm that short DFUs have a simpler 
microbiota consisting of pyogenic cocci but chronic DFUs have a highly polymicrobial 
microbiota. The duration of a DFU may be useful as a guide to directing antimicrobial therapy. 
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3.1.1. INTRODUCTION 
 
In a person with diabetes a “triad” of factors that include peripheral neuropathy, peripheral 
vascular disease and trauma 2, place the foot at risk of developing a wound. Infections of the 
feet in people with diabetes are the primary pathway to lower extremity amputation 3. 
Management of diabetic foot infection (DFI) is underpinned by the requirement to identify the 
pathogen/s of infection and thus direct antimicrobial therapy. Laboratory based methods that 
are culture-dependent are commonly utilised to identify microorganisms that are potential 
pathogens of infection, in addition to examining their density through qualitative and 
quantitative measures. This has shown acute ulcers are usually colonised by S. aureus and/or 
S. agalactiae, and chronic ulcers have a more diverse microbiota, with anaerobic organisms 
and P. aeruginosa becoming more important 25. Culture-dependent techniques select for 
species that flourish under the typical conditions of the diagnostic microbiology laboratory, 
and this may not necessarily reflect the most abundant or clinically important microorganisms 
in DFIs especially anaerobes and species not detected under standard clinical microbiology 
laboratory protocols 312. 
 
Molecular DNA based techniques that are culture-independent have identified the limitations 
of methods when examining the microbiota of wounds. Using amplification and sequence 
analysis of 16s rDNA, a highly-conserved gene present in all prokaryotes (bacteria) but not 
eukaryotes (humans), has revealed a vastly more complex array of bacterial communities in 
non-infected chronic wounds 90. No data exists for acutely infected DFUs using this 
methodology. 
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We explored the microbiota of infected DFUs using 16S rDNA next generation sequencing. 
Data is presented on the microbial diversity, community structure, bacterial load and presence 
of likely pathogens from diabetic foot infections. Molecular findings are correlated against 
clinical factors and treatment outcomes. 
 
3.1.2. MATERIALS AND METHODS  
 
Patients, samples and ethics 
Individuals presenting to a tertiary referral hospital (Liverpool Hospital High Risk Foot Service 
and Liverpool Hospital Emergency Department) with a newly infected diabetic foot ulcer 
occurring below the malleolus 2 were recruited consecutively over a twelve-month study period 
between January 2015 and December 2015. A 3mm (width) x 10mm (depth) tissue punch 
biopsy was obtained from the edge of each DFU after debriding and cleansing the wound with 
NaCl 0. 9%. Patients who had received any systemic or topical antimicrobial therapy two 
weeks prior to enrolment were excluded. Ethics approval for this study is noted in Appendix 
granted by the South West Sydney Local Health District Research and Ethics Committee 
(HREC/14/LPOOL/487, SSA/14/LPOOL/489). The study methodology was designed in 
guidance by STROME-ID and our molecular surveillance data are reported in keeping with 
this 313. 
 
Patient demographic, laboratory and clinical data 
Patient demographics, laboratory and clinical data were collected through patient charts and 
the electronic medical records for correlation against microbiota data. Clinical data and wound 
metrics of interest that were collected included; present or absent foot pulses, foot Doppler 
waveforms, toe brachial indices (TBI) and completion of the modified neuropathic disability 
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score 314. DFU location, duration of DFU prior to presentation, size (length x width in mm), 
depth (mm) and tissue type (granulation, slough, necrosis). Laboratory data included; full blood 
count, inflammatory markers (White cell count [WCC], Erythrocyte sedimentation rate [ESR], 
C-reactive protein [CRP]), glycosylated haemoglobin (HbA1c) and estimated glomerular 
filtration rate (eGFR). All newly infected DFUs were diagnosed clinically, and their severity 
graded using the Infectious Disease Society of America Guidelines for DFI 2. Acute infections 
were defined based on new presenting symptoms (classic signs of infection) being present and 
untreated of less than fourteen days’ duration.  
 
DFUs were classified based on their duration, with shorter duration DFUs (Acute) being less 
than six weeks and longer duration DFUs (Chronic) defined as those greater than six weeks. 
Treatment failure during the study period were defined as no resolution of infective symptoms 
over an appropriate treatment period (>28 days) despite directed anti-infective treatment 2, a 
requirement to replace oral antimicrobial therapy with parenteral delivery due to deterioration 
of infective symptoms, or the need for surgical intervention.  
 
Tissue processing workflow 
DNA Extraction 
5 – 10 mg of human chronic DFU biopsy samples were defrosted on ice prior to DNA 
extraction. Genomic DNA was extracted using Mo Bio PowerBiofilm DNA isolation kit (Mo 
Bio, Carlsbad, CA, United States) following the manufacturer’s instructions. 
 
16S rDNA next generation sequencing to determine bacterial diversity  
DNA sequencing was carried out by a commercial laboratory (Australian Centre for 
Ecogenomics, Brisbane, Australia) targeting the V3-V4 region of the 16S rDNA using 
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eubacterial universal primers 515F and 806R 315. Preparation of the16S library was performed 
using the workflow outlined by the manufacturer (Illumina, San Diego, CA, United States).  
 
In the 1st stage, PCR products were amplified according to the specified workflow with an 
alteration in polymerase used to substitute Q5 Hot Start High-Fidelity 2X Master Mix (New 
England Biolabs, Ipswich, Massachusetts, United States). Resulting PCR amplicons were 
purified using Agencourt AMPure XP beads (Beckman Coulter, Indianapolis, United States). 
Purified DNA was indexed with unique 8bp barcodes using the Illumina Nextera XT 384 
sample Index Kit A-D (Illumina, San Diego, CA, United States) in standard PCR conditions 
with Q5 Hot Start High-Fidelity 2X Master Mix. Indexed amplicons were pooled together in 
equimolar concentrations and sequenced on the Illumina MiSeq platform using paired end 
sequencing with V3 300bp chemistry. 
 
Sequence analysis and quality control  
Reads in FASTQ format were imported to CLC genomics workbench version 8.5.1 using the 
microbial genome finishing module (CLC bio, Qiagen Aarhus, Denmark), for sequence quality 
control and analysis. Workflows for sequence quality control and operational taxonomic units 
(OTU) clustering were based on previously reported wound microbiota analysis 10. OTUs were 
defined as molecular proxies for describing organisms based on their phylogenetic 
relationships to other organisms and were reported at either the genera or species level 
identification where possible. 
 
Sequence and quality control measures were performed using CLC genomic software. Reads 
were paired, merged and fixed trimmed at set averages of greater than 230 base pairs. OTUs 
were clustered, chimeric sequences removed and OTUs aligned using SILVA 316 at 97% 
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similarity to identify microorganisms at the genus level (species level where possible). OTUs 
were defined as molecular proxies for describing organisms based on their phylogenetic 
relationships to other organisms 10. Where OTUs of interest such as Staphylococci which were 
only clustered at the genera level, each genomic sequence was manually reviewed  (read length 
and >300 nucleotides) and utilised for analysis and further referenced for speciation using 
NCBI Mega BLASTtn 10. This resolved a proportion of Staphylococci cases which speciation 
was possible, but overall species determination was limited. To classify microorganisms based 
on their residing origin at the genera level (i.e. skin, gut, environment, oral), microorganisms 
were manually referenced against Bergey’s manual of systematic bacteriology volumes 1-5 317-
321. 
 
Two sets of descriptive data were reported based on the relative abundance OTUs contributed 
to each individual wound (OTUs contributing 1% - 10% - these were considered major 
contributors, the second data set reports OTUs contributing ≥10% - these were considered 
dominant contributors) 10. Next, OTUs were aligned using MUSCLE 10 to reconstruct a 
phylogenetic tree, and then subsampled allowing the estimation of the alpha and beta diversity. 
This included both community richness (Rarefaction) and community diversity (Shannon 
Weaver Index). Rarefaction curves allow the estimation of the number of unique microbial 
taxa within a sample and the Shannon Weaver Index is a measure of diversity that includes the 
number of unique microbial taxa and their relative evenness within each sample. Thus, a higher 
Shannon Weaver Index correlates to a greater diversity in a sample.  
 
16s rDNA quantitative real-time PCR to determine microbial load  
We utilised real-time quantitative PCR (qPCR) using the 16s rDNA eubacterial universal 
primers 341F 5’-CCTACGGGAGGCAGCAG-3’ and 534R 5’-ATTACCGCGGCTGCTGG-
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3’ to amplify a 194bp amplicon of 16s rDNA of all bacteria to determine the microbial load in 
DFUs as previously reported 322,323. The total number of bacteria was expressed as per mg of 
tissue normalised to the average number of copies of the 18S rDNA gene in a mg of human 
tissue. The primer pair used in 18s rDNA real-time PCR was 18s rDNA_756F 5’-
GGTGGTGCCCTTCCGTCA-3’ and 18s rDNA_877R 5’-CGATGCGGCGGCGTTATT-3’ to 
amplify a 122bp amplicon. 16S rDNA copy number per mg tissue were normalised to human 
18s rDNA copy number per mg tissue. 
 
Real-time PCR was carried out in 25 µl reaction mix containing 1X Brilliant II Sybr Green 
qPCR Master mix (Agilent Technologies, Santa Clara, US), 400nM forward and reverse primer 
and 100ng DNA template was analysed on the Mx3000P system (Agilent Technologies, Santa 
Clara, US) with the following cycling conditions: activation of Taq polymerase at 95oC for 10 
min, followed by 40 cycles of denaturation at 95oC for 15 seconds, annealing at 56oC for 30 
sec and extension at 72oC for 30 sec.  
 
Each qPCR was run with standard samples of known concentrations (copies/µl). Ten-fold serial 
dilutions of the quantified 16s rDNA and ten-fold serial dilutions of 18s rDNA PCR amplicon 
solution was kept in aliquots at -20oC and used as external standards of known concentration 
(copies/µl) in real-time PCR reaction. The standard samples were ranged 102–106 copies/µl 
which used to construct a standard curve for each qPCR run. The calibration curve was created 
by plotting the threshold cycle (Ct) corresponding to each standard vs the value of their 
corresponding gene concentration (copies/µl). The copy number of 16s rDNA (copies/µl) was 
normalised against copy number of human 18s rDNA (copies/µl) in each wound sample. 
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Culture-dependent Bacteriological Enumeration and Identification 
Culture-dependent analysis of wound punch biopsies was performed by a hospital pathology 
service (Sydney South West Pathology Service) using methods previously described.163 
Briefly, tissue samples were weighed and homogenized using a sterile tissue pulper in 3 ml of 
sterile saline. Serial dilutions of (1:10, 1:100 and 1:1000) of homogenized tissue was made, 
and two sets of plates were inoculated, one for the neat crushed tissue and one for the dilutions. 
Plates were streaked for isolation onto four quadrants of recommended agars and grown under 
appropriate atmospheres to isolate clinically relevant organisms (both aerobe and anaerobe) 
per standardized methods 324. The number of microorganisms were quantified by colony 
forming units (cfu) and reported as either ≥106 cfu/g of tissue or <106 cfu/g of tissue for each 
isolate. 
 
Statistics 
CLC genomics workbench version 8.5.1 in combination with the microbial genome-finishing 
module (CLC bio, Qiagen Aarhus, Denmark) were used to analyse DNA sequence data. 
Operational taxonomic units (OTU) clustering were based on previously reported wound 
microbiota analysis 10. OTUs were defined as molecular proxies for describing organisms 
based on their phylogenetic relationships to other organisms. Associations between microbiota 
community structure and membership were compared using permutational multivariate 
analysis of variance (PERMANOVA) in combination with principal coordinate analysis PCoA 
Bray-Curtis dissimilarity matrix. Patient demographics, laboratory and clinical data were 
examined using Chi-square and Spearman correlation coefficients. Kappa coefficients were 
used to determine the level of agreement between culture-dependent approaches and DNA 
sequencing. Independent predictors of treatment failure were explored using general linear 
model (GLM). Mann Whitney U test for non-parametric data were undertaken when analysing 
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the subgroups of neuropathic or neuroischemic lesions. Analysis was performed using 
Statistical Package for Social Sciences (SPSS) Version 23, SPSS Inc., Chicago, Illinois, USA. 
For all comparisons and modelling, the level of significance was set at p < .05. Molecular data 
analysed through Bray-Curtis and PERMNOVA incorporated a Bonferroni correction. Data 
are given as mean, median and standard deviation (±).  
 
3.1.3. RESULTS 
39 patients (39 tissue specimens) with newly infected DFUs were recruited over the 12-month 
study period. Broad demographic, clinical and laboratory data are shown in Table 3.1.  
Table 3.1 Patient demographics, clinical and laboratory data for 39 patients presenting 
with diabetic foot infection. Systemic antimicrobial use were based on post-sampling 
rtherapeutic regimens. 
 
Characteristics n=patients (%) (±SD) 
Demographics  
Mean age  57.4 years (±11⋅5) 
Male/Female 28 (71%)/11 (29%) 
Type of Diabetes: Type 1/Type2 4 (10%)/35 (90%) 
Duration of diabetes 12.8 years (±6⋅5) 
Chronic Kidney Disease Stage 5 16 (27%) 
Duration of ulcer prior to presentation 15.7 weeks (±13⋅7) 
Co-morbidities  
Loss of protective sensation 39 (100%) 
Peripheral Arterial Disease 15 (38⋅5%) 
Toe Brachial Index 0.5 (±0.1) 
Laboratory data  
Glycosylated Haemoglobin (HbA1c) (%) 8.5 (±2.5) 
Erythrocyte sedimentation rate (mmol/L) 54.3 (±33) 
C-Reactive Protein (mg/l) 28.1 (±25) 
White Cell Count 9.2 (±2⋅4) 
Infection grading and classification (IDSA)  
Mild 5 (13%) 
Moderate 25 (64%) 
Severe  9 (23%) 
Systemic antimicrobial/route of delivery  
Cephalexin/oral 6 (15%) 
Amoxycillin + clavulanic acid/oral 13 (33.5%) 
Flucoxacillin/oral 3 (8%) 
Clindamycin/oral 1 (2.5%) 
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Ciprofloxacin/oral 1 (2.5%) 
Rifampin + fusidic acid/oral 2 (5%) 
Sulfamethoxazole + trimethoprim/oral 1 (2.5%) 
Combination therapy/oral 3 (8%) 
Piperacillin + tazobactam/Intravenous  6 (15%) 
Cephazolin/Intravenous 3 (8%) 
 
 
16S rDNA next generation sequencing generated 1,028,895 sequences, which were clustered 
and aligned at 97% similarity to reveal 1,139 unique OTUs. A total of seven major phyla were 
identified including Firmicutes (48%), Proteobacteria (26%), Actinobacteria (12%), 
Bacteroidetes (8%), Fusobacteria (2%) and Cyanobacteria (1%). The clustering of OTUs 
contributing to greater than 10% within each DFU sample at the genera/species-level is noted 
in Table 3.2 and those contributing to <10% are noted in Table 3.3. 
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Table 3.2 Microorganisms contributing ≥10% in each DFU sample (representing the dominant taxa)255.  * refers to the species level 
identification of Staphylococcus genus level data. 
Genera/Species Samples Avg abundance % SD min-max avg abu % Aerotolerance 
Staphylococcus spp.: 15 40.7 30.3 12 to 92 Facultative 
*Staphylococcus aureus 8 43.1 32.9 12 to 92 Facultative 
*Unclassified Staphylococcus spp. 7 31.8 28.2 12 to 81 Facultative 
*Staphylococcus pettenkoferi 2 26 3 23 to 29 Facultative 
Corneybacterium striatum 8 32 16.6 12 to 59 Facultative 
Finegoldia spp. 7 12 2.8 10 to 18 Anaerobe 
Peptoniphilus spp. 7 14.5 5.1 10 to 22 Anaerobe 
Acinetobacter baumannii  7 30.5 18.7 16 to 69 Facultative 
Anaerococcus spp. 6 14.3 5.1 12 to 24 Anaerobe 
Streptococcus agalactiae 5 45.2 39 16 to 89 Facultative 
Enterobacter spp. 5 19.6 8.1 10 to 28 Facultative 
Proteus spp. 4 22.7 4.5 19 to 23 Facultative 
Prevotella spp. 4 14.3 4 10 to 18 Anaerobe 
Haemophilus spp. 4 21 14 12 to 42 Facultative 
Blastocatella fastidiosa 3 24 11 12 to 32 Facultative 
Pseudomonas aeruginosa 2 12.5 3.5 10 to 15 Aerobe 
Porphymonas spp. 2 11.5 2 10 to 13 Anaerobe 
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Table 3.3 Microorganisms contributing between 1-10% in each DFU sample (representing major contributors) 255. * Refers to the 
species level identification of Staphylococcus genus level data. 
Genera/Species Samples  Average abundance % SD Range % Aerotolerance 
      
Corynebacterium spp. 13 3.5 2 1 to 8 Aerobe 
Anaerococcus spp. 10 4 2.6 1 to 8 Facultative 
Staphylococcus spp.: - 10 2.9 1.6 1 to 6 Facultative 
*Staphylococcus epidermidis 5 2.8 0.9 2 to 4 Facultative 
*Staphylococcus xylosus 3 1.3 0.6 1 to 2 Facultative 
*Staphylococcus aureus 1 1 0 1 Facultative 
*Staphylococcus simulans 1 1 0 1 Facultative 
Finegoldia spp. 9 4.4 2.6 1.5 to 8 Anaerobe 
Acinetobacter spp.  9 3.8 2 2 to 8.5 Aerobe 
Propionibacterium spp. 8 2.5 1.6 1 to 5 Facultative 
Cyanobacteria_Subsectionl 7 4.9 2.5 2 to 9 N/A 
Cenarchaeum 7 4.4 2.5 1 to 8 N/A 
Streptococcus spp. 6 3.6 2.8 1 to 7.5 Facultative 
Pseudomonas aeruginosa 6 4 2.9 1 to 7.6 Aerobe 
Proteobacteria_ARKDMS-49 6 6.4 1.7 4 to 8 N/A 
Porphymonas spp. 6 4 3.4 1 to 9 Anaerobe 
Peptoniphilus spp. 6 4.9 3.6 1 to 8.5 Anaerobe 
Rhodothermaceae spp. 5 4.7 2.7 2 to 8 N/A 
Veillonella spp. 5 1.6 0.4 1 to 2 Anaerobe 
Proteobacteria_E01-9C-26 marine 5 6.4 3.1 1 to 9 N/A 
Elizabethkingia meniingoseptica 5 4.3 2.1 2 to 7.5 Aerobe 
Candidatus Hepatobacter penaei 5 3.7 2.3 2 to 6.5 Anaerobe 
Aerococcus spp. 5 2.9 1.5 1.5 to 5 Aerobe 
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Staphylococcus spp was the most prevalent microorganism in infected DFUs. This was 
followed by Corynebacterium spp., Finegoldia spp., Peptoniphilus spp., Acinetobacter spp., 
Anaerococcus spp., and Streptococcus spp., We further categorized microorganisms based on 
their residing niche (environmental, skin, oral and gut) to better define the site of origin of 
microorganisms that colonize DFUs (Figure 3.1). Microorganisms commensal to the skin were 
predominant in half of patients (50.6%) followed by environmental (29.1%), gut (14%) and 
oral (6.3%) microorganisms. 
 
Figure 3.1 Residing niche of sampled microorganisms identifies skin, environment, 
gut and oral microbes colonizing DFUs. 
 
 
 
Community structure of DFIs are heterogeneous  
The community structures of DFIs were depicted using rarefaction and Shannon Weaver index 
plots, which explore the richness, and diversity of individual infected DFUs (Figure 3.2).  
Figure 3.2 Community diversity and richness reported for 39 patients with DFI. (a) 
Community diversity of DFUs presented using the Shannon-Weaver index at 
maximum read length of 300. Shannon Weaver Index is a measure of diversity that 
includes the number of unique microbial taxa and their relative evenness within each 
sample. Thus, a higher Shannon Weaver Index correlates to a greater diversity.  (b) 
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Community richness of DFUs presented using richness index reporting the number of 
unique OTUs in each wound sample. Data sets were normalised to remove low 
abundance OTUs contributing to less than 1% within each wound sample.                                               
(a)                                                                                (b) 
               
 
Most DFUs had complex polymicrobial communities with great heterogeneity between 
patients. Rarefaction identified a mean of 56 OTUs (±31.2, range 4 to 125) per DFU, and 
Shannon Weaver index identified mean indices of 2.3 (±0.9, range 0.4 – 4.1). Descriptive 
statistics allowed for a more clinically relevant picture to be composed of the overall 
community structure. We identified three general profiles that sub-divided DFUs based on their 
community structure (Figure 3.3). High frequency taxa mostly comprised of a single 
microorganism (±3) (i.e. monomicrobial infection), High to low frequency taxa were 
comprised of between one to five (±2) dominant microorganisms followed by many low 
frequency taxa (i.e. polymicrobial infection) and low frequency taxa comprised on average of 
≥20 (±) minor microorganisms (complex polymicrobial infection).  
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 (a) High frequency taxa.                                                  (b) High to low frequency taxa.                                         (c) Low frequency taxa. 
                      
 
Figure 3.3 Bar chart represent relative abundances (%) of taxa profiles for 39 DFUs. Each bar represents individual genera/species. (a) High 
frequency taxa were observed in ten patients (26%), mostly comprised of a single microorganism (±3) (i.e. monomicrobial infection) contributing 
to ≥88% (±5.4%) of total abundance. (b) High to low frequency taxa were the most common profile and were observed in 25 patients (64%). Low 
frequency taxa comprised on average of ≥20 (±) minor microorganisms each contributing <1%-5% abundance and no single microorganism 
contributing >10% (complex polymicrobial infection).  (c) Low frequency taxa were infrequently observed in only four patients (10%) and 
contained higher relative abundances of environmental microorganisms (p< 0⋅01).  
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The duration of DFU prior to infection presentation may present a major driver behind the 
microbiota 
 
Five (13%) DFUs at the time of presentation were less than six-weeks in duration and were 
composed of high frequency taxa with one predominant microorganism (Figure 3.4). These 
were S. aureus in three cases and S. algalactaie in two cases. The relative abundance of 
Staphylococcus spp. was far greater in DFUs < six-weeks than DFUs of longer duration where 
it was present but at significantly lower relative abundances (Figure 3.5).  
 
Figure 3.4 Bar chart representing relative abundance of taxa in acute diabetic foot 
ulcers (<6 weeks duration). 
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Figure 3.5 Analysis of variance between Staphylococci spp. relative abundance (%) 
and DFUs based on duration. In DFUs < six weeks, Staphylococcus spp. were present 
as the dominant taxa (high frequency).  
 
 
 
 
Longer duration DFUs (≥6 weeks) with a new acute infective episode (n=34, 87%) were the 
most common presentation. PCoA Bray-Curtis plots with PERMANOVA identified the 
community structures between longer and shorter duration DFUs were dissimilar (p = .003) 
(Figure 3.6 and Figure 3.7).  
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Figure 3.6 PCoA Bray-Curtis plots identify that differences are present in the 
community structures between longer and shorter duration DFUs. 
 
 
Figure 3.7 PCoA Bray-Curtis plot demonstrates how similar/dissimilar the community 
structure of DFUs less than 6 weeks. 
 
 
Furthermore, ulcer duration was positively correlated with relative abundance of 
Proteobacteria (p < .05) and negatively correlated with relative abundance of Firmicutes (p < 
.05) (Figure 3.8). 
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Figure 3.8 Ulcer duration was positively correlated with relative abundance of 
Proteobacteria (p < .05) and negatively correlated with relative abundance of 
Firmicutes (p < .05). 
 
 
 
 
Closer examination of OTUs revealed that Staphylococcus spp., contributed to the positive 
correlation detected between Firmicutes and relative abundance and ulcer duration (p < .05). 
Spearman’s rank correlation coefficients further clarified that DFUs of longer duration were 
polymicrobial, typically having greater number of OTUs and were broader in diversity (p = 
.01). This statistical approach further correlated higher frequencies of DFUs containing 
obligate anaerobes that constituted greater than 30% of the total abundance in DFUs of greater 
duration (p = .03) (Figure 3.9).  
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Figure 3.9 Relative abundance (%) of obligate anaerobes at the individual samples 
level identifies great heterogeneity in thirty-nine patients with infected DFUs. Black 
bars represent DFUs <6 weeks and grey bars represent DFUs >6 weeks. 
 
 
 
Wound observations and clinical factors lack association with the microbiota 
Associations between clinical factors and DFI microbiota were compared using 
PERMANOVA and Spearman’s rank correlation coefficients. The location, depth and the level 
of glycosylated haemoglobin (HbA1C ≥7%) were not associated to any significant bacteria. 
The presence of slough or malodour within an infected DFU were independently associated 
with community structure but were not inversely correlated to each other (p = .7). Slough in an 
infected DFU was associated with higher abundances of obligate anaerobes (slough present 
and ≥30% anaerobe present =13 of 39, 33%, p = .01), as was malodour (malodour DFUs =15, 
mean anaerobe abundance 34%, SD 25.3 versus no malodour of DFUs, mean anaerobe 
abundance 15%, SD 18.4). 
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Infection severity of Diabetic Foot Infections are associated with altered community structures 
PERMANOVA identified some disparity between the community structure and infection 
severity. Mild DFIs were different from both moderate infection (p = .01) and severe infection 
(p < .001) (Figure 3.10) and were positively correlated to fewer OTUs and were less diverse. 
In contrast, severe infections often presented exclusively with low frequency taxa profiles (n=3 
of 4, p = .02). Obligate anaerobes and their abundance within each DFU were explored for 
relationships between infection severities. The abundance of anaerobes was similar across mild 
DFIs (abundance= 29.5%, ±31) moderate DFIs (abundance= 20.5%, ±22.3) and severe DFIs 
(abundance= 27.3%, ±21), indicating that there exist no differences between patients 
presenting with more severe infections and a greater abundance of anaerobes (p = .6).  
 
Figure 3.10 PCoA Bray-Curtis plot demonstrates the community structure difference 
between infection severities in addition to defining the duration of DFU. 
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Neuropathic and Neuroischemic Diabetic Foot Ulcers harbour similar microbiota’s 
Twenty-three patients were classified as having neuropathic DFUs (normal TBI ranges ≥0.9 -
<1.2 and MNDS≥6) and sixteen patients were classified as having neuroischemic DFUs (TBI 
<0.7 to 0.3, and MNDS≥6). Non-parametric approaches identified no difference in the mean 
average abundances between neuropathic and neuroischemic DFUs (Figure 3.11).  
 
Figure 3.11Relative abundance of species of differing aerotolerance in neuropathic 
(n=25) and neuroischemic (n=16) infected diabetic foot ulcers. 
 
 
Culture dependent methods underestimate anaerobic microorganisms 
Kappa coefficients were used to determine the level of agreement between culture-dependent 
methods and 16S rDNA next generation sequencing. Agreement in the identification of 
obligate anaerobes was poor between culture and DNA sequencing (p = .4). Culture 
underestimated obligate anaerobe presence in 90% of samples (detection of obligate anaerobes 
by culture = 4 of 39, 10% vs detection of obligate anaerobes by DNA sequencing = 34 of 39, 
79%).  
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Microbial load of DFUs 
Microbiological information on the microbial load of DFUs was assessed using both 
conventional culture (n = 21, mean cfu / gram of tissue 1.67 x 107, SD 4.16 x 108) and qPCR 
(n = 39, mean DNA copies / gram of tissue 5.92 x 108, SD 1.02 x 109). This identified no 
statistical difference between the two methods (p = .o8) 
 
Table 3.4 The microbial load of DFUs compared using 16S rDNA sequencing and conventional 
culture.  
16S rDNA sequencing 
(DNA copies / per gram of tissue) 
Conventional Culture 
(cfu / per gram of tissue) 
1.64 x 107 1.1 x 105 
3.97 x 107 1.56 x 104 
9.69 x 107 5.62 x 105 
8.32 x 107 1.67 x 106 
5.55 x 108 3.33 x 105 
5.27 x 107 3.53 x 107 
3.03 x 108 2.50 x 106 
4.06 x 107 5.00 x 107 
2.26 x 107 6.44 x 106 
3.81 x 107 3.25 x 104 
1.42 x 108 1.95 x 105 
1.16 x 109 8.33 x 105 
8.35 x 104 1.74 x 107 
2.10 x 107 1.57 x 108 
3.89 x 106 1.57 x 108 
4.97 x 108 9.50 x 107 
1.27 x 108 1.04 x 109 
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1.18 x 109 1.25 x107 
1.05 x 108 1.92 x 109 
3.63 x 106 8.25 x106 
1.35 x 109 1.25 x106 
6.95 x 108 N/A 
4.01 x 109 N/A 
1.46 x 108 N/A 
1.14 x 109 N/A 
3.90 x 108 N/A 
5.757 x 10 N/A 
1.13 x 109 N/A 
6.17 x 107 N/A 
3.34 x 108 N/A 
3.44 x 109 N/A 
2.61 x 109 N/A 
5.99 x 107 N/A 
2.12 x 107 N/A 
6.56 x 107 N/A 
1.02 x 108 N/A 
2.21 x 109 N/A 
6.52 x 109 N/A 
4.07 x 108 N/A 
1.63 x 109 N/A 
1.60 x 108 N/A 
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Treatment parameters and outcomes 
In total, nineteen patients (49%) during the study period experienced treatment failure. Of the 
thirty-three patients who had DFUs >6 weeks, fifteen (45%) with moderate to severe IDSA 
infections experienced treatment failure.  In the group of five patients with DFUs < 6 weeks, 
four patients (80%) with moderate IDSA infections experienced treatment failure. These 
infections were mono-microbial and were predominated by high frequency taxa of either 
Staphylococcus spp. or Streptococcus spp. Correlation coefficients were used to explore if 
DFUs containing high relative abundances of commonly cited pathogens of infection in DFI 
(S. aureus, S. agalactiae and A. baumannii) were at greater risk of treatment failure. This 
revealed the presence of S. agalactiae in DFUs (regardless of duration of DFU) were associated 
with greater treatment failures (p = .007).  
 
PERMANOVA revealed no further differences in the community structures between patients 
who failed therapy and those who experienced treatment success (p = .2). In patient samples 
where obligate anaerobes were identified as contributing to the overall wound microbiota at 
levels greater than both 30% and 50%, there were no increased tendency towards failing 
therapy. The type of anti-infective therapy provided to patients in this study provided adequate 
anaerobe cover (25 of 39 wounds received antimicrobials with anaerobe cover, 64%) and this 
may explain the lack of significance between high relative abundance of anaerobes in DFUs 
and no increased tendency to fail therapy. 
 
Thirteen patients (33.3%) received narrow spectrum antimicrobials with nine (23.1%) of these 
patients having DFUs >6 weeks duration. Four of these nine patients (44.4%) experienced 
treatment failure whilst receiving narrow spectrum antimicrobials, but the five remaining 
patients with DFUs > 6 weeks on narrow spectrum antimicrobials experienced treatment 
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success. The number of cases were too low for statistical analysis. Twenty-five patients 
received broad-spectrum antimicrobials with eleven patients (44%) experiencing treatment 
failure. There were no correlations between a tendency to fail therapy and being on either 
narrow spectrum or broad-spectrum antimicrobials. A Generalised Linear Model (GLM) was 
performed to identify any predictors of treatment failure independent of the microbiota. These 
identified patients having a low TBI (<0.7) as being the only predictor of failure regardless of 
the microbiota (p = .01). No other clinical factors such as a level of glycosylated haemoglobin 
greater than ≥7% (p = .72) or the severity of infection were correlated to treatment failure 
(Mild, p = .13, Moderate, p = .65, Severe, p = .26).  
 
3.1.4. DISCUSSION 
 
In the context of managing diabetic foot infections from an infectious disease viewpoint, 
current guidelines based on culture-dependent data are now subject to the scrutiny of molecular 
DNA based approaches. Of studies employing amplification and sequence analysis of the 16S 
rDNA to characterize the microorganisms involved in DFI, none to date have sampled 
participants with overt clinical signs of infection. Instead the available data report on chronic, 
new or recurrent DFUs that are clinically non-infected. Given the increasing utilisation of 
genomic analysis from both a clinical and research domain, it is essential to understand the 
microbiome of clinically infective DFUs and if current anti-infective practices can be improved 
through the translation of complex bioinformatics arising from the DNA analysis of microbial 
communities. We analysed robust microbiome datasets from infections of the feet in people 
with diabetes, and detailed their clinical outcomes, relating this back to current anti-infective 
practices. The duration of a DFU prior to presenting with a new clinical infection may help 
clinicians decide on the antimicrobial regimen of choice.  
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We identify Staphylococcus spp., as the most commonly sequenced dominant bacteria in 
approximately one third of DFUs in this study, followed closely by Corynebacterium spp. In a 
recent review by our group on the bacteriology of DFUs from both a molecular and culture 
based approach 325, the predominant pathogen/s of infection for DFI was S. aureus. 
Corynebacterium spp., Streptococcus spp., and obligate anaerobes belonging to Clostridiales 
family XI, all identified as major players in this study, were similarly identified in studies of 
chronic non-infected wounds. Based on our molecular data and that of previous molecular and 
culture-based publications, current guidelines that promote the use of antimicrobials targeting 
Gram-positive aerobic cocci as a first line treatment are appropriate. 
 
 Corynebacterium spp. have provided a continuing source of debate regarding their role as a 
non-pathogenic skin commensal 42 or as a pathogen of infection in the presence of an 
immunocompromised patient 9,326. In this study, we seldom identified the presence 
Corynebacterium spp. as a sole pathogen (High frequency taxa), almost exclusively occurring 
in combination with other known pathogens of DFI. This suggests that there may be a role for 
Corynebacterium spp. as part of a polymicrobial infection. Given that many first line 
antimicrobials of choice for DFI are active against this species of microorganism, there may 
not be a requirement to target this microorganism unless a mono-microbial culture is identified.  
 
Community structure is essentially the composition of a community, including the number of 
species in that community, their relative numbers (Richness) and their complexity (Diversity). 
We identify that the duration of DFU is a major driver behind the microbiota, with longer 
duration DFUs typically having greater species richness and diversity. This correlates to 
increased relative abundances of Gram-negative Proteobacteria and reduced relative 
 
 
 128 
abundances of Firmicutes in a pattern previously described by Gardener et al on neuropathic 
non-infected DFUs 10. Proteobacteria are commonly identified in wounds 8,90 and largely 
belong to the Pseudomonadaceae and Enterobacteriaceae families. It is unclear from our data 
if these microorganisms require special attention. For example P. aeruginosa was present as 
minor taxa in only one quarter of samples (8/25 DFUs), thus supporting the general consensus 
2 that P. aeruginosa is not a typical pathogen of infection in DFI (excluding southern 
hemisphere locations) 327, and may not require additional tailored therapy should it be identified 
through cultivation-based methods. 
 
Obligate anaerobes were also identified in 90% of DFUs, but great heterogeneity existed 
between patients with regards to their relative abundances. In most DFUs, obligate anaerobes 
co-existed in high abundances with aerobic microorganisms, suggesting that obligate 
anaerobes likely play a role as co-pathogens in DFI. Current microbiology laboratories do not 
employ culturing methods to isolate many of the obligate anaerobes identified in this study 
through DNA sequencing. However, even in the absence of culture-dependent guidance, many 
commonly utilised antimicrobials for DFI are active against obligate anaerobes.  
 
Furthermore, there are no studies exploring if additional anti-anaerobic therapy improves DFI 
outcome, and in this study, we find no correlation between the high relative abundance of 
obligate anaerobes and a greater tendency to fail antimicrobial therapy. The decision to use 
targeted antimicrobials against obligate anaerobes by clinicians should be administered under 
the guidance of antimicrobial stewardship 328. The pattern of antimicrobial therapy prescribing 
in this study were based on specialist Infectious Disease physicians with experience of 
managing these complex patients, but these results may reflect differently when managed by 
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non-specialist clinicians with limited exposure to these wounds. Further work in this area is 
required.  
 
The current guidance materials available to clinicians managing DFIs are predominantly based 
on culture-dependent data, yet this study employing DNA sequencing techniques re-enforces 
most of this data as being clinically relevant 2,25. Pyogenic cocci were predominant in acute 
DFUs in this study, and this finding supports directed narrow spectrum antimicrobial regimens 
(with consideration for culture sensitivities looking for MRSA). DNA-sequencing methods 
however, highlight the limitation of conventional bacterial cultures with regards to the 
microbial diversity and ability to isolate microorganisms not detected under routine clinical 
microbiology laboratory protocols. Many of these difficult to isolate microorganisms were 
found in chronic wounds that harboured flora similar to the environment, suggesting patients 
expose their wounds to an array of environments (i.e. barefoot walking, showering with no 
wound dressing, gardening etc.). Therefore, patient education is vital in order to minimize 
exposure of DFUs to environmental contaminants and opportunistic pathogens.   
 
Current guidelines for classifying and managing infected DFUs provide guidance (in 
conjunction with local policies and patterns of microbial sensitivities for resistance) on the 
duration and route of delivery of antimicrobials based on infection severity 2,25. The use of 
broad-spectrum antimicrobials delivered parenterally is promoted for severe DFIs, owing to 
the polymicrobial nature of infection. We confirm severe DFIs are extremely diverse, 
polymicrobial and complex, and our data supports current clinical practice by parenteral, 
broad-spectrum antimicrobials is warranted. Exploration from a larger sub-set of patients with 
severe DFI composing of low frequency taxa profiles, may provide greater insight into 
managing these challenging infections. 
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Previous reports have suggested that DFUs complicated by peripheral arterial disease (i.e. 
ischemic or neuroischemic) likely lead to an altered wound microenvironment and thus 
microbiota 10. Additionally, the presence of peripheral vascular disease as a comorbid variable 
in the presence of an infected foot in a person with diabetes has been has been reported as an 
independent predictor of poor outcome 329,330. Sixteen patients in this study had neuroischemic 
ulcers (TBI <0.7 to 0.3) with most DFUs presenting with mild to moderate peripheral arterial 
disease.  
 
We ascertained that both neuropathic and neuroischemic (patients with mild to moderate PAD) 
DFUs harbour similar microbiota’s and the requirement to segregate these differing wound 
aetiologies may not be required for microbiome analysis when using a TBI cut off value of 0.5 
as an arbitrary marker.  
 
Nineteen patients during the study period experienced antimicrobial treatment failure, but no 
differences existed in the microbiota of patients who failed therapy and those who experienced 
treatment success. Furthermore, patients who were treated with either narrow spectrum or 
broad-spectrum antimicrobials experienced similar failure rates (44.4% versus 44%) and this 
suggests that other factors are likely at play including the host immune response to infection, 
patient compliance in adhering to therapy and or peripheral perfusion. A general linear model 
approach identified that the presence of a TBI <0⋅7 was an independent predictor of treatment 
failure regardless of the microbiome, or antimicrobial, emphasising the difficulties in managing 
these complex infected wounds. 
 
Whilst our microbiome data identifies DFUs of greater than six-weeks duration presenting with 
a new clinical infection (includes mild-moderate-severe, with no discrimination) are often 
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polymicrobial, with exception to nearly always targeting aerobic Gram-positive cocci, the 
requirement to also target anaerobes requires further research. Furthermore, whilst DNA 
sequencing provides an extended view of the microbiota, it is limited in providing information 
on “which microorganisms” maybe directly contributing to infection.  
 
This is increasingly important when analysing our data set where regardless of the spectrum of 
activity of antimicrobials (i.e. Narrow or broad-spectrum), patients experienced similar 
outcomes. It may be possible in a highly diverse microbiota, that narrow spectrum 
antimicrobials targeting pyogenic cocci alone, is enough to reduce the virulence/pathogenicity 
of infective symptoms without the requirement to use a shotgun approach to target everything 
broadly. The use of metagenome sequencing may allow us to better understand this question 
325. 
 
This paper provides a useful insight into the bacterial communities in infected DFUs and 
reflects on treatment outcomes of anti-infective therapy and if molecular based data would 
have altered therapeutic regimens. The paper is limited by the sample size and thus 
recommendations based on molecular data are not possible. A larger cohort of patients would 
provide greater detail and where possible analysis of small subsets of interest. This paper also 
identifies the difficulties with obtaining species level data when using the 16S rDNA. 
Furthermore, what is strikingly apparent from our data is that whilst we provide an extended 
view of “which microorganism/s” are present, we cannot be definitive on “which 
microorganism/s” are responsible as contributing as pathogens of infection. The era of 
“metagenomics” that can analyse genes responsible for virulence or pathogenicity may unveil 
these answers.
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Abstract 
There are many facets to diabetic foot disease that contribute to the development of a DFU, in 
particular the “triad” of factors that are peripheral neuropathy, peripheral vascular disease and 
trauma 1. Foot ulceration leaves a physical break in the protective barrier of the skin where 
various invading microorganisms may colonize the wound. In a person with diabetes, a 
retarded immune response is common and this may predispose an ulceration to further 
microbial invasion and replication, resulting in damage to host tissues and an inflammatory 
response that is characterized as clinical infection 2.   
 
In some patients who receive optimal standards of care (these include offloading, regular sharp 
debridement and re-vascularization), and in the absence of overt clinical infection, failure of 
the DFU to heal cannot be explained. Increasing evidence within the literature has identified 
the potential of biofilms to complicate wounds and cause a delay to wound healing. This 
research examines DFUs to ascertain the presence of biofilm, determine their prevalence, 
explore the microbial diversity and ascertain if clinical cues are useful in detecting wound 
biofilm. DFU specimens were obtained from 65 subjects. Scanning electron microscopy (SEM) 
and Fluorescent in situ Hybridisation (FISH) techniques were used to visualize biofilm 
structures. 
 
16S rDNA next generation sequencing were performed to explore the microbial diversity. 
Clinical cues that included the presence of slough, excessive exudate, a gel material on the 
wound bed that reforms quickly following debridement, poor granulation and pyocyanin were 
correlated to microscopy results. Of the 65 DFU specimens evaluated by microscopy, all were 
characterized as containing biofilm (100%, p < .001). Molecular analyses of DFU specimens 
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revealed diverse polymicrobial communities. No clinical correlations were identified in aiding 
clinicians identify wound biofilm. 
 
4.1.1. INTRODUCTION 
 
Foot ulceration is a physical break in the protective barrier of the skin allowing colonization 
by invading microorganisms. In a person with diabetes, an impaired immune response is 
common and this may predispose an ulceration to microbial invasion, with resultant damage to 
host tissues and an inflammatory response that is characterized as clinical infection 2. In some 
patients who receive optimal standards of care (including off-loading, regular sharp 
debridement and re-vascularization), and who do not exhibit overt clinical infection, failure of 
the DFU to heal might be explained by the presence of biofilm. Planktonic microorganisms 
that are responsible for acute infections may be readily identified through cultivation-based 
approaches, while multi-species sessile communities of microorganisms or biofilms may not 
be detected by the same cultivation methods.  
 
There is also a lack of diagnostic tests to define the presence of wound biofilm, and there are 
no quantifiable biomarkers. To augment clinical practice, some clinicians have used what they 
believe are “clinical cues” of biofilm presence through naked eye observations 166,331,332. Such 
signs have included; a shiny, translucent, slimy layer on the non-healing wound surface, the 
presence of slough or fibrin, and gelatinous material reforming quickly following removal in 
contrast to slough and other devitalised tissue or fibrin that often takes longer to reform. As 
biofilms are microscopic in nature, doubt has been expressed as to whether biofilms can be 
visually observed by clinicians. Unfortunately, chronic wound clinical observations have not 
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been cross-correlated to microscopy approaches, which are better suited for defining the 
presence of biofilm. 
 
The primary objective of this study was to visualize and confirm the presence of biofilm in 
DFUs and better understand if they consist of mono or multi-species biofilms. Secondary 
objectives were to ascertain if commonly used clinical cues were accurate in detecting wound 
biofilm. SEM, FISH / PNA-FISH and 16S rDNA next generation sequencing was utilized to 
answer these objectives.   
 
4.1.2. METHODS 
 
Patient population 
In this prospective study, 65 consecutive patients aged over 18 years presenting to the 
Liverpool Hospital High Risk Foot Service with a DFU were enrolled over a six-month period. 
Individuals were eligible for the study if they had either a DFU that had not responded to 
standard care and were not healing within an appropriate timeframe (i.e. chronic DFU), or 
presented with a DFU (acute or chronic DFU) and a new acute clinical infection as defined by 
the Infectious Disease Society of America Guidelines for Diabetic Foot Infection 333. Tissue 
biopsies were obtained from the wound edge for each participant (1 sample per patient) after 
cleansing the wound with NaCl 0.9%. Clinical observations of DFUs were recorded for each 
patient. Ethics approval for this study was granted by the South West Sydney Local Health 
District Research and Ethics Committee (HREC/14/LPOOL/487, SSA/14/LPOOL/489). 
 
Specimen collection, storage and 16S rDNA Next generation DNA sequencing workflows  
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Specimen collection, storage and the work flows for performing DNA extraction and next 
generation DNA sequencing were performed as previously described 334. 
 Fluorescent in situ hybridisation (FISH) and Peptide nucleic acid-based fluorescence in situ 
hybridization (PNA-FISH)  
Biopsy material was embedded in optimal cutting temperature (OTC) embedding matrix 
(Fisher Scientific, Waltham Massachusetts, United States), frozen at –80oC, cryo-sectioned to 
a thickness of 6 𝜇𝜇m and mounted on SuperFrost Plus slides (Menzel-Glaser, Lomb Scientific, 
Australia). Different types of probes were utilized for in situ hybridization as previously 
described by Thurnheer et al (2004) 335. The choice of specific probes was based on DNA 
sequencing results that allowed identification of the major genera/species of interest to target. 
The genus-specific probe; Cy3 labelled Staphylococcus spp., probe (final concentration 5 
ng/µl)336, Fluor 488 labelled Pseudomonas spp., specific probe (final concentration 20ng/µl) 
and a universal bacterial probe; Fluro 488 or Cy3, (final concentration 5 ng/µl) 337 were 
employed. For PNA-FISH, probes and kits were sourced commercially (AdvanDx, Inc., 
Woburn, MA) using previously described methods13.  
 
Briefly, species-specific Staphylococcus aureus/coagulase-negative Staphylococci (CNS) 
probes were used in conjunction with a universal bacterial probe. The hybridization solution, 
was added drop wise to each tissue section and hybridized at 55°C for 90 min. The slides were 
washed for 30 min at 55°C in wash solution. Once dry, the coverslip was mounted using a 
single drop of mounting medium. Slides were examined using CLSM (Zeiss Axio Imager 
Microscope and/or ZEISS LSM 880, Carl Zeiss Ltd., Herefordshire, UK). Images were 
processed using ZEISS ZEN Imaging Software (black edition) and Imaris v 8.4, ImarisXT, 
Bitplane. 
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Scanning Electron Microscopy (SEM) and image interpretation 
DFU biopsy samples were fixed in 3% glutaraldehyde, followed by 3 washes of 0.1M 
phosphate buffer prior to serial ethanol dehydration and hexamethyldisilazane incubation 
(Polysciences, Inc., Warrington, Pa.) as described previously 338.  Dried samples were coated 
with 20-nm gold film in a sputter coater and examined in a scanning electron microscope. Each 
sample was scored based on the amount of bacteria/biofilm observed using an arbitrary five-
point scale as previously reported 339. Each tissue sample (average of 3 pictures per sample) 
was viewed under SEM averaging two hours per sample. Tissue was screened for microbial 
aggregates and extracellular polymeric substances (EPS) from the wound surface downwards, 
working in a zigzag pattern at magnifications ranging from 300X to approximately 5,500X. 
Each sample was scored based on the amount of bacteria/biofilm observed using an arbitrary 
five-point scale as previously reported 78. Score 0 = no bacteria observed; score 1 = single 
individual cells; score 2 = small micro-colonies (~ 10 cells); score 3 = large micro-colonies 
(~100 cells); score 4 = continuous film; score 5 = thick continuous film. 
 
Characterization and visualization of DFU biofilm 
The presence or absence of biofilms in DFUs were confirmed through SEM or FISH / PNA-
FISH. For the purpose of the study, the definition of biofilm was “microbial aggregates 
surrounded by a self-produced or host derived matrix adhering to natural or artificial surfaces 
in the host, or aggregates associated with but not directly adherent to the surface” 93.  
 
Clinical wound observations  
Wound observations at the time of presentation were collected based on previous assumptions 
for “clinical cues” relating to the presence of biofilm. These were; the presence of slough, 
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excessive exudate, poor quality granulation tissue, presence of pyocyanin, gelatinous material 
of the wound surface, gelatinous material reforms quickly.  
 
Statistics 
Data relating to the presence or absence of DFU biofilm and clinical wound observations were 
tested using non-parametric methods (binomial probabilities). The hypothesis for the presence 
of biofilm was based on a previous report that 60% of chronic wounds have biofilm 12,  and 
this was set as the expected proportion. For clinical wound observations, no previous data were 
available. Expected proportions were set at 50% i.e. no more than chance alone of clinical 
wound observations being positive when biofilm positive through microscopy. Data were 
analysed through Statistical Package for Social Sciences Version 23 (SPSS Inc., Chicago, 
Illinois, USA). For all comparisons and modelling, the level of significance was set at p < .05. 
Data are given as mean, median and standard deviation (±). 
 
4.1.3. RESULTS 
 
Over a twelve-month study period, 65 consecutive patients with DFUs were recruited. Study 
demographics are reported briefly. Most patients were male (49, 74.2%) whilst there were 17 
females (25.8%) patients. The mean age of study subjects was 58.5 years (±12.3). Type 2 
diabetes predominated (type 2 =58, 87.9%, type 1=7, 10.6%), and the mean duration of diabetes 
was 13.9 years (±7.3). Clinically infected DFUs were present in forty patients (60.6%). These 
were subdivided by duration of the DFU prior to the development of a new acute infective 
episode; short duration DFU (<6 weeks) with new acute infection (7, 17.5%), chronic DFU >6 
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weeks with new acute infection (33, 82.5%). The remaining patients with DFUs (26, 39.4%) 
were classified as chronic non-healing with no acute clinical infection. 
 
Microscopy analysis 
The presence of biofilm was visualized and confirmed in all samples (65 of 65, 100%) using 
either SEM, FISH / PNA-FISH or both (p < .0001) (Table 4.1).  
Table 4.1 Biofilm analysis and DFU location, wound duration in weeks and whether 
infected or non-infectedPresence (+) or absence (-) of biofilm as determined by SEM 
and FISH analysis, degree of biofilm infection (score) and predominant species 
identified using 16S rDNA sequencing. NS refers to the inability to obtain an 
additional sample for microscopy from that patient. 
 
Patient 
number 
Biofilm 
(+ or -) 
Wound metrics 
 SEM Score 
FISH / 
PNA 
FISH 
 
Biofilm Diversity Location of DFU 
Duration 
of DFU 
(weeks) 
 
Infection status 
S01 + 4 + Multi-species only Plantar metatarsal head 8 Infected 
S02 + 5 + 
Mono-species and 
multi-species Plantar metatarsal head 16 
Infected 
S03 + 4 NS NS Plantar metatarsal head 36 Infected 
S04 + 4 + 
Mono-species and 
multi-species Plantar metatarsal head 14 
Infected 
S05 + 3 NS NS Plantar metatarsal head 24 Infected 
S06 + 4 NS NS 5th toe dorsal 12 Infected 
S07 + 4 + Multi-species only Plantar metatarsal head 72 Infected 
S08 NS NS + Mono-species only 4th toe dorsal 6 Infected 
S09 + 4 + Multi-species only 2nd toe apex 8 Infected 
S10 + 3 NS NS Heel 20 Infected 
S11 + 4 NS NS Heel 12 Infected 
S12 + 3 + 
Mono-species and 
multi-species Plantar metatarsal head 24 
Infected 
S13 + 4 + 
Mono-species and 
multi-species Plantar metatarsal head 6 
Infected 
S14 + 4 NS  Plantar metatarsal head 20 Infected 
S15 NS NS + Multi-species only 4th toe apex 12 Infected 
S16 NS NS + 
Mono-species and 
multi-species Hallux 8 
Infected 
S17 + 4 + Multi-species only Hallux 26 Infected 
S18 + 4 + Mono-species only Plantar metatarsal head 32 Infected 
S19 - 0 + 
Mono-species and 
multi-species Hallux 12 
Infected 
S20 + 3 + Multi-species only 2nd toe apex 16 Infected 
S21 + 5 + 
Mono-species and 
multi-species Medial Hallux 8 
Infected 
S22 NS NS + 
Mono-species and 
multi-species Medial Hallux 18 
Infected 
S23 NS NS + 
Mono-species and 
multi-species Heel 12 
Infected 
S24 + 4 NS NS Heel 24 Infected 
S25 NS NS + Multi-species only Hallux apex 9 Infected 
S26 + 5 + Multi-species only Plantar midfoot 3 Infected 
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S27 + 5 + 
Mono-species and 
multi-species Plantar metatarsal head 3 
Infected 
S28 + 5 NS NS Plantar metatarsal head 6 Infected 
S29 + 5 NS NS Plantar midfoot 52 Infected 
S30 + 4 NS NS Plantar midfoot 30 Infected 
S31 + 5 NS NS Plantar metatarsal head 3 Infected 
S32 + 5 NS NS Plantar metatarsal head 5 Infected 
S33 + 4 + 
Mono-species and 
multi-species Heel 5 
Infected 
S34 + 5 + Multi-species only Heel 12 Infected 
S35 + 5 + 
Mono-species and 
multi-species Heel 6 
Infected 
S36 + 4 NS NS Plantar metatarsal head 12 Infected 
S37 + 4 NS NS Hallux 9 Infected 
S38 + 4 + 
Mono-species and 
multi-species Hallux 8 
Infected 
S39 + 4 + Multi-species only Hallux 12 Infected 
S40 + 4 NS NS Heel 72 Non -infected 
S41 + 4 NS NS Plantar metatarsal head 40 Non -infected 
S42 + 4 + 
Mono-species and 
multi-species Heel 6 
Non -infected 
S43 + 4 NS NS Plantar metatarsal head 24 Non -infected 
S44 NS NS + 
Mono-species and 
multi-species Plantar metatarsal head 12 
Non -infected 
S45 + 4 + 
Mono-species and 
multi-species Heel 36 
Non -infected 
S46 + 5 + 
Mono-species and 
multi-species Plantar metatarsal head 72 
Non -infected 
S47 + 5 + Multi-species only Heel 7 Non -infected 
S48 - 1 + Multi-species only Plantar midfoot 28 Non -infected 
S49 + 4 + Multi-species only Heel 18 Non -infected 
S50 + 5 + Multi-species only Heel 28 Non -infected 
S51 + 4 + 
Mono-species and 
multi-species Plantar metatarsal head 27 
Non -infected 
S52 + 5 + 
Mono-species and 
multi-species Plantar metatarsal head 28 
Non -infected 
S53 + 4 NS NS Hallux 6 Non -infected 
S54 + 5 + 
Mono-species and 
multi-species Hallux 6 
Non -infected 
S55 + 4 + 
Mono-species and 
multi-species Heel 6 
Non -infected 
S56 + 3 + 
Multi-species only 
 Plantar metatarsal head 16 
Non -infected 
S57 + 5 + 
Multi-species only 
 Heel 20 
Non -infected 
S58 + 5 + 
Mono-species and 
multi-species Lateral leg 14 
Non -infected 
S59 + 4 + Multi-species only Heel 10 Non -infected 
S60 + 5 + 
Mono-species and 
multi-species Plantar metatarsal head 27 
Non -infected 
S61 + 4 + Multi-species only Hallux 8 Non -infected 
S62 + 4 + 
Mono-species and 
multi-species Plantar metatarsal head 12 
Non -infected 
S63 + 5 + 
Mono-species and 
multi-species Hallux 6 
Non -infected 
S64 + 5 NS NS Heel 52 Non -infected 
S65 + 5 + Mono-species and multi-species Plantar metatarsal head 9 
Non -infected 
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Multiple images (minimum of three images per tissue sample) were viewed under microscopy 
for each sample to provide an overall score. SEM images identified a predominance of coccoid 
cells, which often appeared to be coated with EPS (Figures 4.1 – 4.4). When scoring samples, 
the majority had large micro-colonies (~100 cells) plus the presence of continuous or thick film 
of extracellular matrix i.e. a score of 4 (52%) or 5 (36%,). Biofilm presence was negative in 
two samples by SEM (S19 and S48), and a further seven SEM samples were not obtained due 
to inadequate amounts of DFU tissue. In the absence of SEM, all samples were positive using 
PNA-FISH with CLSM. DFUs were further sub-categorised for biofilms structures based on 
their duration, with most samples coming from chronic DFUs (>6 weeks with or without 
infection, 60 of 65, 92%). Five DFUs of short duration (<6 weeks) with clinical infection were 
also visualized as containing biofilm. 
 
Figure 4.1 Scanning electron micrograph of DFU obtained from four patients 
demonstrating biofilm structure. Scanning electron micrograph of DFU obtained from 
four patients demonstrating biofilm structure. Red arrow identifies large micro-
colonies of predominantly coccoid microbial cells encased in thick extracellular 
matrix (EPS) and anchored to collagen bundles within the wound (biofilm score 5). 
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Figure 4.2 Identifies large micro-colonies of predominantly coccoid microbial cells 
encased in thick extracellular matrix (EPS) and anchored to collagen bundles within 
the wound (biofilm score 5). 
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Figure 4.3 Identifies large micro-colonies of predominantly coccoid cells covered in 
a thin film of EPS denoted with a red arrow (biofilm score 4). 
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Figure 4.4 Identifies large micro-colonies but less EPS (biofilm score 3). 
 
 
The spatial organisation of microorganisms was explored using PNA-FISH techniques and 
identified dense microbial aggregates (biofilm) (Figure 4.5, 4.6). Generally, biofilms were not 
present in a uniform manner across the entire wound bed. Sampled tissue sections with species-
specific and universal bacterial probes, revealed areas of biofilm that were solely mono-species 
(Figure 4.7) or multi-species biofilms (Figure 4.8). We also identified areas of combinations 
where both mono-species and multi-species were located within the same sampled tissue 
section (Figure 4.9).  
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Figure 4.5 CLSM of biofilm demonstrated via FISH and PNA-FISH. (a) Patient 20, 
FISH with CLSM shows predominantly Gram-negative rods in biofilm using green-
fluro-488-labeled probe targeting Pseudomonas spp., and yellow-Cy3-labeled 
universal bacterial probe. 
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Figure 4.6 Patient 4, PNA-FISH with CLSM illustrates different bacterial morphologies of a multi-species biofilm using fluorescein-labelled 
universal PNA probes. 
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Figure 4.7 FISH and PNA-FISH with CLSM technique to explore the spatial 
organization of microbial aggregates in DFU samples. Patient 18, identifies two mono-
species biofilms in the same wound, bacteria labelled with S. aureus PNA probe (green 
bacteria) and bacteria labelled with coagulase-negative Staphylococcus (red).  
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Figure 4.8 Three-dimensional view depicted using the Imaris software of a DFU biopsy. This highlights the structural complexity of biofilms 
where multi-species biofilm co-exists with mono-species biofilms and planktonic microorganisms. (A) Red-labelled universal PNA probe with (B) 
S. aureus green labelled PNA probe. (C) Mono-species of S. aureus biofilm. (D) Planktonic aggregates. (E) Planktonic aggregates of S. aureus. 
Top right-hand corner viewing bubble demonstrates standard CLSM view of multispecies biofilm under high magnification. 
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Figure 4.9 Patient 35, FISH with CLSM. Green arrow shows mono-species biofilm 
(Staphylococcus spp. specific probe) and orange arrow shows mixed-species biofilms 
(universal bacterial red probe). 
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Clinical wound observations 
Using binomial probabilities, the probability of clinical observations associated with the 
positive presence of biofilm through microscopy were explored (Table 4.2). Except for 
excessive exudate, the probability of clinicians accurately identifying biofilm using clinical 
observations was no better than chance alone.  
 
Table 4.2 The probability a clinical wound observation is related to the presence of 
biofilm. * indicates p value < .05. The binominal probability questions asked here is 
a yes or no response. Therefore, statistical significance should be denoted by an * if 
the visual marker is accurate in detecting biofilm. The benchmark was set at 50% 
occurrence rate for the visual marker to be present. The below results indicate that 
visual markers (with exception of XS exudate) are no better than chance alone. 
Binomial Test 
 Category N 
Observed 
Prop. Test Prop. Exact Sig. (2-tailed) 
Presence of 
slough 
Group 1 Yes 38 .58 .50 .215 
Group 2 No 27 .42   
Total  65 1.00   
XS Exudate Group 1 No 5 .08 .50 .000* 
Group 2 Yes* 60 .92   
Total  65 1.00   
Poor tissue 
quality 
Group 1 No 29 .45 .50 .457 
Group 2 Yes 36 .55   
Total  65 1.00   
Signs of 
pyocyanin 
Group 1 No* 52 .80 .50 .000* 
Group 2 Yes 13 .20   
Total  65 1.00   
Gelatin 
Wound 
Surface 
Group 1 No* 46 .71 .50 .001* 
Group 2 Yes 19 .29   
Total  65 1.00   
Gelatin 
Reforms 
Quickly 
Group 1 No* 53 .82 .50 .000* 
Group 2 Yes 12 .18   
Total  65 1.00   
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16S rDNA Next generation DNA sequencing  
The microbiota of DFUs were explored through 16S rDNA next generation sequencing. 
Microorganisms contributing greater than 10% relative abundance per individual DFU sample 
are reported at the genera and species level where possible (Figure 4.10). The most abundant 
bacteria were (in rank order) Staphylococcus spp., (S. aureus, S. epidermidis), 
Corynebacterium spp., (C. striatum, C. simulans), S. agalactiae, Anaerococcus spp., (P. 
anaerobius), Peptoniphilus spp,, Pseudomonas spp., (P. aeruginosa) and Prevotella spp. (P. 
melaninogenica, P. nanceiensis).  
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Figure 4.10 Bar graph depicting the most common genera of microorganisms in DFUs. The vertical axis refers to relative abundance across DFUs. 
Horizontal axis is the participant number. 
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4.1.4. DISCUSSION 
 
Employing a suite of microscopy and molecular approaches to analyse DFU tissue specimens, 
we identify the presence of densely aggregated colonies (both mono and multi-species) of 
bacteria often surrounded by an extracellular matrix in tissue biopsies from 65 DFUs. This 
represents the largest data set in the literature, and supports the view that biofilms are 
ubiquitous in DFUs and play host to a diverse ecology.  
 
The clinical significance of our findings suggests that biofilms may have a pathogenic role 
across a spectrum of DFU presentations. We identified biofilm in three different wound states; 
short duration DFUs (<6 weeks) with acute infection, chronic DFUs with acute infection and 
chronic DFUs with no infection but non-healing. The visualization of biofilms in chronic non-
healing wounds is as expected, where they have been proposed as a likely cause of wound 
chronicity 141. The exact mechanisms of biofilm impairment on the healing processes of 
wounds remain unclear. In vitro observations suggest the wound is kept in a vicious 
inflammatory state preventing the normal wound healing cycles to occur 179,182,184. Recently, 
data by James and colleagues (2016) 129 proposed a concept of a localized low oxygen tensions 
contributing to wound chronicity. Using oxygen microsensors and transcriptomics (examining 
microbial metabolic activities) to study in situ biofilms, James and colleagues identified steep 
oxygen gradients and induced oxygen-limitation stress responses from bacteria.  
 
The presence of biofilm however, in wounds of short duration (<6 weeks) presenting with an 
acute infection is less commonly reported. Five DFUs of short duration were captured in this 
study (range from 2-5 weeks) with biofilm being visualized in all patients. The general 
consensus is that biofilms are not responsible for acute infective episodes, for which planktonic 
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microorganisms are the major driver 115. People who develop DFUs may be at increased risk 
of the earlier formation of biofilm. This may be explained by several ill-defined immunological 
deficits attributed to underlying hyperglycaemia 18, that contributes to a poor response of 
neutrophils to colonizing or invading microorganisms 340, or from impairments in microbial 
phagocytosis 341. Although the number of samples to draw a valid conclusion is small (n = 5), 
it is unclear whether this phenomenon is specific to DFUs or can be observed in other chronic 
wound types and presents an interesting trend that warrants further exploration.  
 
In this study, all the presenting infected DFUs had biofilm, but given most DFUs were chronic 
at presentation we would expect biofilm to be present, but not necessarily involved as an acute 
pathogen of infection. It is plausible that the biofilm acts a reservoir for bacterial pathogens 
and biofilm dispersal increases the presence of pathogenic planktonic microorganisms 342. To 
support this idea, the most abundant bacteria identified using DNA sequencing in this study 
was S. aureus.  
 
Species-specific probes for S. aureus used in our PNA-FISH analysis also confirmed S. aureus 
as being present in the clear majority of samples as dense microbial aggregates. In the absence 
of direct biofilm culture assays from our clinical isolates, we could refer to the plethora of 
evidence for S. aureus profound ability to form biofilm, particularly on human skin and tissue 
343. Furthermore, S. aureus has long been cited as the most common pathogen of infection in 
diabetic foot infections from culture-dependent studies 42,43. We also identify S. aureus as being 
the predominant microorganism identified through 16S rDNA sequencing and visualized in 
biofilm through microscopy in this study. It is also possible that the acute infections of chronic 
DFUs were caused by a new invasion of planktonic bacteria rather than dispersal from biofilm 
colonies. 
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When analysing the community structure of DFUs, multi-species communities comprising of 
both strict anaerobes and aerobic species were identified. Biofilms can form “microniches” 195, 
with steep oxygen gradients occurring through biofilm or areas of altered pH or nitrate 344. 
These studies confirm that distinct micro niches exist at different depths in biofilms and thus 
make it possible to understand how metabolically diverse microorganisms coexist. While 
aerobic Gram-positive cocci were predominant through samples, several strict anaerobes were 
also present in most samples; Clostridales family XI members Anaerococcus spp., 
Peptoniphilus spp., and Finegoldia spp. Using culture-independent approaches, this group of 
fastidious bacteria have been previously reported as colonizing DFUs in greater abundance 
when compared against laboratory-based culture techniques 75.  
 
The clinical significance of having multi-species biofilms consisting of metabolically diverse 
microorganisms (i.e. aerobic and anaerobic microorganisms) is not clear in wound tissue, and 
there is no direct evidence (from any aspect of human health and disease) to suggest patients 
with multi-species biofilms have less favourable outcomes then those with mono-species 
biofilms. Previous reports in the literature however, have identified the occurrence of 
synergism between metabolically diverse microorganisms that demonstrate a greater 
pathogenicity / virulence and or an enhanced tolerance to therapeutics 345. As with most chronic 
wounds complicated by biofilm, their tolerance to many forms of treatments that include 
systemic antimicrobials, topical antiseptics and disinfectants is well-documented 172,293. This 
has led to expert groups promoting multi-faceted biofilm based woundcare approaches 93 to 
tackle these tolerant phenotypes.  
 
Part of this biofilm-based approach is the use of systemic antimicrobials in the presence of 
clinical infection. A question therefore, that needs to be explored is whether clinicians need to 
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consider altering systemic antimicrobial therapy based on the presence of a multispecies 
biofilms containing additional “hidden” anaerobes? Most clinicians with access to local and 
international antimicrobial stewardship guidelines and guidelines specifically for diabetic foot 
infection, are guided to use empiric first line antimicrobials that provide a broad spectrum of 
activity against anaerobes (such as Amoxicillin and Clavulanic acid). These guidelines also 
promote the use of antimicrobials with further targeted anaerobe action (such a Metronidazole). 
In this instance (and except for biofilm tolerance to antibiotics) most anaerobes are likely 
targeted by conventional regimens. 
 
One assumption when exploring the microbiota of chronic wounds complicated by biofilm 
using 16S rDNA sequence techniques, is that the polymicrobial nature of these wounds must 
in turn equal multi-species biofilms 9. This is not the case. We identify cases where S. aureus 
forms a mono-species biofilm in one section of tissue which could be located next to a 
neighbouring multi-species biofilm. This suggests a non-random distribution of microbial 
biofilms where mono-species biofilm could form in multi-species infections. We do note 
however, that whilst we identify varying sections of tissue with either mono or polyspecies 
biofilms, we did not find entire tissue sections containing only mono-species. 
 
This scenario has been previously documented by Bjarnsholt and colleagues (2009) 41 using 
PNA-FISH on chronic wound samples. They reported that many microbial aggregates were 
mono-microbial and belonged to either Pseudomonas aeruginosa or S. aureus (identified using 
specific probes). Additionally, the depth and location of these microbial aggregates was 
correlated to the depth of the wound bed. S. aureus were primarily located close to the wound 
surface whereas P. aeruginosa was primarily located deeper in the wound bed. The authors 
concluded that microbial aggregates function in a non-random distribution.  
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In a recent study on visualizing wound biofilms, the clinical observation of a gel-like 
substance/film was then correlated to biofilm presence through microscopy 346. The study 
concluded that ten of the sixteen samples revealed recurring wound bed film and that this sign 
was indicative of macroscopic biofilm presence. In contrast, for twenty-six samples analysed 
in this study, except for excessive exudate, the probability of a clinician accurately identifying 
biofilm using clinical observations is not better than chance alone.  
 
Furthermore, wounds that exhibit a gel-like substance where biofilm is confirmed through 
microscopy might have this only in the presence of specific biofilm species as not all wounds 
exhibit this feature (an example of this could be the mucoid P. aeruginosa which produces the 
viscous polysaccharide alginate in cystic fibrosis). We propose that clinical cues are not useful 
for detecting biofilm presence in DFUs, regardless of this, our data show that virtually all 
infected or chronic and non-healing DFUs have biofilm and thus clinicians could just “assume” 
biofilm will be present. Larger sample sizes from both DFUs and other chronic wound 
aetiologies are required to verify our results.  
 
In conclusion, microscopy visualization when combined with molecular approaches, confirms 
biofilms are ubiquitous in DFUs and a paradigm shift of managing these complicated wounds 
needs to consider anti-biofilm strategies.
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Abstract 
Objectives: The performance of Cadexomer Iodine was determined against microbial 
populations from chronic non-healing diabetic foot ulcers (DFUs) complicated by biofilm in 
vivo, using molecular, microscopy and zymography methods. 
 
Method: Chronic non-healing DFUs due to suspected biofilm involvement were eligible for 
enrolment. DNA sequencing and real-time qPCR was used to determine the microbial load and 
diversity of tissue punch biopsies obtained pre-and post-treatment. Scanning electron 
microscopy (SEM) and/or fluorescent in situ hybridisation (FISH) confirmed the presence or 
absence of biofilm. Zymography depicted levels of wound proteases.  
 
Results: 17 participants were recruited over a six-month period. SEM and or FISH confirmed 
the presence of biofilm in all samples. 11 participants exhibited Log10 reductions in microbial 
load after treatment (range 1 Log10 - 2 Log10) in comparison to six patients who experienced 
<1 log10 reduction (p = .04). Samples were tested for levels of wound proteases pre-and post-
treatment. Reductions in the microbial load correlated to reductions in wound proteases pre-
and post-treatment (p =.03). 
 
Conclusion: To the best of our knowledge, this study represents the first in vivo evidence 
employing a range of molecular and microscopy techniques which demonstrates the ability of 
Cadexomer Iodine to reduce the microbial load of chronic non-healing DFUs complicated by 
biofilm. Further analysis correlating log reductions to optimal duration of therapy and 
improvements in clinical parameters of wound healing in a larger cohort are required.  
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5.1.1. INTRODUCTION 
 
In a person with diabetes, foot ulceration leaves a physical break in the protective barrier of the 
skin. Factors including a retarded host immune response and pathogen-related dynamics (such 
as virulence or pathogenicity) may predispose the DFU to further planktonic microbial 
replication and invasion. This may result in damage to host tissues and an inflammatory 
response that is characterized as a clinical infection 2. 
 
Increasing evidence into the role of microorganisms involved in DFUs (and other wound 
aetiologies) have identified single free-floating microorganisms (planktonic) that are 
responsible for acute infections, may not necessarily represent the ecology of microorganisms 
present in chronic non-healing wounds. Instead, the focus has orientated towards the concept 
of biofilms which differ markedly in both their physiology and activity. The exact mechanisms 
of biofilm impairment on the healing processes of wounds are not clear, but general consensus 
suggests that biofilms maintain an elevated inflammatory state within the wound.144 
 
Microorganisms in biofilm exhibit enhanced tolerances to chemical, biological and host attack 
than planktonic forms. In vitro biofilm models have demonstrated that microbial biofilms can 
withstand antimicrobial concentrations 100 to 1000 times higher than that of planktonic 
counterparts 145. This may go towards explaining why some wounds fail to heal with standard 
care and why chronic infections persist 141.  In vitro models assessing the effectiveness of many 
antimicrobials used in wound related products have identified these treatments often have 
variable and poor results against microbial cells in biofilm phenotype 294,297,347. 
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One potential explanation for this treatment failure is because the wound care treatments do 
not target or are ineffective against biofilm. Cadexomer Iodine however, has demonstrated 
superior efficacy against microbial biofilms when tested in vitro and in animal models, when 
compared against other topical antimicrobials used in wound-care dressings 294,297,347. 
 
Therefore, a pilot study using 16S rDNA next generation sequencing, real-time qPCR, 
microscopy techniques (SEM and FISH) and gel zymography, was used to identify if the 
topical antimicrobial Cadeoxmer Iodine could reduce the microbial load of chronic non-healing 
DFUs complicated by biofilm in vivo. Additional interests were to explore the effects of 
Cadexomer Iodine on the microbial communities pre-and post-treatment and determine the 
levels of wound proteases (MMP-2 and MMP-9). It was not the intention of this pilot study to 
correlate any effects of microbial loads or diversity to wound healing outcomes. 
 
5.1.2. MATERIALS AND METHODS 
 
Ethics 
Ethics approval for this study was granted by the South West Sydney Local Health District 
Research and Ethics Committee (HREC/14/LPOOL/487, SSA/14/LPOOL/489). 
 
Exclusion criteria 
Patients with clinical signs of infection as per the Infectious Disease America guidelines 2, 
known osteomyelitis that was associated with the DFU, or patients who had received any 
topical or systemic antimicrobial therapy two weeks prior to enrolment, were not eligible. The 
reason for excluding patients with clinical infection was the assumption that these wounds 
would be driven predominantly by planktonic microorganisms 348. Participants with general 
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contraindications to the use of Cadexomer Iodine as per the manufacturers guidelines were also 
excluded 349. 
 
Subjects and sample collection  
Individuals were eligible for the study if they had a chronic non-healing DFU defined as a 
wound greater than six-weeks duration failing to respond to standard care 350. Cadexomer 
Iodine was applied every second day over a seven-day treatment period (total of 3 applications).  
Sharp debridement of DFUs were withheld over the seven-day treatment period given this was 
likely to significantly impact results 309. A tissue biopsy was obtained from the wound edge for 
each participant before and after treatment. All tissue samples were frozen at -80°C until 
completion of the last patient and processed in bulk as to reduce any bias. Additionally, we 
collected broad demographics and wound metrics. Primary endpoint was a reduction in 
microbial load seven days post-treatment. Secondary analysis included the exploration of 
community richness and diversity of DFUs pre-and post-treatment, visual changes to biofilm 
structures and alteration to levels of wound proteases (MMP-2 and MMP-9). 
 
Cadexomer Iodine (Iodosorb®, Smith and Nephew) 
Iodosorb ointment is designed as a carrier system enabling the delivery of Iodine which can 
penetrate the cell wall of microorganisms and disrupt protein and nucleic acid structure and 
synthesis 351. Iodosorb® consists of small polysaccharide beads (Cadexomer) containing 0.9% 
iodine, which, in the presence of wound exudate causes the polysaccharide beads to swell 
allowing a slow sustained release of Iodine into the wound. 
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Specimen collection and storage 
A 3mm (width) x 10mm (depth) tissue punch biopsy was obtained from the edge of each DFU 
after cleansing the wound with NaCl 0.9%. Tissue biopsy samples were obtained for all 
participants at baseline and day seven.  For SEM, an additional 2mm (width) x 10mm (depth) 
was necessary. Following removal, tissue samples were rinsed vigorously in a phosphate buffer 
solution (PBS) bath to remove any coagulated blood and to reduce the number of planktonic 
microorganisms. Samples were cut transversely into two 1.5mm pieces for DNA sequencing 
and FISH. DNA samples were immediately placed into RNAlater® (Ambion, Inc) for 24 hours 
at 4°C and then frozen at -80°C until DNA extraction. Tissue samples for FISH were 
immediately fixed in 4% paraformaldehyde overnight at 4°C, then transferred into PBS and 
frozen at -80°C. Tissue samples for SEM were immediately fixed in 3% glutaraldehyde 
overnight at 4°C, then transferred into 0.1% phosphate buffer (PB) and frozen at -80°C. All 
tissue samples remained at -80°C until study completion to reduce any bias and were processed 
in bulk.  
 
Tissue processing workflow 
DNA Extraction 
Tissue samples were defrosted on ice prior to DNA extraction and tissue samples were weighed 
individually (range of weights; 5 – 10 mg of human tissue). Genomic DNA was extracted using 
Mo Bio PowerBiofilm DNA isolation kit (Mo Bio Cat# 24000-50) following the 
manufacturer’s instructions. 
 
16S rDNA next generation sequencing to determine bacterial diversity  
16S rDNA sequencing was carried out by a commercial laboratory (Australian Centre for 
Ecogenomics) targeting the V4 region of the 16S rDNA using eubacterial universal primers 
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515F (TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG 
CCAGCAGCYGCGGTAAN) and 806R 
(GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG 
GGACTACHVGGGTWTCTAAT).  
 
Preparation of the 16S rDNA library was performed as described at the Australian Centre for 
Ecogenomics using the workflow outlined by Illumina (San Diego, California, United States). 
In the 1st stage, PCR products of ~466bp were amplified according to the specified workflow 
with an alteration in polymerase used to substitute Q5 Hot Start High-Fidelity 2X Master Mix 
(New England Biolabs, Ipswich, Massachusetts, United States) in standard PCR conditions. 
Resulting PCR amplicons were purified using Agencourt AMPure XP beads (Beckman 
Coulter, Brea, California, United states). Purified DNA was indexed with unique 8bp barcodes 
using the Illumina Nextera XT 384 sample Index Kit A-D (Illumina FC-131-1002) in standard 
PCR conditions with Q5 Hot Start High-Fidelity 2X Master Mix. Indexed amplicons were 
pooled together in equimolar concentrations and sequenced on MiSeq Sequencing System 
(Illumina) using paired end sequencing with V3 300bp chemistry. 
 
Sequence analysis and quality control  
Reads in FASTQ format were imported to CLC genomics workbench version 8.5.1 using the 
microbial genome finishing module (CLC bio, Qiagen Aarhus, Denmark), for sequence quality 
control and analysis. Workflows for sequence quality control and operational taxonomic units 
(OTU) clustering were based on previously reported wound microbiota analysis 10. OTUs were 
defined as molecular proxies for describing organisms based on their phylogenetic 
relationships to other organisms and were reported at either the genera or species level 
identification where possible. 
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Briefly, after sequence and quality control measures, reads were assigned to OTUs using 
SILVA 316 at 97% similarity at the genus level and species level where possible. OTUs were 
aligned using MUSCLE 10 to reconstruct a phylogenetic tree, allowing the estimation of the 
alpha diversity pre and post treatment for each DFU. This included both community richness 
(Rarefaction) and community diversity (Shannon Weaver Index). Rarefaction curves allow the 
estimation of the number of unique microbial taxa within a sample and the Shannon Weaver 
Index is a measure of diversity that includes the number of unique microbial taxa and their 
relative evenness within each sample. Thus, a higher Shannon Weaver Index correlates to a 
greater diversity. 
 
qPCR to determine microbial load in DFU biofilms 
We utilised real-time quantitative PCR (qPCR) to determine microbial load in DFU biofilms 
as previously reported 322,323. To quantify the total amount of bacterial DNA per mg of tissue 
in each wound tissue sample we obtained the copy number of the 16S rDNA (copies/µl), which 
was normalised against the human 18s rDNA (copies/µl) in each chronic wound sample.  
 
Characterization and visualization of DFU biofilm 
The presence or absence of biofilms in chronic non-healing DFUs, was confirmed through 
SEM or FISH. For this study, we used definitions promoted by an expert group 2 to characterise 
biofilm as being; microbial aggregates surrounded by a self-produced or host derived matrix 
adhering to natural or artificial surfaces in the host, or aggregates associated with but not 
directly adherent to the surface 93. 
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Fluorescent in situ hybridisation  
2-3 millimetres of DFU tissue were embedded in optimal cutting temperature (OCT) 
embedding matrix (Tissue-Plus™ O.C.T Compound, Thermo Fisher Scientific, Waltham, 
Massachusetts, USA) and frozen at –80°C overnight. DFU tissue were sectioned to a thickness 
of 6 𝜇𝜇m and mounted on SuperFrost Plus slides (Thermo Fisher Scientific, Waltham, 
Massachusetts, USA). For visualisation of microorganisms and biofilm, confocal laser 
scanning microscopy were combined with fluorescence in situ hybridization. The 
Hybridisation process used was previously described by Thurnheer et al (2004) 335.  
 
Briefly, two different probes were utilised for in situ hybridisation; a) Fluro 488 labelled 
universal probe 337 (final concentration 5 ng/ µl) Cy3 labelled Staphylococcus spp. specific 
probe  (final concentration 5 ng/ µl) 352. All images were examined under confocal laser 
scanning microscope (Carl Zeiss Ltd., Herefordshire, UK). All images were processed using 
ZEISS ZEN Imaging Software (black edition). 
 
 Scanning Electron Microscopy and image interpretation 
In vivo microbial biofilms associated with DFU tissue were sampled at 5–200 μm for optimal 
visualisation  through scanning electron microscopy 120. 2-3 millimetres of DFU tissue were 
fixed in 3% glutaraldehyde, followed by 3 washes of 0.1M phosphate buffer prior to serial 
ethanol dehydration and hexamethyldisilazane (Polysciences, Inc., Warrington, Pa.) as 
described previously.323 Dried samples were coated with 20-nm gold film and examined using 
SEM. Each sample was scored based on the amount of bacteria/biofilm observed using an 
arbitrary five-point scale as previously reported 78. Score 0 = no bacteria observed; score 1 = 
single individual cells; score 2 = small micro-colonies (~ 10 cells); score 3 = large micro-
colonies (~100 cells); score 4 = continuous film; score 5 = thick continuous film. 
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Determination of wound proteases  
Wound fluids were collected from diabetic foot ulcers pre and post treatment and stored at -
80°C for quantitation of matrix metalloproteinase (MMP-2 and total MMP-9) by gel band 
zymography as previously described 353.  
 
Statistics 
Wound metrics and microbiota data were analysed through Statistical Package for Social 
Sciences Version 23 (SPSS Inc., Chicago, Illinois, USA). Wilcoxin signed- rank test for paired 
samples of non-parametric data were performed on pre-and post-treatment microbial Log10 
reductions. Chi-square was used to correlate OTUs and Shannon indices to Log10 reduction. 
One-way ANOVA was used to estimate variances between MMP levels before and after 
treatment. Logistic regression was employed to correlate microbial reduction to MMP levels. 
CLC genomics workbench version 8.5.1 in combination with the microbial genome-finishing 
module (CLC bio, Qiagen Aarhus, Denmark) were used to analyse DNA sequence data. For 
all comparisons and modelling, the level of significance was set at p < .05. Data are given as 
mean, standard deviation (±) and 95% confidence interval (CI). 
 
5.1.3. RESULTS 
 
A total of 17 patients with chronic non-healing DFUs were enrolled. One ulcer from each 
patient was biopsied pre-and-post treatment. Patient demographics and wound metrics are 
shown in Table 5.1.  
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Table 5.1 Patient demographics and wound metrics at baseline. 
   
Patient demographics  
Male  11 (65%) 
Female 6 (35%) 
Type 1 Diabetes 2 (12%) 
Type 2 Diabetes 15 (88%) 
Mean age in years 66 (± 13.6) 
Wound Metrics  
Location of ulcer  
Plantar metatarsal head 8 
Calcaneum  3 
Dorsal foot 2 
Ankle 2 
Hallux 2 
Duration of ulcer in weeks  
Mean duration of ulcer at baseline 25 (± 20.7, range 6 to 72) 
University of Texas Wound 
Classification 
 
1A 7 (41%) 
1C 1 (41%) 
2A 2 (12%) 
2C 1 (6%) 
Size of ulcer  
Mean DFU size at baseline 3.7 x 2.7 cm (L x W) 
  
 
 
Microbial load was determined via qPCR for all 17 DFU samples pre-and post-treatment. 
However, three samples were removed from exploring community richness (Rarefaction) and 
diversity (Shannon Index) due to a low number of 16S rDNA reads, leaving twelve samples 
available for analysis. In total (for these twelve samples), 703, 346 high quality DNA sequences 
were generated (before = 384,772, after = 318,574), with a median of 31,452 per sample level 
data (Range = 1,137 to 61,820). The clustering of OTUs identified 1,976 unique taxa of which 
low abundance OTUs were removed (<0.1%), leaving 368 OTUs for further analysis. Only 
eight wound fluid samples were available for analysis MMPs with the remaining sample 
protein concentrations too low. 
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Confirmation of the presence or absence of biofilms in each DFU  
The presence of biofilm was visualized and confirmed in all 17 participants using SEM, FISH 
or both (Figures 5.1, 5.2). Biofilm architecture was graded (via SEM) using an arbitrary sliding 
scale previously reported 78. The median value of DFU biofilm architecture reduced between 
pre and post treatment samples; pre-treatment median was four (large micro-colonies ~100 
cells, and a continuous film/matrix) and the post-treatment median was three (large micro-
colonies ~100 cells). 
 
Figure 5.1 SEM image from a pre-treatment (Cadexomer iodine) DFU tissue sample. 
Microbial aggregates with self-produced or host derived matrix that we describe as a 
stringy like glue appearance. SEM imaged at 5µm 
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Figure 5.2 FISH image pre-treatment (Cadexomer iodine) of the same DFU tissue 
sample in figure 5.1. Image depicts microbial aggregates of mixed species biofilm 
(Fluro 488 labelled universal bacterial probe [red] and Cy3 labelled Staphylococcus 
spp., specific probe). 
 
 
 
Reduction in microbial load of chronic non-healing DFUs complicated by biofilm 
The application of Cadexomer Iodine resulted in 11 samples achieving up to and greater than 
a 1-log10 reduction (mean log10 microbial load pre-treatment = 8.385 16S copies / per mg of 
tissue versus 3.694 16S rDNA copies / per mg of tissue, p = .02, 95% CI 7.214 to 8.375) (Figure 
5.3). Six samples had no change or increases in log10 (mean log10 microbial load pre-treatment 
= 1.695 16S rDNA copies / per mg of tissue versus 1.595 16S rDNA copies / per mg of tissue). 
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Figure 5.3 Effect of Cadexomer Iodine pre-and post-treatment. Bar graph represents 
the mean log10 values of all 17 patients.  
 
 
 
 
Analysis of community richness and diversity of chronic non-healing DFUs treated with 
Cadexomer Iodine.  
The most abundant OTUs (based on the number of DNA sequences represented when pooling 
samples) are noted in Figure 5.4. The richness and diversity of chronic non-healing DFUs pre-
and post-treatment are also reported at the individual sample level of microorganisms 
contributing to >5% of abundance in rank order (Table 5.2). Post-treatment identified diversity 
shifts with increasing environmental contaminants. These microorganisms are identifiable only 
by molecular methods (in the majority) and included in Proteobacteria-E01-9C-26 Marine 
Group, Proteobacteria-ARKDMS-49, Archaea-Cenarchaeum, Elizabethkingia spp., 
Bacteroidetes-Rhodothermacae and Proteobacteria-Rhodothalssium. Furthermore, some of 
these microorganisms are known extremophiles, existing in hostile, niche environments.  
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Figure 5.4 Denotes the most frequent microorganisms based on the pooling of all DNA 
sequences, and the total number of DNA sequences attributed to each 
microorganism.This graph also exemplifies the contrast between low and high 
frequency taxa at the genus/species level. High-frequency taxa consist of a few 
predominant microorganisms (typically between 1 to 9 microorganisms, samples 31, 
32, 36, 42, 44, 45, 91), or lower-frequency taxa of multiple microorganisms (typically 
ten-fold in comparison to high frequency taxa, >30 to 90 microorganisms, samples 33, 
38, 39, 40, 41).  
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Table 5.2 Pre-and post-treatment community diversity in microorganisms contributing to >5% abundance of each individual sample. 
PRE-TREATMENT 
Genera 
 
 No of 
wounds  
Avg. 
abundance 
(%) 
 
Aerotolerance 
 POST-TREATMENT 
Genera 
 
Samples 
Avg. 
abundance 
(%) 
 
Aerotolerance 
    
     
Pseudomonas spp 5 58.5 Aerobe  E01-9C-26 Marine 8 10 Unknown 
E01-9C-26 Marine 4 11.2 Unknown  ARKDMS49 7 5.7 Unknown 
Staphylococcus spp 4 58 Facultative  Cenarchaeum 5 5.1 Unknown 
Rhodothermaceae spp 3 5 Unknown  Cyanobacteria- 
subsectionl 
5 7.4 Unknown 
Finegoldia spp 3 7.8 Anaerobe  Rhodothermaceae spp 4 5.8 Unknown 
Elizabethkingia meningoseptica 3 6.3 Aerobe  Rhodothalassium spp 3 7 Unknown 
Cornyebacterium spp 3 5.3 Aerobe  Cornyebacterium spp 3 11 Aerobe 
Peptoniphilus spp 2 9.5 Anaerobe  Elizabethkingia 
meningoseptica 
3 6.6 Aerobe 
Ananerococcus spp 2 9.2 Anaerobe  Staphylococcus spp 3 42.8 Facultative 
Proteus penneri 2 20.5 Facultative  Proteus penneri 2 39 Facultative 
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The taxonomic richness and diversity of pre-and post-treatment pooled samples identified no 
differences between mean OTUs (Pre-treatment = 115, SD 69.3 versus Post-treatment = 112, 
SD 74.3, p = .53) and mean Shannon indices (Pre-treatment = 2.8, SD 1.2 versus Post-treatment 
= 3, SD 1.4, p = .58). When exploring this at the individual sample level there was large 
heterogeneity between pre-and post OTU and Shannon indices. To ascertain if the number of 
unique OTUs and their relative abundance were correlated to reductions in Log10 values, a 
chi-square was performed. Reductions in Log10 did not correlate to reductions in either OTUs 
(p = .85) or Shannon indices (p = .72). 
 
MMP levels pre-and post-treatment 
Mean total MMP-9 and MMP-2 levels in eight samples reduced following seven days’ 
application of Cadexomer Iodine (Figure 5.5). However, only total MMP-9 reached statistical 
significance (mean total MMP-9 before = 2202 mg/10uL versus mean total MMP-9 after = 
1065 mg/10uL, 95% CI -14.5 to 2287, p = .05).  Mean MMP-2 before =181.9 versus mean 
MMP-2 after = 89, 95% CI -61.3 to 246.7, p = .197). In general, any reductions in the levels of 
MMPs were correlated to reductions in the microbial load (p = .03). 
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Figure 5.5 (a) total MMP-9 values pre-and post-treatment. (b) MMP-2 values pre-and 
post- treatment. 
                   (a)                                                          
 
 
                  (b) 
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5.1.4. DISCUSSION 
 
Using a combination of DNA sequencing, qPCR, SEM and FISH, the ecology of wounds and 
presence of microbial biofilms was explored. To the best of our knowledge, we are the first to 
employ these suites of molecular and microscopy techniques to show that Cadexomer Iodine 
can reduce the microbial load of chronic non-healing DFUs complicated by biofilm. We also 
show that in reducing microbial load, concomitant reductions in wound proteases are also 
achieved.  
 
16S rDNA sequencing allowed the exploration of chronic non-healing DFU microbiota and 
provided useful insights that these wounds support complex polymicrobial communities. 
Molecular methods also demonstrated that Cadexomer Iodine had a broad level of 
antimicrobial activity in reducing both facultative anaerobes such as Staphylococcus spp., 
Serratia spp., Pseudomonas spp., and obligate anaerobes including Clostridiales family XI. 
However, in 6/17 samples, there was an increase in bacterial load. 
 
Both facultative and obligate anaerobes were detected together in chronic non-healing DFU 
samples positive for biofilm presence. Microelectrode and transcriptomic analysis of in vitro 
biofilms have identified the interior of biofilms house niche areas of altered pH levels, oxygen 
and nutrient depletion.129,172 Oxygen is noted for its depletion at the substratum layers of 
biofilms and in the centre of micro-colonies, explaining why wounds complicated by biofilm 
can harbour such diverse microorganisms. This may indirectly support the action of 
Cadexomer Iodine against biofilms, as it suggests penetration to deeper areas that house 
obligate anaerobes are possible, as identified by 16S rDNA of pre-and post- reductions in 
obligate anaerobes. 
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Using a combined molecular and microscopy approach can provide an extended understanding 
of the effects of antimicrobials on wounds. This approach for example provided insights into 
how Cadexomer Iodine affected microbial populations. Using sample level data, Serratia spp. 
was identified as contributing to 75% of abundance pre-treatment and 0% post-treatment in 
sample 42 (Figure 5.6). This also correlated with a greater than 1-Log10 reduction in microbial 
load as determined by real-time qPCR. Similarly, for sample 44, P. aeruginosa contributed to 
88% of abundance pre-treatment and 0.3% post-treatment, with a 0.76-Log10 reduction in 
microbial load (Figure 5.7). This suggests that Cadexomer Iodine was effective in reducing the 
abundant microorganisms in these cases. 
Figure 5.6 Pre-and post-community diversity identified through 16S rDNA 
sequencing. In the left-hand pane sample 42 identifies Serratia spp., contributing to 
78% abundance pre-treatment and in the right-hand pane this reduces 1% post-
treatment. The top of the graph identified the reduction in microbial load by over 1-
Log10 reduction determined through qPCR (99% reduction in microorganisms). 
Therefore, the left-hand pane is a 1% reflection of the remaining microorganisms. 
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Figure 5.7 Sample 44 identified Pseudomonas spp., Contributing to 78% abundance 
pre-treatment and 0.3% post-treatment with a 0.76 Log10 reduction. 
 
 
 
In contrast, there was no Log10 reduction in microbial load for sample 45 (Pre-treatment = 
4.565. Post-treatment = 4.735). While community profiling revealed a minor reduction in 
Staphylococcus spp., (Figure 5.8) this was countered with a concomitant increase in other 
microorganisms. In this case, FISH could demonstrate the lack of action against the bulk of 
microorganisms in sample 45, with pre-and post-images depicting the presence of microbial 
aggregates as biofilm in chronic non-healing DFU tissue samples (Figure 5.9).  
 
 
 179 
Figure 5.8 Sample 45 identifies a small reduction in S. aureus. This is countered by a 
concomitant increase in other microorganisms allowing an increase in community 
diversity but not overall microbial load. 
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Figure 5.9 FISH image depicting pre-and-post Cadexomer iodine treatment and its 
effects on microbial aggregates. The red colour represents a universal probe (Cy3), 
and the green represents a species-specific probe for S. aureus (Alexa Fluor 633). 
Some reduction in S. aureus aggregates post-treatment is noted. 
 
 
 
 
 
In five patients, no Log10 reduction were noted with the use of Cadexomer Iodine. Considering 
the accepted notion that biofilms are tolerant to antimicrobials and combining the potential 
attributes of extremophile (and non-extremophile) microorganisms, this may explain why some 
wound microorganisms were tolerant to treatment. Post-treatment microbiota analysis 
identified these microorganisms increased in abundance from previously low numbers when 
skin flora microorganisms such as Pseudomonas spp. decreased in abundance following 
treatment (indicating Cadexomer iodine were effective). This community disruption may have 
occurred as nutrient availability increased or where mutual benefit arose 14. 
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In this study we also identified that the mean total MMP-9 and MMP-2 levels reduced 
following seven days’ application of Cadexomer Iodine (only MMP-9 reaching significance p 
= .05). The reduction in protease levels were further correlated to reductions in the microbial 
load (p = .03). Matrix metalloproteinases (MMPs) and tissue inhibitors of matrix 
metalloproteinase (TIMPs) are a family of proteolytic enzymes secreted by cells involved in 
wound healing, and their concentrations vary according to the phase of healing 354. In previous 
studies of chronic wounds, delayed healing was characterized by an increase in MMPs, and a 
decrease in tissue inhibitors of metalloproteinases (TIMPs) 355,356. MMPs also perform multiple 
roles in the normal immune response to infection and or the presence  357.  
 
MMPs destroy components of the extracellular matrix and damage growth factors and their 
receptors that are essential for healing 358. Excessive protease levels which may exist in chronic 
wounds (either independent or dependent on microbial load) could therefore impede healing 
356. Reducing the microbial load in chronic wounds may have downstream effects on protease 
levels and this could further contribute to improvements in wound healing, secondary to 
controlling (reduce, kill or eradicate) biofilm.  
 
Study limitations 
The primary aim of this study was to ascertain the effects of Cadexomer iodine on microbial 
populations associated with the presence of biofilm. Without the controlled conditions afforded 
by in vitro biofilm models, we are not able to fully rule out that planktonic microorganisms 
contaminated samples. Our rationale to provide a strong argument that planktonic 
microorganisms were of a negligible proportion of microbial cells, with the bulk of cells being 
biofilm, is supported by our visualisation techniques using SEM and FISH. These methods 
identified significant aggregates of microbial cells with EPS. Furthermore, we vigorously 
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rinsed all tissue samples during preparation as a method to reduce planktonic microorganisms 
not adhered to tissue. Alternate methods to reduce planktonic microorganisms from 
contaminating biofilm models have only been eluded to from ex vivo animal explants 297, with 
no reports of this approach on human tissue.  
 
To measure total microbial load, qPCR was utilized as the technique of choice, with previous 
wound related PCR studies adopting this methodology 67,359. We acknowledge with this 
approach the inability of qPCR (based on 16s rDNA) to differentiate live or dead bacteria. 
Other commonly employed techniques such as molecular viability testing (the pre-RNA 
analysis) and RT-PCR (viability qPCR) can detect LIVE/DEAD microorganisms. The 
limitations of this technique for our diabetic ulcer samples are the predominantly biofilm 
phenotype cells present in the tissue. Pre-RNA rapidly responds to nutrition stimulation and 
target metabolism, not actual microbial load. Given biofilm cells have low metabolism in 
comparison to planktonic cells, this may lead to variations in the 16S pre-RNA level between 
biofilm and planktonic cells and different growth conditions 360. The log reductions noted in 
this study therefore represents the minimal response and we acknowledge that some of the 
bacteria detected by qPCR could be dead, resulting in a lower calculable efficacy for 
Cadexomer iodine. 
 
Lastly, only eight samples with adequate protein concentration were available for analysis. In 
the majority obtaining enough wound fluid post treatment was difficult, and this may be 
associated with reduced wound inflammation with reductions in microbial loads. Alternatively, 
the time of dipstick applications was undertaken during 30-minute appointments and this may 
not have been long enough to adequately allow wounds to leak onto the three dipsticks 
required. 
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CHAPTER 6   
6.1 EVALUATION OF SHORT EXPOSURE TIMES OF ANTIMICROBIAL 
WOUND SOLUTIONS AGAINST MICROBIAL BIOFILMS: FROM IN VITRO TO 
IN VIVO 
(APPENDIX 10) JOHANI, K., MALONE, M., JENSEN, S. O., GOSBELL, I. B., 
DICKSON, H. G., HU, H., VICKERY K. EVALUATION OF SHORT EXPOSURE 
TIMES OF ANTIMICROBIAL WOUND SOLUTIONS AGAINST MICROBIAL 
BIOFILMS: FROM IN VITRO TO IN VIVO. J ANTIMICROB CHEMOTHER 2017 
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 Wrote the manuscript in full. 
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Abstract 
 
Objectives: Test the performance of topical antimicrobial wound solutions against microbial 
biofilms using in vitro, ex vivo and in vivo model systems at clinically relevant exposure times. 
 
Method: Topical antimicrobial wound solutions were tested under three different conditions; 
(in vitro) 4 % w/v melaleuca oil, polyhexamethylene biguanide, chlorhexidine, povidone iodine 
and hypochlorous acid were tested at short duration exposure times for 15-minutes against 3-
day mature biofilms of S. aureus and P. aeruginosa. (ex vivo) Hypochlorous acid was tested in 
a porcine skin explant model with twelve cycles of 10-minute exposure, over 24 hours, against 
3-day mature P. aeruginosa biofilms. (in vivo) 4 % w/v Melaleuca Oil was applied for 15-
minutes exposure, daily, for seven days, in 10 patients with chronic non-healing Diabetic Foot 
Ulcers (DFUs) complicated by biofilm. 
 
Results: In vitro assessment demonstrated variable efficacy in reducing biofilms ranging 
between 0.5 log10 reductions to full eradication. Repeated instillation of hypochlorous acid in 
a porcine model achieved < one log10 reduction (0.77 log10, p = .1). Application of 4 % w/v 
melaleuca oil in vivo, resulted in no change to the total microbial load of DFUs complicated by 
biofilm (median log10 microbial load pre-treatment = 4.9 log10 versus 4.8 log10 (p = .43). 
 
Conclusion: Short durations of exposure to topical antimicrobial wound solutions commonly 
utilised by clinicians are ineffective against microbial biofilms, particularly when used in vivo. 
Wound solutions should not be used as a sole therapy and clinicians should consider multi-
faceted strategies that include sharp debridement as gold standard. 
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6.1.1. INTRODUCTION 
 
Chronic wounds are a serious cause of morbidity and mortality and are associated with reduced 
patient health-related quality of life. The impacts to health care providers are reflected in the 
staggering cost of managing these wounds and associated comorbidities, with £5.3 billion 
attributed to National Health Service expenditure 361. Increasing evidence about the 
microorganisms involved in chronic wounds have identified that planktonic cells may not 
necessarily represent the phenotypic behaviour of microorganisms involved in chronic non-
healing wounds.  The focus has shifted towards the concept of microbial aggregates (biofilms) 
that differ markedly in both their phenotypic behaviour, which may contribute to the delayed 
healing of wounds 141. 
 
In addition, the ecology of chronic wounds explored through molecular DNA based 
technologies (and not cultivation based methods), have identified these wounds to be 
complicated by complex polymicrobial communities 90.  
 
Once established, complex biofilm communities often become highly tolerant to standard 
treatment and removal/eradication paradigms, yielding several hallmark features that 
distinguish biofilm phenotypes from those of planktonic counterparts. The most notable of 
these are a remarkable tolerance to antimicrobial agents 145,362 and host immune defenses 146. 
The increasing awareness and promotion of biofilm within the wound care arena has led to a 
dramatic rise in the use of topical antimicrobial solutions as part of wound-care therapeutics 
363. 
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Unfortunately, the evidence for use of particular topical antimicrobials in the treatment of 
biofilm-associated wounds is based on in vitro methodologies that lack standardization and 
clinical relevance to their intended applications 364. For example, the anti-biofilm effects of 
wound solutions/irrigates, where outcomes are based on reductions in biofilm markers (i.e., 
biomass, cfu/mL, LIVE/DEAD stain viability), have been reported at exposure times far 
greater than their intended use. Many wound care/device companies promote a 15-minute 
exposure time of their respective antimicrobial solutions (seconds for irrigates), yet the bulk of 
data for effectiveness of these products in vitro have only reported outcomes at 24-hour 
exposure times 288,301,365.  
 
This has important consequences at a treatment level where clinicians often seek guidance from 
laboratory-based studies (due to a lack of available in vivo data) in choosing the most relevant 
and effective agent to reduce microbial biofilms. Therefore, in vitro data based on greater 
exposure times may not reflect the most clinically appropriate outcomes for clinicians using 
these products at shorter exposure times. This is highlighted succinctly by Castaneda et al 
(2016) 303, who showed that in an in vitro biofilm model, antimicrobial susceptibility increased 
with antimicrobial exposure time.  
 
The present study was designed to explore if shorter durations of exposure of antimicrobial 
wound solutions were effective against microbial biofilms (i) in vitro against mature biofilms 
of S. aureus and P. aeruginosa (ii) in an ex vivo porcine skin explant model against mature P. 
aeruginosa biofilms and (iii) in vivo in 10 patients with chronic non-healing Diabetic Foot 
Ulcer (DFUs). 
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6.1.2. MATERIALS AND METHODS 
Bacteria 
Biofilm forming reference strains utilized in vitro were S. aureus (ATCC® 25923™, 
(methicillin-sensitive S. aureus—MSSA) and P. aeruginosa (ATCC® 25619™), and P. 
aeruginosa PA01 (ATCC® BAA-47™) was used in the ex vivo porcine skin explant model.  
 
Antimicrobial wound solutions 
The solutions/irrigates examined, any incorporated antimicrobials/antiseptics and their 
respective manufacturers were as follows: (SBMO) Surfactant based antiseptic solution with 4 
% w/v Melaleuca Oil (Woundaid® Woundwash, Mundipharma, Singapore), (SBPHMB) 
Surfactant based antimicrobial solution with polyhexamethylene biguanide (Prontosan®, B 
Braun Medical, Melsungen, Germany), (SOS) Superoxidized solution contains sodium 
hypochlorite, hypochlorous acid, sodium chloride, and oxidized water (Microcyn®, Oculus 
Technologies of Mexico), (CHX) Chlorhexidine 4.5mg/30mL (0.015% w/v) and cetrimide 
45mg/30mL (0.15% w/v) irrigation solution,  (Pfizer, New York, United States), (PVP-I) 
Povidone iodine antiseptic solution 10%w/v equivalent to 1% w/v available iodine 
(BETADINE®, Mundipharma, Singapore), NaCl 0.9% (Baxter, Illinois, United States). 
 
The decision to use SOS for the ex vivo porcine explant model and SBMO for human in vivo 
study was based on clinical relevance. Both the use and promotion of these “newer generation” 
solutions with antimicrobial properties (as opposed to traditional antimicrobials of CHX and 
PVP-I) by clinicians and industry for action against wound biofilm has increased significantly 
over the last decade. They now represent the predominant products used for wound cleansing 
and debridement.  
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Experimental models 
In vitro model  
Biofilm, containing 107 – 108 cells/coupon of P. aeruginosa (ATCC 25619) and 106 
cells/coupon of S. aureus ATCC 25923 were grown under shear (130 r.p.m.) on polycarbonate 
coupons in a CDC biofilm reactor (BioSurface Technologies Corp., Bozeman, MT) as 
previously described by our group 306, in 400 mL of 15 g/L (50%) Tryptone Soy Broth (TSB) 
(Sigma Aldrich, St. Louis, MO, United states) at 35 °C in batch phase for 48 hours, followed 
by fresh media (20% TSB, 6 g/L) for a further 24 hours. Coupons were washed in 10 mL 
phosphate buffered saline (PBS) to remove loosely attached planktonic bacteria. Each coupon 
had 107 – 108 P. aeruginosa or 106 S. aureus.  
 
Five antiseptic treatments were tested (SBMO, SBPHMB, SOS, CHX, PVP-I); four coupons 
were exposed to each treatment condition for 15 minutes, while an additional four coupons 
were used as controls.  The numbers of bacterial colony forming units (cfu) per coupon were 
tested in triplicate by sonication in an ultrasonic bath (Soniclean, Thebarton, Australia) for 10 
minutes with a sweeping frequency of 42-47 kH at 20oC. The coupon was then vortexed for 2 
minutes in 2 mL of PBS followed by sequential 10-fold dilution and plate count. Pre-and post-
exposure average cfu/ coupon was expressed as log10.   
 
Bacterial cell viability pre-and post-exposure was also assessed using BacLight™ (Live/Dead 
Bacterial Viability Kit, 7012, Molecular Probes, Invitrogen, Carlsbad, CA, United States) in 
conjunction with confocal laser scanning microscopy (CLSM) and expressed as percentage 
viability as determined by Imaris (v 8.4, ImarisXT, Bitplane). For confocal, we used inverted 
laser scanning confocal microscope LSM 880 (ZEISS LSM 880, Carl Zeiss Ltd., 
Herefordshire, UK) for all the samples, with oil-immersion lenses (63x and 
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100x) and acquisition parameters of frame Size: 1024 x 1024, Speed:6, Averaging: 2, Bit 
Depth: 12. 
 
Ex vivo porcine skin explant model 
The ex vivo porcine skin explant biofilm model used in this study is previously described 366. 
Large sheets of fresh pig skin (approximately 30 cm x 30 cm) were obtained from a USDA 
approved commercial meat processing lab.  The skin was thoroughly cleaned, and the hair was 
closely trimmed using an electric clipper and safety razor.  The subcutaneous fat layer was 
trimmed away so that only approximately 1-2 mm thickness remained.  The pig skin was then 
processed based on previous results of experiments assessing KCI VAC-Ulta® therapy (Acelity 
Inc., San Antonio, TX, United States) on porcine skin biofilm explants.   
 
Briefly, a circle shape approximately 12 cm in diameter was traced on the dorsal surface sheet 
of the large, cleaned porcine skin using a marking pen.  A partial thickness excision wound 
measuring 6 cm x 6 cm (36 cm2) and 0.8 mm deep was made in the center of each circular 
explant using an electric Paget dermatome.  The circular explants were then cut from the large 
sheet of pig skin using heavy scissors (Figure 6.1). 
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Figure 6.1 Method for creating partial thickness injuries to porcine skin. 
 
 
 
Explants were sterilized by first submerging the explants in PBS containing 0.6% hypochlorous 
acid and 0.5% Tween 80 for 5 minutes then transferred to a chlorine gas chamber for 45 
minutes, followed by submerging the explants again in PBS containing 0.6% hypochlorous 
acid and 0.5% Tween 80 for 5 minutes.  The sterile explants were rinsed twice in sterile PBS 
then transferred into 150 mm diameter x 25 mm deep culture plates (176 cm2 surface area) 
(Corning 430599) containing 0.5% tryptic soy soft agar containing antibiotic (gentamicin at 50 
mg/mL) to limit planktonic growth and promote biofilm growth on the explants. Partial 
thickness injuries measuring approximately 6 cm x 6 cm x 0.8 mm deep were created using an 
electric Paget dermatome to centre of a circular pig skin explant approximately 12 cm in 
diameter. After sterilization with hypochlorous acid and chlorine gas, explants were placed into 
150 mm diameter sterile culture plate containing 0.5% soft tryptic soy agar with antibiotic then 
inoculated with P. aeruginosa and grown for 3 days at 37ºC.    
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Growth of mature P. aeruginosa biofilm on sterile pig skin explants  
The wound area on each sterile pig skin explant was inoculated with 100 µl of planktonic 
culture containing approximately 107 – 108 colony forming units per milliliter (cfu/mL) of    P. 
aeruginosa bacteria.  The suspension culture of P. aeruginosa planktonic bacteria was in early 
log phase growth (0.2 -0.6 OD640nm) and was serially diluted in phosphate buffered saline (PBS) 
(4.5 mL) and plated in triplicate (0.1 mL) onto tryptic soy agar (TSA) to determine starting 
cfu/mL of planktonic culture.   
 
The P. aeruginosa inoculated explants were incubated for 3 days at 37°C in an atmosphere of 
5 % CO2 in air saturated with water vapor.  The explants were transferred daily to fresh sterile 
0.5% soft TSA supplemented with antibiotic.  After the three days of growth on TSA soft agar, 
the explants with the mature biofilm were rinsed with sterile PBS then transferred into fresh 
150 mm diameter x 25 mm deep culture plates (176 cm2 surface area) (Corning 430599) with 
a base of TSA supplemented with antibiotic.  Any excess PBS was removed from the surface 
of the explants by gentle aspiration.  
 
Treatment of biofilms on pig skin explants with V.A.C. UltaTM instillation system 
Application of the V.A.C. UltaTM therapy system (Acelity Inc., San Antonio, TX, United 
States) to pig skin biofilm explants required two people.  The appropriate sized V.A.C. 
VeraFlow™ Dressing (Acelity Inc., San Antonio, TX, United States) was applied to the surface 
of the porcine explants to cover the explant and ‘wound’ area and a V.A.C. VeraT.R.A.C™ 
Duo Tubing Set (Acelity Inc., San Antonio, TX, United States) was applied over the 
VeraFlow™ dressing (Figure 6.2). 
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Figure 6.2 Application of the V.A.C. VeraT.R.A.C™ Duo Tubing Set to the Pig Skin 
Explant.The appropriate sized V.A.C. VeraFlo™ dressing is applied to the surface of 
the porcine explants to frame the ‘wound’ area.  The drape is pulled and pressed firmly 
over the edge of the culture dish to ensure an air-tight seal between the dish and the 
V.A.C. UltaTM pad during treatment.   
 
 
 
 
 
The drape was pulled and pressed firmly to the surface of the framed pig skin and the edge of 
the culture dish to ensure an air tight seal to the dish. The V.A.C. VeraT.R.A.C™ Duo Tubing 
Set was connected to the canister and irrigation tubing respectively and negative pressure (125 
mm Hg) with instillation of appropriate solutions was applied using the V.A.C.UltaTM 
according to the conditions described below in the four test groups.  The V.A.C.UltaTM therapy 
for this experiment consisted of twelve (12) cycles of two (2) hours duration for each cycle for 
a total of 24 hours of the experiment.  Each cycle consists of instillation of 75 mL of fluid per 
cycle, 10 minutes of soak/dwell time followed by 110 minutes of continuous negative pressure.  
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Test conditions for Experiment 1: 
1. Control negative pressure only - 12 cycles of intermittent negative pressure, no 
instillation   
2. Microcyn -- 12 cycles of V.A.C. UltaTM with instillation of SOS at 10-minute 
dwell 
3. 0.125% bleach -- 12 cycles of V.A.C. UltaTM with instillation of bleach solution 
at 10-minute dwell 
4. Saline -- 12 cycles of V.A.C. UltaTM with instillation of saline solution at 10- 
minute dwell. 
 
Quantitative assessment of biofilm bacteria surviving on pig skin explants  
After 24 hours of treatment (12 treatment cycles), the drape and dressing were removed, and 
six biopsies of 8 mm diameter weretaken aseptically from the wound area of the explant at the 
six points of a hexagon pattern (60 degrees of angle separation) covering the wound bed under 
the V.A.C.UltaTM pad (Figure 6.3).  The six biopsies were transferred to separate tubes 
containing 5 mL of sterile PBS then sonicated in a water bath for 5 cycles of 1.5 minutes of 
sonication with a 1-minute pause between sonication cycles.  The bacterial suspension was 
serially diluted and plated in triplicate onto TSA plates to measure the number of colony 
forming units of biofilm bacteria after 24 hours of culture at 37°C.  Two additional biopsies 
were taken from the center of the wound bed under the V.A.C. UltaTM pad and one was 
processed for scanning electron microscopy (SEM) using standard glutaraldehyde fixation and 
sputter coating and one biopsy was processed for light microscopy by formaldehyde processing 
with paraffin embedding H&E staining. 
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Figure 6.3 Biopsies obtained from the centre of the explant - one for SEM and one for 
light microscopy. 
 
 
 
 
In vivo clinical study 
We used a combined molecular and microscopy approach described previously334  to better 
understand the effects of a topical antimicrobial solution against the microbial load and 
diversity of chronic non-healing DFUs complicated by biofilm Ten patients with chronic non-
healing DFU (and not on current antimicrobial therapy) were enrolled over a six-month period 
from a tertiary referral hospital (Liverpool Hospital High Risk Foot Service, Liverpool, 
Sydney). Ethics approval for this study was granted by the South West Sydney Local Health 
District Research and Ethics Committee (HREC/14/LPOOL/487, SSA/14/LPOOL/489). 
SBMO was soaked in sterile gauze and applied to the wound for 15 minutes, every day for 
seven days.  
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Sharp debridement of tissue was withheld over the seven-day treatment period, as this would 
have likely affected the primary outcome measure 309. Tissue punch biopsies were obtained 
from the wound edge for each participant after cleansing the wound with NaCl 0.9% pre-and 
post-treatment. These were subjected to qPCR to determine the total microbial load, 16S rDNA 
next generation sequencing to explore the microbiota of chronic DFUs and the effect of topical 
antimicrobial therapy on microbial communities, scanning electron microscopy (SEM) to 
visualize biofilm structures and fluorescent in situ hybridisation (FISH) in conjunction with 
CLSM to examine spatial organisation of microbial aggregates.  
 
Specimen collection and storage for in vivo analysis 
Tissue biopsies were obtained from the wound edge for each participant after cleansing the 
wound with NaCl 0.9%. Tissue samples for DNA analysis were placed immediately into 
RNAlater® (Ambion, Inc) for 24 hours at 4°C and then frozen at -80°C until DNA extraction. 
Tissue samples for FISH were immediately fixed in a 4% paraformaldehyde overnight at 4°C, 
then transferred into PBS and frozen at -80°C. An additional tissue punch biopsy was obtained 
for SEM (if possible) and immediately fixed in 3% glutaraldehyde overnight at 4°C, then 
transferred into 0.1% phosphate buffer (PB) and frozen at -80°C.  
 
 
qPCR to determine microbial load in DFU biofilms 
 
We utilised real-time quantitative PCR (qPCR) using the 16S rDNA eubacterial universal 
primers 341F 5’-CCTACGGGAGGCAGCAG-3’ and 534R 5’-ATTACCGCGGCTGCTGG-
3’to determine microbial load in DFU biofilms as previously reported 322,323. The total number 
of bacteria was expressed as per mg of tissue normalised to the average number of copies of 
the 18S rDNA gene in a mg of human tissue.  
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16S rDNA Next generation DNA sequencing of DFUs 
Genomic DNA was extracted from 5-10 mg of DFU biopsy sample using Mo Bio 
PowerBiofilm DNA isolation kit (Mo Bio Cat# 24000-50) following the manufacturer’s 
instructions. DNA sequencing was carried out by a commercial laboratory (Australian Centre 
for Ecogenomics, Brisbane, Australia) targeting the V3-V4 region of the 16S rDNA using 
eubacterial universal primers 515F and 806R 315. Preparation of the16S rDNA library was 
performed using the workflow outlined by the manufacturer (Illumina, San Diego, CA, United 
States).  
 
In the 1st stage, PCR products were amplified according to the specified workflow with an 
alteration in polymerase used to substitute Q5 Hot Start High-Fidelity 2X Master Mix (New 
England Biolabs, Ipswich, Massachusetts, United States). Resulting PCR amplicons were 
purified using Agencourt AMPure XP beads (Beckman Coulter, Indianapolis, United States). 
Purified DNA was indexed with unique 8bp barcodes using the Illumina Nextera XT 384 
sample Index Kit A-D (Illumina, San Diego, CA, United States) in standard PCR conditions 
with Q5 Hot Start High-Fidelity 2X Master Mix. Indexed amplicons were pooled in equimolar 
concentrations and sequenced on the Illumina MiSeq platform using paired end sequencing 
with V3 300bp chemistry. 
 
Sequence analysis and quality control  
Sequence quality control and analyses were performed using QIIME 367. This is an open-source 
bioinformatics pipeline for performing microbiome analysis from raw DNA sequencing data. 
Taxonomy assignment was aligned against the Greengenes reference database (version 
2013/05) at 97% similarity. Statistical analyses and data mining were performed using Calypso 
software 5.8 (http://cgenome.net). Where OTUs of interest (such as those previously cited in 
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infection or delayed healing) were assigned at only the genera level, these sequences were 
further referenced for speciation using NCBI Mega BLASTtn 368. For some OTUs, it was not 
possible to identify to species level. This is a commonly cited limitation when using 
hypervariable regions of 16S rDNA sequencing 369.  
 
Fluorescent in situ hybridisation (FISH) with CLSM  
Biopsy material was embedded in optimal cutting temperature (OTC) embedding matrix 
(Fisher Scientific, Waltham Massachusetts, United States), frozen at –80oC, cryo-sectioned to 
a thickness of 6 𝜇𝜇m and mounted on SuperFrost Plus slides (Menzel-Glaser, Lomb Scientific, 
Australia). Different types of probes were utilized for in situ hybridization as previously 
described 335. PNA-FISH, probes and kits were sourced commercially (AdvanDx, Inc., 
Woburn, MA, United States) using previously described methods 13.  
 
Briefly, species-specific Staphylococcus aureus/coagulase-negative Staphylococci (CNS) 
probes were used. The hybridization solution, was added drop-wise to each tissue section and 
hybridized at 55°C for 90 min. The slides were washed for 30 min at 55°C in wash solution. 
Once dry, the coverslip was mounted using a single drop of mounting medium. Slides were 
examined using CLSM (Zeiss Axio Imager Microscope and/or ZEISS LSM 880, Carl Zeiss 
Ltd., Herefordshire, UK). Images were processed using ZEISS ZEN Imaging Software (black 
edition) and Imaris v 8.4, ImarisXT, Bitplane. 
 
Scanning Electron Microscopy (SEM) and image interpretation 
DFU biopsy samples were fixed in 3% glutaraldehyde, followed by 3 washes of 0.1M 
phosphate buffer prior to serial ethanol dehydration and hexamethyldisilazane incubation 
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(Polysciences, Inc., Warrington, Pa, United States) as described previously 338. Dried samples 
were coated with 20-nm gold film in a sputter coater and examined in a scanning electron 
microscope. Each sample was scored based on the amount of bacteria/biofilm observed using 
an arbitrary five-point scale where score 0 = no bacteria observed; score 1 = single individual 
cells; score 2 = small micro-colonies (~ 10 cells); score 3 = large micro-colonies (~100 cells); 
score 4 = continuous film; score 5 = thick continuous film 339. Each tissue sample was viewed 
under SEM averaging two hours per sample. Tissue was screened for microbial aggregates and 
extracellular polymeric substances (EPS) from the wound surface downwards, working in a 
zigzag pattern at magnifications ranging from 300X to approximately 5,500X.  
 
Characterization and visualization of DFU biofilm in vivo 
The presence or absence of biofilms in DFUs were confirmed through SEM or PNA-FISH. For 
the purpose of the study, the definition of biofilm was “microbial aggregates surrounded by a 
self-produced or host derived matrix adhering to natural or artificial surfaces in the host, or 
aggregates associated with but not directly adherent to the surface” 93.  
 
Statistics  
Mann-Whitney U tests were used to assess differences between pre-and post log10 cfu using 
Statistical Package for Social Sciences Version 23 (SPSS Inc., Chicago, Illinois, USA). CLC 
genomics workbench version 8.5.1 in combination with the microbial genome-finishing 
module (CLC bio, Qiagen Aarhus, Denmark) were used to analyse DNA sequence data. QIIME 
was utilised to visually represent data. Analysis of variance (ANOVA) and permutational 
analysis of variance (PERMANOVA) were used for statistical analysis of alpha and beta 
diversity measures. Principal coordinates analysis (PCoA) plots with Bray–Curtis distances 
were used to assess how dissimilar microbial communities were pre-and-post-treatment. 
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Community richness of DFUs was presented using richness index reporting the number of 
unique OTUs in each wound sample. Shannon Weaver Index is an ecological measure of 
diversity that includes the number of unique microbial taxa and their relative evenness within 
each sample. For all comparisons and modelling, the level of significance was set at p < 0.05. 
Data are given as mean, median and standard deviation (±) and 95% confidence interval (CI). 
 
6.1.3. RESULTS 
 
Antimicrobial efficacies of topical wound solutions/irrigates against mature biofilms in vitro 
The effects of topical antimicrobial solutions on reductions in log10 cfu/coupon following 
treatments at 15 minutes and 24 hours are reported (Figures 6.4 and 6.5). Live/Dead stain with 
CLSM and the percentage of red signal (dead/damaged cells) and green signal (viable cells) at 
15-minute exposure is noted in Figure 6.6. At 15-minute exposures PVP-I was the only solution 
to show complete and efficient killing of both S. aureus and P. aeruginosa biofilms (6 log10 
and 7 log10 reduction, p < .001). CHX was effective against S. aureus biofilms showing 
complete removal of all bacteria (6 log10 reduction, p < .001), and further demonstrated a ≥4 
log10 cfu reduction against P. aeruginosa biofilm (3.96 log10, p = .01).  
 
In contrast, SOS demonstrated complete eradication of P. aeruginosa biofilm (7 log10 
reduction, p < .001), and a ≥4 log10 cfu/mL reduction against S. aureus (4.3 log10 reduction p 
= .01). No significant reduction in S. aureus counts was observed for treatment with SBPHMB 
(0.8 log10 reduction), however it was highly effective against P. aeruginosa biofilm showing 
complete eradication (7 log10 reduction, p = .01). Treatment with SBMO was ineffective 
against both S. aureus and P. aeruginosa biofilm. In contrast, treatment of biofilm with topical 
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antimicrobials for 24-hours exposure showed complete and efficient killing of biofilm, except 
for SBMO that failed to eradicate S. aureus (but still achieved a ≥2.5 log10 cfu/coupon). 
 
Figure 6.4 Bars represent means of logarithms of colony-forming units of viable 
biofilm cells after 15-minute exposure. 
 
 
Figure 6.5 After 24-hours exposure. Error bars represent the standard error of the 
means from three coupons (**p = .01, *** p < .001 – no viable cells). 
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Figure 6.6 Live/Dead stain with CLSM at 15-minute exposure to topical antimicrobial 
solutions. Percentage of red signal (dead/damaged cells) and green signal (viable 
cells) determined by the Imaris software (v 8.4, ImarisXT, Bitplane) 
 (a)    SBMO against S. aureus (ATCC® 25923™)                                                                    
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(b) SBMO against P. aeruginosa (ATCC® 25619™) 
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(c) SBPHMB against S. aureus (ATCC® 25923™) 
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(d) SBPHMB against P. aeruginosa (ATCC® 25619™) 
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(e) CHX against S. aureus (ATCC® 25923™) 
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(f) CHX against P. aeruginosa (ATCC® 25619™) 
 
 
 
 
 
 
 
 
 
 
 
 207 
(g) PVP-I against S. aureus (ATCC® 25923™) 
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(h) PVP-I against P. aeruginosa (ATCC® 25619™) 
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(i) SOS against S. aureus (ATCC® 25923™) 
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(j) SOS against P. aeruginosa (ATCC® 25619™). 
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Antimicrobial efficacy of SOS against mature biofilms in an ex vivo porcine skin explant model 
Levels of P. aeruginosa PA01 viable bacteria after twelve cycles of negative pressure therapy 
and instillation of saline or SOS are shown in Figure 6.7. The total bacterial bioburden 
(planktonic + biofilm) growing on the porcine skin explant was 8.0 log10 cfu/mL, of which 
7.1 log10 cfu/mL were biofilm bacteria, as defined by being tolerate to incubation in 50x MIC 
gentamicin for 24 hours at 37°C.   
 
When porcine skin explants with mature P. aeruginosa biofilm were exposed to 12 cycles of 
negative pressure wound therapy alone without instillation of any solution (Control- negative 
pressure wound therapy), which is equivalent to “pulsed or intermittent negative pressure 
wound therapy”, the level of PAO1 cfu was reduced to 6.9 log10 cfu/mL of total PAO1 
bacteria.  When the porcine skin explants were treated with negative pressure wound therapy 
with 12 cycles of instillation with saline with a 10-minute exposure time, the level of PAO1 
bacteria was the same with 6.9 log10 cfu/mL.   
 
Changing the instillation solution to SOS and using the same 12 cycles of instillation, the level 
of PAO1 bacteria was essentially the same as saline instillation, with 6.8 log10 cfu/mL 
surviving the instillation treatment.  In contrast, planktonic and biofilm bacteria were 
completely eradicated using the in vitro CDC biofilm reactor laboratory test.  
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Figure 6.7 108 cfu of P. aeruginosa PA01 inoculated onto porcine skin explants. After 
3 days of growth at 37˚C, the average cfu of viable total bacteria or biofilm bacteria 
pre-and-post 12 cycles of 10-minute instillations are reported. Instillation was 
undertaken with saline or SOS solutions or only negative pressure wound therapy 
without instillation. 
 
 
 
 
 
 
 
 
 
 
 
1.00E+00
1.00E+01
1.00E+02
1.00E+03
1.00E+04
1.00E+05
1.00E+06
1.00E+07
1.00E+08
1.00E+09
Lo
g 1
0
vi
ab
le
 b
ac
te
ri
a 
(c
fu
/m
L)
 
 
 213 
As shown in figures 6.8 and 6.9, SEM of the wound area in the porcine skin explants post-
treatment with SOS after 12 cycles of 10-minute exposure demonstrated very thick continuous 
biofilm on untreated explants.   
 
Figure 6.8 Un-treated pig skin showing Bacterial shape of Gram-negative rods – P. 
aeruginosa. Arrows illustrate microbial aggregates/bacteria. 
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Figure 6.9 Explants treated with SOS instillation also showed reduction of biofilm 
structure but a persistence of attached bacteria. Thick extracelluar matrix creating a 
stringy web like apperance. Some EPS has collpased as part of the dehydration process 
of SEM. 
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The effect of SBMO against the microbial load and diversity of DFUs complicated by biofilm 
in vivo 
A total of 10 patients with chronic non-healing DFUs were enrolled. 1,306,086 high quality 
DNA sequences were generated (before = 623,117, after = 682,969), with a median of 61,132 
per sample level data (Range = 5,702 to 168,421). The clustering of operational taxonomic 
units (OTUs) identified 1,976 unique taxa of which low abundance OTUs were removed 
(<0.1%), leaving 124 OTUs for further analysis.  
 
Confirmation of the presence or absence of biofilms in each DFU   
Biofilms were visualized and confirmed in all 10 participants using SEM. Biofilm architecture 
was graded using an arbitrary sliding scale from a score of 5 (heavy biofilm) to 0 (no biofilm) 
as previously reported 78. The median value of DFU biofilm architecture reduced from pre-
treatment 4 (large micro-colonies ~100 cells, and a continuous film/matrix) to post-treatment 
3 (large micro-colonies ~100 cells). 
 
Microbial load of chronic non-healing DFUs complicated by biofilm 
The application of SBMO for 15-minutes exposure daily, for seven days, resulted in no change 
to the total microbial load (Figure 6.10) (median log10 microbial load pre-treatment = 4.9 log10 
16S rDNA copies / per mg of tissue, versus 4.8 log10 16S rDNA copies / per mg of tissue (p = 
.43). 
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Figure 6.10 Effects of SBMO pre-and post-treatment of ten chronic non-healing DFUs. 
Box-and-whisper plot represents the median log10 16S rDNA copies / per mg of tissue 
values of all 10 patients. 
 
 
 
 
Analysis of community richness and diversity of chronic non-healing DFUs treated with 
SBMO. 
 
The most abundant OTUs contributing to >1% of the microorganisms within individual DFUs 
are noted in Figure 6.11; P. aeruginosa, S. aureus, Anaerococcus spp., Prevotella spp., and 
Streptococcus spp. were most commonly identified.  
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Figure 6.11 Effects to microbial communities following treatment with SBMO. Pairwise comparisons of pre-and post-treatment 
microbial communities at the genus level for individual wound data identifying the relative abundance (%) of OTUs. 
(a) 
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The % relative abundance of OTUs. P. aeruginosa and S. aureus increased in all but one patient 
post-treatment with SBMO (Figure 6.12), with pooled data from all samples identifying this to 
be statistically significant for Staphylococcus spp., DNA copies (p = .04).  
 
Figure 6.12 Pooled analysis from all samples identifying overall relative abundance 
pre-and-post-treatment with SBMO. 
 
 
 
Additionally, the number of both P. aeruginosa and S. aureus relative abundance increased in 
all but one patient following treatment with SBMO. Only patient 9 seemed to experience a 
reduction to S. aureus levels, however a significant increase in P. aeruginosa was noted as a 
result. SBMO reduced the total number of anaerobic microorganisms (Figure 6.13), but a 
concomitant increase in both aerobes and facultative microorganisms was noted.  
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Figure 6.13 Relative abundance (%) normalised to microbial load for each individual 
wound and then represented as pooled data with regards to aerotolerance.  
 
 
 
 
Analysis of microorganisms contributing to >1% of microbial communities in individual DFUs 
and from pooled data were analysed from alpha and beta diversity measures. Chronic DFUs 
prior to treatment were rich and diverse, yet there were minimal changes to community richness 
(p = .3), diversity (p = .1) or community composition of DFUs post-treatment  
(p = .9) (Figure 6.14 a-c). 
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Figure 6.14 Analysis of microbial communities alpha and beta diversity. (a) Richness 
index identifying unique OTUs. (b) Shannon Index identifies number of OTUs and 
their evenness. (c) Bray-Curtis dissimilarity matrix with PERMANOVA identifies 
differences (or not) in community composition. 
 
(a) 
 
(b) 
 
(c) 
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6.1.4. DISCUSSION 
Summary of key findings 
 
We systematically tested the performance of topical antimicrobial solutions using short 
exposure times for in vitro and ex vivo models and an in vivo human trial. Our results suggest 
that the performance of these solutions is poor when challenged against mature biofilms using 
short exposure times that mimic real clinical use (i.e. 15-minute application). Clinicians using 
topical antimicrobials to eradicate bacteria in chronic wounds as a single therapy under the 
assumption of removing biofilm may experience poor clinical outcomes. Clinicians should 
consider multi-faceted strategies that include sharp debridement as standard 309,370. 
 
What this study adds to the available evidence and new recommendations 
 
There are many facets to the management of chronic wounds, with a large focus on managing 
wounds colonised or infected with either planktonic or biofilm phenotype microorganisms. 
Whilst there is a plethora of data pertaining to the effectiveness of topical antimicrobials in 
vitro against both planktonic and sessile microorganisms, here we identify the inherent 
limitations of in vitro methodologies that fail to consider clinically relevant biofilm models 
when testing topical antimicrobials for use in wound care 288,301,365.  
 
In particular, in vitro models testing topical antimicrobial wound solutions have not considered 
the clinical applications of the products use with regards to the time of exposure 249, and 
outcomes are often reported after 24-hour exposure times.  This does not reflect the typical 
clinical pattern of usage of these products or the ‘instructions for use’ explained in product 
inserts. Nor does the use of immature biofilms (early forming biofilm 24 hours old) that have 
a less organised structure, a more active metabolism and a less pronounced stress response, 
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truly depict the complex, mature and highly tolerant biofilms identified in many chronic 
wounds 90,371. 
 
This may explain why some of the topical antimicrobials tested at clinically relevant times in 
this study performed poorly. Our in vitro model utilised two clinically relevant bacteria, P. 
aeruginosa and S. aureus, which have been noted as causes of delayed wound healing and as 
pathogens of infection 141,372. Testing the efficacy of solutions over a single 15-minute exposure 
time in vitro, we identified great variability in test performances. In general, surfactant based 
topical antimicrobials performed poorly (except for SBPHMB against P. aeruginosa) and was 
no more effective than normal saline (non-antimicrobial).  
 
Traditional antiseptics such as CHX and PVP-I were highly effective, whilst new generation 
solutions such as SOS were also highly efficacious. Chlorohexidine is a cationic bisbiguanide 
with a broad-spectrum biocide active against both Gram-positive and Gram-negative bacteria. 
373 Its primary action is against the negatively charged bacterial cell wall, leading to increased 
cell permeability resulting in cell death 373.  
 
The efficacy of Chlorhexidine in reducing or eradicating single or multi-species biofilm has 
been demonstrated in vitro 374-376, with the combination of cetrimide to chlorhexidine 
producing enhanced antimicrobial or anti-biofilm activity. One explanation for the 
effectiveness of CHX in vitro in this study may be explained by the cationic surfactant 
properties of cetrimide that has a demonstrated capacity to decrease the mechanical stability of 
biofilm (in addition to its proven bactericidal activity), but further work is required to elucidate 
these effects in wound models 377. 
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PVP-I also performed well in vitro, and as a broad-spectrum microbiocide is capable of 
inactivating Gram-positive and Gram-negative bacterial species, bacterial spores, fungi, 
protozoa and several viruses 378.  PVP enables the delivery of free iodine to a target cell 
membrane, where its mechanism of action is to destabilise the structural components of cell 
membranes 378.  It has demonstrated activity against biofilms in vitro 379,380. More recent in 
vitro data on the performance of a wound-care related PVP-I on multi-species biofilms using 
the CDC reactor have corroborated this study’s results 299.  
 
More recently, “newer generation” topical solutions with antimicrobial properties such as 
superoxidized solutions have been utilized as anti-biofilm therapies in wound-care, even in the 
presence of a low evidence base. SOS contains the primary ingredient of hypochlorous acid 
(which is not new generation), and only one in vitro study is available that used the 
concentrations of SOS found in current in wound-care solution 301.  Using a continuous flow 
tube reactor (to mimic the clinical scenario of a catheter) to grow mature six-day old P. 
aeruginosa PA01 biofilms, Sauer and colleagues utilised SOS at the same concentration (80 
ppm) reported in this study, to achieve a 2.5 log10 reduction after 60 minutes exposure.   
 
Our study identified that SOS could eradicate P. aeruginosa biofilms in addition to performing 
well against S. aureus biofilm. This contrasted with the porcine skin model, where SOS 
achieved only 0.77-log10 reduction against P. aeruginosa PA01 biofilms. Potential 
explanations to describe these results could be attributed to the two different strains of P. 
aeruginosa that were used for the study. The in vitro model utilised P. aeruginosa (ATCC® 
25619™) and the porcine skin explant utilised P. aeruginosa (PA01, ATCC® BAA-47™). 
Sauer and colleagues also utilised P. aeruginosa (PA01, ATCC® BAA-47™). Interestingly, 
the use of P. aeruginosa PA01 strain yielded results that identified a reduced effectiveness of 
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SOS. It is possible that whilst our in vitro P. aeruginosa (ATCC® 25619™) strain readily 
formed biofilm with the characteristic P. aeruginosa architecture, it did not develop a high-
level biofilm-specific resistance 381, that may have arisen in the PA01 strain. 
 
The different results observed for SOS in vitro versus the porcine skin model may be explained 
by the surface the biofilms were formed on (i.e. the soft tissue dermal matrix of porcine skin 
which more closely represent an actual wound bed compared to an abiotic polycarbonate disc). 
This may have attributed to alterations in microbial behaviour in response to the presence of 
biotic signals or organic material 382,383. 
 
Biofilms grown on biotic substrates or in vivo often do not display the morphological or 
architectural characteristics of those grown in vitro (e.g., mushroom structures and towers), 
which are important parameters that undoubtedly affect bacterial behaviour 384. Lastly unlike 
an abiotic surface, porcine skin has a striking similarity to human skin in terms of its structure 
and this is important given that microbial aggregates have been identified as forming not only 
on a wound surface, but also penetrating to deeper structures in a non-random distribution 41. 
In this scenario, any topical solution applied to a contact surface would have to penetrate a 
biofilm formed on that contact surface in addition to then penetrating between tissue cells. This 
presents a greater challenge than that already posed by biofilm tolerance mechanisms and may 
contribute to the reduced effectiveness of topical antimicrobials. 
 
Lastly, the performance of SBMO was tested on human tissue in an in vivo study on chronic 
non-healing DFUs. SBMO was applied daily for 15 minutes over a seven-day treatment period, 
with the results identifying no change in the total microbial load from tissue biopsies. 
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Interestingly, our in vivo results identified a correlation between the poor performance of 
SBMO against P. aeruginosa and S. aureus that was also seen in vitro.  
 
16S rDNA next generation sequencing was performed to understand the effects of SBMO on 
microbial communities in chronic non-healing DFUs. The relative abundances of both P. 
aeruginosa and S. aureus within most DFUs increased post-treatment. Conversely, an overall 
reduction in the relative abundance of anaerobic microorganisms and low frequency taxa 
(microorganisms contributing <1% relative abundance) was noted, but the total microbial loads 
within these wounds did not decrease. This suggests that more dominant species such as 
Staphylococcus spp. or Pseudomonas spp. benefit from the increased nutrient availability 
caused by disruption to the microbial community that resulted through removal of competing 
microorganisms 14 thus sustaining the microbial load within tissues.  
 
Treatment with SBMO resulted in the reduction in relative abundance of anaerobic 
microorganisms. Anaerobic microorganisms have been identified as part of polymicrobial 
communities cited for their involvement as a cause of delayed wound healing 6,385, as pathogens 
of infection in the diabetic foot 47 and in biofilm production 386. In this instance, reducing their 
numbers would seem like a positive step to reducing microorganisms with the potential to 
negatively impact the wound environment. Unfortunately, this might not be true given the 
concomitant increases in Staphylococcus spp., and P. aeruginosa that are equally capable 
pathogens. 
 
To assess the overall effects of SBMO treatment on DFU microbiota (community richness, 
diversity, structure and composition), DNA sequence data were analysed using QIIME 98. 
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Minimal reductions were seen in the number of OTUs (Richness) and community diversity of 
chronic DFUs post-treatment. In a recent study by Loesche et al (2017) 31, the temporal analysis 
of chronic DFUs showed that patient samples that had received systemic antimicrobial therapy 
had no alterations to species richness or diversity, and that antimicrobial exposure did not drive 
microbiota variation.  Instead the data indicated that antimicrobial exposure disrupted the 
microbiota when antimicrobials were specifically directed to treat underlying wound infection.  
 
We find a similar pattern of events with our data, in that exposure to SBMO had some effects 
when we explore our samples individually. For example, sample 2 experienced a significant 
disruption to its microbiota. Pre-treatment Staphylococcus spp. contributed <1% relative 
abundance, and post-treatment this significantly increased to >65%. Similar patterns are seen 
across our data, but it is not possible to infer if these changes would result in positive or 
negative effects on a wound. This intriguing aspect requires further longitudinal sampling that 
maps microbiota disruption to wound outcomes.  
 
Our molecular-based data using16S rDNA, while informative in describing “who is there”, is 
unable to truly define “who is doing what” 325.  In some wounds where anaerobic 
microorganisms are acting synergistically with aerobic counterparts to increase pathogenicity 
or virulence in a chronic wound, their reduction may likely lead to positive effects. Conversely, 
and providing food for thought, any perturbations to the complex microflora seen within 
chronic wounds may lead to microbial dysbiosis. Of particular significance is the reduction in 
microbial diversity, which may directly contribute to pathogen selection and persistence. 15 
Longitudinal studies are required to determine if alterations to the microbial diversity of 
chronic non-infected wounds seen through using topical antimicrobials leads to future 
complications. 
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Limitations 
The CDC biofilm reactor used in vitro was performed under flow allowing mature biofilms to 
form on the polycarbonate coupons. This abiotic surface does not reflect the complexity of 
human tissue and the host immune response. Secondly, most chronic wounds are contaminated 
with multiple species of bacteria 90 and this study utilised single species biofilms in vitro. That 
aside, our model tested clinically relevant exposure times against clinically relevant 
microorganisms involved in both chronic and infected wound types in screening the 
performance of topical antimicrobial solutions.  
 
qPCR was utilized to measure total microbial load in vivo 15 however this method has 
limitations in its inability to differentiate live or dead bacteria. The log reductions noted in this 
study therefore represent the minimal response and we acknowledge that some of the bacteria 
detected by qPCR could be dead, resulting in a lower calculable efficacy.  
 
Overall, the limitations in vitro were circumvented by the addition of an in vivo study. The cost 
of performing this study was a factor in not being able to test a wider range of topical 
antimicrobials in vivo. Further studies incorporating a human in vivo design may be required 
to understand the efficacy of products tested in the in vitro stage of this study against microbial 
biofilms. However, when considering the group of studies we performed collectively, there is 
a strong correlation between exposure time and efficacy.  
 
Summary 
Polymicrobial communities forming biofilms in chronic wounds may have extended time 
periods to develop complex, highly tolerant communities that differ greatly from single species 
biofilm models grown on glass coupons for 24-72 hours. The discrepancies between the three 
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different test parameters in this study raise an important question over in vitro testing for anti-
biofilm therapeutics, where results identifying potential effectiveness against biofilm, differ 
markedly when the test parameters are changed.  
 
In vitro testing for anti-biofilm strategies are a screening tool identifying potential therapeutics 
that may perform well on the next stage of testing (i.e. when taken to animal models or to 
clinical studies). The effectiveness of an anti-biofilm therapeutic at this in vitro stage is not 
absolute, yet for many medical devices companies this is the only data available for use in the 
promotion of products. When using porcine explants and human in vivo tissue samples, our 
data is highly suggestive that the exposure time of topical antimicrobial wound solutions and 
irrigation solutions is too short, and that exposure time is critical in determining the efficacy of 
these products. Clinicians using these topical antimicrobial solutions as a sole therapy under 
the assumption of killing or eradicating biofilm should consider adopting multi-faceted 
strategies that include sharp debridement as gold standard. 
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CHAPTER 7   
7.1 APPROACHES TO BIOFILM-ASSOCIATED INFECTIONS: THE NEED FOR 
STANDARDIZED AND RELEVANT BIOFILM METHODS FOR CLINICAL 
APPLICATIONS 
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7.1.2. INTRODUCTION  
 
Since the early 1970’s, an explosion of research on the concept of biofilms and their 
involvement in human health and disease have appeared in the medical literature 131. This new 
wealth of information, driven largely by advancements in emerging technologies and 
techniques applicable to the study of bacterial populations in situ, have advanced the 
understanding of “microbial biofilms”. The concept of biofilms in human health and disease is 
now universally accepted in chronic wounds 12,141 periodontal disease and dental caries 134,387, 
cystic fibrosis 135,136,388, in-dwelling medical device infection 389,390, otitis media and other 
upper respiratory infections 139,140, orthopaedic infections 391 and tuberculosis 133.   
 
Current definitions have described biofilms as microbes attached to surfaces or to each other 
in aggregates or clumps. They encapsulate in a self-produced extracellular polymeric  
substance (EPS) or matrix, that can also contain host derived components. As such biofilms 
show extreme tolerance to antimicrobials and host defenses 196,392-394. A plethora of in vitro 
biofilm models have elucidated that bacterial biofilms are more tolerant to antiseptics and 
disinfectants 395 as well as withstanding antimicrobial concentrations 100 to 1000 times higher 
than that of planktonic counterparts 145,172 
 
Despite the wealth of research undertaken to identify biofilm tolerance to antimicrobials, no 
single causative mechanism has been identified. Instead it has been suggested that a likely 
combination of factors contributes to biofilm tolerance 265,278 with several areas of interest 
including but not limited to; slow or incomplete permeation of antimicrobials through 
extracellular polymeric substance (EPS) 172,396, altered microenvironment and niches within 
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biofilms promoting slow growth rates and adaptive stress response 129,177, efflux pumps 276, and 
the role of low frequency dormant “persister” cells 257. 
 
Regardless of whether researchers fully uncover the answers to the biofilm riddle of tolerance, 
the practical implications are that individual patients suffer with prolonged chronic infections 
that often require multiple rounds of antibiotics 145.  The current treatment strategy for chronic 
infections comes at a high cost to the healthcare system and, more importantly, to the patient, 
both economically and in the potential loss in their quality of life. 
 
7.1.3. EXPLORING THE CONCEPT OF WHAT IS A RELEVANT REDUCTION FOR 
MEDICALLY RELEVANT BIOFILMS? 
 
Antimicrobial therapies for acute infections based on minimum inhibitory concentrations 
(MIC) (planktonic microorganism’s susceptibility to antibiotics) target rapidly multiplying 
planktonic microorganisms with high efficacy. Therapies based on MIC results employed 
against biofilm phenotype microorganisms that differ markedly in both their physiology and 
activity typically fail to eradicate the problem, leading to a chronic infection for the patient. 
For some patients, with in-dwelling medical devices for example, who have failed anti-biofilm 
strategies, the infection cannot be resolved until the material is completely removed 397.  
 
Researchers generally evaluate the efficacy of anti-biofilm strategies using susceptibility test 
results based on assays that identify the minimum biofilm eradication concentration (MBEC 
assay) through in vitro models such as the Calgary biofilm device 398.  The lack of correlation 
between conventional susceptibility test results and therapeutic success in chronic infections 
may be reflective of biofilm presence. A recent Cochrane review on standard versus biofilm 
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antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis identified that 
biofilm susceptibility testing was not superior to conventional antimicrobial susceptibility 
testing399. The Cochrane review suggests that biofilm antimicrobial susceptibility testing may 
be more appropriate in the development of newer, more effective formulations of drugs that 
can be tested in clinical trials.  
 
In addition to antibiotics, various agents have been explored for anti-biofilm activity. These 
have included peptides, antiseptics and oral and topical antimicrobials. How these agents are 
delivered to the biofilm has also varied greatly with mechanisms including coatings, drug 
eluting materials, wound gels, nanoparticles, irrigations and solutions, all being explored. 
Several alternate techniques have been developed to quantify outcome measures for these 
agents in vitro. Biofilm biomass has been explored, typically in 96-well microtiter plates and 
flow systems using staining methods (crystal violet, Syto9 staining) with optical density 
(ODnm) or confocal laser scanning microscopy (CLSM) to detect live/dead cells (expressed as 
percentages or ODnm) 400,401. Plate counts to enumerate viable cells that calculate antimicrobial 
efficacy expressed as cfu/ml, cfu/surface area, cfu/per mg tissue have also been utilised.  
 
The absence of a “target” reference value required to ascertain the “effectiveness” of anti-
biofilm strategies in aiding the host immune response to clear infective microorganisms is a 
problem. This has important consequences at a treatment level where clinicians often seek 
guidance from laboratory-based studies (often due the lack of in vivo data) to choose the most 
relevant and effective agent to reduce microbial colonization/infection. These decisions have 
historically been based on the use of planktonic paradigms.  
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Importantly, when deciphering what may be a “target reference” there are two sides of the 
fence to consider. Firstly there is a regulatory perspective that looks to determine a “target 
reference” based on standardized approaches using statistical attributes of an agent 402,403. 
Secondly, there is the issue of how well in vitro or ex vivo results translate to clinical efficacy 
and if those “target references” correlate to improvements in clinical symptoms and resolution 
of chronic infections. 
 
With respect to what would be a potential “target reference” value, there are no data to support 
what a reasonable figure would be. A target reference value may move depending on the type 
of infection, the infecting strain or the immune status of the patient. For example, data to 
support a reasonable target reference value for in vitro testing must take into consideration that 
when bacteria are expressing biofilm phenotype, infectivity in vivo may alter drastically. The 
most conservative approach is that the drug or device must demonstrate complete eradication 
of the biofilm in in vitro testing.”  The obvious approach to determine a reference value would 
be to transition from in vitro testing to in vivo clinical trials, as this would allow direct 
observations of what worked and what did not. In many cases, however, it may not be possible 
to obtain biofilm data directly from patients.   
 
The United States Environmental Protection Agency (EPA) addressed this concern for human 
health biofilm disinfection claims by proposing a 6-log reduction in biofilm as a standard. 
However, if industry wants to be “highly confident that they will achieve this target log 
reduction, then they need to formulate the biocide to completely kill the biofilm.   
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7.1.4. HOW SHOULD WE APPROACH ASSESSING THE “EFFECTIVENESS” OF ANTI-
BIOFILM THERAPIES BASED ON IN VITRO MODELS TO PREDICT CLINICAL 
RESULTS 
 
Biofilms exist in many niches and vary significantly from niche to niche. This likely restricts 
the ability to develop an assay that could be used universally, especially also given the large 
variation in biofilm architecture from in vitro to in vivo.  Whether one is evaluating biocides 
for use against biofilm in toilets, or antibiotics to treat chronic wounds, it is virtually impossible 
to perfectly mimic an actual infection or environment in the laboratory.   
Various publications have stated the need for the standardization of methods for assessing the 
“effectiveness” of anti-biofilm therapies.  
 
A problem however, facing anyone attempting to decipher the literature or attempting to 
replicate biofilm models for new therapies has been the lack of standardized methods for 
experimentally studying biofilms. This has caused much confusion when attempting to 
compare results between different research groups and has led to discrepancies when 
attempting to replicate the results between different laboratories. The lack of standardised 
methods also means there is no pathway for companies to follow when attempting to register 
a new device or drug with a regulatory agency.  
 
In the most applied sense, standard methods development is the creation of laboratory protocols 
for comparison, both within a single laboratory and among various laboratories.  Researchers 
choose to use a standard method for various reasons.  For instance, because every step of the 
laboratory process is exactly defined, a standard method is useful for teaching proper laboratory 
protocol or monitoring equipment performance.  The impetus for the development of many 
microbial standard methods, though, is efficacy testing for product registration with a 
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regulatory agency.  Regulatory agencies require efficacy data when a product is registered to 
ensure the quality, safety, and efficacy of antimicrobials (biocides, disinfectants, sterilants).  
 
For this purpose, standardized methods that are repeatable, reproducible, rugged and 
responsive are required 404.  A standard method should also be reasonable, meaning it should 
utilize equipment that is “typical” for a laboratory and it should not require an excessive amount 
of time, supplies or highly specialized training. Many biofilm research methods can uncover 
intriguing scientific insights even though the results are qualitative. However, regulatory 
authorities and standard setting organizations mostly prefer quantitative measures of efficacy. 
 
Uniform test conditions permit comparison of results between products and laboratories. To 
support a claim of bactericidal action for a disinfectant for example, efficacy against planktonic 
P. aeruginosa, P. vulgaris, E. coli and S. aureus is required by the Australian Therapeutic 
Goods Administration (TGO 54) 405, with efficacy against similar organisms being required by 
other regulatory organizations. All these organisms are biofilm producers and are associated 
with clinically relevant biofilm infections, so it seems reasonable to include anti-biofilm testing 
for these (or a subset of these) organisms. Unfortunately, standard methods only exist for 
biofilms formed by P. aeruginosa (ASTM Methods for E2196, E2562, E2647, and E2799). 
 
Importantly, a relevant laboratory method should adequately emulate “real use” conditions so 
that a laboratory test is predictive of how well a device (or test product of interest) will perform 
in vivo. Highlighting the decontamination of equipment and clinical surfaces with disinfectants/ 
sterilants as an example, it is of importance for users (or clinicians) responsible for the 
decontamination of instruments or surfaces to understand that the product they are using has 
been tested under conditions that best resemble the purpose to be applied to, such as the hospital 
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environment. Therefore, in terms of relevance, there are two basic strategies that researchers 
should strive to answer and that clinicians should strive to understand.  
 
The first strategy is to engineer a biofilm in a laboratory test to have specific characteristics 
that emulate the biofilm in vivo, matching for example, the architecture, thickness, strength of 
attachment and host factors such as proteins or immune cells. This is because alterations in any 
of these parameters can lead to alterations in the test outcomes. For example, the sensitivity of 
biofilm to disinfectants varies with both the age of the biofilm and the method of growth 406. 
This is well demonstrated in a paper by Buckingham-Meyer et al (2007) 362 where kill rate (log 
reduction) decreased as the amount of shear on the test biofilm during growth increased.  
 
The ASTM standard biofilm methods were developed based upon this relevance strategy 
(Table 7.1). By employing basic fluid dynamic concepts with regards to fluid shear and flow 
dynamics, the ASTM methods describe how to grow a biofilm that represents a general biofilm 
grown under high shear in a continuous stirred tank reactor (CSTR) (ASTM Method E2562) 
407, in medium shear in a CSTR (ASTM Method E2196) 408, low shear in a plug flow reactor 
close to the air liquid interface (ASTM Method E2647) 409 and minimal shear in a batch reactor 
(ASTM Method E 2799) 410. Others have recently reviewed the applicability of the biofilm 
reactors described in the ASTM Methods for various applications 122,411,412. 
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Table 7.1 Commonly employed laboratory models for biofilm investigation.Commonly 
Biofilm model Method  Nutrient availability  Potential applications and relevance  
Rotating disc reactor (annular reactor) 
(ASTM E2196 – approved 2002) 
This test method is used for growing a reproducible P. 
aeruginosa biofilm in a continuously stirred tank reactor 
(CSTR) under medium shear conditions.  
Open system 
Dynamic 
Continuous flow 
Rotating disc reactors are designed for laboratory 
evaluations of biocide efficacy, biofilm removal, and 
performance of anti-fouling materials. Example is to 
model a toilet bowl 413. It is important to note that the 
rotating disk and CDC reactor were not originally 
designed to study medically relevant biofilms. 
 
Drip flow reactor  
(ASTM E2647 – approved 2008) 
This test method is to grow, sample, and analyze a P. 
aeruginosa biofilm under low fluid shear and close to the 
air/liquid interface. 
Open system 
Dynamic 
Batch or continuous flow  
DFR are employed for growing biofilms for direct in 
situ visualization. The DFR can model environments 
such as food-processing conveyor belts, catheters, and 
the oral cavity 414 415. 
 
CDC biofilm reactor 
(ASTM E2562 – approved 2007) 
This test method is used for growing 
P. aeruginosa biofilm under moderate to high shear. The 
resulting biofilm is representative of generalized 
situations where biofilm exists under high shear rather 
than being representative of one environment. 
Open system 
Dynamic 
Batch or continuous flow 
Studies that utilized this reactor showed that it could 
be used for detecting biofilm formation, characterizing 
biofilm structure 416 and assessing the effect of 
antimicrobial agents on the biofilm (Note there is a 
large body of literature on how researchers are using 
the CDC, DFR and MBEC for various research 
applications.) 
MBEC assay / microtiter plates. 
(ASTM E2799 – approved 2011) 
This test method specifies the operational parameters 
required to grow and treat a P. aeruginosa biofilm in a 
high throughput-screening assay. 
Closed system 
Low shear (the reactor sits on a 
shaker) 
Batch 
MBEC assay allow rapid throughput of multiple 
samples of anti-biofilm therapeutics such as 
antibiotics, antiseptics, compounds and peptides 417. 
Single tube disinfection  
(ASTM 2871- approved 2013) 
Standard test method for evaluating disinfectant efficacy 
against P. aeruginosa biofilm grown in the CDC biofilm 
reactor using the single tube method. 
The single tube method is only 
an efficacy test.  Biocides are 
tested in a batch system, with 
no mixing at room temperature. 
This test was originally designed to determine the 
efficacy of liquid biocides against biofilm (bleach, 
quats, hydrogen peroxide blends, etc). Although it has 
been optimized using biofilm grown in the CDC 
reactor, the original intent was that the biofilm could 
originate from any biofilm reactor, if the appropriate 
controls were carried along. 
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The second basic strategy in methods development involves using reactors that incorporate the 
most important physiochemical and biological characteristics in the environment of interest 
418,419. An effective strategy that was followed for the development of the ASTM biofilm 
methods was to partition methods into sets of components.  For testing the efficacy of 
disinfectants or antibiotics these components include growing a repeatable and relevant 
biofilm, applying the antimicrobial treatment, harvesting a sample of the treated biofilm, and 
analyzing the sample for viable cells.  To better visualize this concept, Figure 7.1 shows a 
product testing and development guidance tree that outlines some of the numerous parameters 
under consideration for medically relevant biofilm standard methods.  
 
Figure 7.1 Decision tree for product testing and development guidance 
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The decision-making process for Figure 7.1, begins with understanding the mechanism of 
action (MOA) of the of the anti-biofilm technology.  The technology then determines the 
regulatory claim. For instance, an antimicrobial surface would most likely be associated with 
a “prevents initial attachment” or “reduces biofilm accumulation” claim, whereas a biocide 
manufacturer would most likely pursue a “kills” or “removes” biofilm claim. The claim then 
determines the necessary test output that will provide the necessary data to support the claim.  
For instance, a test that measures the log reduction in viable biofilm bacteria would provide 
the relevant data for “kill” claim.  The next step is to determine which laboratory growth and 
treatment methods best mimic the real-world application.  
 
Various parameters of concern for biofilm methods are included in this figure, but it is 
important to note that the list is not exhaustive.  The growth and treatment will often determine 
how the laboratory biofilm will be harvested and analysed. For instance, biofilm grown in 
microtiter plates is often not harvested, but stained directly and placed into a plate reader.  
Finally, every standard method must meet the statistical attributes listed in the Figure 7.1.  The 
text highlighted in red demonstrates the standardization path taken to measure the efficacy 
(kill) of biocides against biofilm.  
 
In this case, a single species biofilm is grown under high shear in the CDC reactor. The mature 
biofilm is removed from the reactor and tested under static conditions for a contact time 
specified by the biocide manufacture. Appropriate controls are always included. Sonication 
and vortexing is used to harvest the biofilm and the viable cells are enumerated using viable 
cells counts.  Finally, the proposed method has to undergone a collaborative study to verify 
that it meets the required statistical attributes.  The text highlighted in purple demonstrates a 
potential strategy for testing antimicrobial surfaces engineered to prevent biofilm attachment. 
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Despite the above, many researchers involved in biocide disinfection of a surface (not for 
medical devices or antimicrobial therapies) may still pose questions such as how well does the 
hydrated biofilm formed on a coupon or in the MBEC plate represent biofilm on a clinical 
surface which is in a semi-dehydrated state and encased in thickened EPS. It is unlikely that a 
biofilm formed on coupons or in an MBEC device will present the same challenge to biocides 
as biofilm that has been subjected to multiple rounds of decontamination e.g. biofilm 
contaminating endoscope channels 420.  
 
Biofilms form on all material types within the clinical environment, ranging from fabrics to 
plastics to stainless steel. Therefore, should research design questions be directed towards 
testing on different types of surfaces? For example, how relevant is a hard surface test as seen 
with current standards to killing biofilm on fabric? The CDC biofilm reactor (used in ASTM 
E2562) 407 uses removable coupons and thus has the capacity to compare different hard surface 
carriers with a range in free energy values and hydrophobicity e.g. glass, plastic, porcelain and 
steel. The premise of pushing the boundaries of any test condition and allowing researchers the 
“artistic” flexibility to mimic “real use” conditions often increases the complexity of the test 
methodology. Typically, methods that try to exactly match every parameter of interest in this 
manner are complex and therefore, when the method is verified in an inter-laboratory study (or 
ring trial), they do not perform well.
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7.2.4. EXPERT COMMENTARY  
 
Biofilm research has grown exponentially over the last two decades yet there are minimal data 
correlating in vitro results to clinical outcomes. In addition, whilst the medical community has 
a greater awareness of the role of biofilms in human health and disease, there are still many 
areas of confusion for clinicians, who in particular find it difficult to understand how in vitro 
methods translate to something of clinical relevance 125.  This begs the question, why are we 
not further along in the battle against biofilm associated infections? What is holding us back? 
 
In trying to understand why the pursuit of new anti-biofilm therapies has been lethargic in some 
areas of medically relevant biofilm research, potential explanations are a lack of standardized 
methods for testing anti-biofilm models that are clinically applicable (to be discussed in the 
next section) 362,421 , the lack of regulatory guidance for setting performance standards for 
biofilm related product claims in the medical device arena, a poor understanding of what 
defines “effectiveness” when applied to anti-biofilm strategies, the slow response of industry 
in pursuing new anti-biofilm therapeutics, perhaps due to the lack of regulatory guidance, 
standard methods, the cost of research and development and the cost of appropriate human 
clinical trials, factors that inadvertently force the industry to test their potential anti-biofilm 
therapies using methods that do not correlate to clinical outcomes, lack of funding resources to 
support the development of standard methods and lastly, the slow progression in translating 
anti-biofilm research and therapeutics to clinically relevant information 122.  
 
With increasing evidence detailing most aspects of biofilm involvement in human health and 
disease, clinicians and regulatory agencies have been hesitant to accept and pursue anti-biofilm 
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treatment strategies. In contrast, the chemical disinfection world for example, has lobbied hard 
for inclusion of anti-biofilm claims on products and these efforts have led to the development, 
validation and approval of standard methods for testing of anti-biofilm products. Examples of 
these are five ASTM standard test methods (E2196, E2562, E2647, E2799 and E2871) (Table 
7.1). The culmination of working towards developing standardized approaches that industry 
can utilise has meant that within the next two years, we may well see products with “kills 
biofilm” claims.   
 
However, the overall the lack of advancement in anti-biofilm strategies from industry that 
include medical device and biocide companies, may be explained by their haste to test their 
current therapeutics. Historically promoted for use against planktonic microorganisms in acute 
infections, the drive to ascertain if antimicrobials now have an action against biofilms may 
explain why industry are not moving towards new research and development specifically 
targeting anti-biofilm strategies. A major contributor for this is most likely the significant 
investment costs required to develop new therapies utilising evidence from in vitro through to 
in vivo trials.  The experimental designs in human studies, for example, would likely need to 
include many patients for a statistically relevant conclusion to be reached.  
 
In tandem with a lack of investment from industry is the challenge to find funding to support 
the development of standard methods, and the time it takes to develop a standard method.  Once 
a standard operating procedure is written, the method needs to go through rigorous intra-
laboratory testing to accumulate sufficient data to demonstrate that the method is repeatable, 
responsive and rugged.  This process may take one to two years, depending upon how 
compatible for standardization the research methodology is.  The method is then taken to a 
standard setting organization where each step is critically reviewed and discussed, a process 
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which may also take a few years.  Finally, the method goes through a multi-laboratory 
collaborative study to determine the reproducibility of the method. Assuming the method 
performs well, the process is complete.  But, if the method does not do well, it goes back to a 
standard setting organization (i.e. ASTM group) and is modified, extending the cost and time 
associated with standardizing it. 
 
Why haven’t clinicians lobbied for the same development of anti-biofilm therapeutics? Or why 
medical device companies have been slow to pursue new therapeutics. One reason to explain 
this slow progress is when clinicians come across a new drug and/or device, the regulations on 
the wording of the claim/documentation is focused on curing or preventing infection.  Biofilm 
does not become part of the discussion.   
 
This may seem to be a case of semantics, but simply not having biofilm be part of the discussion 
means generally it is not included as part of the clinician’s decision making in terms of infection 
management. With regards to an appropriate outcome, clinicians would also need to understand 
what “effectiveness” of a product meant, whether biofilm was reduced (if so, by how much?) 
or if a 100% kill was achieved. Importantly, any reductions or killing of a biofilm would need 
to be associated with a reduction of infective symptoms and improved patient outcome. 
 
For a change to happen, clinicians need to start asking if the patient has a chronic biofilm or an 
acute infection. In orthopaedic-device, catheter or cardiac valve related infections, clinicians 
are fully aware of the presence of biofilm. In fact, treatment is directed at biofilm with well-
documented anti-biofilm activity such as fluroquinolones 422,423 or rifampin 254, often in 
combination with another antibiotic 424 since resistance to rifampin can occur with a single 
point mutation 425. In surgery, more aggressive debridement is also being practiced as an anti-
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biofilm strategy, treating biofilm infections more like an aggressive cancer which can come 
back with devastating consequences unless completely eradicated. However, specific biofilm 
targeted treatment options are limited and if the biofilm is not eradicated there is an increased 
probability of generating resistance, leading to further complications for treating the infection 
down the road. This translates into demand for new strategies/treatments to cure biofilm 
infections. 
 
Aiding in the confusion and lack of association between biofilm and chronic infection are the 
huge disparity in diagnostics. There are no diagnostic tools or biomarkers to help identify when 
biofilm is the driver of infection 93,342. In the age of science-based medicine, how can clinicians 
be expected to deviate from standard measures of treating planktonic infections based on 
antimicrobial stewardships and make decisions to treat the infection as a biofilm infection, if 
there is no way to verify it?  
 
When medical devices companies decide to pursue anti-biofilm strategies they are faced with 
the barriers of navigating the minefield of regulatory standards. In this instance, regulatory 
agencies want clinical data that demonstrates a new drug or device’s ability to decrease 
infection rates in patients. Historically, the regulatory tests to make these claims have been 
based on the minimum inhibitory concentration for planktonic microorganisms (Clinical 
laboratory standards institute (CLSI), M02-A12, M07-A10, M100 –S26). This is different than 
showing that a device prevents and/or reduces biofilm.  Although logically, a person cannot 
develop a biofilm-based infection if no biofilm forms, but this is not the outcome that is being 
regulated or monitored by clinicians.   
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Even though researchers have demonstrated that biofilm is the root cause of many chronic 
infections there is limited clinical biofilm data because clinicians do not routinely collect 
samples for biofilm specific diagnostics. Granted this would be extremely challenging, but with 
advancements in new non-invasive technologies, the possibility certainly exists that a 
mechanism for collecting these samples will exist in the future. This can be exemplified in 
chronic non-healing wounds complicated by biofilm, where in general practice the clinician 
does not collect a swab or tissue sample of the wound bed to quantify the biofilm to direct 
antimicrobial therapy to treat the infection.  
 
Based upon data from industrial research, bacterial counts in the process water do not 
necessarily correlate to counts on the pipe’s surface. This could also hold true in the human 
body.  A low count in the urine does not mean that no biofilm is present; it just means that the 
biofilm has not grown to the point where the body is showing signs of infection.  And of course, 
it would be unethical to do a study where catheters are removed over time to record the biofilm 
that forms and correlate this number to when the “typical” person begins to show signs of an 
infection (which is what occurs in industrial models for biofilm testing).  
 
However, it is only useful to develop biofilm specific sampling if clinical microbiology has the 
tools for appropriate diagnostics. Currently confocal microscopy is considered the most direct 
way of demonstrating biofilms in clinical specimens 120 but these methods are time consuming 
and require highly specialized training. 
 
This leads to a very important question. We do not know what the necessary log reduction in 
biofilm bacteria is that will ultimately cure the infection.  For testing measures pertaining to 
the performance standards of an antimicrobial against planktonic microorganisms, the 
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necessary reduction in microorganism counts has been defined as a greater than 3 log reduction 
(If the reproducibility standard deviation is 1 log10 then the antimicrobial must achieve a 
greater than 4 log10 reduction) 426. Without knowing what this reference value is for biofilm-
based infections, a conservative approach maybe for regulatory agencies to require that the 
antibiotic/device must kill everything. 
 
If this were the case what does this mean for antimicrobial therapies currently employed against 
biofilm that exhibit only partial reductions against biofilm in vitro. Using the concept of 
rifampin, the more commonly employed antimicrobial against biofilm, evidence has identified 
it does not entirely kill the bacterial biofilm in most in vitro models 254,427. Does this account 
to regulatory agencies not validating its future use against biofilm-associated infections, and or 
clinicians not using it for the same purpose? Presently the simple answer is no, clinicians will 
still likely use this systemic antimicrobial, evidence or not, because right now that is their only 
option and clinicians are committed to trying to help the patient to the best of their ability.   
 
Currently, the FDA would also not register an antibiotic or new drug based solely upon in vitro 
data as they are limited and do not consider a human immune response, nor can any statements 
be made about preventing or curing infection. Ideally the systemic antimicrobial is working in 
combination with the person’s immune system to resolve the infection, but the presence of 
biofilm can restrict this response 428. This may explain why people with chronic biofilm 
infections require multiple doses (and combinations) of systemic antimicrobials over extended 
periods of time (sometimes even in the order of magnitude of months or years). This 
exemplifies the main underlying theme of this review paper, which is that current in vitro 
biofilm tests are inadequate, and therefore are not predicting how the antibiotic will perform 
clinically.  This may explain why there is little correlation between in in vitro and clinical 
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results.  The requirement for better designed (more clinically relevant) in vitro biofilm tests 
that have gone through a standardization process may improve clinical outcomes and help 
direct clinicians to using antimicrobials with proven efficacy against biofilm. Once the standard 
methods are in place, then correlation to clinical data and ideally performance standards will 
follow. 
7.2.5 FIVE-YEAR VIEW 
 
Is there a clear path towards the direction of standardized approaches to biofilm strategies? 
Many examples outlined in this review article highlight the biofilm specific issues that need to 
be addressed to help provide better guidance to clinicians managing biofilm associated 
infections. When the performance of an anti-biofilm strategy relates to the clinical care of 
patients, there is a need to achieve a standardized biofilm method “utopia”. This will provide 
pharmaceutical / device manufacturers all the experimental parameters required so that a 
collaborative study may be done. From a regulatory perspective, this would also allow for the 
method’s reproducibility standard deviation (SD) to be determined. This requirement is highly 
relevant for clinicians to appreciate, who may read a paper on a new technology that performed 
fabulously in a one laboratory study, did fine in an animal model, but failed miserably in a 
clinical trial. If an appropriate statistical analysis had been performed the probability of failure 
would have been predicted.  In general, a large percentage of experiments may lack the 
statistical attributes that are required of a standard method, and without statistics, there is no 
statistical confidence in the outcome.    
 
In the same instance their needs to be delineation between absolute standard methods and 
research methods, with the latter affording the flexibility for researchers to advance new 
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therapeutic strategies towards biofilm-associated infections. Roberts et al (2015) 122 referred to 
this notion, suggesting that researchers should not be afraid of undertaking initial in vitro 
screening (non-standardized experiments). In doing so, this may provide greater predictive 
power for in vivo activity, and allow side-by-side comparative studies with established 
antimicrobial agents.  This may enhance the capability to better understand biofilm associated 
infections. 
 
However, Roberts et al (2015) make the same conclusion as we would, which is the most 
relevant system should be used based upon the questions being asked. Although preliminary 
experiments will allow researchers to make advances in our basic understanding of these 
biofilm infections, regulatory agencies require data collected with methods that have been 
statistically validated, which generally means the method has gone through a standardization 
process.  Perhaps it is the reluctance of medical researchers to use standard methods that has 
provided a roadblock and explains why the medical field lags the biocide/industrial field with 
regards to biocide claims.  
7.2.6. KEY ISSUES 
 
• Biofilms show remarkable tolerance to many forms of treatments and the host immune 
response. 
 
• The lack of correlation between conventional susceptibility test results and therapeutic 
success in chronic infections maybe reflective of biofilm presence. 
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• The absence of a “target” reference value required to ascertain the “effectiveness” of 
anti-biofilm strategies to clear infective microorganisms suggests complete eradication 
is required. 
 
• A potential way forward for performance testing could be to develop a simplified 
biofilm assay that allows standardized adaptations (calibrated) to test parameters 
allowing the performance of a product to aid in predicting successful in vivo outcomes. 
 
• No in vitro test provides a prediction on how well a product will work in vivo, but it 
does provide confidence to move forward onto animal models or costly clinical in vivo 
trials. 
 
• Many areas of confusion regarding anti-biofilm strategies still exist for clinicians who 
are caught either finding it difficult to understand how in vitro methods translate to 
something of clinical relevance or think that successful in vitro outcomes will provide 
similar results in vivo
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CHAPTER 8  
FINAL DISCUSSION, LINKING OF DATA AND FUTURE WORK 
 
8.1. 16S RDNA NEXT GENERATION SEQUENCING  
 
Summary of key findings 
 
When taken collectively, the genomic data presented in this thesis provides an extended view 
of the microbiota of infected tissues from the feet of people with diabetes. The data is 
comprehensive in providing an extended view of the microbiota in contrast to conventional 
culture methods, yet at the same time provides a conundrum in deciphering what the 
importance of these additional “hidden” microorganisms may be. “So, what” if a DFU has fifty 
bacterial genera colonising it. What does this mean? Does this affect clinical outcomes? How 
does this data provide alternate insights into the microbiota of DFI in comparison to 
conventional culture data? 
 
In short, this genomic data (utilising 16S rDNA next generation sequencing) has identified many 
similarities with respect to the likely pathogens of infection when compared to culture-
dependent approaches. This seems to suggest that anti-infective practices based on 
conventional culture data are appropriate for most patients. For example, pathogens of infection 
similar to those found by conventional culture were identified and illustrates the predominant 
role of pyogenic cocci (Staphylococcus aureus and Streptococcus spp.). This data supports 
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many expert guidelines that suggest anti-infective therapy should be directed towards these 
microorganisms.  
 
Skin flora or pathogens of infection? 
 
Corynebacterium spp. is often cited as commensal skin flora and ignored as a potential 
pathogen of infection, yet these aerobic Gram-positive bacilli were identified in most infected 
DFUs, contributing as one of the major taxa. Another group of microorganisms that has been 
poorly defined in DFI are anaerobes, because the ability to culture these microorganisms in 
conventional microbiology laboratories requires exhaustive measures. By circumventing 
conventional microbiology and utilising DNA sequencing, fastidious anaerobes (and other 
anaerobes) such as Clostridiales family XI (Finegoldia spp., Anaerococcus spp., Peptoniphilus 
spp.) were found to be prevalent in up to 80% of infected tissues and contribute as major taxa. 
The high relative abundance of Corynebacterium spp. or anaerobes in infected tissues suggests 
they may contribute as part of polymicrobial infections.  
 
At a clinical level, many first line antimicrobials of choice for DFI are active against these 
microorganisms. As such there may not be a requirement to target them specifically unless 
mono-microbial cultures are identified, or infective episodes are not responding to first line 
therapies (in the presence of known antimicrobial susceptibilities). In the clinical data from 
patients enrolled in Chapter 3, no trends were observed towards an increased likelihood to fail 
therapy in the presence of a high abundance of anaerobes. This supports the assumption that 
many first line antimicrobials used for DFI are active against anaerobes. 
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Additionally, DNA data from patients with infected DFUs where diverse polymicrobial 
communities that included both pyogenic cocci and anaerobes, are examined, treatment with 
narrow spectrum antimicrobials resolved some of these infective episodes. Studies to determine 
the most efficacious anti-infective regimes for DFI are limited and there have been no 
publications to date to explore if broad spectrum antimicrobials improve outcomes over narrow 
spectrum antimicrobials. The limited sample size of 39 patients did not allow the exploration 
of this concept and while the previous paragraph leaves more unanswered questions than 
answered ones, this presents a scope for further investigation with trying to better understand 
why some polymicrobial infections seemingly resolve with narrow targeted therapeutics.  
 
Most foot ulcers are chronic long-standing wounds that develop acute infections? 
 
An important clinical scenario identified from Chapter 3 is the matter of DFU duration, and 
how this may help guide clinicians in determining the most appropriate ant-infective therapy. 
The duration of ulceration prior to infection was a major driver in determining the microbiota 
of infected wounds. For most DFIs, the microbiota was rich and diverse, but a pattern was 
identified where newer DFUs (<6 weeks) presented with fewer microorganisms that were 
typically a high frequency taxa profile or mono-microbial.  This suggests that clinicians could 
safely use narrow spectrum antimicrobials directed towards aerobic Gram-positive cocci. 
Conversely, DFUs of longer duration (>6 weeks) had complex polymicrobial communities 
with high to low or low frequency taxa profiles suggesting that broad spectrum antimicrobials 
maybe better suited in these scenarios. Ultimately the sample size of this data restricts the 
ability to generalise further on these concepts, but this once again provides an opportunity for 
further investigation.  
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Correlating clinical data to microbiome analysis may identify patterns of interest to target 
therapy 
 
Using simple descriptive statistics, three taxa profiles emerged from patients with DFI in this 
thesis. These were; High frequency taxa mostly comprised of a single microorganism (±3) (i.e. 
monomicrobial infection), High to low frequency taxa were comprised of between one to five 
(±2) dominant microorganisms followed by many low frequency taxa (i.e. polymicrobial 
infection) and low frequency taxa comprised on average of ≥20 (±) minor microorganisms 
(complex polymicrobial infection).  
 
The ability to group microbial profiles in this manner represents an attractive analysis for 
researchers, most notably because it allows for pattern recognitions that may prove useful for 
targeted therapeutics. For example, it may prove possible that high frequency taxa in DFI as 
identified in this thesis being predominantly composed of Staphylococcus spp. or 
Streptococcus spp., only require narrow spectrum antibiotics as compared to say a low 
frequency taxa profile. Therefore, profiling patients based on DNA data could aid antimicrobial 
stewardship and reduce unnecessary used of broad agents. 
 
Profiling patient’s microbiota in this thesis is not a unique analysis to apply to wound 
microbiota’s. The ability to cluster samples based on their microbiota profiles was undertaken 
by Loesche et al (2016) who performed Dirichlet multinominal mixture (DMM) model-based 
approaches. This is a rigorous statistical approach, unlike the general observations of 
descriptive statistics performed in this thesis. However, regardless of this fact, the microbiota 
profiles identified by Loesche et al (2016) were similar to those reported herein. Loesche et al 
reported community types labelled as CT1, CT2, CT3 and CT 4. CT1 and CT2 were highly 
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heterogeneous with no dominant bacteria (this is reflective of high to low and low frequency 
profiles in this thesis), CT3 were characterized as having high relative abundance of 
Streptococcus spp., and CT4 DFUs had high relative abundances of S. aureus (this is reflective 
of high frequency profiles in this thesis).  
 
Other clinical data that were collected from patients enrolled as part of this thesis were the 
classifications of infection severity from patients presenting with DFI. These are graded 
according to the IDSA DFI guidelines as being mild, moderate or severe infections. One could 
imagine that large data sets or a registry could be compiled mapping infection severity to DNA 
based microbial profiles. This could allow for potential analysis of patterns of presenting 
microbiota’s based on infection severity, in order to distinguish if certain infection severities 
harbour similar or dissimilar microbiota’s. 
 
In this thesis, patients with severe infections in DFUs >6 weeks presented with microbiota’s 
that were complex, diverse and lacking any predominant or major taxa/pathogen (low 
frequency taxa profiles). Current guidelines for the treatment of severe DFI promote the use of 
intravenous broad-spectrum antimicrobials to cover both pyogenic cocci and anaerobes. The 
data from this thesis supports this action but presents a potential area for further exploration. 
Only four patients with these taxa profiles presented which makes correlating clinical and 
laboratory data impossible. These taxa profiles are intriguing from a microbial ecology 
perspective because they reflect the concept of functional equivalent pathogroups (FEP) 9, 
where a consortia of genotypically distinct bacteria act symbiotically to produce a pathogenic 
community. Understanding these complex infections that may often fail antimicrobial therapies 
may allow for better therapeutics. 
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In reflection of this area of analysis, development of translating clinically useful information 
on taxa profiling will only be possible where large data sets exist. Future works could look at 
developing a registry of sorts whereby clinicians utilsing DNA based approaches for DFI could 
contribute to creating large enough data sets for analysis. 
 
8.2 MICROSCOPY TECHNIQUES  
 
16S rDNA next generation sequencing affords the ability to depict which microorganisms are 
residing in that given tissue section. Conventional microbiology and development of 
antimicrobials have been solely based on planktonic paradigms, through methods developed in 
the early 1800’s. For acute infections, classic microbiology has defined the causative organisms 
as being planktonic, rapidly multiplying cells, that damage host tissue and induce a host 
response, that clinicians visualise as overt clinical infection. Bacteria however, can exist in two 
(maybe more?) phenotypic or different growth forms, that being the planktonic form, and the 
second as aggregated communities of slow growing cells in a biofilm form. Biofilm infections 
have been defined as causing alternate symptomology, in part due to their 
behavioral/phenotypic changes. Of particular importance are thier noted involvement in 
chronic, persistent infections, in varying human health and disease pathologies 93. 
 
Summary of key findings 
 
Because many of the microorganisms in biofilm are not rapidly dividing or metabolizing (i.e. 
they show slow growth or dormant like state), the conventional culture techniques required to 
grow them are exhaustive, if not impossible. Methods to confirm the presence of biofilm 
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structures in tissue samples have therefore relied upon microscopy approaches to visualise 
biofilm structures in situ, or to analyse the spatial organization of microorganisms. 
 
Chapter 4 of this thesis presents a human in vivo study of 65 DFUs classified as infected or 
chronic and non-healing. Microscopy and molecular techniques that included SEM, PNA-
FISH with confocal laser scanning microscopy and 16S rDNA next generation sequencing were 
utilised to observe the presence of biofilms in all 65 (100%) of DFUs. Biofilms were ubiquitous 
and contained both mono-species and complex polymicrobial communities in the same 
sections of DFU tissue. This data set currently represents the largest collection of consecutive 
samples from DFUs within the literature. The clinical significance of our findings suggests that 
biofilms may have a pathogenic role across a spectrum of DFU presentations. 
 
Do we need to change the way we treat chronic wounds? 
 
When combined with previous data in the literature, this thesis presents a strong argument to 
support a paradigm shift in the management of chronic and infected wounds. Management is 
traditionally based on treating planktonic infections that respond rapidly to single therapies. 
Sessile microorganisms residing as biofilm communities are highly tolerant to these treatments 
and may not respond in a typical fashion to therapies that are short in duration and narrowly 
focused. For changes to occur in management, clinicians must begin to discuss and 
acknowledge the potential that biofilms contribute to infective processes in wounds. Currently 
this discussion does not occur and recent antimicrobial stewardship guidelines for wound-care 
omit any reference to biofilms 328.  
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For patients presenting with acute wounds that develop acute infections, the above planktonic 
based approach is most certainly appropriate, but the evidence presented in this thesis suggests 
that many patients present with chronic wounds that have acute infective episodes containing 
complex polymicrobial communities residing in biofilms. Using planktonic approaches for 
culture and establishment of sensitivities to anti-infective agents may not provide the best 
possible clinical outcomes. Anecdotally, as a clinician, chronic wound infections often require 
prolonged therapy and multi-faceted wound-care approaches. The major problem in driving 
changes to anti-infective practices has been the limited evidence-base for studies that have 
attempted to delineate treatment using either a planktonic based approach or biofilm-based 
approach. The area of treatment of chronic wounds presents an ideal avenue for further research 
both from an antibiotic perspective and from a topical antimicrobial wound-care standpoint. 
 
Duration of the wound in a person with diabetes; does it predispose to greater opportunities 
of biofilm formation?  
 
The majority of biofilms visualised in vivo chronic wounds in this thesis, were of longer 
duration (>6 weeks). However, biofilm was also identified in five DFUs of shorter duration 
(<6 weeks). The visualization of biofilms in chronic non-healing DFUs is expected, but 
formation of biofilm in shorter duration DFUs may suggest that diabetes increases the risk of 
biofilm formation. This could be explained by several ill-defined immunological deficits 
attributed too underlying hyperglycaemia 18, that contributes to a poor response of neutrophils 
to colonizing or invading microorganisms 340, or from impairments in microbial phagocytosis 
341.  
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The number of shorter duration DFU samples with biofilm presence are too small to draw valid 
conclusions, but this presents an interesting trend that warrants further exploration.  
As previously described, planktonic microorganisms have been labelled as the drivers of acute 
infections. In 39 infected DFUs sampled by microscopy techniques, biofilm structures were 
visualised. One question as a result of these findings is at what level of microbial infection do 
biofilms involve themselves? This data highlights a possibility whereby wound biofilm act as 
reservoirs for pathogens and biofilm dispersal increases the presence of planktonic 
microorganisms 342, that may be opportunistic or known pathogens 429. Thus, acute infective 
wound symptoms may arise directly from a nidus chronic pathology.  
 
To support this idea, the most abundant bacteria identified using 16S rDNA sequencing was S. 
aureus. PNA-FISH species-specific probes for S. aureus confirmed S. aureus as being present 
in the clear majority of samples as dense microbial aggregates. S. aureus has long been cited 
as the most common pathogen of infection in diabetic foot infections from culture-dependent 
studies 42, and here it is identified as being the predominant pathogen of infection in the 
presence of visualized biofilm. This data may help with regards to the development of future 
anti-biofilm strategies for DFU treatment where researchers should consider that anti-biofilm 
strategies target or be effective against S. aureus. This is one of the primary reasons why an 
ATCC strain of S. aureus was utilised for all the in vitro testing as outlined in chapters 6 & 7. 
 
In addition to testing commonly cited microorganisms such as S. aureus, PNA-FISH and 16S 
rDNA next generation sequencing highlights the ability for wounds to also contain complex 
polymicrobial communities existing as biofilms. This adds to the potential complexity for anti-
biofilm research that must further consider using in vitro or in vivo animal biofilm models that 
are clinically relevant and include polymicrobial species.  
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8.3 TESTING THE EFFECTIVENESS OF TOPICAL ANTIMICROBIALS USED 
IN WOUND PRODUCTS AGAINST BIOFILM 
 
Within the literature, a handful of research teams have developed in vitro and animal biofilm 
models incorporating polymicrobial species 150,385,415,430. A limitation of these approaches has 
been the lack of standardisation between models, with each model varying significantly. This 
makes comparing the results from each model impossible for clinicians, albeit the uptake of 
these varying models in general has been limited by both researchers/clinicians. The major 
reason for this has been the inherent difficulty of establishing polymicrobial models 384,385,431. 
The challenge lies in culturing common (and uncommon) microbes that are found together in 
wounds and replicating these interactions in vitro. Often, co-culturing different species of 
microorganisms can result in the undesired killing of one or more species, even though they 
coexist stably in their natural environment 430.  
 
One of the specific aims of this thesis was to develop a protocol that allowed human in vivo 
investigation of topical antimicrobials and their effects on wound biofilm, thus circumventing 
the requirement to perform either in vitro or animal model testing. The major rationale for 
pursuing this pathway was the large gap in the available literature, with no previous reports on 
human in vivo testing for wound related antimicrobials using advanced molecular and 
microscopy approaches. In chapters 6 & 7, the ability to undertake human in vivo trials is 
demonstrated. To the best of my knowledge this represents the first data in the literature which 
utilises a combination of molecular and microscopy approaches to better understand the effect 
of topical antimicrobials on human wounds.  
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Topical Cadexomer Iodine ointment 
 
In chapter 6, the effectiveness of Cadexomer iodine was tested against DFUs complicated by 
suspected biofilm. Cadexomer iodine is a topical antimicrobial used exclusively in woundcare 
and was chosen for analysis based on its demonstrated superior efficacy against microbial 
biofilms when tested in vitro and in animal models, when compared against other topical 
antimicrobials 294,297,347. In total 17 patients with chronic non-healing DFUs were recruited for 
analysis. The presence of dense biofilm was visualized and confirmed in all 17 participants 
using SEM, FISH or both. Following one week of application, qPCR determined the 
application of Cadexomer iodine resulted in 11 samples achieving up to and greater than a 1-
log10 reduction.  
 
The richness and diversity of chronic non-healing DFUs pre-and-post treatment were explored 
using 16S rDNA next generation sequencing. This identified that the majority of chronic DFUs 
enrolled into the study, harboured polymicrobial communities, with Cadexomer iodine 
showing broad spectrum activity. In six patients, topical antimicrobial therapy failed to reduce 
the microbial load. Post-treatment analysis identified diversity shifts with increasing 
environmental contaminants that were present in pre-treatment samples as low frequency taxa. 
The microorganisms increased in relative abundance post-treatment and included in 
Proteobacteria-E01-9C-26 Marine Group, Proteobacteria-ARKDMS-49, Archaea-
Cenarchaeum, Elizabethkingia spp, Bacteroidetes-Rhodothermacae and Proteobacteria-
Rhodothalssium. The microorganisms listed above are identifiable only by molecular methods 
(in the majority), with some of these cited as known extremophiles, existing in hostile, niche 
environments.  
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Considering the accepted notion that biofilms are tolerant to antimicrobials and combining the 
potential attributes of extremophile (and non-extremophile) microorganisms, this may explain 
why some wound microorganisms were tolerant to treatment. Post-treatment microbiota 
analysis identified these microorganisms increased in abundance from previously low 
numbers, when skin flora microorganisms such as Pseudomonas spp., decreased in abundance 
following treatment (indicating Cadexomer iodine were effective). This diversity shift may 
have occurred as nutrient availability increased or where mutual benefit arose.14 
 
Topical Antimicrobial wound solutions  
 
In Chapter 7, the evaluation of topical antimicrobial solutions used to clean wounds were 
evaluated in vitro, ex vivo porcine skin explant model, and in vivo human DFUs as described 
above. The rationale for performing this evaluation were based on clinical experiences of many 
woundcare/medical devices companies reporting the effectiveness of such products against 
biofilm, whilst the accompanying literature presented was poor to low evidence. A major 
problem for many medical device companies are the limited data on their wound related 
products. The majority of evidence is further restricted to in vitro testing, using non-
standardised models that are not clinically relevant.  
 
The in vitro biofilm model undertaken in chapter 7 tested both P. aeruginosa and S. aureus 
(clinically relevant wound pathogens) against varying topical antimicrobials at short exposure 
times of 15 minutes (clinically relevant). The results demonstrate variable efficacy in reducing 
biofilms, ranging between 0.5 log10 reductions to full eradication.  Repeated instillation 
(mimicking multiple wound cleansing applications) of hypochlorous acid for 10-minute 
exposures in a porcine model achieved < one log10 reduction. Lastly, the application of 4 % 
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w/v melaleuca oil in vivo, resulted in no change to the total microbial load of DFUs complicated 
by biofilm over a seven-day period.  
 
The results suggest that the performance of topical solutions is poor when challenged against 
mature biofilms using short exposure times that mimic real clinical usage (i.e. 15-minute 
application). The study design also identifies that antimicrobial solutions require greater 
exposure times to be more effective against mature biofilms. This is supported from the 24-
hour exposure in vitro arm, whereby log10 reductions increased for most solutions.  
 
16S rDNA next generation sequencing was performed to understand the effects of a topical 
antimicrobial on microbial communities in vivo chronic wounds. Overall, antimicrobial 
treatments caused a minor decrease in the diversity of wounds, shifting the residing 
communities to those microorganisms that were aerotolerant. This reduction in the relative 
abundance of anaerobe microorganisms and other low frequency taxa were not associated with 
reductions in microbial load. This was because for a large percentage of samples the relative 
abundances of both P. aeruginosa and S. aureus increased post-treatment within each wound. 
This suggests the diversity shift towards more dominant species such as Staphylococcus spp. 
was in response to increased nutrient availability (that resulted through removal of competing 
microorganisms) 14 thus sustaining the microbial load within tissues.  
 
In contrast, Cadexomer iodine that is applied to the wound bed for a 48-72 hours exposure 
time, is able to achieve a >1-log10 reduction, whilst community diversity remains fairly 
constant. This is likely because the broad-spectrum activity of Cadexomer iodine is able to 
affect multiple microbial cells instead of targeting or being effective against certain 
microorganisms.  
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Is any topical antimicrobial woundcare product better than the other? 
 
Regardless of both in vivo results, no topical antimicrobial tested in this thesis demonstrated a 
high efficacy in eradicating in vivo polymicrobial biofilms. This supports the requirement for 
further research into more effective anti-biofilm strategies. The findings also suggest there is 
still much to understand regarding the effects of topical antimicrobials on wound 
biofilm/microbial communities. Furthermore, the presence of complex polymicrobial 
communities that harbour uncultivable/unusual microorganisms are likely a reflection of both 
the longevity and continual exposure of wounds to the external environment. However, the 
observed community diversity shifts from common flora that typically inhabit skin to 
uncultivable/unusual microorganisms or low frequency taxa, suggests in some scenarios 
disruption to a community could bring about a negative impact on the wound.   
 
8.4 FUTURE WORK 
 
The breadth of this thesis has included the exploration of complex microbial communities to 
visualising the presence and composition of wound biofilms to testing the effectiveness of 
varying antimicrobial agents used in woundcare. This has produced a significant amount of 
data, yet at the centre of this thesis has been a primary aim to translate these findings into 
something of clinical relevance. In some respects, more questions outweigh answers, however 
undertaking this thesis has provided me with unique perspective in the areas I feel hold 
significant value going forward in the study to better understand diabetic foot infections. These 
works can be broken down into the below categories: 
 
 
 
 264 
1. Translate microbiome evidence into practice; 
 
Rapidly increasing antimicrobial resistance and the advent of antimicrobial stewardship is a 
reflection in the urgent requirement to alter how we prescribe antibiotics to patients with 
infections. DFIs are a classic example of patients who often receive multiple courses of anti-
infectives, for prolonged periods and of broad spectrum. Most current guidelines including 
eTGA guidance materials propose using broad spectrum antibiotics for new infections until 
culture results are available to target therapy. No evidence is available to explore if outcomes 
for wound infections are improved based on the spectrum of activity or if new wounds of mild 
to moderate infection classification could be treated effectively using narrow, targeted empiric 
therapy.  
 
Using16S rDNA next generation sequencing, this thesis has identified that pyogenic cocci (S. 
aureus and Streptococcus agalactaie), Corynebacterium spp., and obligate anaerobes most 
frequently reside in infected DFUs (albeit our understanding of the latter are the matter of 
debate). Some DFUs are monomicrobial, but most are polymicrobial, yet clinical correlation 
regarding the spectrum of activity of antibiotics, identified patient outcomes of infection 
resolution or failure were similar between groups. This supports the potential to undertake a 
clinical trial exploring the concept of narrow versus broad spectrum antibiotics for DFI and 
outcomes. Analysis of infected tissues using molecular and microscopy approaches would 
provide a robust assessment of longitudinal samples in a temporal analysis of the effects of 
antibiotics on microbial load, communities and presence of pathogens.   
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2. In diabetic foot infections, better understanding microbial infection and the host response 
by employing “Omics” (metagenomics, transcriptomics, proteomics); 
 
DFI is a complex pathology to manage, with many patients requiring lower extremity 
amputation due to failure of therapy. Treatment failure may occur due to uncontrolled 
infection, signaling a poor response to antimicrobial therapy or a reflection of the poor host 
response to microbial invaders. To better understand DFI, metagenomic may help us to 
explore; the interactions of microbes in polymicrobial communities, better depict 
microorganisms, fungi, viruses residing in infected tissues, explore host-microbe interaction. 
Other research fields have applied these techniques and have differentiated known genes for 
protein coding sequences from which the biological functions such as pathogenicity, virulence, 
antibiotic susceptibility or metabolic pathways of a specific microbe-host interactions 
(Transcriptome and Proteome). As such this technique may help in understanding “who” did 
it? and aid in providing information on how we should or could direct therapy.  
 
3. Develop / explore / research new anti-biofilm strategies; 
 
Over the last decade many research teams/collaborations have focused their efforts towards 
exploring new compounds, peptides and combination therapies, that possess specific 
mechanisms of action against microbial aggregates or termed “anti-biofilm”. One potential 
avenue for example, is biofilm dispersal which presents an opportunity to trigger biofilm 
degradation with cells reverting to planktonic susceptible forms. A review by Fleming & 
Rumbaugh (2017) 121 details approaches to dispersing medical biofilms, yet they summarise 
that  some of the hurdles to development have been the lack of in vivo testing.  
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Here in presents a unique opportunity for future research and collaborations. The works 
undertaken in this thesis highlight the ability to perform human in vivo clinical trials on 
potential new agents. New therapies that are effective at eradicating (or removing enough 
biofilm to resolve infective episodes) biofilms are needed. The data presented in this thesis is 
testament to this. Many topical antimicrobials demonstrated in my work that are used in 
woundcare are traditional antiseptics based on historic formulations. They broadly target 
varying microbial function. Because biofilms present several mechanisms of enhanced 
tolerance such as the presence of EPS, the likelihood is that many topical therapies fail to work 
because they can’t reach their intended targets (in sufficient quantities). This is demonstrated 
by my results where effectiveness of topical solutions and ointments produce variable and often 
poor results. The lack of effectiveness of many topical antimicrobials used in woundcare 
highlights the requirement to focus on anti-biofilm strategies. Chronic infections of the skin 
and soft tissue in the form of ulcers are a serious cause of morbidity and mortality, and the 
economic impacts to healthcare providers is significant. 
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CHAPTER 3
The Microbiome of Diabetic Foot Ulcers
and the Role of Biofilms
M. Malone
High Risk Foot Service, Liverpool Hospital, South West Sydney LHD, Sydney, Australia and Liverpool Diabetes Collaborative
Research Unit, Ingham Institute
1. DIABETIC FOOT INFECTION
Themost common pathway leading to a foot infection in a personwith diabetes is through
a physical break in the protective barrier of the skin, in the form of a diabetic foot ulcer
(DFU).1 Once the skin is breached, a DFU exposes the underlying soft tissues to potential
bacterial colonization with infection arising if certain conditions favor bacterial replica-
tion. Further contiguous extension to deeper structures may produce scenarios where
failure in controlling the spread of infection leads to extensive damage of host tissue
and bone, and this in part may be driven by several aspects of altered immunologic
function.2 Of particular focus is the reduction in polymorphonuclear leukocyte response
to bacterial infection and the role of hyperglycemia, all being extensively reviewed.3 This
scenario optimizes the pathway to lower extremity amputation in a person with diabetes.
Bacteria that contaminate and colonize wounds likely originate from the surrounding
skin flora but other sources include the environment and endogenous mucous mem-
branes, such as the gastrointestinal tract or nares.4 One reason for this is that DFUs present
an ideal environment for harboringmicroorganisms since they offer a warm,moist, nutri-
tive home, especially if devitalized tissue is present in the wound bed.4 The longer a
wound remains open, the greater the chances of a more diverse and abundant bacterial
colonization, with the type, depth, location, level of perfusion and the efficacy of the host
immune response dictating the niche of colonizing bacteria.4,5
1.1 Colonization Versus Infection?
Bacterial colonization of wounds versus infection is an area that must be greatly appre-
ciated by treating clinicians, so that the appropriate use of antimicrobials and adjunct ther-
apies can be made effectively. While all wounds contain bacteria, colonization refers to a
specific scenario where bacteria are presently multiplying but the sum of their actions are
not enough to elicit an immune response.4 Diabetic Foot Infections (DFIs) have been
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described as occurring when bacterial organisms proliferate within a wound (i.e., infra-
malleolar) and, in the course of doing so, cause substantial tissue damage that induces a
host response accompanied by inflammation, which is clinical infection.6 For this reason,
the diagnosis of DFI has been promoted by expert groups as a “clinical diagnosis” using
more than two clinical signs of infection: inflammation, erythema, local tenderness or
pain, warmth and purulent discharge.6
In some people with diabetes, the overt clinical signs of infection are diminished or
absent, and this may be due to the failure to exhibit an inflammatory response7 with
reports identifying that people with diabetes and infected chronic wounds express ery-
thema less frequently than people without diabetes.8 This has led to a clinical perspective
that some chronic DFUs may have “secondary signs” of infection that include but are not
limited to malodor, delayed wound closure and poor quality wound bed tissue.7,9
The fine line between colonization and infection can be clinically challenging and
some clinicians have adopted more quantitative measures to differentiate potential
“healthy” colonization from pathogenic infection by relying on the density of bacteria
present per gram of tissue. Greater than 105 colony forming units (cfu) of bacteria per
gram of tissue has been widely used as a key indicator of potential “bioburden” as the
causative factor associated with delayed wound healing. This numerical indicator is based
largely on early evidence from various wound aetiologies10 and further incorporated by
others,11 yet controversy persists over whether a burden of>105 cfu of bacteria per gram
of tissue is required to cause wound infection.
Kingsley12 proposed a wound infection continuummodel that placed an emphasis on
the progression from colonization of bacteria within a wound through to infection
(Fig. 1).12 An important component of the wound continuum model is the concept
of “critical colonization” which refers to the multiplication of organisms within a wound
without invasion or interfering with wound healing. While the concept of critical col-
onization is still the center of much debate, it is often used by clinicians to explain delayed
wound healing in the absence of any overt clinical signs of infection and other
wound-delaying variables. This concept “if true” may be of importance for clinicians,
as chronic wounds with critical colonization may benefit from local and/or topical treat-
ments such as antimicrobial wound dressings and wound debridement, rather than sys-
temic management with the use of antibiotics; however, no quantifiable data exists to
prove or disprove this theory.
1.2 How to Obtain Adequate Cultures for Infected DFUs
The current method to identify potential pathogens of infection fromDFUs is by obtain-
ing a wound culture following the removal of devitalized tissue (either by debridement or
curettage) after cleansing. The most widely available method employed by many clini-
cians is the use of a cotton or nylon swab of the superficial tissue using the Levine
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technique13; however, the concordance between superficial swabbing using the Levine
technique and tissue biopsy has been reported at 78% providing only a “reasonably accu-
rate measurement”13 and much debate still surrounds this collection method.
The Infectious Disease Society of America (IDSA) currently propose that tissue sam-
ples are the gold standard method of collection for identifying potential bacterial path-
ogens from infected DFUs, as they yield the most accurate results.6 This is exemplified by
recent studies employing molecular DNA-based techniques where tissue biopsy samples
from both the superficial and deep tissues of a DFU identified that the pathogens of infec-
tion were from microorganisms residing in deeper tissues.14–16 In all instances the path-
ogens of infection were situated within deeper tissues and were typically fastidious
aerobes along with anaerobes that were more frequently underrecognized from superfi-
cial cultures. Importantly, this supports the requirement in both a clinical scenario and for
studies exploring the microbiome of wounds to utilize samples of tissue that capture both
the superficial and deeper tissues through the use of a punch biopsy.
The importance in managing DFIs is underpinned by the requirement to identify any
pathogen/s of infection so that antimicrobial therapy can be directed. Traditional
culture-dependent methods have been utilized to identify planktonic organisms sub-
jected to controlled laboratory conditions. The limitations of such are that
culture-dependent methods select for species that flourish under the controlled condi-
tions of the diagnostic microbiology lab and this may not necessarily reflect the most
abundant or clinically important organisms in DFIs.17
Local infection
Subdued features
or secondary signs
Heat
Systemic
features with overt
clinical signs
Infection
Critical
colonizationColonizationContamination
Erythema
inflammation
Purulence
Systemic infection
Fig. 1 A wound infection continuum model.
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1.3 Cultivation-Based Approaches to Defining the Bacteriology
of Infected DFUs
Current culture-dependent studies on the bacteriology of DFIs have widely reported the
involvement of aerobic Gram-positive cocci, mainly Staphylococcal and Streptococcal
species as being the most common etiological agents that acutely infect DFUs.18,19 In
particular, the spotlight has centered on the well-known pathogen Staphylococcus aureus
and its role in DFI has been well reported.1,18–20
In two large culture-dependent studies on the bacteriology of infected DFUs18,19
samples from over 1266 patients indicated the predominant pathogens of infection as
being Staphylococcal and Streptococcal species with Enterococcus spp. andCorynebacterium
spp. also playing prominent roles. In both studies, anaerobes were generally reported as
being of low abundance with one of the studies identifying the ratio of aerobe to anaer-
obe isolates being7:118 and the other study identifying the overall percentage of anaer-
obe isolates in only 28% of samples.19
Further complicating the picture of DFI, it can occur in those patients with reduced
immune-mediated responses, whereby the potential involvement of low-virulence col-
onizers of devitalized tissue or bone such as coagulase-negative Staphylococci and Coryne-
bacterium spp. may assume a more pathogenic role.21 Additionally, while it is generally
regarded that DFUs of short duration presenting with acute infection are
monomicrobial,1 chronic infected DFUs seem to harbor a much more complex polymi-
crobial flora including Pseudomonas spp., Enterococci, Enterobacteriaceae and other obli-
gate anaerobes.22
1.4 Current Studies Employing Molecular Microbiology for Diabetic
Foot Infections
The advent of new molecular DNA-based techniques that are culture-independent have
identified limitations of traditional culture-dependent methods, acknowledging their
capacity to identify a limited number of known culturable bacteria (<1%).23
DNA-based techniques, supported by ever-growing gene reference libraries, allow
for the characterization of microbial communities or microbiomes that encompass the
sum of all microorganisms residing on and within the host—bacterial, fungal, and viral.24
Characterizing the microbiome of infected and uninfected DFUs using molecular
methods is in its infancy, and only four studies with comparable data have been published
in recent years5,25–27 (Fig. 2).
In addition to the limited work in the area of DFUs, composite evidence by authors
employing molecular techniques exist for chronic wounds, where studies have pooled
multiple wound etiologies to provide an overview of the chronic wound micro-
biome.28–31 Most chronic wound microbiome studies to date have employed pyrose-
quencing centered approaches that amplify and sequence the small subunit ribosomal
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Culture-independent
Author Phylum
(%) total samples
Wolcott et al.
(2015)25
910 noninfected 
DFUs
Firmicutes (64%)
Proteobacteria (26%)
Actinobtacteria (9.6%)
Bacteroidetes (1%)
Staphylococcus represented 
>10% abundance in 51% of 
DFUs (464 of 910 DFUs).
S. aureus constituted majority
of sequences at species level 
with avg. abundance of 15% 
across 910 DFUs  
Genus / Species level
Gardner et al. 
(2013)5
52 noninfected 
DFUs
Firmicutes (67%)
Actinobacteria (14%)
Proteobacteria (9.8%)
Bacteroidetes (7.3%)
Fusobacteria (1.4%)
Staphylococcus present in 49 
of 52 DFUs, comprising 
29.6% sequences with 
majority classified as
S. aureus (96.5%)  
Dowd et al.
(2008a)26
10 noninfected 
DFUs
Firmicutes (65%)
Proteobacteria (27%)
S. aureus most abundant
species across all samples 
(39%) using shotgun Sanger 
sequencing 
Dowd et al. 
(2008b)34
40 Infected 
DFUs
Firmicutes (39%)
Actinobacteria (32%)
Proteobacteria (16%)
Bacteroidetes (8%)
Fusobacteria (3%)
Corynebacteriummost 
common genera found in 30 
of 40 DFUs. Bacteroidetes 
and Peptoniphilus second 
most common 
microorganisms in 25 of 40 
DFUs
Culture-dependent
Genus / Species level Phylum
(%) total samples
Author
Staphylococcus most
common isolate in DFUs 
(389 of 1607, 24%). 
Majority of isolates
being S. aureus (214 of
389, 55%)    
Firmicutes (55%)
Proteobacteria (12.5%)
Actinobacteria (9%)
Bacteroidetes (20%)
Citron et al.
(2007)
454 Infected 
DFUs
Staphylococcus most 
common isolate in DFUs
(645 of 1817, 35.5%). 
Majority of isolates
being S. aureus (305 of
645, 47%)  
Firmicutes (64%)
Proteobacteria (20.7%)
Actinobacteria (8.7%)
Bacteroidetes (3.8%)
Ge et al. (2002)
812 Infected 
DFUs
Example of discordance between culture and molecular methods 
Anaerobes via culture Anaerobes via molecular
6%–26% avg. abundance 42%–45% avg. abundance 
Combined results
1. DFUs predominantly 
colonized by firmicutes
(63%)
2. At the genus level, 
Staphylococcus 
predominates (avg. 
abundance 35%)
3. At the species level
S. aureus is the most
abundant (avg. 37%)   
4. Ratio of anaerobe 
identification by culture 
vs. DNA sequencing is 
discordant.
Fig. 2 Microbiome of infected and uninfected diabetic foot ulcers. Source: used with permission from Malone M, Gosbell IB, Dickson HG, Vickery K,
Espedido BA, Jensen SO. Can molecular DNA-based techniques unravel the truth about diabetic foot infections? Diabetes Metab Res Rev 2017;
33:e2834. http://dx.doi.org/10.1002/dmrr.2834. Wiley.
RNA (16S rRNA) gene, a highly conserved gene present in all prokaryotes (bacteria) but
not eukaryotes (humans). This has revealed a vastly more complex array of bacterial com-
munities than those identified by traditional culture-dependent methods. The 16S rRNA
gene is an ideal target for bacterial analysis given that it possesses nine hypervariable
regions that have considerable sequence diversity between bacterial taxa.32 The hyper-
variable regions are bordered by stretches of sequences that are highly conserved between
bacteria, ideal for designing universal and species-specific primers to amplify the hyper-
variable regions by Polymerase Chain Reaction (PCR).33
The first report in the literature on the microbiome of DFUs was undertaken by
Dowd et al.34 reporting on 10 chronic DFUs using multiple genomic approaches that
included: partial ribosomal amplification and pyrosequencing (PRAPS), full ribosomal
amplification, cloning and Sanger sequencing (FRACS), density gel electrophoresis
(DGGE), and Sanger sequencing (PRADS). Identification of species was undertaken
using operational taxonomic units (OTUs); these are clusters of single DNA sequences
grouped together based on their similarity and used to define microorganisms to a species
or genus-level. DNA reads from each wound were compiled to create a pooled DNA
data set from multiple DFUs. Facultative and strict anaerobic Gram-positive cocci
formed the majority of sequences with genus-level identification highlighting the pre-
dominance of Staphylococcus spp. (PRAPS¼10,874 of 36,508 sequences, 30%;
FRACS¼70 of 178 sequences, 39%) in addition to Peptoniphilus, Anaerococcus, Rhodop-
seudomonas, Enterococcus,Veillonella, Bacterioides,Clostridium, and Finegoldia spp., each con-
tributing to >5% of the microbial diversity.
The second study to explore the DFU microbiome was undertaken by Dowd et al.26
who employed bacterial tag-encoded FLX amplicon pyrosequencing (bTEFAP) to sam-
ple 40 chronically infected DFUs from a range of locations on the foot and ankle. Dowd
et al.26 hypothesized that a single major pathogen would be associated with all wounds;
therefore DNA reads for each DFU were reported individually and not pooled. This
allowed the compilation of community profiles for each DFU, including the accurate
identification of the number of samples of each genera that were detected, and the aver-
age percentage each genus contributed to its positive sample.
Results identified that each DFU contained a rich diversity of microorganisms with
Corynebacterium (30 of 40 DFUs, avg abundance¼14.4%), Bacteroides (25 of 40 DFUs,
avg abundance¼24.2%), Peptoniphilus (25 of 40 DFUs, avg abundance¼13.6%), Fingol-
dia spp. (23 of 40 DFUs, avg abundance¼6.7%) Anaerococcus (22 of 40 DFUs, avg
abundance¼7.7%), and Streptococcus (21 of 40 DFUs, avg abundance¼36.5%) being pre-
sent in all samples. Surprisingly, Staphylococcus was only present in 13 of 40 (avg
abundance¼8.3%) DFUs compared to a previous study by the same authors that iden-
tified Staphylococcus as the major bacterial genus in 10 infected DFUs.34 The location of
ulcers originating from multiple sites of the foot and ankle may have increased the het-
erogeneity observed between samples in the latter study. Some DFUs may have been
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purely ischemic or neuroischemic in origin, increasing the likelihood of the presence of
devitalized, hypoxic tissue and favoritism towards low-virulent colonizers and anaerobic
microorganisms.
No single genus of bacteria was present in all 40 DFUs and this led Dowd et al.26 to
hypothesize that the microbiome of DFUs (and chronic wounds) is dominated by mul-
tiple species that cooperate in a biofilm, a concept Dowd et al. “coin” as functionally
equivalent pathogroups (FEP). This centers on genotypically distinct bacteria working
cooperatively to induce pathogenesis, similar to what is observed from a known single
pathogen, such as S. aureus; however, there is currently limited data available to
support this.
Gardner and colleagues5 profiled the microbiome of 52 individuals with noninfected
DFUs using 16S rRNA gene sequence analysis and were the first to restrict the sampling
of patients to a homogenous sample of DFUs (neuropathic DFUs only). The group pro-
posed that previous studies within the area26,28,29,34 were tainted by heterogeneous sam-
pling (e.g., pooled samples of differing chronic wounds) and of all three DFU etiology
types (neuropathic, ischemic, and neuroischemic) and, as such, these pathophysiologi-
cally distinct lesions likely harbored their own unique microenvironments and thus
microbiota.
In characterizing the microbiome of 52 noninfected DFUs, a total of 13 phyla were
reported from 300,660 DNA sequences with the majority being classified into Firmicutes
(67%), Actinobacteria (14%), Proteobacteria (9.8%), Bacteroidetes (7.3%), and Fusobac-
teria (1.4%). Staphylococcus was identified as the most common and abundant genus in
49 of 52 DFU samples (DNA sequences¼88,995 of 300,660, abundance¼29.6%). At
a species-level the majority of sequences belonged to the common pathogen S. aureus
(S. aureus sequences¼85,880 of 88,995, 96.5%), an unsurprising finding considering
the highly documented role of this microorganism in diabetes-related foot infection.6
Further analysis of microbial diversity in 52 DFUs reported on average 30 OTUs per
DFU (range 7–64) in comparison to culture-dependent analysis that detected on average
4 OTUs per DFU (P< .0001). Comparisons of the relative bacterial abundances within
each DFU using culture-dependent analysis identified the overestimation in the abun-
dance of Staphylococcus spp. (0.47 vs 0.32, P¼ .0001) and underestimation of anaerobes
(0.11 vs 0.18, P¼ .0063) in comparison to 16S rRNA gene sequence analysis. By culture,
anaerobes were identified as the predominant organisms in only 6 of 52 DFUs (12%), a
finding consistent with the known limitations of culture-dependent methods, particu-
larly in the identification of slow-growing, fastidious anaerobic organisms.5 In contrast,
16S rRNA gene sequence analysis identified twice this amount (12 DFUs, 23%); this is of
importance at a clinical level where the role of anaerobes in DFI and wounds is often
underestimated. Their significance as highly virulent pathogens, detrimental to the
wound environment or as pathogens of DFI, is only becoming appreciated through
advances in new molecular techniques that are culture-independent.
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Gardner et al.5 also depicted bacterial community structure using a statistical approach
of Euclidean distances to determine how similar DFU attributes were to the indicators of
wound bioburden (microbial load, diversity, and presence of pathogens). The partition-
ing of data identified three clusters, which Gardener et al.5 referred to as EUC1, EUC2,
and EUC3. EUC1 contained significantly greater OTU richness (P¼ .006), diversity
(P¼ .02), and bacterial load (P¼ .02), whereas EUC2 contained a greater abundance
of Staphylococcus and lower abundance of anaerobes (P¼ .0003), and EUC3 contained
the highest abundance of Streptococcus (P¼ .0002).
Euclidean clusters were also mapped against clinical markers that included HbA1c,
mean tissue oxygenation, ulcer duration, ulcer depth, ulcer surface area, and necrotic tis-
sue. EUC1 containing greater OTU richness, diversity, and bacterial load, were associ-
ated with DFUs of longer duration (P¼ .02) and increased ulcer depth (P¼ .01). The
EUC1 cluster also contained a greater abundance of anaerobes (P¼ .01) and Proteobac-
teria (P¼ .005), a likely association with wound longevity and deeper tissue involvement.
EUC2 and EUC3 had the highest proportions of both Staphylococci and Streptococci with
laboratory markers from these participants recording the highest levels of glycosylated
hemoglobin (HbA1c %) (Median EUC 2 HbA1c¼9.2% versus median EUC 3
HbA1c¼9.4%).
Assumptions on infections in people with diabetes have repeatedly associated Staph-
ylococci and Streptococci as major pathogens, noting higher colonization rates in those with
suboptimal glycemic control.35 A plethora of studies have also identified that hypergly-
cemia causes immunosuppression, and a reduction in glucose by a variety of means
reverses immune function deficits.36–38 However, no evidence exists identifying direct
links between hyperglycemia, infection and potential deficits in the immune response to
specific microorganisms.6,39
Gardner et al.5 invested a significant proportion of their analysis on undertaking a sta-
tistical approach to partitioning DFUs into meaningful clusters based on their associations
to the three dimensions of bioburden (i.e., microbial load, microbial diversity, and pres-
ence of pathogens). Interpretation and validation of cluster analysis occurred through a
silhouette score (SI), a method used to report the graphical representation of how well
each object lies within its cluster in comparison to other clusters. An average SI score of
0.42 was reported byGardner et al.,5 but an SI score of<0.5 signifies only modest support
for the proposed cluster algorithms.40,41 Wu et al.42, who explored gut microbial enter-
otypes using molecular approaches, recommended using a high SI threshold (0.75) for
validating clusters.
The statistical significance of partitioning 52 DFUs into similar clusters given the
moderate SI score should be aired on the side of caution, as a low SI score suggests that
clustering could be due to chance. Further studies aiming to increase cluster validity
through higher SI scores may be required in supporting the partitioning of the DFU
microbiome to clinical indicators similar to those observed by Gardner et al.
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Wolcott et al.25 retrospectively reported 910 noninfected DFUs using 16S rRNA
pyrosequencing and currently represents the largest body of evidence surveying the
microbiome of DFUs. Wound samples were collected from superficial debridement
material obtained from the wound bed and relative abundances were calculated from
species-level OTUs constituting >10% of all DNA reads per sample. Given the large
sample size from multiple wound etiologies, individual wound microbiomes were not
reported and DNA sequences were pooled. Of 910 DFUs, the most abundant phylum
was the Firmicutes (64%) followed by Proteobacteria (26%), Actinobacteria (9.6%), and
Bacteroidetes (1%). Staphylococcus (31%) was the most abundant OTU with S. aureus
(48%) and S. epidermidis (35%) predominating at the species-level.
In review of the studies employing amplification and sequence analysis of the 16S
rRNA gene to characterize the microorganisms involved in DFI, few have sampled par-
ticipants with overt clinical signs of infection. It is generally regarded that clinically unin-
fected wounds should not be treated with antimicrobials and therefore should not be
cultured.6,43 The clinical relevance of culturing uninfected DFUs to characterize the
microbiome is thus debatable, and worth expanding upon further. In patients with dia-
betes presenting with overt clinical signs of infection, the decision to obtain a culture
from a wound to identify a pathogen of infection is clinically justified. It has been well
addressed in the literature; however, many patients with diabetes do not display overt
clinical signs of infection in the presence of a nonhealing DFU.7,44
Some clinical researchers have proposed under these circumstances to utilize second-
ary signs and symptoms (i.e., malodor, increased exudate, and poor quality tissue) to diag-
nose infections that may be more pertinent to guiding clinicians facing wounds that are
nonhealing in the presence of standard care.45 Therefore, obtaining cultures to examine
the microbiome of patients with “masked” signs of infection in DFUs, that are nonheal-
ing despite standard care, may prove greatly beneficial. With the exception of Gardner
et al.,5 who restricted sampling to a homogenous group of DFUs (neuropathic), all other
microbiome studies have included the sampling of different DFU etiologies. The extent
to which community diversity is affected through variances in wound etiologies is cur-
rently the focus of debate. It is generally accepted that DFUs of ischemic origin may con-
tain a wound bed environment of devitalized, slough tissue. This may perpetuate very
different bacteria from those of the healthy vascularized tissue common in neuropathic
DFUs.1,46 Further studies comparing each DFU etiology individually may clarify this
matter further.
Lastly, it has been cited in the literature that certain aerobic species are often over-
estimated as the primary pathogens in DFI. When comparing the evidence on the bac-
teriology of DFIs through both culture-dependent and -independent approaches, both
corroborate S. aureus as being the predominant pathogen colonizing DFUs. In tandem
with this, reports have also suggested that the abundance and role of anaerobes are greatly
underestimated. The significance, however, at a clinical level of identifying additional
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“hidden” anaerobes that often form part of a polymicrobial infection is yet undefined.
Many antimicrobial agents commonly used in the treatment of DFIs have a broad spec-
trum of activity to cover most anaerobes. Furthermore, no published studies are available
reporting improved clinical outcomes when adding additional antianaerobic directed
therapy to concurrent regimes.
2. BIOFILMS
During most of the history and development of microbiology, the general understanding
of the role microbes play in human health and disease has been that they exist as plank-
tonic or free-floating single-cell organisms. Seminal works by Louis Pasteur and Robert
Koch in the mid-to-late 1800s paved the way in the field of microbiology, and labora-
tories still use the 150-year-old methods developed by these pioneers. These techniques
postulate that microbial cells act in a planktonic state: that is, they disperse in a liquid
environment.
However, emerging evidence from the previous century, based on microbial studies
of aquatic environments and dental plaque, provided insights that microorganisms have
a natural tendency to associate surfaces, preferring a sessile lifestyle.47,48 This early
work, which focused predominantly on environmental samples, later provided a platform
for the contemporary medical models that we have come to understand as “microbial
biofilms.” Biofilms are frequently defined based on in vitro observations through
methods such as scanning electron microscopy (SEM) or peptide nucleic acid-flourescent
in situ hybridization (FISH) (Fig. 3A and B).
The classic definitions often describe biofilms as bacteria attached to surfaces, encap-
sulated in a self-producedmatrix, and tolerant to antimicrobials.49,50 The biofilm concept
and its involvement in human health and disease were first described in the medical
literature in 1978,48 with much debate following. This was followed by an explosion
of biofilm analysis in human health and disease in the 1980s, which was driven largely
Fig. 3 Scanning electron microscopy (SEM) and peptide nucleic acid fluorescent in situ hybridization
(FISH) methods for detection of biofilms (A and B, respectively).
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by advancements in emerging technologies and techniques applicable to the study of bac-
terial populations in situ. Using light and electron microscopy, in combination with spe-
cific probes to define cell surface structures, William Costerton (1934–2012), a microbial
ecologist, was credited with advancing the understanding of the role biofilms play in
human health and disease.
Costerton’s early enterprising works were fixed on environmental models, but this
quickly transcended to the medical arena with thoughts of “how does a bacterium
know whether it is in a urinary catheter or an alpine stream?” hypothesizing that the bac-
terium would grow as a biofilm on both surfaces regardless.51 Costerton and colleagues
were also the first to propose the role of Pseudomonas aeruginosa biofilms in the sputum
of cystic fibrosis patients,52 much to the energetic refutation of medical peers at the time.
The concept of biofilms in human health and disease is now universally accepted in
tuberculosis,53 periodontal disease and dental caries,54 cystic fibrosis,52,55,56 in-dwelling
medical device infections,57 otitis media and other upper respiratory infections,58,59 and
chronic wounds.60,61
Early work by Costerton and colleagues62 identified that bacteria growing on medical
devices existed within a biofilm, and that they exhibited a remarkable tolerance to both
host defenses and antimicrobial therapy. A plethora of in vitro biofilm models have elu-
cidated that bacterial biofilms can withstand antimicrobial concentrations 100–1000
times higher than those of planktonic counterparts.63–65 This would suggest that biofilm
cells harbor the capability to switch on multidrug resistance mechanisms that they only
express during biofilm growth. If this were true, then mutants expressing the same resis-
tance would have been seen in rapidly multiplying planktonic cultures. This has not been
the case, which has therefore led to the riddle of how a biofilm can be resistant to killing
by many antimicrobials in the absence of specific resistance mechanisms.66
In spite of the wealth of research undertaken to identify biofilm resistance and/or
tolerance to antimicrobials, no single causative mechanism has been identified. Instead,
it has been suggested that a likely combination of factors contributes to biofilm recalci-
trance, with several areas of interest including but not limited to: slow or incomplete per-
meation of antimicrobials through extracellular polymeric substance (EPS)63 altered
microenvironment and niches within biofilms promoting slow growth rates and adaptive
stress response,67,68 efflux pumps,69 and the role of “persisters.”70
2.1 Clinical Significance of Bacterial Biofilms in Chronic Wounds
2.1.1 How Do Biofilms Impede Wound Healing?
The exact mechanisms of biofilm impairment on the healing processes of wounds remain
ambiguous. Existing data suggest a chronic wound is kept in either a vicious inflamma-
tory state, or subject to localized low oxygen tensions. The pathways behind this are not
clear, but several systemic and local factors may contribute to the occurrence and main-
tenance of the wound chronicity.
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2.1.2 Biofilms Sustain Hyperinflammation
In a review article, Wolcott and colleagues71 present a detailed hypothesis summarizing
that once a biofilm community becomes established, its stubbornness and frequent failure
to many treatments propagates hyperinflammation. Specifically, they propose that bio-
film phenotype bacteria produce proteases that inhibit and destroy extracellular matrix.
In addition, the chronic wound environment also possesses host-derived proteases.
Together this may overfill a chronic wound with a proteolytic mix of proteases, elastases,
and gelatinases (these are commonly referred to as matrix metalloproteinases, or MMPs).
In parallel, biofilm adherence to the wound bed may also potentially inhibit the release of
the natural suppressor of MMPs—tissue inhibitors of MMPs (TIMPS). This scenario may
therefore sustain a perpetual state of hyperinflammation.
Walcott and colleagues also put forward the potential of biofilms to “bait” the
immune system through releasing planktonic bacteria. Walcott and colleagues suggest
that the presence of anaerobic bacteria play a key role throughout, releasing a cell wall
constituent lipopolysaccharide, a potent inflammatory inducer. In an animal model on
cystic fibrosis patients, biofilms forming P. aeruginosa were shown to undergo lipopoly-
saccharide modifications that induced greater inflammatory responses in mice.72 No
human in vivo data exist to support this theory for chronic wounds.
2.1.3 Biofilms May Contribute to Localized Areas of Low Oxygen Tension
Within a Wound
Early microelectrode studies of aerobic in vitro biofilm models found discrete areas
within biofilm that had significant oxygen depletion.67 This suggested that areas of bio-
film housed microniches favoring differing microorganisms, and may explain how the
presence of anaerobes in mixed-species biofilms exist, contribute and cooperate with aer-
obic neighbors.
Further studies employing microelectrodes with Confocal Laser Scanning Micros-
copy (CLSM) have identified microdomains with different biochemical environments
including alterations in pH and oxygen.73 Recent data by James and colleagues68 have
provided further evidence to support a concept of localized low oxygen tensions con-
tributing to wound chronicity. Using oxygen microsensors and transcriptomics (exam-
ining microbial metabolic activities) to study in situ biofilms, steep oxygen gradients and
induced oxygen-limitation stress responses were identified from bacteria. Additionally,
through transcriptomics, it was established that metabolic activities of the biofilm and
the recruitment of cells that consume oxygen for host defensive processes were the pri-
mary pathways of oxygen depletion. Taken collectively, this data supports the concept
of a biofilm establishing and maintaining localized low oxygen tensions in a wound,
thus contributing to chronicity.
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3. SUMMARY
The progression of infection in a person with diabetes can lead to the devastating
requirement for a lower extremity amputation. Therefore the clinical identification
of infection and the grading of its severity is key. To direct targeted therapy, clinicians
need to understand the microorganisms involved in the process, but it is clear that
molecular DNA-based approaches identify many “hidden” microorganisms. Both
the progress and application of current DNA sequencing continues to rapidly evolve,
but thus far we have only been enlightened with a broader view of “which microor-
ganisms are there.” The interpretation and any clinical implications of additional bac-
teria within samples remain unclear, but as DNA-based evidence increases we may be
enlightened. Importantly, the concept of biofilms and their involvement as contributors
to chronic nonhealing wounds and in the pathogenesis of chronic infection poses a sig-
nificant shift in therapeutic paradigms. This needs to be approached cautiously, with
input from antimicrobial stewardships, wound-care clinicians and the broader medical
community.
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Abstract
Diabetes foot infections (DFIs) are a common condition and a major causal
pathway to lower extremity amputation. Identification of causative pathogens
is vital in directing antimicrobial therapy. Historically, clinicians have relied
upon culture-dependent techniques that are now acknowledged as both being
selective for microorganisms that thrive under the physiological and nutri-
tional constraints of the microbiology laboratory and that grossly underesti-
mate the microbial diversity of a sample. The amplification and sequence
analysis of the 16S rRNA gene has revealed a diversity of microorganisms in
DFIs, extending the view of the diabetic foot microbiome. The interpretation
of these findings and their relevance to clinical care remains largely unex-
plored. The advent of molecular methods that are culture-independent and
employ massively parallel DNA sequencing technology represents a potential
‘game changer’. Metagenomics and its shotgun approach to surveying all
DNA within a sample (whole genome sequencing) affords the possibility to
characterize not only the microbial diversity within a DFI (i.e. ‘which microor-
ganisms are present’) but the biological functions of the community such as
virulence and pathogenicity (i.e. ‘what are the microorganisms capable of
doing’), moving the focus from single species as pathogens to groups of
species. This review will examine the newmolecular techniques for exploration
of the microbiome of infected and uninfected diabetic foot ulcers, exploring the
potential of these new technologies and postulating how they could translate to
improved clinical care. Copyright © 2016 John Wiley & Sons, Ltd.
Keywords microbiome; diabetic foot infection; DNA sequencing; metagenomics
Introduction
One of the causal pathways to lower extremity amputation in a person with
diabetes is the development of a diabetic foot ulcer (DFU) that becomes
infected (diabetes foot infection or DFI) [1]. In a person with diabetes, the
development of a DFU is most commonly associated with loss of protective
sensation (peripheral neuropathy), altered foot architecture and some form
of trauma. These factors allow a physical break in the protective barrier of
the skin to go unnoticed and provide an ideal environment for colonization
with various opportunistic microorganisms [2]. Factors including a retarded
host immune response and pathogen-related dynamics (such as virulence or
pathogenicity) may predispose the DFU to further microbial replication and
REVIEW ARTICLE
Received: 11 February 2016
Revised: 24 May 2016
Accepted: 25 May 2016
Copyright © 2016 John Wiley & Sons, Ltd.
DIABETES/METABOLISM RESEARCH AND REVIEWS
Diabetes Metab Res Rev (2016)
Published online in Wiley Online Library (wileyonlinelibrary.com) DOI: 10.1002/dmrr.2834
invasion, resulting in damage to host tissues and an
inflammatory response that is characterized as a clinical
infection [3].
Expert consensus opinion has promoted the diagnosis
of DFI as a clinical diagnosis using greater than two
clinical signs that include inflammation, erythema, local
tenderness or pain, warmth and purulent discharge [3].
Further spread of bacteria may lead to both the involve-
ment of deeper structures with extensive damage to both
tissue and bone and the presence of a systemic inflamma-
tory response syndrome requiring hospitalization. Un-
controlled DFI may lead to lower extremity amputation
in a person with diabetes.
DFU bacteriology via culture
dependent techniques
Ideal management of DFIs requires identification of any
pathogen so that antimicrobial therapy can be directed
against them. Traditional culture-dependent methods
have been utilized to identify planktonic organisms. The
limitations of this are that culture-dependent methods
select for species thatflourish under the controlled conditions
of the diagnostic microbiology laboratory, and this may not
necessarily reflect the most abundant or clinically important
organisms in DFIs [4].
Current culture-dependent studies on the bacteriology
of DFIs have widely reported the involvement of aerobic
Gram-positive cocci, with staphylococcal and streptococ-
cal species being the most common aetiological micro-
organisms that acutely infect DFUs (Table 1) [5,6]. In
particular, the spotlight has centred on the well-known
pathogen Staphylococcus aureus, and its role in DFI has
been well reported [2,5–8].
Two large culture-dependent studies on the bacteriol-
ogy of infected DFUs sampled over 1266 patients. The
predominant pathogens as staphylococcal and streptococ-
cal species with enterococcal species and corynebacterial
species also playing prominent roles [5,6]. In both
studies, anaerobes were generally reported as being of
low abundance, with one of the studies identifying the
ratio of aerobe to anaerobe isolates of approximately 7: 1
[5] and the other study identifying anaerobe isolates in
28% of samples [6].
Complicating the picture of DFI are those patients with
reduced immune-mediated responses, where low virulence
colonizers of devitalized tissue or bone, such as coagulase-
negative staphylococci, and corynebacteria may assume a
more pathogenic role [9]. Additionally, while DFUs of short
duration presenting with acute infection are generally
monomicrobial [2], chronic infected DFUs appear to har-
bour a much more complex polymicrobial flora including
Pseudomonadaceae, Enterococci, Enterobacteriaceae and
other obligate anaerobes [6,10,11].
Current studies employing molecular
microbiology to explore DFUs
The advent of new molecular DNA based techniques that
are culture-independent has identified limitations of tra-
ditional culture-dependent methods, acknowledging their
capacity to identify a limited number of known cultivable
bacteria (less than 1%) [4].
DNA-based techniques, supported by ever-growing
gene reference libraries, allow for the characterization of
microbial communities or microbiomes that encompass
the sum of all microorganisms residing on and within
the host – bacterial, fungal and viral [12].
Characterizing the microbiome of DFIs using molecular
methods is in its infancy. Only four studies with compara-
ble data have been published in recent years (Figure 1)
[13–15]. In all of these studies, both infected and unin-
fected tissue or swabs were obtained fromDFUs. Composite
evidence by authors employing molecular techniques exists
for other chronic wounds to provide an overview of the
chronic wound microbiome [16–19]. Most chronic wound
microbiome studies to date have employed pyrosequencing
centred approaches that amplify and sequence the small
subunit ribosomal RNA (16S rRNA) gene, a highly con-
served gene present in all prokaryotes (bacteria) but not
eukaryotes (humans). This has revealed a vastly more com-
plex array of bacterial communities than those identified by
traditional culture-dependentmethods. The 16S rRNA gene
is an ideal target for bacterial analysis given that it possesses
nine hypervariable regions that have considerable
sequence diversity between bacterial taxa [20]. The
hypervariable regions are bordered by stretches of
sequences that are highly conserved between bacteria,
ideal for designing universal and species-specific primers
to amplify the hypervariable regions by polymerase chain
reaction (PCR) [21]. The workflows required to generate
data on microbiome studies that include chronic wounds
are depicted in Figure 1.
The first report in the literature on the microbiome of
DFUs was by Dowd et al. reporting on ten chronic DFUs
using multiple genomic approaches that included partial
ribosomal amplification and pyrosequencing (PRAPS), full
ribosomal amplification, cloning and Sanger sequencing
(FRACS), density gel electro-phoresis (DGGE) and Sanger
sequencing (PRADS) [22]. Identification of species was un-
dertaken using operational taxonomic units (OTUs). These
are clusters of single DNA sequences grouped together based
on their similarity and used to define microorganisms to a
species or genus level. Sequences identified both facultative
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and strict anaerobic Gram-positive cocci that included
Staphylococcus, clostridales family XI (Peptoniphilus,
Anaerococcus and Finegoldia) Rhodopseudomonas, Entero-
coccus, Veillonella and Bacterioides.
The second study to explore DFU microbiome was
undertaken by Dowd et al. who employed bacterial tag-
encoded FLX amplicon pyrosequencing (bTEFAP) to sam-
ple 40 chronic DFUs from a range of locations on the foot
and ankle [15]. Results identified each DFU contained a
rich diversity of microorganisms with Corynebacterium
(30 of 40 DFUs, avg abundance=14.4%), Bacteroides
(25 of 40 DFUs, avg abundance=24.2%), Peptoniphilus
(25 of 40 DFUs, avg abundance=13.6%), Fingoldia spp.
(23 of 40 DFUs, avg abundance=6.7%), Anaerococcus
(22 of 40 DFUs, avg abundance=7.7%) and Streptococ-
cus (21 of 40, avg abundance=36.5%) being present
in all samples.
Gardner and colleagues profiled the microbiome of 52
individuals with non-infected DFUs using 16S rRNA gene
sequence analysis and were the first to restrict the
sampling of patients to a homogenous sample of DFUs
(neuropathic DFUs only) [14]. The group proposed that
previous studies within the area [15–17,22] were tainted
by heterogeneous sampling [e.g. pooled samples of differ-
ing chronic wounds and of all three DFU aetiology types
(neuropathic, ischemic and neuroischemic)], and as such,
these pathophysiologically distinct lesions likely harboured
their own unique microenvironments and thus microbiota.
In characterizing the microbiome of 52 non-infected
DFUs, Staphylococcus was identified as the most common
and abundant genus in 49 of 52 DFU samples. At a
species-level, the majority of sequences belonged to the
common pathogen S. aureus, an unsurprising finding
considering the highly documented role of this microor-
ganism in diabetes related foot infection [3]. Comparisons
of the relative bacterial abundances within each DFU
using culture-dependent analysis identified the overesti-
mation in the abundance of Staphylococcus spp. (0.47 vs.
0.32, p=0.0001) and underestimation of anaerobes
(0.11 vs. 0.18, p=0.0063) in comparison with 16S rRNA
gene sequence analysis.
By culture, anaerobes were identified as the predomi-
nant organisms in only 6 of 52 DFUs (12%) a finding
consistent with the known limitations of culture-dependent
methods, particularly in the identification of slow-growing,
fastidious anaerobic organisms [14]. In contrast, 16S rRNA
gene sequence analysis identified twice this amount (12
DFUs, 23%); this is of importance at a clinical level where
the role of anaerobes in DFI and wounds is often
underestimated. Their significance as highly virulent
pathogens, detrimental to the wound environment [23] or
as pathogens of DFI [10] is only becoming appreciated
through advances in new molecular techniques that are
culture-independent.
Gardner et al. also depicted bacterial community struc-
ture using a statistical approach of Euclidean distances to
Table 1. Bacteriology of DFI. A comparison of culture dependent and independent analysis
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determine how similar DFU attributes were to the indica-
tors of wound bioburden (microbial load, diversity and
presence of pathogens). The partitioning of data identified
three clusters; EUC1 contained significantly greater OTU
richness (p=0.006), diversity (p=0.02) and bacterial load
(p=0.02). This cluster was associated with DFUs of longer
duration (p=0.02), increased ulcer depth (p=0.01),
contained a greater abundance of anaerobes (p=0.01)
and proteobacteria (p=0.005). This is likely associatedwith
wound longevity and deeper tissue involvement.
EUC2 contained a greater abundance of Staphylococcus
and lower abundance of anaerobes (p=0.0003), and
EUC3 contained the highest abundance of Streptococcus
(p=0.0002). EUC2 and EUC3 had the highest propor-
tions of both staphylococci and streptococci with lab-
oratory markers from these participants recording the
highest levels of glycosylated haemoglobin (HbA1c %)
(Median EUC2 HbA1c=9.2% versus median EUC3
HbA1c=9.4%).
Lastly, Wolcott et al. retrospectively characterized 910
non-infected DFUs using 16S rRNA pryrosequencing,
and this currently represents the largest survey of the
microbiome of DFUs [13]. Wound samples were collected
from superficial debridement material obtained from the
wound bed, and relative abundances were calculated
from species-level OTUs constituting >10% of all DNA
reads per sample. Given the large sample size from multi-
ple wound aetiologies, individual wound microbiomes
were not reported, and DNA sequences were pooled. Of
910 DFUs, the most abundant phylum was the Firmicutes
(64%) followed by Proteobacteria (26%), Actinobacteria
(9.6%) and Bacteroidetes (1%). Staphylococcus (31%)
was the most abundant OTU with S.aureus (48%) and
S. epidermidis (35%) predominating at the species-level.
Infected or non-infected?
Of the studies employing amplification and sequence
analysis of the 16S rRNA gene to characterize the microor-
ganisms involved in DFI, few have sampled participants
with overt clinical signs of infection. Expert consensus
opinion is that clinically uninfected wounds should not
Figure 1. An overview of a common polymerase chain reaction (PCR) and massively parallel sequencing (MPS)-based workflow
employed for microbiome research into chronic wounds, diabetic foot ulcers and diabetes foot infections. WGS, whole genome
sequencing
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be treated with antimicrobials and therefore should not
be cultured [3,24]. The clinical relevance of culturing
uninfected DFUs to characterize the microbiome is debat-
able. In patients with diabetes presenting with overt clin-
ical signs of infection, the decision to obtain a culture
from a wound to identify a pathogen of infection is clini-
cally justified. Many patients with diabetes, however, do
not display overt clinical signs of infection in the presence
of a non-healing DFU [25,26].
Some clinical researchers have proposed under these
circumstances to utilize secondary signs and symptoms
(i.e. malodour, increased exudate and poor quality tissue)
to diagnose infections, signs that could be more pertinent
to guiding action by clinicians in treating wounds that are
non-healing with standard care [27]. Obtaining cultures
to examine the microbiome of patients with ‘masked’ signs
of infection in DFUs that are non-healing despite standard
care may prove greatly beneficial.
Sole pathogen or polymicrobial
infection?
Lastly, certain aerobic species are often overestimated as the
primary pathogens in DFI. When comparing the evidence on
the bacteriology of DFIs through both culture-dependent and
culture-independent approaches, both corroborate S.aureus
as being the predominant pathogen colonizing DFUs
(Figure 1). In tandem with this, reports have also suggested
that the abundance and role of anaerobes are greatly
underestimated. This is of additional importancewhen defin-
ing the pathophysiology behind a DFU with previous reports
documenting the increased role of anaerobes in ischemic and
neuroischemic DFUs [2,10]. The significance however at a
clinical level of identifying additional ‘hidden’ anaerobes that
often form part of a polymicrobial infection are yet unde-
fined. Many antimicrobial agents commonly used in the
treatment of DFIs have a broad-spectrum of activity to cover
most anaerobes. Furthermore, no published studies are avail-
able reporting improved clinical outcomeswhen adding addi-
tional anti-anaerobic directed therapy to concurrent regimes.
Applying metagenomics to DFI – could
this be a ‘game changer’ in defining
‘which microorganisms are present,
what are they capable of doing and
who did it’?
Advancements in molecular technologies have seen the
emergence of massively parallel sequencing (MPS) that
greatly increases the throughput of sequencing large
amounts of DNA. This significantly reduces the cost to
analyse clinical samples and makes MPS platforms widely
applicable to use in clinical practice [28] (Figure 1). How-
ever, MPS platforms generate large and complex genomic
data sets that require analysis. To complement the
increasing use of MPS by both researchers and clinicians,
the development of bioinformatics programs and software
packages have become essential tools. Open-source soft-
ware such as QIIME [29] and MOTHUR [30], for example,
have been widely used in microbiome research for their
ability to construct details on three areas of importance
to clinicians dealing with chronic wounds: the microbial
load, the microbial diversity and the presence of patho-
gens [31].
Unlike the targeted amplification and sequence analysis
of 16S rRNA gene through PCR, metagenomics employs a
complement of molecular technologies and techniques to
sequence DNA extracted directly from a sample. DNA in
metagenomic approaches are sheared into smaller
fragments and independently sequenced in a technique
commonly referred to as whole genome sequencing
(WGS). This approach produces sizeable data sets requir-
ing the alignment of DNA reads to known genes through
open-access reference databases, such as NCBI GenBank
[32]. When combined, these ever growing gene reference
libraries enable the analysis of varying components of
microbial ecology and their functions.
Applyingmetagenomics to DFImay allow for an extended
picture of which microorganisms are there. What are they
capable of doing and ‘who’ did it? WGS identifies all
genomic DNA including bacteria, fungi, archaea and viruses
(microbiome). In addition to DNA sequences involving the
taxonomically informative genes, other genes of interest
may be identified through WGS such as protein coding
sequences from which the biological functions of the
microbe can be inferred (e.g. pathogenicity (pathogenicity
islands), virulence, antibiotic susceptibility [33] or meta-
bolic pathways [34]). These protein sequences are identified
through databases containing resources required for under-
standing high-level functions and utilities of biological
systems, including known proteins for microbial cells (Kyoto
Encyclopedia of Genes andGenomes –Kegg andMG-RAST).
Whole genome sequencing is however limited in its
capacity to provide information on the actual metabolic
activity of a microbial community, as it cannot differentiate
between expressed and non-expressed genes [35]. To
circumvent this limitation, metagenomicmethods have been
combined with other molecular approaches, such as tran-
scriptomics and proteomics, which are capable of identifying
expressed biological signatures such as RNA transcripts or
proteins, respectively, that control metabolic activities in
microbial communities [36,37]. In this respect, combining
WGS with transcriptome or proteome analysis may afford
DFI Microbiome
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the possibility to characterize not only the microbial diversity
within a DFI (i.e. ‘which microorganisms are present’) but
the functional potential (i.e. ‘whichmicroorganisms are pres-
ent andwhat are they capable of doing andwho did it’) [34].
Thus, it would be highly desirable to determine which
microbes are the potential ‘assailants’, ‘co-conspirators’
and ‘bystanders’; this would allow for targeted antimicro-
bial therapy. One study exemplifying the combined use of
WGS with proteomic analysis was by Lassek et al. who elu-
cidated pathogen-protein expression of catheter-biofilm
associated urinary tracts infections [38]. Both Pseudomonas
aeruginosa and Morganella morganii were identified as the
predominant microorganisms through WGS community
analysis. Proteomic analysis then revealed several interest-
ing findings at a functional level, which implicated P.
aeruginosa as the primary driving pathogen and identified
that it up-regulated proteins involved in the degradation of
red blood cells, the siderophore systems for iron acquisition
(i.e. bacterial growth), biofilm formation, antibiotic resis-
tance and pathogenicity. Currently, no studies employing
WGS in combination with transcriptome, proteome or
metabolome data have been undertaken for DFI.
Limitations of different molecular
technologies and techniques
PCR amplification of DNA fragments requires the use of
primers to bind to a specific region of the 16S rRNA gene
to produce a PCR product. The use of some universal
primers may not be broad enough to detect the bacteria that
often cause polymicrobial infections in chronic DFUs [39].
Although the hypervariable regions of the 16S rRNA gene
are highly diverse, this variation is reduced between closely
related taxa. This limitation can be somewhat partially offset
through the use of multiple primer sets (multiplexing PCR)
to amplify different hypervariable regions. Lastly, current
DNA-based methods are unable to distinguish between live
or dead bacteria, amplifying all DNA regardless.
Whole genome sequencing posses gargantuan and
complex data sets generating up to 600 Gb of sequence
data when performing sequencing runs [40]. Further-
more, both human-host DNA and microbial DNA are se-
quenced with approximately 90% of DNA from a sample
being human [33]. Therefore, obtaining adequate
coverage of microbial DNA requires deep sequencing
(i.e. large data sets) with removal of human DNA se-
quences via computational resources.
Summary
Amplification and sequence analysis of the 16S rRNA gene
for profiling the microbiome of infected and non-infected
DFUs have already provided insights for the medical
community by identifying that many more bacteria are
present in DFUs than the corresponding view from
culture-dependent methods [14]. Despite the wealth of
knowledge gained from molecular microbiology, the use
of PCR-based approaches have not been routinely
employed in frontline clinical microbiology services for
the identification of pathogens associated with infection.
This limited uptake has been attributed to the low
throughput and relatively high sample sequencing costs
using PCR-based platforms. This may account for why it
has been primarily confined as a researchers tool for
characterizing the microbial profile of various infective
pathologies in human health and disease.
While the progress and application of current DNA
sequencing continue to rapidly evolve, thus, far we have
only been enlightened with a broader view of ‘which
microorganisms are there’. The potential of molecular
methods that employ metagenomics, transcriptomics,
proteomics and metabolomics represents a potential
future ‘game changer’ to improving clinical care in people
with DFI. Their usage may help to reveal the full extent of
DFI: ‘which microorganisms are present, what are they
capable of doing and which microorganism was responsi-
ble’? In doing so, this may allow targeted antimicrobial
therapeutics.
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We thank Kalan and colleagues (1) for sharing their data onthe role of fungi in chronic wounds, an area that has to date
been understudied, with only one previously published article
within the literature (2). Their study is therefore of great interest
for clinicians in understanding the role of fungi in chronicwounds
and in ascertaining whether alterations from antimicrobials to
antifungals might improve outcomes.
The data presented are, however, difficult to interpret within
the context of clinical management. First, Kalan and colleagues
report the sampling of chronic wounds undertaken using the
Levine technique with a swab. This culture method has been the
subject of great debate in the diabetic foot arena, with opinions
divided. Some expert groups promote tissue biopsy as the most
appropriate sampling method for identifying pathogens of infec-
tion and for exploring both the microbiome and the role of bio-
films (3, 6).
We note a previous study from the authors’ group suggesting
good concordance between culture-independent swab samples
(DNA sequencing) and tissue samples (4). However, the use of
swab samples from superficial tissue makes it difficult to ascertain
whether any fungi identified merely resided on wound surfaces as
colonizers or whether the fungi were invasive and involved deeper
tissue (this may suggest a more pathogenic involvement) (5).
Second, and more importantly, Kalan and colleagues report
only on the ITS1 sequences (18S rRNA) and do not include bac-
terial or archaeal sequences (16S rRNA). In doing so, the clinical
relevance of fungi in chronic wounds becomes lost. This is be-
cause, without identifying all themicroorganisms within a wound
(bacterial, fungal, archaeal), one cannot determine the overall
microbial load for fungi or what their relative abundances are
in relation to those of other microorganisms. This allows us to
understand whether a microorganism is a dominant, major, or
minor player. Therefore, no assumptions can be made on the
community structure, and the “mycobiome” becomes clini-
cally uninterpretable.
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Abstract: The presence of biofilms in chronic non-healing wounds, 
has been identified through in vitro model and in vivo animal data. 
However, human chronic wound studies are under-represented and 
generally report low sample sizes. For this reason we sought to 
ascertain the prevalence of biofilms in human chronic wounds by 
undertaking a systematic review and meta-analysis. Our initial search 
identified 554 studies from the literature databases (Cochrane 
Library, Embase, Medline). After removal of duplicates, and those not 
meeting the requirements of inclusion, nine studies involving 185 
chronic wounds met the inclusion criteria. Prevalence of biofilms in 
chronic wounds was 78.2 % (confidence interval [CI 61.6–89, 
p<0.002]). The results of our meta-analysis support our clinical 
assumptions that biofilms are ubiquitous in human chronic non-
healing wounds.
Declaration of interest: This work was supported with funding from 
Smith and Nephew. Authors received travel and accommodation 
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U
nlike planktonic microorganisms, biofilm 
phenotypes have been defined as structured 
consortiums of aggregated microbial cells, 
surrounded by a polymer matrix, that 
adhere to natural surfaces, to artificial 
surfaces or to themselves.1 The concept of biofilms in 
human health and disease is now universally accepted 
in tuberculosis,2 periodontal disease and dental caries,3 
cystic fibrosis,4–6 in-dwelling medical device infections,7 
otitis media and other upper respiratory infections,8,9 
and chronic wounds.10,11 So highly attuned are 
researchers to the wide involvement of biofilm-
associated infections across the spectrum of human 
health and disease, that the US Department of Defense 
has recognised the significance of biofilm as being 
problematic in wound healing, and has prioritised 
research in this area.12 
biofilm ● systematic review ● wound healing ● infection ● non-healing
Biofilm-phenotype microorganisms residing within a 
chronic non-healing wound may promote a hyper-
inflammatory response, detrimental to the host.13–15 
Recent observations using oxygen microsensors and 
transcriptomics (examining oxygen depletion in micro 
niches and microbial metabolic activities) have 
provided alternate insights suggesting that bacterial 
biofilm in chronic wounds may promote localised 
tissue hypoxia, reducing the availability of oxygen 
required for wound healing.16  
Once established, biofilm often become highly 
tolerant to standard treatment and removal/eradication 
paradigms such as mechanical debridement.17 Several 
features that distinguish biofilm phenotypes from their 
planktonic counterparts are their tolerance to 
antimicrobial agents,18 disinfectants and the host’s 
immune defences.19,20
While non-healing chronic wounds represent an 
umbrella terminology for a range of pathologies, 
biofilms have been cited across all related aetiologies 
including venous leg ulcers (VLUs),21 pressure ulcers 
(PUs)14,22 and diabetic foot ulcers (DFUs).10  
Collectively, these chronic wounds contribute to 
significant morbidity, mortality and increased health-
care expenditure. Importantly, the continuing rise in 
antimicrobial resistance has placed a greater emphasis 
on correctly diagnosing and managing biofilm-
associated infections in non-healing chronic wounds. 
This will require a shift in treatment paradigms to 
more multifaceted biofilm-based approache, given the 
resilience of biofilms in responding to planktonic-
based treatments. 
The prevalence of biofilms in chronic 
wounds: a systematic review  
and meta-analysis of published data
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As the presence of biofilms across the spectrum of 
chronic wounds has significant implications both 
medically and economically, clear and concise 
information is required to help guide health-care 
professionals managing these recalcitrant causes of 
delayed healing. An increasing body of evidence from 
in vitro models23 and animal24 and human studies25 has 
identified the capacity of wound isolates to grow as 
biofilms, and for chronic non-healing wound samples 
to harbour biofilm.26 This has been driven largely by 
advancements in molecular microbiology, microscopy 
technology and techniques for the study of bacterial 
populations in situ. This has allowed authors to identify 
biofilm as the cause of non-healing chronic wounds and 
in the development of associated clinical infections. 
The bulk of evidence supporting the notion that 
biofilms complicate non-healing chronic wounds is 
from in vitro model and in vivo animal data.27–30 A recent 
review of the scientific literature for the presence of 
biofilms in chronic wounds has eloquently explored the 
models used.31 However, human chronic wound studies 
are under represented, with most having low sample 
sizes. For this reason, we aim to determine the prevalence 
of biofilms recognised in human chronic wounds by 
systematically reviewing the literature published on 
in vivo human chronic wound studies and to increase 
sample size and power by performing a meta-analysis.
Methods
Search strategy 
A start date of 2008 was used based on a decision by the 
authors that this best represented the start of 
publications that used acceptable terminology and 
visualisation methods that best described and depicted 
microbial aggregates, extracellular polymeric substance 
(EPS) and the spatial orientation of microorganisms in 
samples. A systematic review of the Cochrane Library, 
Embase, and Medline (PubMed) databases was 
conducted for articles published between January 2008 
and December 2015 using the following search terms: 
‘biofilm’ [all fields] AND ‘chronic wounds’. 
A secondary search was undertaken using ‘biofilm’ 
with supplementary keyword filters: OR ‘diabetic foot 
ulcers’ OR ‘venous leg ulcers’ OR ‘pressure ulcers’ OR 
‘decubitus ulcers’ OR ‘non-healing surgical wounds’, OR 
‘visualization’, OR ‘scanning electron microscopy’ OR 
‘fluorescent in-situ hybridization’, OR ‘16S rRNA’.  Only 
articles in the English language were included. The 
search was limited to prospective clinical studies, case 
reports, case series and published conference abstracts. 
The systematic review was conducted in accordance 
with the PRISMA guidelines.32
Data extraction
Investigators (MM and TB) independently reviewed 
titles and abstracts of all articles to establish their 
eligibility on the basis of predefined criteria. All 
eligible article references were tabled and their 
abstracts obtained for review. Articles meeting the 
eligibility criteria were hand-searched for additional 
studies. For the purpose of the meta-analysis, we 
extracted the following domains or variables from the 
articles: date of study publication (2008–2015), 
prevalence rates (number of confirmed tissue samples 
over the total number of samples screened), sample 
size and study design.
Study eligibility 
Articles publishing data on in vivo human chronic 
wounds, in participants over the age of 18, were 
included. Chronic wound aetiologies included in the 
search were DFUs, VLUs, PUs and non-healing surgical 
wounds (NHSWs). Individual searches of the 
methodology section were undertaken and universal 
definitions of a chronic wound or phrases denoting the 
chronicity of participant wounds such as ‘non-healing’, 
‘delayed healing’ and/or ‘chronic’ were used to ensure 
eligibility. 
Only articles detailing the presence of biofilm and 
bacteria in general through microscopy with or without 
combined molecular methods were included for review. 
In line with recent guidelines33 the following 
visualisation techniques were deemed appropriate for 
the confirmation of biofilm presence: scanning electron 
microscopy (SEM), transmission electron microscopy 
(TEM), confocal laser scanning microscopy (CLSM), 
conventional and peptide nucleic acid–fluorescent in 
situ hybridisation (PNA–FISH) and microscopy with or 
without staining methods. Articles diagnosing biofilm 
presence by clinical observation were excluded. 
Confirmation of biofilm included all visualisations of 
aggregated bacteria within the wound bed.34
Additionally, to meet inclusion criteria, articles 
must have cited optimal collection methods for the 
Fig 1. PRISMA flow diagram of literature search
Full-text articles assessed 
(n=9)
Failed to meet study inclusion 
criteria
(n=443)
Duplicates removed
(n=102)
Database article sources
(n=554)
Medicine=368
Cochrane library=4
Embase=182
Title and abstract screened
(n=452)
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sampling of chronic wounds with tissue biopsy, 
curettage or debridement material being regarded as 
gold standard. Swab cultures of the wound bed were 
excluded for being inadequate for biofilm 
identification, given the inability to distinguish 
between planktonic and biofilm phenotype.33
Statistical analysis
Data from studies were extracted as raw numbers using 
the number of samples with confirmed biofilm over the 
total number of samples obtained. Data were analysed 
using comprehensive meta-analysis software (Biostat 
Inc., NJ, US). Prevalence estimate rates, weighted 
averages and 95 % confidence intervals (CIs) were 
undertaken using fixed-effects meta-analysis. Forest 
plots were reported for inconsistencies in effect sizes 
and their CIs. Between-study variance or heterogeneity 
in estimates was modelled using Cochran’s Q and the 
I2 statistic. Where Cochran’s Q value was reported with 
p-values less than 0.10 and I2 values exceeded  50  %, a 
random-effects model was used.35
Results
Search results
The search identified 554 studies from the literature 
databases. After removal of duplicates, exclusion and 
the screening of 452 titles and abstracts, eight studies 
involving 185 chronic wounds met the inclusion 
criteria (Fig 1). The numbers of each respective chronic 
wound were: DFUs (n=33), VLUs (n=67), PUs (n=26), 
NHSWs (n=28), unspecified chronic wounds (n=31). 
There were eight articles from prospective cohort 
studies with the remaining one study being case 
reports/series (Table 2). Primary authors were contacted 
for data from two studies in order to clarify the number 
of positive biofilm samples.36,37 Between-study results 
identified heterogeneity (Q test p<0.022, I2=55 %); to 
address this, a random-effects model was used with 
prevalence rates reported. 
Prevalence of biofilms in chronic wounds
The prevalence of biofilms in chronic wounds was 
78.2  % [CI 61.6–89, p<0.002]. Biofilm prevalence across 
studies identified the percentage(s) of positive biofilm 
samples was no lower than 60  % (noted in three 
studies),10,38,39 with all remaining studies identifying 
100 % biofilm prevalence.36,37,40–43 Given the relatively 
small sample size and the covariable of four different 
chronic wound aetiologies, inferences regarding 
whether biofilms were more prevalent in one particular 
chronic wound were not possible.
Discussion
Early publications providing evidence for the presence 
of biofilm in chronic wounds have provided guidance 
for clinicians and researchers alike.10,11,39 These studies 
Table 1. Random–effects model of nine chronic wound biofilm studies
Author/s (year) Study design Number of 
participants
Visualisation 
methods 
Chronic wound 
aetiologies
Number of samples 
with confirmed 
biofilm (%)
James et al. (2008)10 Prospective study 
case versus control
66 Light microscopy, 
SEM 16S rRNA with 
DGGE
13 DFUs, 21 PUs
8 VLUs, 24 NHSWs
30/50 (60%)
Kirketerp-Møller et al. (2008)39 Prospective cohort 
study
22 PNA-FISH, CLSM Unspecified chronic wounds 13/22  (60%)
Fazli et al. (2009)41 Prospective cohort 
study
9 PNA-FISH, CLSM 10 VLUs 10/10  (100%)
Thomsen et al. (2009)44 Prospective cohort 
study, sub analysis
2 PNA-FISH, 16S 
rRNA
2 VLUs 2/2  (100%)
Han et al. (2011)38 Prospective cohort 
study
15 PNA-FISH, CLSM
16S rRNA
4 DFUs, 5 PUs, 2 VLUs
4 NHSWs
9 /15  (60%)
Neut et al. (2011)43 Case report 2 CLSM 2 DFUs 2 /2  (100%)
Oates et al. (2014)40 Prospective cohort 
study, sub analysis
4 FISH, SEM 4 DFUs 4 /4 (100%)
Martinez-Velasco et al. (2014)36 Prospective cohort 
study, conference 
abstract
20 SEM, LM Unspecified chronic wounds 20/20  (100%)
Honorato-Sampaio et al. (2014)37 Prospective cohort 
study
45 TEM 45 VLUs 45/45  (100%)
SEM–scanning electron microscopy; 16S rRNA–16S ribosomal RNA sequencing for identification of microbes; DGGE–denaturing gradient gel electrophoresis; PNA–FISH–peptide nucleic 
acid–fluorescent in situ hybridisation, CLSM–confocal laser scanning microscopy; LM–light microscopy; TEM– transmission electron microscopy; DFU–diabetic foot ulcer; PU–pressure 
ulcer; VLU–venous leg ulcer; NHSW–non-healing surgical wound
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identified that biofilms were present in 60 % of non-
healing chronic wounds. Since then, studies employing 
combined molecular and microscopy methods to 
directly visualise biofilms have gathered pace.
This systematic review and meta-analysis has collated 
all available in vivo studies pertaining to the 
identification of biofilms from non-healing human 
chronic wounds. In doing so, our meta-analysis results 
suggest that biofilms are prevalent in all these wounds. 
Prevalence rates identify that 78 % of non-healing 
chronic wounds harbour biofilms, with prevalence 
rates varying between 60 % and 100 %. We propose, 
therefore, that biofilms are ubiquitous in nearly all 
non-healing chronic wounds and the disparity in 
prevalence rates may be a reflection of study design and 
methodological limitations. For example, we argue that 
heterogeneous distribution of microorganisms within 
wounds may allow for variability in sampling, 
increasing the likelihood of returning negative or 
inconclusive samples. 
Previous studies,39,44,45 have highlighted the 
heterogeneous spatial distribution of wound microbiota 
through sampling multiple areas of the wound bed, 
identifying vast shifts in community diversity. This 
suggests that relying on a single site for sampling may 
reduce the chances of visualising biofilm. Obtaining 
samples from multiple sites of the wound may improve 
the detection of biofilm. However, this is often not 
feasible at a clinical level and is reflected in many 
studies that employ tissue collection methods.
The primary aim of this systematic review and meta-
analysis was to provide a statistical approach for further 
justifying the evidence that biofilms are present in 
chronic non-healing wounds. We acknowledge that our 
analysis has obvious limitations, in particular the low 
number of human studies available and the requirement 
for further in vivo studies with larger sample sizes to 
support existing data. This, however, further emphasises 
our rationale of performing a meta-analytical approach. 
It was also not our intention to provide guidance for 
treatment of chronic wounds; for that we would like to 
refer to the European Society of Clinical Microbiology 
and Infectious Diseases (ESCMID) guideline for the 
diagnosis and treatment of biofilm infections.33
Another limitation or difficulty with analysing the 
presence of biofilm in chronic wounds has centred 
around ‘what we define as a biofilm’. Often, biofilms 
are defined based on in vitro observations, and these 
describe biofilms as bacteria attached to surfaces 
within a self-produced extracellular matrix and 
tolerant to antimicrobials. In addition, biofilm 
development is often described over three to five 
stages, initiated by planktonic bacteria attaching to a 
surface, maturation of the biofilm and, lastly, dispersal 
of bacteria from the biofilm.46 
However, in vitro observations based on flow cell 
models using glass surfaces and fresh oxygenated 
culture media continuously flowing over the bacterium, 
differ greatly from the conditions within chronic 
wound infections.34 Here, the bacteria are not exposed 
to a continuous flow of fresh media and are not 
attached to a glass surface (or to a surface at all).10,39 
In  vivo chronic wound biofilms are also often 
encapsulated in a matrix, which includes host material, 
making dispersal problematic. 
Therefore, using in vitro observations to define, 
diagnose and treat biofilm in chronic infections may 
provide a misguided impression.47 There are, however, 
Table 2. Random–effects model of nine chronic wound biofilm studies
Study authors (year) Statistics for each study Event rate  
and 95% confidence interval 
Event rate Lower limit Upper limit Z-value p-value
James et al. (2008)10 0.600 0.460 0.725 1.405 0.160
Kirketerp-Moller et al. (2008)39 0.591 0.382 0.772 0.848 0.396
Fazli et al. (2009)42 0.955 0.552 0.997 2.103 0.035
Thomsen et al. (2009)44 0.833 0.194 0.990 1.039 0.299
Han et al. (2011)38 0.600 0.348 0.808 0.769 0.442
Nuet et al. (2011)43 0.833 0.194 0.990 1.039 0.299
Oates et al. (2014)40 0.900 0.326 0.994 1.474 0.140
Martinez-Velasco et al. (2014)36 0.976 0.713 0.999 2.594 0.009
Honorato-Samaio et al. (2014)37 0.989 0.849 0.999 3.172 0.002
Total 0.782 0.616 0.890 3.102 0.002
−1.00 −0.50 0.00 0.50 1.00
Favours biofilm  
not prevalent
Favours biofilm is prevalent
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commonalities between in vitro and in vivo evidence 
that can help in providing a definition of a biofilm. 
These include: aggregation of bacteria, some sort of 
matrix that is not restricted to self-produced as it can 
also be of host origin, and extreme tolerance and 
protection against most antimicrobial agents and the 
host defence. 
We suggest following this simplified definition in 
order to define biofilm in chronic infections: an 
aggregate of bacteria tolerant to treatment and the 
host defence.  
Conclusion 
When combining the results of our systematic review 
and meta-analysis with the available in vitro models 
and animal studies it seems highly likely that biofilms 
are ubiquitous in non-healing human chronic 
wounds. It is important that clinicians appreciate the 
distinct differences of biofilm phenotypes to their 
planktonic counterparts, in particular the challenges 
in eradicating and removing biofilm from a wound. A 
paradigm shift to a biofilm-based wound care 
approach should be adopted. JWC
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The Microbiota of Chronic wounds 
 
1. Purpose of Proposed Investigation 
Research into chronic wound bacteria has traditionally focused on planktonic cells, however 
bacteria encountered in nature and medical diseases commonly function as multispecies 
communities that communicate, live and work together in a symbiotic and or pathogenic 
manner (microbiota).  
 
This multispecies community can advance to encase itself in a protective extracellular 
polymeric substance and attach to a living or non-living surface, and this has been commonly 
described as a biofilm 144. More than 99% of bacteria found in nature exist in these stable, 
persistent biofilms, and there are reasons to believe this bacterial theme also holds true in the 
chronic wound environment. 
 
In recent years electron microscopy of biopsies from chronic wounds have found that 60% of 
the specimens contained biofilm structures in comparison to only 6% of biopsies from acute 
wounds 12. The significance of the bacterial diversity and any symbiotic and pathogenic 
relationships between bacterial organisms in addition to the aetiological role of biofilms in 
causing chronic wound infection remains poorly understood. Currently culture based 
techniques to determine the bacterial organisms residing in chronic wounds select for species 
which flourish under the typical nutritional and physiological conditions of the diagnostic 
microbiology laboratory and this may not necessarily reflect the most abundant or clinically 
important organisms in chronic wounds 10.  
 
 
 
 
An observational study is therefore proposed using advanced molecular techniques 
(Pyrosequencing), confocal laser scanning microscopy (CLSM) and labelled DNA probes for 
the in situ identification of microorganisms (FISH) in exploring the bacterial diversity 
(microbiota) that reside in chronic wounds.  Additional primary aims are to explore if biofilms 
are present within chronic wounds and if so are they mainly comprised of planktonic or 
multiple species of bacterial organisms. Our secondary aims are to correlate clinical wound 
parameters with the positive presence of biofilm. 
 
We also plan to undertake a separate pilot study testing the effectiveness of two antimicrobial 
woundcare treatments in reducing bacterial numbers and biofilm formation within chronic 
wounds in vivo. An analysis of biofilm structure will be utilized to determine effect using the 
parameters; species composition and the total number of bacteria. 
 
2. Background  
Chronic wounds including diabetic foot ulcers (DFU) represent a significant cost in both 
financial and human terms. This cost is sure to rise as the prevalence of diabetes and obesity 
increases with a concomitant increase in the incidence of chronic wounds. Four interlinked 
factors are responsible for contributing to chronic wounds. These are local tissue hypoxia, 
bacterial colonisation/infection, repetitive ischaemia-reperfusion injury and general patient 
aging. Each component of the pathogenesis is deleterious in isolation but together they can 
overwhelm the healing response in many patients. Of these, the only factor that is readily 
treatable in all wounds is bacterial infection. 
 
 
 
 
 
 
 
The role of bacteria in chronic wounds 
All chronic wounds contain bacteria. The presence of bacteria in the wound does not, however, 
indicate infection or a barrier to wound healing. The impact of bacterial organisms on healing 
will depend on the pathogenicity of the organism, the bacterial load and diversity, the toxin 
produced and the host response. Extensive research into the role of bacteria in causing chronic 
wound infections has identified contrasting evidence. In particular, the focus has centred on 
the roles of single, free-floating bacteria (planktonic) and or the interaction of multiple species 
of bacteria in causing infection.  In some chronic wounds one or more species of organisms 
may proliferate in the wound and it is this ecological community of commensal, symbiotic, and 
pathogenic microorganisms that constitute the “microbiota”  
 
The microbiota in some chronic wounds may additionally form a highly organized, dynamic 
heterogenous community of organisms that has been termed a ‘biofilm’. At the most basic level 
a biofilm has been described as a “microbial population that has attached to a biological or non-
biological surface and in an attempt to flourish this community embeds itself in a protective 
extracellular polymeric substance (slimy barrier of sugars and proteins) 93. 
 
Once the formation of a biofilm exists in a chronic wound the opportunity of this community 
to attack the host tissue may lead to tissue damage and a host response that is infection. Whilst 
bacterial colonization and infection play an integral role in chronic wounds the exact role of 
biofilms has remained unclear. In recent years’ electron microscopy of biopsies from chronic 
wounds have found that 60% of the specimens contained biofilm structures in comparison to 
only 6% of biopsies from acute wounds 12,141. The role of biofilms has now been well 
documented as medical problems associated with implants and certain other diseases.  
 
 
 
 
However, the nature and importance of wound biofilms is only now beginning to be realized 
as reviewed and discussed in the scientific literature 12. Chronic wounds, including diabetic 
foot ulcers (DFUs), venous leg ulcers (VLUs), and pressure injuries (PIs), are often resistant to 
natural healing and require long term medical care and are also implicated as a major source of 
both morbidity, mortality that carry extensive healthcare and quality of life costs.   
 
Methods of identifying bacterial organisms 
Traditionally, to detect potential pathogens of infections, wound cultures have been utilised to 
identify free floating (planktonic) organisms in addition to looking at their density through 
qualitative and quantitative measures. The limitations of such are that culture-based techniques 
select for species that flourish under the typical conditions of the diagnostic microbiology lab 
and this may not necessarily reflect the most abundant or clinically important organisms in 
chronic wound infections. It has also been recognised that bacterial organisms within biofilms 
cannot be detected using normal wound culture methods 13. 
 
More recently molecular based microbiological techniques have raised doubts about the role 
of traditional culturing techniques and may eliminate the bias open to traditional methods. 
Using amplification and sequence analysis of 16s rRNA subunit, a highly-conserved gene 
present in all prokaryotes (bacteria) but not eukaryotes (humans) that contains hypervariable 
regions allowing for bacterial identification, has revealed a vastly more complex array of 
bacterial communities than those identified by traditional culture methods in chronic wounds 
152-155. 
This presents an important problem and discrepancy because many of the bacteria in wound 
biofilms are recalcitrant to culture. Thus, there is a lack of information about the diversity of 
populations that occur in association with chronic wound pathogenic biofilms. A better 
 
 
 
 
understanding of bacterial populations associated with wound biofilms is necessary to enable 
development of next generation management and therapeutics.  
 
Methods of visualizing bacteria 
Bacterial biofilms are encased within an extracellular polymeric substance (EPS) of which the 
bacteria themselves produce. It has been generally accepted within the medical community that 
biofilms are not visible to the naked eye. However, EPS has been visualized by scanning 
electron microscopy (SEM), whilst Individual bacteria and bacterial microcolonies have also 
been observed using fluorescence in situ hybridization (FISH) on chronic wound biopsy 
sections, which permits the visualization and identification of individual bacteria in human 
disease states in situ 93.  
 
The infection continuum in chronic wounds 
The concept of the wound infection continuum model places an emphasis on progression from 
colonization of bacteria within a wound through to infection, with infection being dependent 
on an increase in microbial load. An important component of the wound continuum model is 
the concept of “critical colonization”. Critical colonization is defined as “multiplication of 
organisms without invasion but interfering with wound healing. Whilst this concept of critical 
colonization is still the center of much debate its concept has been used by clinicians to explain 
an alteration in the wound bioburden associated with delayed wound healing in the absence of 
clinical infection. This concept is important for clinicians as chronic wounds with critical 
colonization may benefit from local and or topical treatments such as antimicrobial wound 
dressings and wound debridement, rather than systemic management with the use of 
antibiotics. 
 
 
 
 
 
Clinical Methods of identifying infection and biofilm in Chronic Wounds 
Identification of Infection in chronic wounds such as DFU’s is imperative to prevent 
complications such as amputation. In persons with diabetes it is thought that over 90% of 
Infections are the primary pathway to lower extremity amputation. Whilst there has been much 
debate as to the optimal methods to diagnose infection, the Infectious Disease Society of 
America have recommended a specific combination of clinical signs and symptoms to aid 
diagnosis in their consensus guidelines on diagnosing diabetic foot infections 2.  Underpinning 
the guidelines are the recommendations that the presence of infection be based on the presence 
of purulent exudate or two or more signs if inflammation (pain, erythema, heat or oedema). 
 
In contrast to the above are reports from other groups who have highlighted that clinical signs 
of infection may however, not always present in some people with chronic wounds, with the 
classic signs of infection being retarded by confounding variables such as the presence of 
peripheral neuropathy, peripheral arterial disease, hyperglycaemia and established biofilm 
phenotypes.  
 
Wound Infection is the host response to tissue injury with an inflammatory response being the 
first line of defence against bacterial invasion. It has been reported however that many chronic 
wounds do not express these signs of clinical infection despite high microbial loads and or the 
presence of pathogenic organisms. For this reason Gardner and colleagues proposed a second 
guideline to follow in cases of suspected infection in a chronic wound where the ‘classic’ 
clinical signs maybe absent 19. The clinical signs and symptoms checklist (CSSC) objectively 
measures clinical signs of infection in chronic wounds and is a linear combination of 12 
separate signs of infection.  
 
 
 
 
It is generally regarded the biofilm is not visible to the naked eye and there is significant debate 
as to whether clinicians can rely on clinical indicators to determine the presence of a biofilm 
in a chronic wound. In a recent publication by Keast et al 2014, a table of clinical indicators 
that may present in the presence of chronic wound biofilm were proposed based on supporting 
evidence 432.  
 
Overview of the current research - gaps in the evidence 
Little is currently known about the types of bacteria that might contribute to the bacterial 
diversity in infected chronic wounds. More importantly there is a large gap in the available 
evidence on what and which bacteria play important roles in chronic wound infections and if 
these infections are caused by free floating planktonic pathogens or biofilm phenotypes. 
 
In particular, there is limited evidence from researchers employing molecular based 
microbiology and of these only a few recent surveys of bacterial populations associated with 
various chronic wounds including diabetic foot ulcers are available within the literature. Most 
have focused on the role of easily cultured and well-known pathogens such as Staphylococcus 
aureus and Pseudomonas aeruginosa. These organisms are cultured easily using traditional 
microbiological evaluations, and, therefore, standard non-molecular methods likely 
overestimate the contribution of these species to the microbiota of chronic wounds. 
 
Of the available molecular based studies on the microbiota of chronic wounds and DFUs, few 
have sampled from participants with clinical signs of infection. Whilst the standard treatment 
for diabetic foot infection and chronic wound infection includes but is not limited to the use of 
systemic antimicrobial therapies the clinical significance of sampling clinically uninfected 
DFU’s remains unclear.  
 
 
 
 
Other studies within the context of chronic wound microbiota sampled wounds that were 
heterogeneous in aetiology. Gardner and colleagues 2013, undertook one of the only available 
studies on DFU microbiota and proposed that the sampling of DFU’s should be from a 
homogenous DFU aetiology group 10. For this reason, Gardner and colleagues sampled the 
microbiota of neuropathic ulcers, however this does not reflect the typical patterns of 
presentation in the diabetes foot population, with neuroischemic DFU’s forming most clinical 
presentations.  
 
The microbiota of chronic wounds from a molecular perspective remains largely ambiguous. 
Understanding the roles differing organisms play and the role of biofilm phenotypes in causing 
infection in chronic wounds would be highly significant both economically and medically and 
may allow for target specific treatment modalities. 
 
3. Study Rationale 
The significance of the bacterial diversity and any symbiotic and pathogenic relationships 
between bacterial organisms in addition to the aetiological role of biofilms in causing infections 
in chronic wounds remains poorly understood.  
 
We propose to explore the bacterial diversity in infected wounds (microbiota) by comparing 
results from standard lab-based culture against advanced molecular techniques (PCR), 
Confocal Laser Scanning Microscopy (CLSM) and labelled DNA probes for the in situ 
identification of microorganisms (FISH). A better understanding of bacterial populations and 
the role of biofilms associated with chronic wound infection is necessary to enable the 
development of next generation management and therapeutics.  
 
 
 
 
 
Secondly, it has been recognised within the literature that bacterial organisms within biofilms 
cannot be detected using normal wound culture methods and wound biofilm are not visible to 
the naked eye. We propose to correlate any relevant clinical wound parameters with 
microscopy results for positive biofilm presence against previously suggested clinical 
indicators of biofilm presence in chronic wounds. This may allow for the development of a 
clinical based tool based on signs and symptoms of possible biofilm presence that may aid 
clinicians in a timely diagnosis and the potential to alter treatment regimes.  
 
Thirdly, we propose to undertake a pilot study to determine the effectiveness of two commonly 
used antimicrobial woundcare treatments on reducing bacterial numbers and biofilm formation 
over a 7-day period in vivo. Chronic wounds with suspected high bacterial loads (critical 
colonisation) or biofilm formation are commonly treated with various antiseptic or 
antimicrobial wound dressings and or ointments that have purported mechanisms of action to 
aid wound healing by reducing the amount of bacteria present in the wound. Most works 
undertaken in this arena are from in vitro sources. 
 
Disappointingly, these wound care treatments often have variable results with some chronic 
wounds progressing to a more serious infection and possibly amputation. One potential 
explanation for this treatment failure is because the wound care treatments do not target or are 
ineffective against biofilm. If successful this pilot study may improve patient care and pave the 
way for future studies in this developing area. Given the financial implications of utilising new 
advanced molecular and microscopy techniques we plan to undertake this pilot study only if 
we can secure funding from external sources.  
 
 
 
 
 
 
Statistical Power 
Phase I will be the initial observational study of 30 patients with chronic wound infection and 
will be self-funded. 
 
Contingent on obtaining adequate funding, Phase II aims to recruit sufficient patients to provide 
a robust estimate of the required sample size for a larger trial. An additional 30 patients (15 per 
cohort) will be recruited as part of Phase II.   
 
We estimate that n=30 patients will accommodate a 15% drop out rate while retaining sufficient 
statistical power to estimate the effect size and variance of the effects of each wound treatment. 
 
4. Study design 
This study has two clear phases. The first phase is to undertake an observational study of 30 
participants exploring the diversity and relationships of bacterial organisms within chronic 
wounds. The second phase is a pilot study of 30 participants designed to estimate the 
effectiveness of two commonly used woundcare treatments in reducing bacterial burden in 
chronic wounds in vivo. 
 
4.1 Primary and Secondary aim/s of Cohort 1  
4.1.1 Primary aim/s 
• To explore what bacterial organisms commonly reside in infected and non-infected 
chronic wounds. 
 
• To determine if biofilms are present in chronic wounds and if they are principally 
composed of single or multiple species of bacteria. 
 
 
 
 
 
• If biofilms are identified, is there a common bacterial organism responsible for creating 
the biofilm. 
 
• To compare lab-based culture against PCR, SEM and FISH.   
 
4.1.2  Secondary aim/s 
• Correlate clinical indicators to the presence of biofilm. 
 
4.1.3 Primary aim of cohorts 2 and 3 
1. Assess the effectiveness of an antimicrobial woundcare treatment in reducing bacterial 
numbers and biofilm formation in vivo. An analysis of biofilm structure will be utilized to 
determine effect using the parameters; species composition and the total number of bacteria. 
5. Methodology  
Phase I  
A convenience sample of 30 participants presenting with chronic wound infection will be 
enrolled from Liverpool Hospital High Risk Foot Service over a 12-month recruitment period.  
 
Cohort one: will consist of 30 chronic wounds (DFU’s, venous leg ulceration, pressure 
ulceration) with clinical signs of infection, which are located on the lower extremity. One tissue 
biopsy sample measuring 3mm will be obtained from the wound edge for each participant at 
initial presentation. 
 
Phase II 
 
 
 
 
A convenience sample of 30 participants presenting with a chronic wound and signs of high 
bioburden but no clinical infection will be enrolled from Liverpool Hospital High Risk Foot 
Service clinic over a 12-month recruitment period.  
 
Cohorts two and three will consist of 15 chronic wounds in each cohort with no clinical 
infection but signs of a high bioburden (critical colonization) that maybe responsible for the 
delayed healing of the wound. In these cohorts, it is planned to assess the effectiveness in 
reducing chronic wound biofilm over a 7- day period.  
 
Cohort two: An antimicrobial wound irrigation solution and antimicrobial hydrogel (Wound 
aid® wash, and woundaid® hydrogel, Rye Pharmaceuticals) will be applied daily for 7 days. 
One tissue biopsy sample measuring 2mm will be obtained from the wound edge for each 
participant at initial presentation. An additional 2mm tissue biopsy for this cohort will be 
obtained at day 7 following the consecutive daily application of the products. A smaller biopsy 
size of 2mm will be used for cohort 2 as we do not plan to send for routine laboratory culture 
and as such less tissue is required for analysis. 
 
Cohort three: An antimicrobial ointment (Cadeoxmer Iodoine, Iodosorb®, Smith and 
Nephew) will be applied twice over the 7-day period, at initial presentation and at day 4. One 
tissue biopsy sample measuring 2mm will be obtained from the wound edge for each 
participant at initial presentation. An additional 2mm tissue biopsy for this cohort will be 
obtained at day 7. A smaller biopsy size of 2mm will be used for cohort 2 as we do not plan to 
send for routine laboratory culture and as such less tissue is required for analysis. 
 
 
 
 
 
In addition to the above all participants will undergo a wound assessment at each visit in 
keeping with standard care. 
 
Analysis of tissue 
Tissue biopsies for participants in cohort 1 will be subjected to routine laboratory culture-based 
analysis and advanced molecular microbiological and microscopy techniques, with routine 
laboratory culture-based analysis being omitted for cohort 2. Samples will be processed for;  
 
• Amplification and sequence analysis of 16s rDNA (bacteria) and 18s rDNA (human). This is 
necessary to determine all the bacterial species in the wound biopsy in addition to performing 
qPCR to obtain the total number of bacteria per mg of tissue expressed as a percentage. 
 
• Bacterial aggregates will be detected and located by fluorescence in situ hybridization (FISH) 
using fluorescent labeled bacterial universal probes and bacterial species-specific probes. 
Bacteria are detected with 16S rDNA fluorescein labeled EUB537 universal probe that detects 
all species of bacteria. 
 
• Routine laboratory culture-based analysis for microbiology, culture and sensitivity that will 
be used first and foremost by the high-risk foot team to guide any treatment therapeutics and 
or management plans for the newly diagnosed chronic wound infection. The quantitative 
analysis section of the tissue sample will also help to determine species and bacterial density 
that will be used as the comparison against FISH, CLSM and PCR. 
 
 
 
 
 
• Confocal Laser Scanning Microscopy to determine the presence of biofilm will be 
undertaken in selected participants. This will be dependent upon the ability to obtain an 
additional 1mm tissue biopsy sample. 
 
It is also intended to collect additional clinical data which forms part of routine care; 
• Broad demographic data 
• Broad clinical data including wound size, location of the ulcer, ulcer etiology, 
University of Texas ulcer grade classification. 
 
• Broad laboratory data including FBC; WCC, ESR, CRP, HbA1C  
 
All participants will continue to receive standard care over the study period, of which the 
treatment for the chronic wound will be dependent upon the medical requirements of each study 
participant. Additionally, the collection of tissue biopsies from people with suspected infection 
and high bioburden form part of gold standard care and is the preferred culturing technique to 
identify pathogens of infection. The technique of obtaining tissue biopsies from the wound 
edge in chronic wounds have shown rapid healing and do not result in delayed overall healing 
of the wound. 
 
5.1 Inclusion criteria  
• Type 1 or type 2 diabetes mellitus 
 
• Chronic wound >6 weeks duration (Neuroischemic Diabetic Foot Ulceration, Venous 
Ulceration, Pressure Ulceration). Neuroischemic DFU is defined as; 
 
 
 
 
1. A modified neuropathic disability score >6 and ABI>0.5 / in-palpable pedal pulses with 
Doppler waveform of bi-phasic and above and or confirmed vascular disease in the 
medical history with further evidence through vascular diagnostic imaging. 
2. A University of Texas wound classification of 1B and 2B. 
 
• Clinical signs of infection as per IDSA guidelines or masked signs of infection as per the 
clinical signs and symptoms checklist (CSSC).   
 
• ABI >0.5 
 
•  No known osteomyelitis 
 
5.2 Exclusion criteria for cohort 1 
• No oral, topical or systemic antimicrobial therapy 2 weeks prior to enrolment 
 
• Current anticoagulation therapy such as warfarin, clopidogrel and INR>2.0 
 
5.3 Exclusion criteria for cohorts 2 and 3 
• A change in current antibiotic regime within 2 weeks prior to enrolment and or during the 
treatment period. 
 
• Current anticoagulation therapy such as warfarin, clopidogrel and INR>2.0 
 
5.4 Identification of Infection 
5.4.1 Clinical signs of infection 
 
 
 
 
The Infectious Disease Society of America Guidelines 2012 will be used to identify clinical 
infection 2. 
 
5.4.2 Secondary signs of infection 
Secondary signs of infection in chronic wounds have been proposed by Gardner and colleagues 
(2009) 19 and will be used to identify potential chronic wounds with masked signs of infection. 
 
5.4.3 Identification of clinical parameters to determine the presence of wound biofilm 
Clinical parameters that maybe associated with wound biofilm have been proposed by Keast 
et al (2014) 432. The clinical parameters will be collected for each participant at each visit. 
 
5.4.4 Identifying wounds with high bioburden / critical colonisation BUT not infection 
Local signs of delayed wound healing due to possible high bioburden have been proposed when 
all other treatment modalities are in place; peri-wound erythema, pain, odour, oedema, or heavy 
exudate. 
 
5.5 Antimicrobial wound Irrigation solution (Woundaid® wound wash, TGA number 
AUST L 221556) 
In Australia, Woundaid® wound wash has been approved by the Therapeutic Goods 
Administration (TGA, Wound Wash TGA registered AUST L 221556) for the use of irrigation, 
moistening the wound bed, removing devitalised tissue and managing bioburden from;  
• Acute Wounds – cuts, abrasions, lacerations 
• Chronic Wounds – diabetic, pressure & venous ulcers, abscesses 
• Entry Ports & Peristomal Skin; 
 
 
 
 
• For intraoperative cleansing of wounds, during negative pressure closure, and to 
moisturise gauzes, bandages and other physical dressings during dressing changes 
 
The active antimicrobial agent is 4% tea tree oil with the surfactant PEG-35 castor oil to aid in 
the reduction of surface tension. The Woundaid wash has fully solubilised Melaleuca Oil 
within the liquid. This enables the Melaleuca Oil to be more quickly bio-available – hence 
better suited to lower contact time wash. Furthermore, the increased surfactant aids reduction 
of surface tension – with clinical studies indicating benefits in breaking down bio-films. 
 
5.6 Antimicrobial wound hydrogel (Woundaid® TGA registered AUST L 114360) 
In Australia, Woundaid® hydrogel has been approved by the Therapeutic Goods 
Administration for the use of moistening the wound bed, removing devitalised tissue and 
managing bioburden from;  
• Acute Wounds – cuts, abrasions, lacerations 
• Chronic Wounds – diabetic, pressure & venous ulcers, abscesses 
• Entry Ports & Peristomal Skin; 
• For intraoperative cleansing of wounds, during negative pressure closure, and to 
moisturise gauzes, bandages and other physical dressings during dressing changes. 
The active antimicrobial agent is 4% tea tree oil with a sustained, slow release action to 
complement the pre-application of woundwash. The surfactant Polysorbate 20, is to aid 
solubilisation. The surfactant used in Woundaid Wound Hydrogel is Tween 20 – a non-ionic 
surfactant. The surfactant concentration is a much lower level in Woundaid Hydrogel than in 
Woundaid wash. In the hydrogel, the Melaleuca Oil is physically trapped in the gel and not 
fully solubilised in the system, leading to a slower rate of bio-availability of the Melaleuca Oil 
 
 
 
 
in the wound – hence a slower release over a period of time due physical contact and changes 
in the gel structure. 
 
5.7 Antimicrobial Cadexomer Iodine (Iodosorb® Ointment TGA registered AUST R 
43364) 
Iodosorb® has been approved by the Therapeutic Goods Administration as an antimicrobial 
medicated ointment used in various types of chronic or acute wounds. Iodosorb® reduces the 
bacterial count, facilitates de-sloughing, absorbs exudate and maintains a moist wound 
environment to promote healing of chronic skin ulcers. Iodine is physically immobilised within 
the matrix of the dry cadexomer iodine and is slowly released in an active form during uptake 
of wound fluid.  This mechanism of release provides antibacterial activity both at the wound 
surface and within the formed gel. 
 
5.8 Specimen collection 
5.8.1 Tissue biopsy 
A 2mm or 3mm punch biopsy will be obtained from the wound edge of each chronic wound. 
A clinician with a competency in tissue biopsy technique will obtain biopsy samples following 
a standard punch biopsy method. 
 
5.8.2 The use of local anaesthesia 
We envisage that a high percentage of the patient population who present with chronic wounds 
whom are eligible for this study will have a peripheral neuropathy through underlying disease 
processes such as diabetes mellitus. In these circumstances, it is unlikely that a local 
anaesthesia will be required prior to undertaking the tissue biopsy procedure. In participants 
who do not have a peripheral neuropathy, a local anaesthesia via sub-cutaneous injection will 
 
 
 
 
be required. Other clinicians at enrolled sites will administer their local anaesthesia in keeping 
with their own competency and local guidelines.  
 
5.8.3 Possible complications from tissue biopsy 
Complications are uncommon following this simple procedure but all medical procedures carry 
a potential risk. Possible complications following a tissue biopsy include: 
• Excessive bleeding at the site of biopsy (haemorrhage) 
• Infection 
• Puncture damage to nearby tissue or organs such as arterial vessels 
• Skin numbness around the biopsy site 
 
5.8.4 Minimization of risk for tissue biopsy 
It is expected that some bleeding will occur during the biopsy procedure. In most cases this can 
be controlled by applying local pressure and or a haemostatic dressing if required. To minimize 
the risk of excessive bleeding anyone on anticoagulation therapy such as warfarin or 
clopidogrel will be excluded from this study. 
 
To minimize infection all procedures will be undertaken in an aseptic manner and in keeping 
with the tissue biopsy protocol. In cohort 1 we already suspect the presence of underlying 
infection and therefore the risk of further infection from a biopsy procedure is minimal and 
outweighed by the requirements to correctly identify the potential pathogen/s of the already 
suspected infection.   
 
Puncture damage to potential vessels will minimized by following biopsy protocols. Skin 
numbness may not present a problem for a high percentage of participants who will already 
 
 
 
 
have underlying peripheral neuropathy, however adherence to the correct technique as outlined 
previously will help limit potential complications.  
 
In all cases the size of tissue biopsy has been set at the lowest size possible to obtain an adequate 
analysis for all tests. No single tissue biopsy size is greater than 3mm in dimension and as such 
the biopsy site/s will not require suturing to close. For cohort 1 a 3mm tissue biopsy is required 
for testing PCR, FISH and lab-based culture. For Cohort 2 a 2mm tissue biopsy is sufficient to 
run analyses on just PCR and FISH.  
 
For CLSM an adequate size of tissue would not be possible from undertaking just one biopsy 
sample. Therefore, an additional tissue sample of 1mm (the lowest of all tissue punch biopsies 
available) is required and this is additional to standard care. We will ensure all participants are 
appropriately aware of this prior to consent. Having to seek this additional tissue sample is in 
keeping with previous published methodologies. The protocol for deciding to take an additional 
1mm tissue sample for CLSM will be if the chronic wound is >40mm in size.  
 
5.8.5 Tissue Processing 
Cohort 1 tissue samples for PCR, FISH and lab-based culture will be immediately split into 
three – 1mm pieces at the time of biopsy using tissue scissors in an aseptic manner. Cohort 2 
tissue samples will be split into two 1.5mm pieces. One portion of tissue will be placed in a 
sterile jar with 30ml normal saline and transported to the microbiology department immediately 
for lab based quantitative microbiology, culture and sensitivity. Another sample will be placed 
in a sterile jar with 30ml of normal saline and transported immediately to the Ingham Institute. 
Here it will be placed in a microcentrifuge tube and frozen at –80∘C until study end for 16S 
rDNA analysis.  
 
 
 
 
 
Lastly, a tissue sample will be placed in a sterile jar with 30 ml of saline and transported to 
Macquarie University where it will be embedded in optimal cutting temperature (OCT) 
embedding matrix and frozen at –80∘C until study end for FISH analysis. In cases where it is 
not possible to transport this sample immediately, samples maybe refrigerated for a maximum 
of 4 hours prior to transportation.  Any additional 1mm tissue sample obtained for CLSM 
analysis will be placed in a sterile jar with normal saline and transported in a similar fashion as 
the FISH samples also to Macquarie University.   
 
Tissue sampling workflow sequence. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.  
Biopsy taken in clinic 
2.  
Biopsy sample split into 3 
5. 
SEM 
4. 
PCR and FISH 
3. 
Lab based Culture 
 
 
 
7. 
Sent to SWAPS 
 
 
8. 
Samples stored -80°C 
At Inghams 
9. 
Transported to Macquarie 
University 
10. 
Samples processed upon 
completion of enrolment in 
batches of 5  
11. 
Samples processed in 
batches of 5 
 
 
 
 
5.9 Process of Bacterial identification, their relative abundance and biofilm identification 
5.9.1 16S rDNA next generation sequencing workflow 
5.9.2 DNA Extraction 
5 – 10 mg of human chronic DFU biopsy samples stored in RNAlater (Qiagen) will be defrosted 
on ice prior to DNA extraction. Genomic DNA will be extracted using Mo Bio PowerBiofilm 
DNA isolation kit (Mo Bio Cat# 24000-50) following the manufacturer’s instructions. 
 
5.9.3 16S rDNA qPCR to determine bacterial load 
The quantification of total bacterial DNA in each chronic wound tissue will be calculated by 
real-time quantitative PCR (qPCR) using universal eubacterial primer 16s rRNA_341F 5’-
CCTACGGGAGGCAGCAG-3’ and 16s rRNA_534R 5’-ATTACCGCGGCTGCTGG-3’ to 
amplify a 194bp amplicon of 16s rDNA of all bacteria. Human 18s rDNA gene is used as a 
reference gene to normalise the amount of wound tissue used in the DNA extraction. The 
primer pair utilised will be 18s rRNA gene real-time PCR is 18s rRNA_756F 5’-
GGTGGTGCCCTTCCGTCA-3’ and 18s rRNA_877R 5’-CGATGCGGCGGCGTTATT-3’ to 
amplify a 122bp amplicon.  
 
Real-time PCR will be undertaken using the Mx3000P qPCR system (Agilent Technologies, 
CA, United States). 25µl reaction mix containing 1X Brilliant II Sybr Green qPCR Master mix 
(Agilent Technologies, CA, United States), 400nM forward and reverse primers, and 100ng 
DNA template, will be subjected to the following cycling conditions: activation of Taq 
polymerase at 95oC for 10 min, followed by 40 cycles of denaturation at 95oC for 15 seconds, 
annealing at 56oC for 30 sec and extension at 72oC for 30 sec.  
Each qPCR run is undertaken with standard samples of known concentrations (copies/µl). Ten-
fold serial dilutions of the quantified 16s rDNA, and ten-fold serial dilutions of 18s rDNA PCR 
 
 
 
 
amplicon solution, kept in aliquots at -20oC are used as external standards of known 
concentration (copies/µl) in real-time PCR reaction. The standard samples are ranged between 
102–106 copies/µl, which is used to construct a standard curve for each qPCR run. The 
calibration curve is created by plotting the threshold cycle (Ct) corresponding to each standard 
vs the value of their corresponding gene concentration (copies/µl). The copy number of 16S 
rDNA (copies/µl) is normalised against the copy number of human 18s rDNA (copies/µl) in 
each chronic wound sample. 
 
Calculations of total bacteria number per mg tissue based on qPCR 16S rDNA copy number 
Convert 16S rDNA copy number to total bacterial number was based on average of 5 copies 
of 16S rDNA per bacterial cell.  Direct conversion: total bacterial number per mg tissue = 16S 
rDNA copy number (copies/µl) x DNA elution volume 100 (µl) = Total 16S rDNA copy 
number from extracted tissue. Total 16S rDNA copy number extracted from tissue / weight of 
tissue (5 mg) = 16S rDNA copy number per mg tissue. 16S rDNA copy number per mg tissue 
/ 5 = total bacteria number per mg tissue. 
 
Indirect conversion normalises to human 18S rDNA: total bacterial number per mg tissue. This 
is more accurate independent to DNA extraction yield. Human genome size is average 3.2 Gb 
base pair and each human genome contains 225 copy number of 18S rDNA. Molecular weight 
of each human genome DNA is 3.2 x 10^9 X 660 = 2.112 x 10^12.  One mole (6.023 X 10^23 
copy) of human genome DNA would be 2.112 x 10^12 g, or 2.112 x 10^18 µg.  One µg of 
human genome DNA would have 6.023 x 10^5 / 2.112 human genome copy = 2.85 x 10^5 
copy of human genome = 2.85 x 225 x 10^5 18S rDNA copy number = 6.41 x 10^7 18S rDNA 
copy number. Average genomic DNA extracted from fresh human tissue using Protease K 
digestion and phenol chloroform precipitation method is 1.98 µg per mg human tissue (based 
 
 
 
 
on 30 human breast capsule tissue). One mg human tissue would have 1.98 x 6.41 x 10^7 = 
1.27 x 10^8 copy number of 18S rDNA. 16S rDNA copy number per mg tissue = 16s rDNA 
copy number (copies/µl) x 1.27 x 10^8 / 18S rDNA copy number (copies/µl). Total bacterial 
number per mg tissue = 16S rDNA copy number per mg tissue / 5. 
 
5.9.4 PCR amplification and Amplicon sequencing 
DNA sequencing will be carried out by a commercial laboratory (Australian Centre for 
Ecogenomics, Brisbane, Australia) targeting the V3-V4 region of the 16S rDNA using 
eubacterial universal primers 515F and 806R 315. Preparation of the 16S rDNA library will be 
performed using the workflow outlined by the manufacturer (Iluumina Inc. Part # 15044223 
Rev. B).  
 
In the 1st stage, PCR products are amplified according to the specified workflow with an 
alteration in polymerase used to substitute Q5 Hot Start High-Fidelity 2X Master Mix (New 
England Biolabs, Ipswich, Massachusetts, United States). Resulting PCR amplicons are 
purified using Agencourt AMPure XP beads (Beckman Coulter). Purified DNA is indexed with 
unique 8bp barcodes using the Illumina Nextera XT 384 sample Index Kit A-D (Illumina FC-
131-1002) in standard PCR conditions with Q5 Hot Start High-Fidelity 2X Master Mix. 
Indexed amplicons will be pooled together in equimolar concentrations and sequenced on the 
Illumina MiSeq platform using paired end sequencing with V3 300bp chemistry. 
 
 
5.9.5 Fluorescence in situ Hybridization (FISH) 
Biopsy material embedded in optimal cutting temperature (OTC) embedding matrix (Fisher 
Scientific, Walthamm Massachusetts, United States), frozen at –80oC, will be cryo-sectioned 
 
 
 
 
to a thickness of 6 𝜇𝜇m and mounted on SuperFrost Plus slides (Menzel-Glaser, Lomb Scientific, 
Australia). Different types of probes will be utilized for in situ hybridization as previously 
described by Thurnheer 335. For PNA-FISH, probes and kits will be sourced commercially 
(AdvanDx, Inc., Woburn, MA) using previously described methods13.  
 
Briefly, either species-specific probes or universal bacterial probes will be utilised. A 
hybridization solution is added drop wise to each tissue section and hybridized at 55°C for 90 
min. Slides are washed for 30 min at 55°C in wash solution. Once dry, a coverslip is mounted 
using a single drop of mounting medium. Slides will be examined using CLSM (Zeiss Axio 
Imager Microscope and/or ZEISS LSM 880, Carl Zeiss Ltd., Herefordshire, UK). Images are 
processed using ZEISS ZEN Imaging Software (black edition) and Imaris v 8.4, ImarisXT, 
Bitplane. 
 
5.10 Duration of patient participation 
Participants in cohort 1 will be identified when they attend for their appointment. A tissue 
biopsy will be taken during this time; therefore, an additional appointment will not be required 
solely for obtaining a tissue biopsy in this cohort.  As such participant duration will only be 
required for the removal of the tissue biopsy over one, 30-minute appointment. 
 
Participants in cohort 2 will be required to attend seven consecutive daily appointments for the 
application of the antimicrobial wound irrigation solution and antimicrobial hydrogel.  
Appointments will last for 20 minutes approximately. In people with chronic wound infection 
the average number of dressing changes by a health professional over a weekly period can 
range from two to four visits / dressing changes over the week. As such the schedule of 
consecutive visits does not alter greatly from routine care. 
 
 
 
 
 
Participants in cohort 3 will be required to attend two, 30 minute appointments over the 7 days. 
Application of the antimicrobial ointment will be applied at day 1 and at day 4. This is in 
keeping with a normal dressing regime and does not constitute any additional visits to standard 
care. 
 
All participants may continue to be followed in the high-risk foot service as part of their routine 
care for their wound after the completion of the study.  
 
5.11 Source Data 
Standardised Clinical Report Forms (CRFs) will be used for data collection.  
 
CRFs will be labelled with a unique identifier, de-identifying the data. However as per routine 
clinical practice, master lists of patients and their unique identifiers will be held.  It is possible 
that study data will be re-identifiable but all master lists will be held securely in locked filing 
cabinets with access only given to clinical trials staff. 
 
CRFs will be entered into a secured (by password and 128-bit industry standard encryption) 
centralised database.  Access to the database will only be provided to clinical trials staff. 
 
No identifying data will be published. 
 
Source data and analyses will be held in secure and locked storage for the required period 
according to relevant legislation. 
 
 
 
 
 
6. Withdrawal of patients 
6.1 Patient withdrawal criteria 
Patients may be withdrawn from the study if: 
• The chronic wound deteriorates prior to the completion of the last tissue biopsy and a 
change in treatment regime is clinically indicated such as surgical intervention, change in 
oral or intravenous antimicrobial, application of topical antimicrobial is applied. 
or: 
• Withdrawal of consent 
 
6.3.2 Patient drop out 
Recruitment will continue to make up for patients who withdraw or who are lost to follow up.  
 
7. Treatment of patients 
7.1 Additional appointments 
Where the consecutive days of treatment fall on a weekend, it is planned to use community 
nursing to change the participants wound dressing and apply the antimicrobial wound products. 
It is standard practice for the high-risk foot clinic to utilise community nursing for weekend 
home visits to change the dressings of patients. In this scenario, the community nurse will be 
provided with an instruction procedure on how to apply the products and the dressing regime.  
 
In some instances, it will not be possible to arrange community nursing over the weekends. If 
this occurs the podiatrist will teach the participant how to apply the products and provide them 
with a product application leaflet.  
 
7.2 Monitoring adherence 
 
 
 
 
The advantage of following participants in cohort two for seven consecutive days is so that the 
application of the antimicrobial wound products can be confirmed. 
 
8. Statistics 
8.1 Methods and significance levels 
For cohort one, descriptive statistics will be calculated appropriate to the data. Comparisons 
with results in the published literature will be made as appropriate. 
 
For cohorts two and three an analysis of biofilm structure will be utilized to determine effect 
using the parameters; species composition and the total number of bacteria. A student’s t-test 
will be used to determine the difference in biofilm structure before and after treatment.  
 
All analyses will be done using the Statistical Package for Social Sciences (SPSS Inc., Chicago, 
Illinois, USA). 
 
8.2 Sample size 
Phase I of this study a sample size of 30 patients is deemed adequate to draw conclusions. For 
phase II, an additional 30 patients (15 per cohort) will be recruited.  We estimate that n=30 
patients will accommodate a 15% drop out rate while retaining sufficient statistical power to 
estimate the effect size and variance of the effects of each wound treatment.  
9. Study timeline 
 
 
 
 
 
 
 
 
 
 
 
 
10. Ethical considerations 
The study will conform to the Australian Code for Responsible Conduct of Research 
(http://www.nhmrc.gov.au/guidelines/publications/r39 ) and the National Statement on Ethical 
Conduct in Human Research 2007 - Updated 2009. 
( http://www.nhmrc.gov.au/guidelines/publications/e72 ). 
 
JAN – MAR 2015 APRL – JUNE 2015 JUL – SEPT 2015 OCT – DEC 2015 
Cohort 1 (patients 1-8) 
* Begin recruitment 
 
* Screening for inclusion 
  
* Tissue biopsy taken and split 
into 3. 
 
* Freeze tissue sample for PCR  
 
* Send tissue sample 
immediately for FISH / CLSM 
/ Lab culture. 
 
Cohort 1 (patients 9-15) 
* Screening for inclusion  
 
* Tissue biopsy taken and split 
into 3. 
 
* Freeze tissue sample for PCR 
 
* Send tissue sample 
immediately for FISH / CLSM 
/ Lab culture. 
 
 
 
Cohort 1 (patients 16-22) 
* Screening for inclusion  
 
* Tissue biopsy taken and split 
into 3. 
 
* Freeze tissue sample for PCR 
 
* Send tissue sample 
immediately for FISH / CLSM  
/ Lab culture. 
 
 
 
Cohort 1 (patients 22-30) 
* Screening for inclusion  
 
* Tissue biopsy taken and split 
into 3. 
 
* Freeze tissue sample for PCR 
 
* Send tissue sample 
immediately for FISH / CLSM  
/ Lab culture. 
 
* process frozen tissue samples 
for PCR analysis in batches of 
5. 
JAN – MAR 2016 APRL – JUNE 2016 JUL – SEPT 2016 OCT – DEC 2016 
 
Cohort 2 and 3 (patients 31-
38)  
  *Begin recruitment 
 
* Screening for inclusion 
 
* Scheduled daily visits 
commence for 5 days. 
 
* Tissue biopsy day 1 and day 
5. Sample split into 3. 
 
* Send tissue samples 
immediately for FISH / CLSM  
/ Lab culture 
 
* Freeze tissue sample for 
PCR. 
Cohort 2 and 3 (patients 39-
46)  
* Screening for inclusion 
 
* Scheduled daily visits 
commence for 5 days. 
 
 * Tissue biopsy day 1 and day 
5. Sample split into 3 
 
* Freeze tissue sample for PCR 
until study end. 
 
* Send tissue sample 
immediately for FISH / CLSM  
/ Lab culture. 
 
 
Cohort 2 and 3 (patients 47-
54)  
* Screening for inclusion 
 
* Scheduled daily visits 
commence for 5 days. 
 
 * Tissue biopsy day 1 and day 
5. Sample split into 3 
 
* Freeze tissue sample for PCR 
until study end. 
 
* Send tissue sample 
immediately for FISH / CLSM 
/ Lab culture. 
 
Cohort 2 and 3 (patients 55-
60)  
* Screening for inclusion 
 
* Scheduled daily visits 
commence for 5 days. 
 
* Tissue biopsy day 1 and day 
5. Sample split into 3 
 
* Freeze tissue sample for PCR 
until study end. 
 
* Send tissue sample 
immediately for FISH / CLSM   
/ Lab culture. 
 
*Study end process all sample  
 
 
 
 
Study related monitoring, audits, HREC review and regulatory inspections will be permitted at 
all sites with direct access to source data as required. Any conflicts of interest from any 
investigating staff will be declared before commencement of the study. All patients entering 
the study will provide informed consent. Patient confidentiality will be respected. No data 
identifying individual patients will be published. 
 
11. Insurance and financing 
11.1 investigator-initiated study 
 South Western Sydney LHD will assume the risk for the study conducted on its premises as 
this is an investigator-initiated study. Internal finances will be utilised to fund the study (Allied 
Health SP&T 588298). 
 
11.2 Study costs 
The bulk of study costs are related to the advanced molecular and microscopy techniques. The 
costs have been broken down into the two study phases. Phase I represents the analysis for a 
student PhD and as such labour costs are excluded. This phase will be self-funded from a 
Liverpool Hospital internal research trust fund. Phase II is an analysis of a woundcare product 
and the calculations of costs for this phase will include labour costs. 
 
Phase I 
FISH analysis will be undertaken at Macquarie University and will cost $100 for each sample. 
At 30 samples the cost for FISH will be $3000. Pyrosequencing for bacterial identification will 
be undertaken at the Ingham Institute of Applied Medical Research and will cost $150 per 
sample. This equates to 30 samples at a cost of $4500. Access fee for the CLSM and sample 
preparation reagents, stubs, gold coating comes to $50 per sample. At 30 samples the cost for 
 
 
 
 
CLSM will be $1500. Laboratory based culture and quantitative analysis will be undertaken at 
SWAPS and will cost $50 per sample at 30 samples - $1,500. 
 
The total costs to cover cohort 1 will be $10,500 
 
Phase II 
CLSM, Fish analysis and pyrosequencing will be undertaken at Macquarie University and will 
cost $15,000 exc GST for 15 participants for each cohort, total cost $30,000 exc GST. This is 
calculated at 15 participants requiring analysis of two tissue samples, SEM $200 per sample, 
FISH $150 per sample, Pyrosequencing $150 per sample.  
 
12. Publication Policy 
It is intended to publish the data in International Medical Journals in addition to presenting at 
national and International conferences.  
 
13. Reimbursement of participants 
We do not plan to reimburse participants for their time in this study, as the treatment forms part 
of routine practice.  
 
14. Supplementary material 
 
IDSA Guidelines for diabetic foot infection 
 
 
 
 
 
 
 
 
Bacterial Bioburden, from contamination to infection 
Cohort 2 & 3 Cohort 1 
 
 
 
 
Clinical signs and symptoms checklist for infection. 
 
 
 
Clinical indictors to determine the presence of wound biofilm. 
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We used next generation DNA sequencing to profile the microbiome of infected Diabetic Foot Ulcers (DFUs). The
microbiota was correlated to clinical parameters and treatment outcomes to determine if directed antimicrobial
therapy based on conventional microbiological cultures are relevant based on genomic analysis. Patients
≥ 18 years presentingwith a newDiabetic Foot Infection (DFI)whohad not received topical or oral antimicrobials
in the two weeks prior to presentation, were eligible for enrolment. Tissue punch biopsies were obtained from
infected DFUs for analysis. Demographics, clinical and laboratory data were collected and correlated against mi-
crobiota data. Thirty-nine patients with infected DFUs were recruited over twelve-months. Shorter duration
DFUs (bsix weeks) all had one dominant bacterial species (n = 5 of 5, 100%, p b 0.001), Staphylococcus aureus
in three cases and Streptococcus agalactiae in two. Longer duration DFUs (≥six weeks) were diversely
polymicrobial (p b 0.01) with an average of 63 (range 19–125) bacterial species. Severe DFIs had complex
microbiomes and were distinctly dissimilar to less severe infections (p = 0.02), characterised by the presence
of low frequency microorganisms. Nineteen patients (49%) during the study period experienced antimicrobial
treatment failure, but no overall differences existed in the microbiome of patients who failed therapy and
those who experienced treatment success (p = 0.2). Our results confirm that short DFUs have a simpler
microbiome consisting of pyogenic cocci but chronic DFUs have a highly polymicrobialmicrobiome. The duration
of a DFU may be useful as a guide to directing antimicrobial therapy.
© 2017 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
In a person with diabetes a “triad” of factors that include peripheral
neuropathy, peripheral vascular disease and trauma (Lipsky et al.,
2012), place the foot at risk of developing a wound. Infections of the
feet in people with diabetes are the primary pathway to lower extrem-
ity amputation (Lavery et al., 2003). The management of diabetes foot
infection (DFI) is underpinned by the requirement to identify the path-
ogen/s of infection and thus direct antimicrobial therapy. Laboratory
basedmethods that are culture-dependent have been utilised to identi-
fy planktonic microorganisms that are potential pathogens of infection,
in addition to examining their density through qualitative and quantita-
tive measures. This has shown acute ulcers are usually colonised by
Staphylococcus aureus and/or Streptococcus agalactiae (Group B Strepto-
coccus), and chronic ulcers have a more diverse microbiome, with
anaerobic organisms and Pseudomonas aeruginosa becoming more im-
portant (Lipsky et al., 2016a,b). Culture-dependent techniques select
for species that flourish under the typical conditions of the diagnostic
microbiology laboratory, and this may not necessarily reflect the most
abundant or clinically important microorganisms in DFIs especially an-
aerobes and species not detected under standard clinical microbiology
laboratory protocols (Grice et al., 2008).
Molecular DNA based techniques that are culture-independent have
identified the limitations of traditional cultivation basedmethodswhen
examining the microbiome of wounds. Using amplification and se-
quence analysis of 16s rDNA, a highly-conserved gene present in all pro-
karyotes (bacteria) but not eukaryotes (humans), has revealed a vastly
more complex array of bacterial communities in non-infected chronic
wounds (Dowd et al., 2008a,b; Gardner et al., 2013; Rhoads et al.,
2012a,b; Smith et al., 2016). No data exists for acutely infected DFUs
using this methodology.
We explored themicrobiome of infectedDFUs using next generation
DNA sequencing. Data is presented on the microbial diversity,
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community structure, bacterial load and presence of likely pathogens
from diabetic foot infections. Molecular findings are correlated against
clinical factors and treatment outcomes.
2. Materials and Methods
2.1. Patients, Samples and Ethics
Individuals presenting to a tertiary referral hospital (Liverpool Hos-
pital High Risk Foot Service and Liverpool Hospital Emergency Depart-
ment) with a newly infected diabetic foot ulcer occurring below the
malleolus (Lipsky et al., 2012) were recruited consecutively over a
twelve-month study period between January 2015 and December
2015. A 3 mm (width) × 10 mm (depth) tissue punch biopsy was ob-
tained from the edge of each DFU after debriding and cleansing the
wound with NaCl 0.9%. Patients who had received any systemic or top-
ical antimicrobial therapy twoweeks prior to enrolmentwere excluded.
Ethics approval for this study was granted by the South West Sydney
Local Health District Research and Ethics Committee (HREC/14/LPOOL/
487, SSA/14/LPOOL/489). The studymethodologywas designed in guid-
ance by STROME-ID and ourmolecular surveillance data are reported in
keeping with this (Field et al., 2014).
2.2. Patient Demographic, Laboratory and Clinical Data
Patient demographics, laboratory and clinical data were collected
through patient charts and the electronic medical records for correla-
tion against microbiome data. Clinical data and woundmetrics of inter-
est that were collected included; present or absent foot pulses, foot
doppler waveforms, toe brachial indices (TBI) and completion of the
modified neuropathic disability score (Abbott et al., 2002). DFU location,
duration of DFU prior to presentation, size (length x width in mm),
depth (mm) and tissue type (granulation, slough, necrosis). Laboratory
data included; full blood count, inflammatorymarkers (White cell count
[WCC], Erythrocyte sedimentation rate [ESR], C-reactive protein [CRP]),
glycosylated haemoglobin (HbA1c) and estimated glomerular filtra-
tion rate (eGFR). All newly infected DFUs were diagnosed clinically,
and their severity graded using the Infectious Disease Society of
America Guidelines for DFI (Lipsky et al., 2012). Acute infections
were defined based on new presenting symptoms (classic signs of
infection) being present and untreated of less than fourteen days
duration.
DFUs were classified based on their duration, with shorter duration
DFUs (Acute) being less than six weeks and longer duration DFUs
(Chronic) defined as those greater than six weeks. Treatment failure
during the study periodwere defined as no resolution of infective symp-
toms over an appropriate treatment period (N28 days) despite directed
anti-infective treatment (Lipsky et al., 2012), a requirement to replace
oral antimicrobial therapy with parenteral delivery due to deterioration
of infective symptoms, or the need for surgical intervention.
2.3. Specimen Collection, Sampling Processing and the Work Flow for Un-
dertaking Molecular and Culture Dependent Approaches
Specimen collection, storage and theworkflows for performingDNA
extraction, next generation DNA sequencing, sequence analysis and
quality control of DNA reads and qPCR to determine the microbial
load, were performed as previously described by our group (Malone et
al., 2017) and can be found in supplementary appendix (S1). Culture-
dependent bacteriological enumeration and identification from tissue
cultures was performed by a hospital pathology service (Sydney South
West Pathology Service) using methods previously described (Oates et
al., 2014).
2.4. Statistics
CLC genomics workbench version 8.5.1 in combination with themi-
crobial genome-finishing module (CLC bio, Qiagen Aarhus, Denmark)
were used to analyse DNA sequence data. Operational taxonomic units
(OTU) clustering were based on previously reported wound
microbiome analysis (Gardner et al., 2013). OTUs were defined as mo-
lecular proxies for describing organisms based on their phylogenetic re-
lationships to other organisms. Associations between microbiome
community structure and membership were compared using permuta-
tional multivariate analysis of variance (PERMANOVA) in combination
with principal coordinate analysis PCoA Bray-curtis dissimilaritymatrix.
Patient demographics, laboratory and clinical datawere examined using
Chi-square and Spearman correlation coefficients. Kappa coefficients
were used to determine the level of agreement between culture-depen-
dent approaches and DNA sequencing. Independent predictors of treat-
ment failure were explored using general linear model (GLM). Mann
Whitney U test for non-parametric data were undertaken when
analysing the subgroups of neuropathic or neuroischemic lesions. Anal-
ysis was performed using Statistical Package for Social Sciences (SPSS)
Version 23, SPSS Inc., Chicago, Illinois, USA. For all comparisons and
modelling, the level of significance was set at p b 0.05. Molecular
data analysed through Bray-curtis and PERMNOVA incorporated a
Bonferroni correction. Data are given asmean,median and standard de-
viation (±).
3. Results
39 patients (39 tissue specimens) with newly infected DFUs were
recruited over the 12-month study period. Broad demographic, clinical
and laboratory data are shown in Table 1. Next generation DNA se-
quencing generated 1,028,895 sequences, which were clustered and
Table 1
Patient demographics, clinical and laboratory data for 39 patients presentingwith diabetic
foot infection.
Characteristics n = patients (%) (±SD)
Demographics
Mean age 57.4 years (±11.5)
Male/female 28 (71%)/11 (29%)
Type of diabetes: type 1/type2 4 (10%)/35 (90%)
Duration of diabetes 12.8 years (±6.5)
Chronic kidney disease stage 5 16 (27%)
Duration of ulcer prior to presentation 15.7 weeks (±13.7)
Co-morbidities
Loss of protective sensation 39 (100%)
Peripheral arterial disease 15 (38.5%)
Toe brachial index 0.5 (±0.1)
Laboratory data
Glycosylated haemoglobin (HbA1c) (%) 8.5 (±2.5)
Erythrocyte sedimentation rate (mmol/L) 54.3 (±33)
C-reactive protein (mg/l) 28.1 (±25)
White cell count 9.2 (±2.4)
Infection grading and classification (IDSA)
Mild 5 (13%)
Moderate 25 (64%)
Severe 9 (23%)
Systemic antimicrobial/route of delivery
Cephalexin/oral 6 (15%)
Amoxycillin + clavulanic acid/oral 13 (33.5%)
Flucoxacillin/oral 3 (8%)
Clindamycin/oral 1 (2.5%)
Ciprofloxacin/oral 1 (2.5%)
Rifampin + fusidic acid/oral 2 (5%)
Sulfamethoxazole + trimethoprim/oral 1 (2.5%)
Combination therapy/oral 3 (8%)
Piperacillin + tazobactam/intravenous 6 (15%)
Cephazolin/intravenous 3 (8%)
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aligned at 97% similarity to reveal 1139 unique OTUs. A total of seven
major phyla were identified including Firmicutes (48%), Proteobacteria
(26%), Actinobacteria (12%), Bacteroidetes (8%), Fusobacteria (2%) and
Cyanobacteria (1%). The clustering of OTUs contributing to greater
than 10% within each DFU sample at the genera/species-level is noted
in Table 2 and those contributing to b10% are noted in (S2). Staphylococ-
cus spp. was the most commonly sequenced microorganism in infected
DFUs. This was followed by Corynebacterium spp., Finegoldia spp.,
Peptoniphilus spp., Acinetobacter spp., Anaerococcus spp., and Streptococ-
cus spp.,We further categorizedmicroorganisms based on their residing
niche (environmental, skin, oral and gut) to better define the site of or-
igin of microorganisms that colonize DFUs (S3). Microorganisms com-
mensal to the skin were predominant in half of patients (50.6%)
followed by environmental (29.1%), gut (14%) and oral (6.3%)
microorganisms.
3.1. Community Structure of DFIs are Heterogeneous
The community structures of DFIs were depicted using rarefaction
and Shannon Weaver index plots, which explore the richness, and di-
versity of individual infected DFUs (Fig. 1). Most DFUs had complex
polymicrobial communities with great heterogeneity between patients.
Rarefaction identified a mean of 56 OTUs (±31.2, range 4 to 125) per
DFU, and Shannon Weaver index identified a mean indices of 2.3
(±0.9, range 0.4–4.1). Descriptive statistics allowed for amore clinically
relevant picture to be composed of the overall community structure.We
identified three general profiles that sub-divided DFUs based on their
community structure (Fig. 2). High frequency taxa mostly comprised
of a single microorganism (±3) (i.e. monomicrobial infection), high to
low frequency taxa were comprised of between one to five (±2) dom-
inant microorganisms followed by many low frequency taxa (i.e.
polymicrobial infection) and low frequency taxa comprised on average
of ≥20 (±) minor microorganisms (complex polymicrobial infection).
3.2. The Duration of DFU Prior to Infection Presentation may Present a Ma-
jor Driver Behind the Microbiome
Five (13%)DFUs at the time of presentationwere less than six-weeks
in duration, and were composed of high frequency taxa with one pre-
dominant microorganism (Fig. 3). These were S. aureus in three cases
and S. algalactiae in two cases. The relative abundance of Staphylococcus
spp., was far greater in DFUs b six-weeks then DFUs of longer duration
where it was present but at significantly lower relative abundances
(Fig. 4).
Longer duration DFUs (≥6 weeks) with a new acute infective epi-
sode (n = 34, 87%) were the most common presentation. PCoA bray-
curtis plots with PERMANOVA identified the community structures be-
tween longer and shorter duration DFUs were dissimilar (p b 0.003)
(Fig. 5 and S4). Furthermore, analysis of variance identifies that longer
durationDFUs (N6weeks)were associatedwith a greater relative abun-
dance of Proteobacteria (p b 0.05), whilst shorter duration DFUs
(b6 weeks) were associated with greater relative abundance of
Firmicutes (p b 0.001). (Fig. 6) Closer examination of OTUs revealed
Table 2
Microorganisms contributing ≥10% in each sample (representing the dominant taxa) (Rhoads et al., 2012a,b).
Genera/species Samples Avg abundance % SD Min-max avg. abu % Aerotolernace
Staphylococcus spp.: 15 40.7 30.3 12 to 92 Facultative
Staphylococcus aureusa 8 43.1 32.9 12 to 92 Facultative
Unclassified Staphylococcus sppa 7 31.8 28.2 12 to 81 Facultative
Staphylococcus pettenkoferia 2 26 3 23 to 29 Facultative
Corneybacterium striatum 8 32 16.6 12 to 59 Facultative
Finegoldia spp. 7 12 2.8 10 to 18 Anaerobe
Peptoniphilus spp. 7 14.5 5.1 10 to 22 Anaerobe
Acinetobacter baumannii 7 30.5 18.7 16 to 69 Facultative
Anaerococcus spp. 6 14.3 5.1 12 to 24 Anaerobe
Streptococcus agalactiae 5 45.2 39 16 to 89 Facultative
Enterobacter spp. 5 19.6 8.1 10 to 28 Facultative
Proteus spp. 4 22.7 4.5 19 to 23 Facultative
Prevotella spp. 4 14.3 4 10 to 18 Anaerobe
Haemophilus spp. 4 21 14 12 to 42 Facultative
Blastocatella fastidiosa 3 24 11 12 to 32 Facultative
Pseudomonas aeruginosa 2 12.5 3.5 10 to 15 Aerobe
Porphymonas spp. 2 11.5 2 10 to 13 Anaerobe
a Refers to the species level identification of Staphylococcus genus level data.
Fig. 1. Community diversity and richness reported for 39 patients with DFI. (A)
Community diversity of DFUs presented using the Shannon-Weaver index at maximum
read length of 300 (Price et al., 2009). Shannon Weaver Index is a measure of diversity
that includes the number of unique microbial taxa and their relative evenness within
each sample. Thus, a higher Shannon Weaver Index correlates to a greater diversity. (B)
Community richness of DFUs presented using richness index reporting the number of
unique OTUs in each wound sample. Data sets were normalised to remove low
abundance OTUs contributing too less then 1% within each wound sample.
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that Staphylocci spp., were contributing to the positive correlation de-
tected between Firmicutes and relative abundance and ulcer duration
(p b 0.05).
Spearman's correlation coefficients further clarified that DFUs of lon-
ger duration were polymicrobial, typically having greater number of
OTUs and were broader in diversity (p b 0.01). This statistical approach
further correlated higher frequencies of DFUs containing obligate anaer-
obes that constituted greater than 30% of the total abundance in DFUs of
greater duration (p b 0.03) (S5).
3.3. Wound Observations and Clinical Factors Lack Association With the
Microbiome
Associations between clinical factors andDFImicrobiomewere com-
pared using PERMANOVA and spearman rank correlation coefficients.
The location, depth and the level of glycosylated haemoglobin (HbA1C
≥ 7%) were not associated to any significant microbiota. The presence
of slough ormalodourwithin an infectedDFUwere independently asso-
ciated with community structure, but were not inversely correlated to
each other (p = 0.7). Slough in an infected DFU was associated with
higher abundances of obligate anaerobes (slough present and ≥30% an-
aerobe present = 13 of 39, 33%, p b 0.01), as was malodour (malodour
DFUs=15,mean anaerobe abundance 34%, SD25.3 versus nomalodour
of DFUs, mean anaerobe abundance 15%, SD 18.4).
3.4. Infection Severity of Diabetic Foot Infections are Associatedwith Altered
Community Structures
PERMANOVA identified some disparity between the community
structure and infection severity. Mild DFIs were different from both
Fig. 2.Bar chart represents relative abundances (%) of taxa profiles for 39DFUs. Each bar represents individual genera/species. (A)High frequency taxawere observed in tenpatients (26%),
mostly comprised of a singlemicroorganism (±3) (i.e. monomicrobial infection) contributing to ≥88% (±5.4%) of total abundance. (B) High to low frequency taxawere themost common
profile and were observed in 25 patients (64%). Low frequency taxa comprised on average of ≥20 (±) minor microorganisms each contributing b1%–5% abundance and no single
microorganism contributing N10% (complex polymicrobial infection). (C) Low frequency taxa were infrequently observed in only four patients (10%) and contained higher relative
abundances of environmental microorganisms (p b 0.01).
Fig. 3. Bar chart representing relative abundance of taxa in acute diabetic foot ulcers (b6 weeks duration).
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moderate infection (p b 0.01) and severe infection (p b 0.001) (Fig. 7),
and were positively correlated to fewer OTUs and were less diverse. In
contrast, severe infections often presented exclusively with low fre-
quency taxa profiles (n = 3 of 4, p = 0.02). Obligate anaerobes and
their abundance within each DFU were explored for relationships be-
tween infection severities. The abundance of anaerobes was similar
acrossmildDFIs (abundance=29.5%,±31)moderate DFIs (abundance
= 20.5%, ±22.3) and severe DFIs (abundance = 27.3%, ±21), indicat-
ing there exist no differences between patients presenting with more
severe infections and a greater abundance of anaerobes (p = 0.6).
3.5. Neuropathic and Neuroischaemic Diabetic Foot Ulcers Harbor Similar
Microbiomes
Twenty-three patients were classified as having neuropathic DFUs
(normal TBI ranges ≥0.9–b1.2 and MNDS ≥ 6) and sixteen patients
were classified as having neuroischaemic DFUs (TBI b 0.7 to 0.3, and
MNDS ≥ 6). Non-parametric approaches identified no difference in the
mean average abundances between neuropathic and neuroischaemic
DFUs (S6).
3.6. Culture DependentMethods Underestimate Anaerobic Microorganisms
Kappa coefficients were used to determine the level of agreement
between culture-dependent methods and DNA sequencing. Agreement
in the identification of obligate anaerobes was poor between culture
and DNA sequencing (p= 0.4). Culture underestimated obligate anaer-
obe presence in 90% of samples (detection of obligate anaerobes by cul-
ture = 4 of 39, 10% vs detection of obligate anaerobes by DNA
sequencing = 34 of 39, 79%).
3.7. Treatment Parameters and Outcomes
In total, nineteen patients (49%) during the study period experi-
enced treatment failure. Of the thirty-three patients who had DFUs
N 6 weeks, fifteen (45%) with moderate to severe IDSA infections expe-
rienced treatment failure. In the group of five patients with DFUs
b 6 weeks, four patients (80%) with moderate IDSA infections experi-
enced treatment failure. These infections were mono-microbial and
were predominated by high frequency taxa of either Staphylococcus
spp. and Streptococcus spp. Correlation coefficientswere used to explore
if DFUs containing high relative abundances of commonly cited patho-
gens of infection in DFI (S. aureus, S. agalactiae and A. baumannii) were
at greater risk of treatment failure. This revealed the presence of S.
agalactiae in DFUs (regardless of duration of DFU) were associated
with greater treatment failures (P b 0.007). PERMANOVA revealed no
further differences in the community structures between patients who
failed therapy and those who experienced treatment success (p= 0.2).
In patient samples where obligate anaerobes were identified as con-
tributing to the overall wound microbiome at levels greater than both
30% and 50%, therewere no increased tendency towards failing therapy.
The type of ant-infective therapy provided to patients in this study pro-
vided adequate anaerobe cover (25 of 39 wounds received antimicro-
bials with anaerobe cover, 64%) and this may explain the lack of
significance between high relative abundance of anaerobes in DFUs
and no increased tendency to fail therapy.
Thirteen patients (33.3%) received narrow spectrum antimicrobials
with nine (23.1%) of these patients having DFUs N 6 weeks duration.
Four of these nine patients (44.4%) experienced treatment failurewhilst
Fig. 4.Analysis of variance between Staphylocci spp., relative abundance (%) inDFUs based
on duration. In DFUs b six weeks Staphyloccci spp., were present as the dominant taxa
(high frequency). The average relative abundance of Staphyloccci in DFUs N six-weeks is
far less and this is because DFUs of longer duration are typically polymicrobial.
Fig. 5. PCoA bray-curtis plots identify that differences are present in the community structures between longer and shorter duration DFUs.
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receiving narrow spectrum antimicrobials, but the five remaining pa-
tients with DFUs N 6 weeks on narrow spectrum antimicrobials
experienced treatment success. The number of cases were too low for
statistical analysis. Twenty-five patients received broad-spectrum anti-
microbials with eleven patients (44%) experiencing treatment failure.
There were no correlations between a tendency to fail therapy whether
on narrow spectrum or broad-spectrum antimicrobials.
A GLMwas performed to identify any predictors of treatment failure
independent of the microbiome. These identified patients having a low
TBI (b0.7) as being the only predictor of failure regardless of the
microbiome (p=0.01). No other clinical factors such as a level of glyco-
sylated haemoglobin greater than ≥7% (p = 0.72) or the severity of in-
fection were correlated to treatment failure (Mild, p = 0.13, Moderate,
p = 0.65, Severe, p = 0.26).
4. Discussion
In the context of managing diabetes foot infections from an infec-
tious disease viewpoint, current guidelines based on culture-dependent
data, are now subject to the scrutiny of molecular DNA based ap-
proaches. Furthermore, studies employing amplification and sequence
analysis of the 16S rRNA gene to characterize the microorganisms in-
volved in DFI, none to date have sampled participantswith overt clinical
signs of infection. Instead the available data report on chronic, new or
recurrent DFUs that are clinically non-infected (Dowd et al., 2008a,b;
Gardner et al., 2013; Price et al., 2009; Smith et al., 2016; Wolcott et
al., 2015). Given the increasing utilisation of genomic analysis from
both a clinical and research domain, it is essential to understand the
microbiota of clinically infective DFUs and if current anti-infective prac-
tices can be improved through the translation of complex bioinformat-
ics arising from the DNA analysis of microbial communities. We
analysed robustmicrobiota datasets from Infections of the feet in people
with diabetes, and detailed their clinical outcomes, relating this back to
current anti-infective practices. We found that the duration of a DFU
prior to presenting with a new clinical infection may help clinicians de-
cide on the antimicrobial regimen of choice.
We identify Staphylococci spp. as the most commonly sequenced
dominant bacteria in approximately one third of DFUs in this study,
Fig. 6. Analysis of variance identifies that ulcer duration N6 weeks was associated with a greater relative abundance of Proteobacteria (p b 0.05), whilst ulcer duration b6weeks was
associated with greater relative abundance of Firmicutes (p b 0.001). The genera responsible for the high relative abundance of firmicutes in DFUs b6 weeks were Staphylococcus spp.,
and Streptococcus spp predominantly.
Fig. 7. PCoA Bray-curtis plot demonstrates the community structure difference between infection severities in addition to defining the duration of DFU.
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followed closely by Corynebacterium spp. In a recent review by our
group on the bacteriology of DFUs from both a molecular and culture
based approach (Malone et al., 2016), the predominant pathogen/s of
infection for DFIwas S. aureus. Additionally, Corynebacterium spp., Strep-
tococcus spp., and obligate anaerobes belonging to Clostridiales family XI
all identified as major players in this study were similarly identified in
studies of chronic non-infected wounds. Based on our molecular data
and that of previous molecular and culture based publications, current
guidelines that promote the use of antimicrobials targeting Gram-posi-
tive aerobic cocci as a first line treatment are appropriate.
Corynebacterium spp. has provided a continuing source of debate re-
garding its role as a non-pathogenic skin commensal (Citron et al.,
2007), or as a pathogen of infection in the presence of an in immuno-
compromised patient (Dowd et al., 2008a,b; Uçkay et al., 2015). In this
study, we seldom identified the presence Corynebacterium spp. as a
sole pathogen (High frequency taxa), with it almost exclusively occur-
ring in combination with other known pathogens of DFI. This suggests
that there may be a role for Corynebacterium spp. as part of a
polymicrobial infection. Given that many first line antimicrobials of
choice for DFI are active against this microorganism, there may not be
a requirement to target this sole microorganism unless a mono-micro-
bial culture is identified.
Community structure is essentially the composition of a community,
including the number of species in that community, their relative num-
bers (Richness) and their complexity (Diversity). We identify that the
duration of DFU is a major driver behind the microbiome, with longer
duration DFUs typically having greater species richness and diversity.
This correlated to increased relative abundances of Gram-negative
proteobacteria and reduced relative abundances of firmicutes in a pat-
tern previously described by Gardener et al. on neuropathic non-infect-
ed DFUs (Gardner et al., 2013). Proteobacteria are commonly identified
in wounds (Dowd et al., 2008a;Wolcott et al., 2015) and largely belong
to the Pseudomonadaceae and Enterobacteriaceae families. It is unclear
from our data if these microorganisms require special attention, for ex-
ample P. aeruginosa was present as minor taxa in only one quarter of
samples (eight DFUs), thus supporting the general consensus (Lipsky
et al., 2012) that P. aeruginosa is not a typical pathogen of infection in
DFI (excluding southern hemisphere locations) (Sivanmaliappan and
Sevanan, 2011), andmay not require additional tailored therapy should
it be identified through cultivation based methods.
Obligate anaerobes were also identified in 90% of DFUs, but great
heterogeneity existed between patients with regards to their relative
abundances. In most DFUs, obligate anaerobes co-existed in high abun-
dances with aerobic microorganisms, suggesting that obligate anaer-
obes likely play a role as co-pathogens in DFI. Current microbiology
laboratories do not employ enhanced culturing methods to isolate
many of the obligate anaerobes identified in this study through DNA se-
quencing. However, even in the absence of culture-dependent guidance,
many commonly utilised antimicrobials for DFI are active against obli-
gate anaerobes.
Furthermore, there are no studies exploring if additional anti-anaer-
obic therapy improves DFI outcome, and in this study, we find no corre-
lation between the high relative abundance of obligate anaerobes and a
greater tendency to fail antimicrobial therapy. The decision to use
targeted antimicrobials against obligate anaerobes by clinicians should
be administered under the guidance of antimicrobial stewardship
(Lipsky et al., 2016a,b). The pattern of antimicrobial therapy prescribing
in this study were based on specialist Infectious disease physicians with
experience of managing these complex patients, but these results may
reflect differently when managed by non-specialist clinicians with lim-
ited exposure to these wounds. Further work in this area is required.
The current guidancematerials available to cliniciansmanagingDFIs
are predominantly based on culture-dependent data, yet this study
employing DNA sequencing techniques re-enforces most of this data
as being clinically relevant (Lipsky et al., 2012; Lipsky et al., 2016a,b).
Pyogenic cocci were predominant in acute DFUs in this study, and
thus, supports directed narrow spectrum antimicrobial regimens
(with consideration for culture sensitivities looking forMRSA). DNA se-
quencing methods however, highlighted the limitation of conventional
bacterial cultures with regards to the microbial diversity and ability to
isolate microorganisms not detected under standard clinical microbiol-
ogy laboratory protocols. Many of these microorganisms were found in
chronic wounds that harboured flora similar to the environment, sug-
gesting patients expose their wounds to an array of environments (i.e.
barefoot walking, showering with no wound dressing, gardening etc.).
Therefore, patient education is vital in order of minimizing exposure
of DFUs to environmental contaminants and opportunistic pathogens
of infection.
Current guidelines for classifying and managing infected DFUs pro-
vide guidance (in conjunction with local policies and patterns of micro-
bial sensitivities for resistance) on the duration and route of delivery of
antimicrobials based on infection severity (Lipsky et al., 2012; Lipsky et
al., 2016a,b). The use of broad-spectrumantimicrobials delivered paren-
terally is promoted for severe DFIs, owing to the polymicrobial nature of
infection. We confirm severe DFIs are extremely diverse, polymicrobial
and complex, and our data supports current clinical practice by paren-
teral, broad-spectrum antimicrobials is warranted. Exploration from a
larger sub-set of patients with severe DFI composing of low frequency
taxa profiles, may provide greater insight intomanaging these challeng-
ing infections.
Previous reports have suggested that DFUs complicated by peripher-
al arterial disease (i.e. ischemic or neuroischemic) likely lead to an al-
tered wound microenvironment and thus microbiota (Gardner et al.,
2013). Additionally, the presence of peripheral vascular disease as a co-
morbid variable in the presence of an infected foot in a person with di-
abetes has been reported as well known independent predictor of poor
outcome (Hinchliffe et al., 2016; Prompers et al., 2008). Sixteen patients
in this study had neuroischemic ulcers (TBI b 0.7 to 0.3)withmost DFUs
presenting with mild to moderate peripheral arterial disease. We
ascertained that both neuropathic and neuroischemic (patients with
mild to moderate PAD) DFUs harbor similar microbiomes and the re-
quirement to segregate these differing wound aetiologies may not be
required for microbiota analysis when using a TBI cut off value of 0.5
as an arbitrary marker.
Nineteen patients during the study period experienced antimicrobi-
al treatment failure, but no differences existed in themicrobiome of pa-
tients who failed therapy and those who experienced treatment
success. Furthermore patients who were treated with either narrow
spectrum or broad-spectrum antimicrobials experienced similar failure
rates (44.4% versus 44%) and this suggests that other factors are likely at
play including the host immune response to infection, patient compli-
ance in adhering to therapy and or peripheral perfusion. A general linear
model approach identified that the presence of a TBI b 0.7 was an inde-
pendent predictor of treatment failure regardless of the microbiota, or
antimicrobial, emphasising the difficulties in managing these complex
infected wounds.
Whilst our microbiome data identifies DFUs of greater than six-
weeks duration presenting with a new clinical infection (includes
mild-moderate-severe,with no discrimination) are often polymicrobial,
with exception to nearly always targeting aerobic Gram-positive cocci,
the requirement to also target provide additional anti-anaerobe therapy
requires further research.
Furthermore, whilst DNA sequencing provides an extended view of
themicrobiome, it is limited in providing information on “whichmicro-
organisms”maybe directly contributing to infection. This is increasingly
important when analysing our data set where regardless of the spec-
trum of activity of antimicrobials (i.e. Narrow or broad-spectrum), pa-
tients experienced similar outcomes. It may be possible in a highly
diversemicrobiota, that narrow spectrum antimicrobials targeting pyo-
genic cocci alone, is enough to reduce the virulence/pathogenicity of in-
fective symptoms without the requirement to use a scatter gun
approach to target everything broadly. The use of whole genome
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sequencingmay allow us to better understand this question (Malone et
al., 2016).
This paper provides a useful insight into the bacterial communities
in infected DFUs and reflects on treatment outcomes of anti-infective
therapy and ifmolecular baseddatawould have altered therapeutic reg-
imens. The paper is limited by the sample size and thus recommenda-
tions based on molecular data are not possible. A larger cohort of
patients would provide greater detail and where possible analysis of
small subsets of interest. This paper also identifies the difficulties with
obtaining species level data when using the 16s rRNA subunit. Further-
more, what is strikingly apparent from our data is that whilst we pro-
vide an extended view of “which microorganism/s” are present, we
cannot be definitive on “which microorganism/s” are responsible as
contributing as pathogens of infection. The era of “metagenomics” and
whole genome sequencing that can analyse genes responsible for viru-
lence or pathogenicity may unveil these answers.
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Abstract
Increasing evidence within the literature has identified the presence of biofilms in
chronic wounds and proposed that they contribute to delayed wound healing. This
research aimed to investigate the presence of biofilm in diabetic foot ulcers (DFUs)
using microscopy and molecular approaches and define if these are predominantly
mono- or multi-species. Secondary objectives were to correlate wound observations
against microscopy results in ascertaining if clinical cues are useful in detecting
wound biofilm. DFU tissue specimens were obtained from 65 subjects. Scanning
electron microscopy (SEM) and peptide nucleic acid fluorescent in situ hybridisation
(PNA-FISH) techniques with confocal laser scanning microscopy (CLSM) were used
to visualise biofilm structures. Next-generation DNA sequencing was performed to
explore the microbial diversity. Clinical cues that included the presence of slough,
excessive exudate, a gel material on the wound bed that reforms quickly following
debridement, poor granulation and pyocyanin were correlated to microscopy results.
Of the 65 DFU specimens evaluated by microscopy, all were characterised as contain-
ing biofilm (100%, P< 0⋅001). The presence of both mono-species and multi-species
biofilms within the same tissue sections were detected, even when DNA sequencing
analysis of DFU specimens revealed diverse polymicrobial communities. No clinical
correlations were identified to aid clinicians in identifying wound biofilm. Microscopy
visualisation, when combined with molecular approaches, confirms biofilms are ubiq-
uitous in DFUs and form either mono- or multi-species biofilms. Clinical cues to aid
clinicians in detecting wound biofilm are not accurate for use in DFUs. A paradigm shift
of managing DFUs needs to consider anti-biofilm strategies.
Introduction
Foot ulceration is a physical break in the protective barrier
of the skin that allows colonisation by invading microorgan-
isms. In a person with diabetes, an impaired immune response
is common, and this may predispose an ulceration to micro-
bial invasion, with resultant damage to host tissues and an
Key Messages
• DFUs are a serious cause of morbidity and mortality
and are associated with significant burdens to health care
providers
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• the role of microorganisms involved in causing infection
in these wounds have primarily centred around plank-
tonic microorganisms as causative agents in acute dia-
betic foot infections
• supporting data from researchers exploring if DFUs are
complicated by biofilm have been sparse and are often
reported using low sample sizes
inflammatory response that is characterised as a clinical infec-
tion (1). In some patients who receive optimal standards of
care (including off-loading, regular sharp debridement and
re-vascularisation) and who do not exhibit overt clinical infec-
tion, failure of the DFU to heal might be explained by the pres-
ence of biofilm. Planktonic microorganisms that are respon-
sible for acute infections may be readily identified through
cultivation-based approaches, while multi-species sessile com-
munities of microorganisms or biofilms may not be detected by
the same cultivation methods.
There is also a lack of diagnostic tests to define the presence
of wound biofilm, and there are no quantifiable biomarkers.
To augment clinical practice, some clinicians have used what
they believe are ‘clinical cues’ of biofilm presence through
naked eye observations (2–4). Such signs have included a shiny,
translucent, slimy layer on the non-healing wound surface; the
presence of slough or fibrin; and gelatinous material reforming
quickly following removal in contrast to slough and other
devitalised tissue or fibrin, which often take longer to reform.
As biofilms aremicroscopic in nature, doubt has been expressed
as to whether biofilms can be visually observed by clinicians.
Unfortunately, chronic wound clinical observations have not
been cross-correlated to microscopy approaches, which are
better suited for defining the presence of biofilm.
The primary objectives of this study were to visualise and
confirm the presence of biofilm in DFUs and better under-
stand if they consist of mono- or multi-species biofilms. Sec-
ondary objectives were to ascertain if commonly used clin-
ical cues were accurate in detecting wound biofilm. SEM,
FISH/PNA-FISH and next-generation DNA sequencing were
utilised to answer these objectives.
Methods
Patient population
In this prospective study, 65 consecutive patients aged over
18 years presenting to the Liverpool Hospital High Risk Foot
Service with a DFU were enrolled over a 6-month period.
Individuals were eligible for the study if they had either a
DFU that had not responded to standard care and were not
healing within an appropriate timeframe (i.e. chronic DFU)
or presented with a DFU (acute or chronic DFU) and a new
acute clinical infection as defined by the Infectious Disease
Society of America Guidelines for Diabetic Foot Infection
(5). Tissue biopsies were obtained from the wound edge for
each participant after cleansing the wound with NaCl 0⋅9%.
Clinical observations of DFUs were recorded for each patient.
Ethics approval for this study was granted by the South West
Sydney Local Health District Research and Ethics Committee
(HREC/14/LPOOL/487, SSA/14/LPOOL/489).
Specimen collection, storage and next-generation DNA
sequencing workflows
Specimen collection, storage and the work flows for performing
DNA extraction and next-generation DNA sequencing were
performed as previously described (6).
Fluorescent in situ hybridisation (FISH) and peptide
nucleic acid-based fluorescence in situ hybridisation
(PNA-FISH)
Biopsy material was embedded in an optimal cutting temper-
ature (OTC) embedding matrix (Fisher Scientific, Waltham,
MA), frozen at –80∘C, cryo-sectioned to a thickness of 6 𝜇m
and mounted on SuperFrost Plus slides (Menzel-Glaser, Lomb
Scientific, Sydney, Australia). Different types of probes were
utilised for in situ hybridisation as previously described by
Thurnheer (7). The choice of specific probes was based on
DNA sequencing results that allowed the identification of the
major genera/species of interest to target. The genus-specific
probe Cy3 labelled Staphylococcus spp. probe (final concen-
tration 5 ng/μl) (8), Fluor 488 labelled Pseudomonas spp. spe-
cific probe (final concentration 20ng/μl) and a universal bac-
terial probe Fluro 488 or Cy3 (final concentration 5 ng/ul) (9)
were employed. For PNA-FISH, probes and kits were sourced
commercially (AdvanDx, Inc., Woburn, MA) using previously
described methods (10). Briefly, species-specific Staphylococ-
cus aureus/coagulase-negative Staphylococci (CNS) probes
were used in conjunction with universal bacterial probe. The
hybridisation solution was added drop-wise to each tissue
section and hybridised at 55∘C for 90 minutes. The slides
were washed for 30 minutes at 55∘C in wash solution. Once
dry, the coverslip was mounted using a single drop of mount-
ing medium. Slides were examined using CLSM (Zeiss Axio
Imager Microscope and/or ZEISS LSM 880, Carl Zeiss Ltd.,
Herefordshire, UK). Images were processed using ZEISS ZEN
Imaging Software (black edition) and Imaris v 8⋅4, ImarisXT,
Bitplane.
Scanning electron microscopy (SEM) and image
interpretation
DFU biopsy samples were fixed in 3% glutaraldehyde, fol-
lowed by three washes of 0⋅1M phosphate buffer prior to
serial ethanol dehydration and hexamethyldisilazane incuba-
tion (Polysciences, Inc., Warrington, PA) as described previ-
ously (11). Dried samples were coated with 20-nm gold film
in a sputter coater and examined in a scanning electron micro-
scope. Each sample was scored based on the amount of bac-
teria/biofilm observed using an arbitrary 5-point scale as previ-
ously reported (12). Each tissue samplewas viewed under SEM,
averaging 2 hours per sample. Tissue was screened for micro-
bial aggregates and extracellular polymeric substances (EPS)
from thewound surface downwards, working in a zigzag pattern
at magnifications ranging from ×300 to approximately ×5500.
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Characterisation and visualisation of DFU biofilm
The presence or absence of biofilms in DFUs was confirmed
through SEM or FISH/PNA-FISH. For the purpose of the study,
the definition of biofilm was ‘microbial aggregates surrounded
by a self-produced or host-derived matrix adhering to natural or
artificial surfaces in the host, or aggregates associated with but
not directly adherent to the surface’ (13).
Clinical wound observations
Wound observations at the time of presentation were collected
based on previous assumptions of ‘clinical cues’ relating to
the presence of biofilm. These were the presence of slough,
excessive exudate, poor-quality granulation tissue, presence
of pyocyanin, gelatinous material on the wound surface and
gelatinous material that reforms quickly.
Statistics
Data relating to the presence or absence of DFU biofilm and
clinical wound observations were tested using non-parametric
methods (binomial probabilities). The hypothesis for the pres-
ence of biofilm was based on a previous report that 60% of
chronic wounds have biofilm (14), and this was set as the
expected proportion. For clinical wound observations, no pre-
vious data were available. Expected proportions were set at
50%, that is, no more than chance alone of clinical wound
observations being positive when biofilm was found to be posi-
tive throughmicroscopy. Data were analysed through Statistical
Package for Social Sciences Version 23 (SPSS Inc., Chicago,
IL). For all comparisons andmodelling, the level of significance
was set at P< 0⋅05. Data are given as mean, median and stan-
dard deviation (±).
Results
Over a 12-month study period, 65 consecutive patients with
DFUs were recruited. Study demographics are reported briefly.
The majority of patients were male (49, 74⋅2%), and there were
17 female (25⋅8%) patients. Themean age of study subjects was
58⋅5 years (±12⋅3). Type 2 diabetes predominated (type 2= 58,
87⋅9%, type 1= 7, 10⋅6%), and the mean duration of diabetes
was 13⋅9 years (±7⋅3). Clinically infectedDFUswere present in
40 patients (60⋅6%). These were subdivided by duration of the
DFU prior to the development of a new acute infective episode:
short-duration DFU (<6 weeks) with new acute infection (7,
17⋅5%) and chronic DFU >6 weeks with new acute infection
(33, 82⋅5%). The remaining patients with DFUs (26, 39⋅4%)
were classified as chronic non-healing with no acute clinical
infection.
Microscopy analysis
The presence of biofilm was visualised and confirmed in all
samples (65 of 65, 100%) using either SEM, FISH/PNA-FISH
or both (P= 0⋅0001) (Table 1). Multiple images were viewed
under microscopy for each sample to provide an overall score.
SEM images identified a predominance of coccoid cells, which
often appeared to be coated with EPS (Figure 1). When scoring
samples, the majority had large micro-colonies (approximately
100 cells) plus the presence of continuous or thick film of
extracellular matrix, that is, a score of 4 (52%) or 5 (36%).
Biofilm presencewas negative in two samples by SEM (S19 and
S48), and a further seven SEM samples were not obtained due
to inadequate amounts of DFU tissue. In the absence of SEM,
all samples were positive using PNA-FISH with CLSM. DFUs
were further sub-categorised for biofilms structures based on
their duration, with most samples coming from chronic DFUs
(>6weeks with or without infection, 60 of 65, 92%). FiveDFUs
of short duration (<6 weeks) with clinical infection were also
visualised as containing biofilm.
The spatial organisation of microorganisms was explored
using PNA-FISH techniques and identified dense microbial
aggregates (biofilm) (Figure 2). Generally, biofilms were not
present in a uniform manner across the entire wound bed. Sam-
pled tissue sections with species-specific and universal bacterial
probes revealed areas of biofilm that were solely mono-species
(Figure 3A) or multi-species biofilms (Figure 3B). We also
identified areas of combinations where both mono-species and
multi-species were located within the same sampled tissue
section (Figure 3C).
Clinical wound observations
Using binomial probabilities, the probability of clinical obser-
vations associated with the positive presence of biofilm through
microscopy were explored (Table 2). Except for excessive exu-
date, the probability of clinicians accurately identifying biofilm
using clinical observations was no better than chance alone.
Next-generation DNA sequencing
The microbiome of DFUs was explored through
next-generation DNA sequencing. Microorganisms con-
tributing greater than 10% relative abundance per individual
DFU sample are reported at the genera and species level where
possible (Figure 4). The most abundant bacteria were (in
rank order) Staphylococcus spp. (S. aureus, S. epidermidis),
Corynebacterium spp. (C. straitum, C. simulans), Strepto-
coccus agalactiae, Anaerococcus spp. (Peptostreptococcus
anaerobius), Peptoniphilus spp., Pseudomonas spp. (Pseu-
domonas auerginosa) and Prevotella spp. (P. melaninogenica,
P. nanceiensis).
Discussion
Employing a suite of microscopy and molecular approaches
to analyse DFU tissue specimens, we identify the presence of
densely aggregated colonies (both mono- and multi-species) of
bacteria often surrounded by an extracellular matrix in tissue
biopsies from 65 DFUs. This represents the largest data set in
the literature and supports the view that biofilms are ubiquitous
in DFUs and play host to a diverse ecology.
The clinical significance of our findings suggests that
biofilms may have a pathogenic role across a spectrum of DFU
presentations. We identified biofilm in three different wound
states: short-duration DFUs (<6 weeks) with acute infection,
© 2017 Medicalhelplines.com Inc and John Wiley & Sons Ltd 3
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Table 1 Biofilm analysis and DFU location, wound duration in weeks and whether infected or non-infected. Presence (+) or absence (−) of biofilm as
determined by SEM and FISH analysis, degree of biofilm infection (score) and predominant species identified using massively parallel DNA sequencing
Biofilm(+ or −) Wound metrics
Patient
number SEM Score FISH/PNA-FISH Biofilm diversity Location of DFU Duration of DFU (weeks) Infection status
S01 + 4 + Multi-species only Plantar metatarsal head 8 Infected
S02 + 5 + Mono-species and multi-species Plantar metatarsal head 16 Infected
S03 + 4 NS NS Plantar metatarsal head 36 Infected
S04 + 4 + Mono-species and multi-species Plantar metatarsal head 14 Infected
S05 + 3 NS NS Plantar metatarsal head 24 Infected
S06 + 4 NS NS Fifth toe dorsal 12 Infected
S07 + 4 + Multi-species only Plantar metatarsal head 72 Infected
S08 NS NS + Mono-species only Fourth toe dorsal 6 Infected
S09 + 4 + Multi-species only Second toe apex 8 Infected
S10 + 3 NS NS Heel 20 Infected
S11 + 4 NS NS Heel 12 Infected
S12 + 3 + Mono-species and multi-species Plantar metatarsal head 24 Infected
S13 + 4 + Mono-species and multi-species Plantar metatarsal head 6 Infected
S14 + 4 NS Plantar metatarsal head 20 Infected
S15 NS NS + Multi-species only Fourth toe apex 12 Infected
S16 NS NS + Mono-species and multi-species Hallux 8 Infected
S17 + 4 + Multi-species only Hallux 26 Infected
S18 + 4 + Mono-species only Plantar metatarsal head 32 Infected
S19 − 0 + Mono-species and multi-species Hallux 12 Infected
S20 + 3 + Multi-species only Second toe apex 16 Infected
S21 + 5 + Mono-species and multi-species Medial hallux 8 Infected
S22 NS NS + Mono-species and multi-species Medial hallux 18 Infected
S23 NS NS + Mono-species and multi-species Heel 12 Infected
S24 + 4 NS NS Heel 24 Infected
S25 NS NS + Multi-species only Hallux apex 9 Infected
S26 + 5 + Multi-species only Plantar midfoot 3 Infected
S27 + 5 + Mono-species and multi-species Plantar metatarsal head 3 Infected
S28 + 5 NS NS Plantar metatarsal head 6 Infected
S29 + 5 NS NS Plantar midfoot 52 Infected
S30 + 4 NS NS Plantar midfoot 30 Infected
S31 + 5 NS NS Plantar metatarsal head 3 Infected
S32 + 5 NS NS Plantar metatarsal head 5 Infected
S33 + 4 + Mono-species and multi-species Heel 5 Infected
S34 + 5 + Multi-species only Heel 12 Infected
S35 + 5 + Mono-species and multi-species Heel 6 Infected
S36 + 4 NS NS Plantar metatarsal head 12 Infected
S37 + 4 NS NS Hallux 9 Infected
S38 + 4 + Mono-species and multi-species Hallux 8 Infected
S39 + 4 + Multi-species only Hallux 12 Infected
S40 + 4 NS NS Heel 72 Non-infected
S41 + 4 NS NS Plantar metatarsal head 40 Non-infected
S42 + 4 + Mono-species and multi-species Heel 6 Non-infected
S43 + 4 NS NS Plantar metatarsal head 24 Non-infected
S44 NS NS + Mono-species and multi-species Plantar metatarsal head 12 Non-infected
S45 + 4 + Mono-species and multi-species Heel 36 Non-infected
S46 + 5 + Mono-species and multi-species Plantar metatarsal head 72 Non-infected
S47 + 5 + Multi-species only Heel 7 Non-infected
S48 − 1 + Multi-species only Plantar midfoot 28 Non-infected
S49 + 4 + Multi-species only Heel 18 Non-infected
S50 + 5 + Multi-species only Heel 28 Non-infected
S51 + 4 + Mono-species and multi-species Plantar metatarsal head 27 Non-infected
S52 + 5 + Mono-species and multi-species Plantar metatarsal head 28 Non-infected
S53 + 4 NS NS Hallux 6 Non-infected
S54 + 5 + Mono-species and multi-species Hallux 6 Non-infected
S55 + 4 + Mono-species and multi-species Heel 6 Non-infected
S56 + 3 + Multi-species only Plantar metatarsal head 16 Non-infected
S57 + 5 + Multi-species only Heel 20 Non-infected
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Table 1 Continued
Biofilm(+ or −) Wound metrics
Patient
number SEM Score FISH/PNA-FISH Biofilm diversity Location of DFU Duration of DFU (weeks) Infection status
S58 + 5 + Mono-species and multi-species Lateral leg 14 Non-infected
S59 + 4 + Multi-species only Heel 10 Non-infected
S60 + 5 + Mono-species and multi-species Plantar metatarsal head 27 Non-infected
S61 + 4 + Multi-species only Hallux 8 Non-infected
S62 + 4 + Mono-species and multi-species Plantar metatarsal head 12 Non-infected
S63 + 5 + Mono-species and multi-species Hallux 6 Non-infected
S64 + 5 NS NS Heel 52 Non-infected
S65 + 5 + Mono-species and multi-species Plantar metatarsal head 9 Non-infected
NS, inability to obtain an additional sample for microscopy from that patient.
Figure 1 Scanning electron micrograph of DFU obtained from four patients demonstrating biofilm structure. (A) and (B) show large micro-colonies of
predominantly coccoid microbial cells encased in thick extracellular matrix (EPS) and anchored to collagen bundles within the wound (biofilm score 5).
(C) shows large micro-colonies of predominantly coccoid cells covered in a thin film of EPS (biofilm score 4). (D) Shows large micro-colonies but less
EPS (biofilm score 3).
chronic DFUs with acute infection and chronic DFUs with no
infection but are non-healing. The visualisation of biofilms in
chronic non-healing wounds is as expected, where they have
been proposed as a likely cause of wound chronicity (15).
The exact mechanisms of biofilm impairment on the healing
processes of wounds remain unclear. In vitro observations
suggest the wound is kept in a vicious inflammatory state,
preventing the normal wound healing cycles to occur (16–18).
Recently, data by James and colleagues proposed a concept of
localised low-oxygen tensions contributing to wound chronic-
ity (19). Using oxygen microsensors and transcriptomics
(examining microbial metabolic activities) to study in situ
© 2017 Medicalhelplines.com Inc and John Wiley & Sons Ltd 5
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Figure 2 CLSM of biofilm demonstrated via FISH and PNA-FISH. (A) Patient 20, FISH with CLSM shows predominantly Gram-negative rods in biofilm
using green-fluro-488-labelled probe targeting Pseudomonas spp. and yellow-Cy3-labelled universal bacterial probe. (B) Patient 4, PNA-FISHwith CLSM
illustrates different bacterial morphologies of a multi-species biofilm using fluorescent-labelled universal PNA probes. (C) Patient 48, FISH with CLSM
using red-fluro-488-labelled universal probe is viewed at low magnification and illustrates the total amount of microbial biofilm on the tissue.
biofilms, James and colleagues identified steep oxygen gra-
dients and induced oxygen-limitation stress responses from
bacteria.
The presence of biofilm, however, in wounds of short
duration (<6 weeks) presenting with an acute infection is
less commonly reported. Five DFUs of short duration were
captured in this study (range from 2 to 5 weeks) with biofilm
being visualised in all patients. The general consensus is
that biofilms are not responsible for acute infective episodes,
for which planktonic microorganisms are the major driver
(20). People who develop DFUs may be at increased risk
of the earlier formation of biofilm. This may be explained
by several ill-defined immunological deficits attributed to
underlying hyperglycaemia (21) that contributes to a poor
response of neutrophils to colonising or invading microorgan-
isms (22) or from impairments in microbial phagocytosis (23).
Although the number of samples to draw a valid conclusion
is small (n= 5), it is unclear whether this phenomenon is
specific to DFUs or can be observed in other chronic wound
types and presents an interesting trend that warrants further
exploration.
In this study, all the presenting infected DFUs had biofilm,
but given that most DFUs were chronic at presentation, we
would expect biofilm to be present but not necessarily involved
as an acute pathogen of infection. It is plausible that the biofilm
acts a reservoir for pathogens, and biofilm dispersal increases
the presence of pathogenic planktonic microorganisms (24). To
support this idea, the most abundant bacteria identified using
DNA sequencing in this study was S. aureus. Species-specific
probes for S. aureus used in our PNA-FISH analysis also con-
firmed S. aureus as being present in the clear majority of sam-
ples as dense microbial aggregates. In the absence of direct
biofilm culture assays from our clinical isolates, we could refer
to the plethora of evidence for S. aureus’ profound ability
to form biofilm, particularly on human skin and tissue (25).
Furthermore, S. aureus has long been cited as the most com-
mon pathogen of infection in diabetic foot infections from
culture-dependent studies (26), and we also identify S. aureus
as being the predominant pathogen of infection in the presence
of visualised biofilm in this study. It is also possible that the
acute infections of chronic DFUs were caused by a new inva-
sion of planktonic bacteria rather than dispersal from biofilm
colonies.
When analysing the community structure of DFUs,
multi-species communities comprising of both strict anaer-
obes and aerobic species were identified. Biofilms can form
‘microniches’ (27), with steep oxygen gradients occurring
through biofilm or areas of altered pH or nitrate (28). These
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Figure 3 FISH and PNA-FISHwith CLSM technique to explore the spatial organisation of microbial aggregates in DFU samples. (A) Patient 18, identifies
twomono-species biofilm in the samewound, bacteria labelled with S. aureus PNA probe (green bacteria) and bacteria labelled with coagulase-negative
Staphylococci (red). (B) Patient 27, three-dimensional view of a DFU biopsy depicted using the Imaris software. This highlights the structural complexity
of biofilms where multi-species biofilm coexist with mono-species biofilms and planktonic microorganisms. (A) coagulase-negative Staphylococci
is red-labelled PNA probe with (B) S. aureus, a green-labelled PNA probe. (C) Mono-species of S. aureus biofilm. (D) Planktonic aggregates of
coagulase-negative Staphylococci. (E) Planktonic aggregates of S. aureus. Top right corner viewing bubble demonstrates standard CLSM view of
multi-species biofilm under high magnification. (c). Patient 35, FISH with CLSM. Green arrow shows mono-species biofilm (Staphylococcus spp.
specific probe), and orange arrow shows mixed-species biofilms (universal bacterial red probe).
studies confirm that distinct microniches exist at different
depths in biofilms and thus make it possible to understand
how metabolically diverse microorganisms coexist. While
aerobic Gram-positive cocci were predominant through sam-
ples, several strict anaerobes were also present in the majority
of samples, particularly Clostridales family XI members
Anaerococcus spp., Peptoniphilus spp. and Finegoldia spp.
Using culture-independent approaches, this group of fastidious
bacteria have been previously reported as colonising DFUs in
greater abundance when compared against laboratory-based
culture techniques (29).
The clinical significance of having multi-species biofilms
consisting of metabolically diverse microorganisms (i.e., aero-
bic and anaerobic microorganisms) is not clear, and there is no
direct evidence to suggest patients with multi-species biofilms
have less favourable outcomes than those with mono-species
biofilms. Previous reports in the literature, however, have
identified the occurrence of synergism between metabolically
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Table 2 The probability that a clinical wound observation is related to the presence of biofilm†
Binomial test
Category N Observed prop. Test prop. Exact Sig. (two-tailed)
Presence of slough Group 1 Yes 38 0⋅58 0⋅50 0⋅215
Group 2 No 27 0⋅42
Total 65 1⋅00
XS Exudate Group 1 No 5 0⋅08 0⋅50 0⋅000*
Group 2 Yes* 60 0⋅92
Total 65 1⋅00
Poor tissue quality Group 1 No 29 0⋅45 0⋅50 0⋅457
Group 2 Yes 36 0⋅55
Total 65 1⋅00
Signs of pyocyanin Group 1 No* 52 0⋅80 0⋅50 0⋅000*
Group 2 Yes 13 0⋅20
Total 65 1⋅00
Gelatin Wound Surface Group 1 No* 46 0⋅71 0⋅50 0⋅001*
Group 2 Yes 19 0⋅29
Total 65 1⋅00
Gelatin Reforms Quickly Group 1 No* 53 0⋅82 0⋅50 0⋅000*
Group 2 Yes 12 0⋅18
Total 65 1⋅00
*P value<0⋅05.
†The binominal probability questions asked here is a yes or no response. Therefore, statistical significance should be denoted by an * if the visual
marker is accurate in detecting biofilm. The benchmark was set at 50% occurrence rate for the visual marker to be present. The results below indicate
that visual markers (with exception of XS exudate) are no better than chance alone.
Figure 4 Next-generation DNA sequencing of 65 DFUs. Bar graphs depict the most common genera of microorganisms in DFUs. The vertical axis
refers to relative abundance across DFUs. Horizontal axis is the participant number.
diverse microorganisms that demonstrate a greater pathogenic-
ity/virulence and or an enhanced tolerance to therapeutics
(30). As with most chronic wounds complicated by biofilm,
their tolerance to many forms of treatments that include sys-
temic antimicrobials, topical antiseptics and disinfectants is
well-documented (31,32). This has led to expert groups promot-
ing multi-faceted biofilm-based wound-care approaches (13) to
tackle these tolerant phenotypes.
Part of this biofilm-based approach is the use of systemic
antimicrobials in the presence of clinical infection. A question,
therefore, that needs to be explored is whether clinicians need
to consider altering systemic antimicrobial therapy based on
the presence of multi-species biofilms containing additional
‘hidden’ anaerobes? Most clinicians with access to local and
international antimicrobial stewardship guidelines and guide-
lines specifically for diabetic foot infection are guided to use
empirical first-line antimicrobials that provide a broad spec-
trum of activity against anaerobes (such as Amoxicillin and
Clavulanic acid). These guidelines also promote the use of
antimicrobials with further targeted anaerobe action (such
a Metronidazole). In this instance (and except for biofilm
tolerance to antibiotics), most anaerobes are likely targeted by
conventional regimens.
One assumption when exploring the microbiome of chronic
wounds complicated by biofilm using DNA sequence tech-
niques is that the polymicrobial nature of these wounds must,
in turn, equal multi-species biofilms (33). This is not the
case. We identify cases where S. aureus forms a mono-species
biofilm next to a neighbouring multi-species biofilm. This sug-
gests a non-random distribution of microbial biofilms where
mono-species biofilm could form in multi-species infections.
This scenario has been previously documented by Bjarnsholt
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and colleagues using PNA-FISH on chronic wound samples
(34). They reported that many microbial aggregates were
mono-microbial and belonged to either P. aeruginosa or S.
aureus (identified using specific probes). Additionally, the
depth and location of these microbial aggregates was correlated
to the depth of the wound bed. S. aureuswere primarily located
close to the wound surface, whereas P. aeruginosa was primar-
ily located deeper in the wound bed. The authors concluded that
microbial aggregates function in a non-random distribution.
In a recent study on visualising wound biofilms, the clini-
cal observation of a gel-like substance/film was then correlated
to biofilm presence through microscopy (35). The study con-
cluded that 10 of the 16 samples revealed recurring wound
bed film and that this sign was indicative of macroscopic
biofilm presence. In contrast, for 26 samples analysed in this
study, except for excessive exudate, the probability of a clin-
ician accurately identifying biofilm using clinical observa-
tions is not better than chance alone. Furthermore, wounds
that exhibit a gel-like substance where biofilm is confirmed
throughmicroscopymight have this only in the presence of spe-
cific biofilm species as not all wounds exhibit this feature (an
example of this could be the mucoid P.aeruginosa, which pro-
duces the viscous polysaccharide alginate in cystic fibrosis).We
propose that clinical cues are not useful for detecting biofilm
presence in DFUs, but larger sample sizes from both DFUs
and other chronic wound aetiologies are required to verify our
results.
In conclusion, microscopy visualisation, when combined
with molecular approaches, confirms biofilms are ubiquitous in
DFUs, and a paradigm shift of managing these complicated
wounds needs to consider anti-biofilm strategies.
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Objectives: The performance of cadexomer iodine was determined against microbial populations from chronic
non-healing diabetic foot ulcers (DFUs) complicated by biofilm in vivo, using molecular, microscopy and zymog-
raphy methods.
Methods: Chronic non-healing DFUs due to suspected biofilm involvement were eligible for enrolment. DNA
sequencing and real-time quantitative PCR was used to determine the microbial load and diversity of tissue
punch biopsies obtained pre- and post-treatment. Scanning electron microscopy and/or fluorescence in situ hy-
bridization confirmed the presence or absence of biofilm. Zymography was used to determine levels of wound
proteases.
Results: Seventeen participants were recruited over a 6 month period. Scanning electron microscopy and or
fluorescence in situ hybridization confirmed the presence of biofilm in all samples. Eleven participants exhibited
log10 reductions in microbial load after treatment (range 1–2 log10) in comparison with six patients who
experienced ,1 log10 reduction (P"0.04). Samples were tested for levels of wound proteases pre- and post-
treatment. Reductions in the microbial load correlated to reductions in wound proteases pre- and post-
treatment (P"0.03).
Conclusions: To the best of our knowledge, this study represents the first in vivo evidence, employing a range of
molecular and microscopy techniques, of the ability of cadexomer iodine to reduce the microbial load of chronic
non-healing DFUs complicated by biofilm. Further analyses correlating log reductions to optimal duration of ther-
apy and improvements in clinical parameters of wound healing in a larger cohort are required.
Introduction
In a person with diabetes, foot ulceration leaves a physical break in
the protective barrier of the skin. Factors including a retarded host
immune response and pathogen-related dynamics (such as viru-
lence or pathogenicity) may predispose the diabetic foot ulcer
(DFU) to further planktonic microbial replication and invasion. This
may result in damage to host tissues and an inflammatory re-
sponse that is characterized as a clinical infection.1
Increasing evidence into the role of microorganisms involved in
DFUs (and other wound aetiologies) has identified that single free-
floating microorganisms (planktonic) that are responsible for acute
infections, may not necessarily represent the ecology of micro-
organisms present in chronic non-healing wounds. Instead, the
focus has orientated towards the concept of biofilms, which differ
markedly in both their physiology and activity. The exact mechan-
isms of biofilm impairment on the healing processes of wounds
are not clear, but general consensus suggests that biofilms main-
tain an elevated inflammatory state within the wound.2
Microorganisms in biofilm exhibit enhanced tolerances to
chemical, biological and host attack compared with those in plank-
tonic forms. In vitrobiofilm models have demonstrated that micro-
bial biofilms can withstand antimicrobial concentrations 100–
VC The Author 2017. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy.
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1000 times higher than that of their planktonic counterparts.3–6
This may go towards explaining why some wounds fail to heal
with standard care and why chronic infections persist.7 In vitro
models assessing the effectiveness of many antimicrobials used in
wound-related products have identified that these treatments
often have variable and poor results against microbial cells in bio-
film phenotypes.8–10
One potential explanation for this treatment failure is because
the wound care treatments do not target or are ineffective against
biofilm. Cadexomer iodine, however, has demonstrated superior
efficacy against microbial biofilms when tested in vitro and in ani-
mal models, when compared against other topical antimicrobials
used in wound care dressings.8–10
Therefore, as a pilot study massively parallel DNA sequencing,
real-time quantitative PCR (qPCR), microscopy techniques [scan-
ning electron microscopy (SEM) and fluorescence in situ hybridiza-
tion (FISH)] and gel zymography were used to identify if the topical
antimicrobial cadexomer iodine could reduce the microbial load
of chronic non-healing DFUs complicated by biofilm in vivo.
Additional interests were to explore the effects of cadexomer iod-
ine on the microbial communities pre- and post-treatment, and
determine the levels of wound proteases [matrix metalloprotei-
nase (MMP)-2 and MMP-9]. It was not the intention of this pilot
study to correlate any effects of microbial loads or diversity to
wound healing outcomes.
Materials and methods
Ethics
Ethics approval for this study was granted by the South West Sydney Local
Health District Research and Ethics Committee (HREC/14/LPOOL/487, SSA/
14/LPOOL/489).
Exclusion criteria
Patients with clinical signs of infection as per the IDSA guidelines,1 known
osteomyelitis that was associated with the DFU, or patients who had
received any topical or systemic antimicrobial therapy 2 weeks prior to en-
rolment, were not eligible. The reason for excluding patients with clinical in-
fection was the assumption that these wounds would be driven
predominantly by planktonic microorganisms.11 Participants with general
contraindications to the use of cadexomer iodine as per the manufacturer’s
guidelines were also excluded.12
Subjects and sample collection
Individuals were eligible for the study if they had a chronic non-healing DFU
defined as a wound of .6 weeks duration failing to respond to standard
care.13 Cadexomer iodine was applied every second day over a 7 day treat-
ment period (total of three applications). Sharp debridement of DFUs was
withheld over the 7 day treatment period given this was likely to impact the
results significantly.14 A tissue biopsy was obtained from the wound edge for
each participant before and after treatment. All tissue samples were frozen
at#80C until completion of the last patient and processed in bulk so as to re-
duce any bias. Additionally, we collected broad demographics and wound
metrics. Primary endpoint was a reduction in microbial load 7 days post-
treatment. Secondary analysis included the exploration of community rich-
ness and diversity of DFUs pre- and post-treatment, visual changes to biofilm
structures and alteration to levels of wound proteases (MMP-2 and MMP-9).
Cadexomer iodine (IodosorbV
R
, Smith & Nephew)
IodosorbV
R
ointment is designed as a carrier system enabling the delivery of
iodine, which can penetrate the cell wall of microorganisms and disrupt
protein and nucleic acid structure and synthesis.15 IodosorbV
R
consists of
small polysaccharide beads (cadexomer) containing 0.9% iodine, which, in
the presence of wound exudate, causes the polysaccharide beads to swell
allowing a slow sustained release of iodine into the wound.
Specimen collection and storage
A 3 mm (width)%10 mm (depth) tissue punch biopsy was obtained from
the edge of each DFU after cleansing the wound with 0.9% NaCl. Tissue bi-
opsy samples were obtained for all participants at baseline and day 7. For
SEM, an additional 2 mm (width)%10 mm (depth) was necessary.
Following removal, tissue samples were rinsed vigorously in a PBS bath to
remove any coagulated blood and to reduce the number of planktonic
microorganisms. Samples were cut transversely into two 1.5 mm pieces for
DNA sequencing and FISH. DNA samples were immediately placed into
RNAlaterV
R
(Ambion, Inc.) for 24 h at 4C and then frozen at#80C until DNA
extraction. Tissue samples for FISH were immediately fixed in 4% parafor-
maldehyde overnight at 4C, then transferred into PBS and frozen at
#80C. Tissue samples for SEM were immediately fixed in 3% glutaralde-
hyde overnight at 4C, then transferred into 0.1% PBS and frozen at#80C.
All tissue samples remained at#80C until study completion to reduce any
bias and were processed in bulk.
Tissue processing workflow
DNA extraction
Five to ten milligrams of human chronic DFU biopsy samples was defrosted
on ice prior to DNA extraction. Genomic DNA was extracted using a Mo Bio
PowerBiofilm DNA isolation kit (Mo Bio cat. no. 24000–50) following the
manufacturer’s instructions.
Next-generation DNA sequencing to determine
bacterial diversity
Massively Parallel DNA sequencing was carried out by a commercial labora-
tory (Australian Centre for Ecogenomics) targeting the V4 region of the
16S rRNA gene using eubacterial universal primers 515F (TCGTCGGCAGCGT
CAGATGTGTATAAGAGACAGCCAGCAGCYGCGGTAAN) and 806R (GTCTCG
TGGGCTCGGAGATGTGTATAAGAGACAG GGACTACHVGGGTWTCTAAT).
Preparation of the 16S library was performed as described at the
Australian Centre for Ecogenomics using the workflow outlined by Illumina.
In the first stage, PCR products of466 bp were amplified according to the
specified workflow with an alteration in polymerase used to substitute Q5
Hot Start High-Fidelity 2X Master Mix (New England Biolabs, Ipswich, MA,
USA) in standard PCR conditions. Resulting PCR amplicons were purified
using Agencourt AMPure XP beads (Beckman Coulter, Brea, CA, USA).
Purified DNA was indexed with unique 8 bp barcodes using the Illumina
Nextera XT 384 sample Index Kit A-D (Illumina FC-131–1002) in standard
PCR conditions with Q5 Hot Start High-Fidelity 2X Master Mix. Indexed
amplicons were pooled together in equimolar concentrations and
sequenced on the MiSeq Sequencing System (Illumina) using paired end
sequencing with V3 300 bp chemistry.
Sequence analysis and quality control
Reads in FASTQ format were imported to CLC genomics workbench version
8.5.1 using the microbial genome finishing module (CLC bio; Qiagen,
Aarhus, Denmark), for sequence quality control and analysis. Workflows for
sequence quality control and operational taxonomic units (OTUs) clustering
were based on previously reported wound microbiome analysis.16 OTUs
were defined as molecular proxies for describing organisms based on their
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phylogenetic relationships to other organisms, and were reported at either
the genera or species level identification where possible.
Briefly, after sequence and quality control measures, reads were as-
signed to OTUs using SILVA17 at 99% similarity at the genus level and spe-
cies level where possible. OTUs were aligned using MUSCLE18 to reconstruct
a phylogenetic tree, allowing the estimation of the alpha diversity pre- and
post-treatment for each DFU. This included both community richness
(rarefaction) and community diversity (Shannon–Weaver Index).
Rarefaction curves allow the estimation of the number of unique microbial
taxa within a sample and the Shannon–Weaver Index is a measure of diver-
sity that includes the number of unique microbial taxa and their relative
evenness within each sample. Thus, a higher Shannon–Weaver Index cor-
relates to a greater diversity.
qPCR to determine microbial load in DFU biofilms
We utilized qPCR to determine microbial load in DFU biofilms, as previously
reported.19,20 To quantify the total amount of bacterial DNA/mg of tissue in
each wound tissue sample we obtained the copy number of the 16S rRNA
gene (copies/lL), which was normalized against the human 18S rRNA gene
(copies/lL) in each chronic wound sample.
Characterization and visualization of DFU biofilm
The presence or absence of biofilms in chronic non-healing DFUs was con-
firmed through SEM or FISH. For the purpose of this study, we used defin-
itions promoted by an expert group to characterize biofilm as being
(i) microbial aggregates surrounded by a self-produced or host-derived ma-
trix adhering to natural or artificial surfaces in the host, or (ii) aggregates
associated with, but not directly adherent to, the surface.21
FISH. Two to three millimetres of DFU tissue was embedded in optimal
cutting temperature (OCT) embedding matrix (Tissue-PlusTM O.C.T
Compound, Thermo Fisher Scientific, Waltham, MA, USA) and frozen at
#80C overnight. DFU tissues were sectioned to a thickness of 6lm and
mounted on SuperFrost Plus slides (Thermo Fisher Scientific). For visualiza-
tion of microorganisms and biofilm, confocal laser scanning microscopy
was combined with FISH. The hybridization process used was previously
described by Thurnheer et al.22 Briefly, two different probes were utilized for
in situ hybridization: Fluor 488-labelled universal probe23 (final concentra-
tion 5 ng/lL); and Cy3-labelled Staphylococcus spp.-specific probe (final
concentration 5 ng/lL).24 All images were examined under confocal laser
scanning microscopy (Carl Zeiss Ltd, Herefordshire, UK). All images were
processed using ZEISS ZEN Imaging Software (black edition).
SEM and image interpretation
In vivo microbial biofilms associated with DFU tissue were sampled at
5–200lm for optimal visualization through SEM.25 Two to 3 mm of DFU tis-
sue was fixed in 3% glutaraldehyde, followed by three washes of 0.1 M
PBS prior to serial ethanol dehydration and hexamethyldisilazane
(Polysciences, Inc., Warrington, PA, USA), as described previously.20 Dried
samples were coated with 20 nm gold film and examined using SEM. Each
sample was scored based on the amount of bacteria/biofilm observed
using an arbitrary five-point scale as previously reported:26 score 0"no
bacteria observed; 1" single individual cells; 2" small microcolonies
(10 cells); 3" large microcolonies (100 cells); 4" continuous film; and
5" thick continuous film.
Determination of wound proteases
Wound fluids were collected from DFUs pre- and post-treatment and
stored at#80C for quantification of MMPs (MMP-2 and total MMP-9) by gel
band zymography, as previously described.27
Statistics
Wound metrics and microbiome data were analysed through Statistical
Package for Social Sciences Version 23 (IBM, Armonk, NJ, USA). Wilcoxon
signed-rank tests for paired samples of non-parametric data were per-
formed on pre- and post-treatment microbial log10 reductions. v
2 was used
to correlate OTUs and Shannon–Weaver indices to log10 reduction.
One-way ANOVA was used to estimate variances between MMP levels be-
fore and after treatment. Logistic regression was employed to correlate mi-
crobial reduction to MMP levels. CLC genomics workbench version 8.5.1 in
combination with the microbial genome-finishing module (CLC bio; Qiagen)
was used to analyse DNA sequence data. For all comparisons and model-
ling, the level of significance was set at P,0.05. Data are given as mean,
standard deviation (+) and 95% CI.
Results
A total of 17 patients with chronic non-healing DFUs were en-
rolled. One ulcer from each patient was biopsied before and after
treatment. Patient demographics and wound metrics are shown
in Table 1. Microbial load was determined via qPCR for all 17 DFU
samples pre- and post-treatment. However, three samples were
removed from exploring community richness (rarefaction) and
diversity (Shannon–Weaver Index) due to a low number of 16S
rRNA gene sequence reads, leaving 12 samples available for
analysis. In total (for these 12 samples), 703346 high-quality
DNA sequences were generated (before"384772 and after-
"318574), with a median of 31452 per sample level data
(range 1137–61820). The clustering of OTUs identified 1976
unique taxa from which low abundance OTUs were removed
(,0.1%), leaving 368 OTUs for further analysis. Only eight wound
fluid samples were available for analysis. Protein concentrations
in the remaining samples were too low for analysis.
Table 1. Patient demographics and wound metrics at baseline
Patient demographics
male 11 (65%)
female 6 (35%)
type 1 diabetes 2 (12%)
type 2 diabetes 15 (88%)
mean age in years 66 (+13.6)
Wound metrics
location of ulcer
plantar metatarsal head 8
calcaneum 3
dorsal foot 2
ankle 2
hallux 2
duration of ulcer in weeks
mean duration of ulcer at baseline 25 (+20.7, range 6–72)
University of Texas wound classification
1A 10 (59%)
1C 1 (5.8%)
2A 5 (29.4%)
2C 1 (5.8%)
size of ulcer
mean DFU size at baseline 3.7%2.7 cm (L%W)
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Confirmation of the presence or absence of biofilms in
each DFU
The presence of biofilm was visualized and confirmed in all 17 par-
ticipants using SEM, FISH or both (Figure 1a and b). Biofilm architec-
ture was graded (via SEM) using an arbitrary sliding scale
previously reported.26 The median value of DFU biofilm architec-
ture reduced between pre- and post-treatment samples; pre-
treatment median was 4 (large microcolonies 100 cells and a
continuous film/matrix) and the post-treatment median was
3 (large microcolonies100 cells).
Reduction in microbial load of chronic non-healing DFUs
complicated by biofilm
The application of cadexomer iodine resulted in 11 samples
achieving up to and greater than a 1 log10 reduction (mean micro-
bial load pre-treatment"5.92 log10 16S copies/mg of tissue ver-
sus 4.56 log10 16S copies/mg of tissue, P"0.02, 95% CI 3.43 to
4.61 log10) (Figure 2). Six samples had no change or increases in
log10 (mean microbial load pre-treatment"5.22 log10 16S copies/
mg of tissue versus 5.20 log10 16S copies/mg of tissue).
Analysis of community richness and diversity of chronic
non-healing DFUs treated with cadexomer iodine
The most abundant OTUs (based on the number of DNA sequences
represented when pooling samples) are noted in Figure 3. The rich-
ness and diversity of chronic non-healing DFUs pre- and
post-treatment are also reported at the individual sample level of
microorganisms contributing to .5% of abundance in rank order
(Table 2). Post-treatment identified diversity shifts with increasing
environmental contaminants. These microorganisms are identifi-
able only by molecular methods (in the majority), and included in
the Proteobacteria-E01-9C-26 Marine Group, Proteobacteria-
ARKDMS-49, Archaea-Cenarchaeum, Elizabethkingia spp., Bacteroi-
detes-Rhodothermacae and Proteobacteria-Rhodothalssium.
Furthermore, some of these microorganisms are known extremo-
philes, existing in hostile, niche environments.
The taxonomic richness and diversity of pre- and post-
treatment pooled samples identified no differences between
mean OTUs (pre-treatment"115, SD"69.3 versus post-treat-
ment"112, SD"74.3, P"0.53) and mean Shannon–Weaver in-
dices (pre-treatment"2.8, SD 1.2 versus post-treatment"3,
SD"1.4, P"0.58). When exploring this at the individual sample
level there was large heterogeneity between pre- and post-
treatment OTUs and Shannon–Weaver indices. To ascertain if the
number of unique OTUs and their relative abundance were corre-
lated to reductions in log10 values, a v
2 test was performed.
Reductions in log10 did not correlate to reductions in either OTUs
(P"0.85) or Shannon–Weaver indices (P"0.72).
MMP levels pre- and post-treatment
The mean total MMP-9 and MMP-2 levels in eight samples reduced
following 7 days application of cadexomer iodine (Figure 4).
However, only total MMP-9 reached statistical significance (mean
total MMP-9 before"2202 mg/10lL versus mean total MMP-9
after"1065 mg/10lL, 95% CI#14.5 to 2287, P"0.05). Mean
MMP-2 before"181.9 versus mean MMP-2 after"89 (95% CI
#61.3 to 246.7, P"0.197). In general, any reductions in the levels
of MMPs were correlated to reductions in the microbial load
(P"0.03).
(a)
5 µm
(b)
Figure 1. (a) SEM from a sample pre-treatment. Microbial aggregates with self-produced or host-derived matrix that we describe as a stringy-like
glue appearance. SEM imaged at 5lm. (b) FISH image depicts microbial aggregates of mixed species biofilm [Fluor 488-labelled universal bacterial
probe (red) and Cy3-labelled Staphylococcus spp.-specific probe].
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Discussion
Using a combination of DNA sequencing, qPCR, SEM and FISH, the
ecology of wounds and presence of microbial biofilms was
explored. To the best of our knowledge, we are the first to employ
these suites of molecular and microscopy techniques to show that
cadexomer iodine can reduce the microbial load of chronic non-
healing DFUs complicated by biofilm. We also show that in reduc-
ing microbial load, concomitant reductions in wound proteases are
also achieved.
Massively parallel DNA sequencing allowed the exploration of
chronic non-healing DFU microbiome, and provided useful insights
that these wounds support complex polymicrobial communities.
Molecular methods also demonstrated that cadexomer iodine had
a broad level of antimicrobial activity in reducing both facultative
anaerobes such as Staphylococcus spp., Serratia spp.,
Pseudomonas spp. and obligate anaerobes including Clostridiales
family XI.
Both facultative and obligate anaerobes were detected to-
gether in chronic non-healing DFU samples positive for biofilm
presence. Microelectrode and transcriptomic analysis of in vitro
biofilms have identified that the interior of biofilms house niche
areas of altered pH levels, oxygen and nutrient depletion.3,28
Oxygen in particular is noted for its depletion at the substratum
layers of biofilms and in the centre of microcolonies, explaining
why wounds complicated by biofilm can harbour such diverse
microorganisms. This may indirectly support the action of
cadexomer iodine against biofilms, as it suggests penetration to
deeper areas that house obligate anaerobes is possible, as identi-
fied by 16S rRNA of pre- and post-treatment reductions in obligate
anaerobes.
Using a combined molecular and microscopy approach can
provide an extended understanding of the effects of antimicrobials
on wounds. This approach for example provided insights into how
cadexomer iodine affected microbial populations. Using sample
level data, Serratia spp. were identified as contributing to 75% of
abundance pre-treatment and 0% post-treatment in sample
42 (Figure 5a). This also correlated with a.1 log10 reduction in mi-
crobial load as determined by qPCR. Similarly, for sample 44, P. aer-
uginosa contributed to 88% of abundance pre-treatment and
0.3% post-treatment, with a 0.76 log10 reduction in microbial load
(Figure 5b). This suggests that cadexomer iodine was effective in
reducing the abundant microorganisms in these cases.
In contrast, there was no log10 reduction in microbial load for
sample 45 (pre-treatment"4.565 and post-treatment"4.735).
While community profiling revealed a minor reduction in
Figure 3. Most frequent microorganisms based on the pooling of all DNA sequences and the total number of DNA sequences attributed to each
microorganism. This graph also exemplifies the contrast between low- and high-frequency taxa at the genus/species level. High-frequency taxa con-
sist of a few predominant microorganisms (typically between 1 and 9 microorganisms; samples 31, 32, 36, 42, 44, 45 and 91) and low-frequency
taxa consist of multiple microorganisms (typically 10-fold in comparison with high-frequency taxa; .30–90 microorganisms; samples 33, 38, 39, 40
and 41).
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Staphylococcus spp. (Figure 6a), this was countered with a con-
comitant increase in other microorganisms. In this case, FISH was
able to demonstrate the lack of action against the bulk of micro-
organisms in sample 45, with pre- and post-treatment images
depicting the presence of microbial aggregates as biofilm in
chronic non-healing DFU tissue samples (Figure 6b).
In five patients, no log10 reduction was noted with the use of
cadexomer iodine. Considering the accepted notion that biofilms
are tolerant to antimicrobials, and combining the potential attri-
butes of extremophile (and non-extremophile) microorganisms,
this may explain why some wound microorganisms were tolerant
to treatment. Post-treatment microbiome analysis identified that
these microorganisms increased in abundance from previously
low numbers, whereas skin flora microorganisms such as
Pseudomonas spp. decreased in abundance following treatment
(indicating cadexomer iodine were effective). This diversity shift
may have occurred as nutrient availability increased or where mu-
tual benefit arose.29
Study limitations
The primary aim of this study was to ascertain the effects of
cadexomer iodine on microbial populations associated with the
presence of biofilm, however without the controlled conditions af-
forded by in vitro biofilm models we are not able to fully rule out
that planktonic microorganisms contaminated samples. Our ra-
tionale to provide a strong argument that planktonic microorgan-
isms were of a negligible proportion of microbial cells, with the bulk
of cells being biofilm, is supported by our visualization techniques
using SEM and FISH. These methods identified significant aggre-
gates of microbial cells with extracellular polymeric substance
(EPS). Furthermore, we vigorously rinsed all tissue samples during
preparation as a method to reduce planktonic microorganisms not
adhered to tissue. Alternative methods to reduce planktonic
microorganisms from contaminating biofilm models have only
been alluded to from ex vivo animal explants,10 with no reports of
this approach on human tissue.
To measure total microbial load, qPCR was utilized as the
technique of choice, with previous wound-related PCR studies
adopting this methodology.30,31 We acknowledge with this ap-
proach the inability of qPCR (based on 16S rRNA gene) to
Table 2. Pre- and post-treatment community diversity in microorgan-
isms contributing to.5% abundance of each individual sample
Genera Samples
Average
abundance
(%) Aerotolerance
Pre-treatment
Pseudomonas spp. 5 58.5 aerobe
E01-9C-26 Marine 4 11.2 unknown
Staphylococcus spp. 4 58 facultative
Rhodothermaceae spp. 3 5 unknown
Finegoldia spp. 3 7.8 anaerobe
Elizabethkingia meningoseptica 3 6.3 aerobe
Cornyebacterium spp. 3 5.3 aerobe
Peptoniphilus spp. 2 9.5 anaerobe
Ananerococcus spp. 2 9.2 anaerobe
Proteus penneri 2 20.5 facultative
Post-treatment
E01-9C-26 Marine 8 10 unknown
ARKDMS49 7 5.7 unknown
Cenarchaeum 5 5.1 unknown
Cyanobacteria—subsection I 5 7.4 unknown
Rhodothermaceae spp. 4 5.8 unknown
Rhodothalassium spp. 3 7 unknown
Cornyebacterium spp. 3 11 aerobe
Elizabethkingia meningoseptica 3 6.6 aerobe
Staphylococcus spp. 3 42.8 facultative
Proteus penneri 2 39 facultative
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Figure 4. (a) Total MMP-9 values pre- and post-treatment. (b) MMP-2 values pre- and post-treatment. Boxplots show the median and IQR, with
whiskers showing the range apart from outliers (.1.5%IQR).
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(a)
(b)
Figure 5. Pre- and post-treatment community diversity identified through 16S rRNA sequencing. (a) In the left-hand side, sample 42 identifies
Serratia spp. contributing to 75% abundance pre-treatment, and in the right-hand side, this reduces to 0% post-treatment. Top of the graph identi-
fied the reduction in microbial load by over 1 log10 reduction determined through qPCR (99% reduction in microorganisms). Therefore, the left-hand
pane is a reflection of the remaining 1% of microorganisms. (b) Sample 44 identified Pseudomonas spp. contributing to 88% abundance pre-treat-
ment and 0.3% post-treatment with a 0.83 log10 reduction.
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differentiate live or dead bacteria. Other commonly employed
techniques such as molecular viability testing (pre-RNA analysis
or RT-qPCR) are able to detect live or dead microorganisms. The
problem with using these techniques for our diabetic ulcer sam-
ples is the predominance of biofilm phenotype cells present in
the tissue. Pre-RNA rapidly responds to nutrition stimulation
and target metabolism, not actual microbial load. Given that
biofilm cells have low metabolism in comparison with plank-
tonic cells, this may lead to variations in the 16S pre-RNA level
between the biofilm and planktonic cells and different growth
conditions.32 The log reductions noted in this study therefore
represent the minimal response and we acknowledge that
some of the bacteria detected by qPCR could be dead, resulting
in a lower calculated efficacy for cadexomer iodine.
Lastly, only eight samples with adequate protein concentration
were available for analysis. In the majority, obtaining enough
wound fluid post-treatment was difficult, which may be associ-
ated with reduced wound inflammation with reductions in micro-
bial loads. Alternatively, the time of dipstick applications were
undertaken during 30 min appointments and this may not have
been long enough to allow the wounds to leak adequately onto
the three dipsticks required.
(a)
(b)
Figure 6. (a) Sample 45 identifies a small reduction in S. aureus. This is countered by a concomitant increase in other microorganisms allowing an in-
crease in community diversity, but not overall microbial load. (b) This lack of action is also identified through FISH. Red colour represents a universal
probe (Fluor 488) and the green represents a species-specific probe for S. aureus (Cy3). Some reduction in S. aureus aggregates post-treatment is
noted, but the biofilm remains in bulk.
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Objectives: Test the performance of topical antimicrobial wound solutions against microbial biofilms using
in vitro, ex vivo and in vivomodel systems at clinically relevant exposure times.
Methods: Topical antimicrobial wound solutions were tested under three different conditions: (in vitro) 4% w/v
Melaleuca oil, polyhexamethylene biguanide, chlorhexidine, povidone iodine and hypochlorous acid were tested
at short duration exposure times for 15min against 3 day mature biofilms of Staphylococcus aureus and
Pseudomonas aeruginosa; (ex vivo) hypochlorous acid was tested in a porcine skin explant model with 12 cycles
of 10min exposure, over 24h, against 3 day mature P. aeruginosa biofilms; and (in vivo) 4% w/v Melaleuca oil
was applied for 15min exposure, daily, for 7days, in 10 patients with chronic non-healing diabetic foot ulcers
complicated by biofilm.
Results: In vitro assessment demonstrated variable efficacy in reducing biofilms ranging from 0.5 log10 reduc-
tions to full eradication. Repeated instillation of hypochlorous acid in a porcine model achieved ,1 log10 reduc-
tion (0.77 log10, P"0.1). Application of 4% w/v Melaleuca oil in vivo resulted in no change to the total microbial
load of diabetic foot ulcers complicated by biofilm (median log10 microbial load pre-treatment"4.9 log10 versus
4.8 log10, P"0.43).
Conclusions: Short durations of exposure to topical antimicrobial wound solutions commonly utilized by clini-
cians are ineffective against microbial biofilms, particularly when used in vivo. Wound solutions should not be
used as a sole therapy and clinicians should consider multifaceted strategies that include sharp debridement as
the gold standard.
Introduction
Chronic wounds are a serious cause of morbidity and mortality,
and are associated with reduced patient health-related quality of
life. The impacts on healthcare providers are reflected in the
staggering cost ofmanaging thesewoundsandassociated comor-
bidities, with £5.3 billion attributed to UK National Health Service
expenditure.1 Increasing evidence on themicroorganisms involved
in chronic wounds has identified that planktonic cells may not
necessarily represent the phenotypic behaviour of microorgan-
isms involved in chronic non-healing wounds. The focus has
shifted towards the concept of microbial aggregates (biofilms),
which differ markedly in their phenotypic behaviour and may
contribute to the delayed healing of wounds.2 In addition, the
ecology of chronic wounds explored through molecular DNA-
based technologies (and not cultivation-based methods) has
identified these wounds to be complicated by complex polymi-
crobial communities.3
VC The Author 2017. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy.
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Once established, complex biofilm communities often become
highly tolerant to standard treatment and removal/eradication
paradigms, yielding several hallmark features that distinguish bio-
film phenotypes from those of planktonic counterparts. The most
notable of these is a remarkable tolerance to antimicrobial
agents,4,5 and host immune defences.6 The increasing awareness
and promotion of the biofilm concept within thewound care arena
has led to a dramatic rise in the use of topical antimicrobial solu-
tions as part ofwound care therapeutics.7
Unfortunately, the evidence for use of particular topical antimi-
crobials in the treatment of biofilm-associatedwounds is based on
in vitro methodologies that lack standardization and clinical
relevance to their intended applications.8 For example, the anti-
biofilm effects of wound solutions, for which outcomes are based
on reductions in biofilmmarkers (i.e. biomass, cfu/mL, LIVE/DEADV
R
stain viability), have been reported at exposure times far greater
than their intended use. Many wound care/device companies
promote a 15min exposure time for their respective antimicrobial
solutions (seconds for irrigation solutions), yet the bulk of data
for effectiveness of these products in vitro have only reported
outcomes at 24h exposure times.9–11 This has important conse-
quences at the treatment level where clinicians often seek guid-
ance from laboratory-based studies (owing to a lack of available
in vivo data) in choosing the most relevant and effective agent to
reducemicrobial biofilms. Therefore, in vitro data based on greater
exposure times may not reflect the most clinically appropriate
outcomes for clinicians using these products at shorter exposure
times. This is highlighted succinctly by Castaneda et al.,12 who
showed that in an in vitro biofilmmodel, antimicrobial susceptibil-
ity increasedwith antimicrobial exposure time.
The present study was designed to explore whether shorter
durations of exposure to antimicrobial wound solutions were
effective against microbial biofilms: (i) in vitro against mature bio-
films of Staphylococcus aureus and Pseudomonas aeruginosa; (ii) in
an ex vivo porcine skin explantmodel againstmature P. aeruginosa
biofilms; and (iii) in vivo in 10 patients with chronic non-healing
diabetic foot ulcers (DFUs).
Materials and methods
Bacteria
The biofilm-forming reference strains utilized in vitrowere S. aureus [ATCCV
R
25923TM (MSSA)] and P. aeruginosa (ATCCV
R
25619TM), and P. aeruginosa
PA01 (ATCCV
R
BAA-47TM)was used in the ex vivo porcine skin explantmodel.
Antimicrobial wound solutions
The solutions examined, any incorporated antimicrobials/antiseptics and
their respective manufacturers, were as follows: surfactant-based antiseptic
solution with 4% w/v Melaleuca oil (SBMO; WoundaidV
R
Woundwash;
Mundipharma, Singapore); surfactant-based antimicrobial solution with
polyhexamethylene biguanide (SBPHMB; ProntosanV
R
; B. Braun Medical,
Melsungen, Germany); superoxidized solution (SOS) containing sodiumhypo-
chlorite, hypochlorous acid, sodium chloride and oxidized water (MicrocynV
R
;
Oculus Technologies of Mexico); chlorhexidine (CHX) 4.5mg/30mL (0.015%
w/v) and cetrimide 45mg/30 mL (0.15% w/v) irrigation solution (Pfizer, New
York, USA); povidone iodine antiseptic solution 10%w/v equivalent to 1%w/v
available iodine (PVP-I; BETADINEV
R
; Mundipharma, Singapore); NaCl 0.9%
(Baxter, IL, USA).
The decision to use SOS for the ex vivo porcine explantmodel and SBMO
for the human in vivo study was based on clinical relevance. Both the use
and promotion of these ‘newer generation’ solutions with antimicrobial
properties (as opposed to traditional antimicrobials of CHX and PVP-I) by
clinicians and industry for action against wound biofilm has increased
significantly over the last decade. They now represent the predominant
products used forwound cleansing and debridement.
Experimental models
In vitro model
Biofilm, containing 107–108 cells/coupon of P. aeruginosa (ATCC 25619) and
106 cells/coupon of S. aureus ATCC 25923 was grown under shear
(130 rpm) on polycarbonate coupons in a CDC biofilm reactor (BioSurface
Technologies Corp., Bozeman, MT, USA) as previously described by our
group,13 in 400mL of 15g/L (50%) tryptic soy broth (Sigma–Aldrich,
St Louis, MO, USA) at 35 C in batch phase for 48h, followed by incubation in
fresh medium (20% tryptic soy broth, 6g/L) for a further 24h. Coupons
were washed in 10mL PBS to remove loosely attached planktonic bacteria.
Each coupon had 107–108 P. aeruginosa or 106 S. aureus. Five antiseptic
treatments were tested (SBMO, SBPHMB, SOS, CHX, PVP-I); four coupons
were exposed to each treatment condition for 15min, while an additional
four couponswere used as controls.
The numbers of bacterial colony forming units (cfu) per coupon were
tested in triplicate by sonication in an ultrasonic bath (Soniclean; JMR,
Australia) for 10min with a sweeping frequency of 42–47kHz at 20C. The
couponwas then vortexed for 2min in 2mLof PBS followed by a sequential
10-fold dilution and plate count. Pre- and post-exposure average cfu/cou-
pon was expressed as log10. Bacterial cell viability pre- and post-exposure
was also assessed using BacLightTM (LIVE/DEADV
R
Bacterial Viability Kit,
7012; Molecular Probes, Invitrogen, Carlsbad, CA, USA) in conjunction with
confocal laser scanning microscopy (CLSM) and expressed as the percent-
age of viability as determined by Imaris (v8.4, ImarisXT, Bitplane). For CLSM,
we used an inverted laser scanning confocal microscope (ZEISS LSM 880;
Carl Zeiss Ltd, Herefordshire, UK) for all the samples, with oil-immersion
lenses (63% and 100%) and acquisition parameters of: frame size,
1024%1024; speed, 6; averaging, 2; bit depth, 12.
Ex vivo porcine skin explant model
The ex vivo porcine skin explant biofilm model used in this study is previ-
ously described14 and a detailed description can be found in the
Supplementary data (Part S1, available as Supplementary data at JAC
Online). One pig was used to obtain all explants, which were freshly
harvested, shaved, cleaned and inflicted with a partial thickness excision
wound. Explants were then sterilized by first submerging the explants in
PBS containing 0.6% hypochlorous acid and 0.5% Tween 80 for 5min then
transferring them to a chlorine gas chamber for 45min, followed by sub-
merging the explants again in PBS containing 0.6% hypochlorous acid and
0.5% Tween 80 for 5min. The sterile explants were rinsed twice in sterile
PBS then transferred into 150mm diameter by 25mm deep culture plates
(176cm2 surface area) (Corning 430599) containing 0.5% tryptic soy soft
agar containing antibiotic (gentamicin at 50mg/mL) to limit planktonic
growth and promote biofilm growth on the explants. One hundred micro-
litres of P. aeruginosa PA01 (107–108 cfu/mL) was inoculated onto the
explants and incubated for 3days at 37 C. Porcine explantswere subjected
to three test groups: (i) negative pressure wound therapy alone (control);
(ii) negative pressure wound therapy with instillation therapy for 12 cycles
of 10min of soak/dwell with SOS, totalling 24h for the experiment; and
(iii) negative pressure with instillation therapy for 12 cycles of 10min of
soak/dwell with saline (NaCl 0.9%). After 24h, six 8mm biopsies were
obtained from the porcine skin explant and processed for measurement of
cfu/mL and scanning electron microscopy (SEM). For each test group, six
experimentswere established and the cfuwas averaged over these.
Johani et al.
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In vivo clinical study
We used a combinedmolecular andmicroscopy approach described previ-
ously15 to better understand the effects of a topical antimicrobial solution
against the microbial load and diversity of chronic non-healing DFUs com-
plicated by biofilm (Supplementary data Part S2). Ten patients with chronic
non-healing DFUs (and not on current antimicrobial therapy) were enrolled
over a 6month period from a tertiary referral hospital (Liverpool Hospital
High Risk Foot Service, Liverpool, Sydney). Ethics approval for this study was
granted by the South West Sydney Local Health District Research and
Ethics Committee (HREC/14/LPOOL/487, SSA/14/LPOOL/489). Sterile gauze
was soaked in SBMO and applied to the wound for 15min, every day for
7days. Sharp debridement of tissuewaswithheld over the 7day treatment
period, as this would likely have affected the primary outcomemeasure.16
Tissue punch biopsies were obtained from thewound edge for each partici-
pant after cleansing the wound with NaCl 0.9% pre- and post-treatment.
These were subjected to quantitative PCR (qPCR) to determine the total
microbial load, next generation DNA sequencing to explore themicrobiome
of chronic DFUs and the effects onmicrobial communities following topical
antimicrobial therapy, SEM to visualize biofilm structures and fluorescent in
situ hybridization in conjunction with CLSM to examine spatial organization
ofmicrobial aggregates.
Statistics
Mann–Whitney U-tests were used to assess differences between pre- and
post-log10 cfu using the Statistical Package for Social Sciences Version
23 (SPSS Inc., Chicago, IL, USA). CLC genomics workbench version 8.5.1 in
combination with the microbial genome-finishing module (CLC bio, Qiagen
Aarhus, Denmark) was used to analyse DNA sequence data. QIIME was
utilized to visually represent data. Analysis of variance and permutational
analysis of variance were used for statistical analysis of alpha and beta
diversity measures. Principal coordinates analysis plots with Bray–Curtis
distances were used to assess how dissimilar microbial communities were
pre- andpost-treatment. Community richness of DFUswaspresentedusing
richness index reporting the number of unique operational taxonomic units
(OTUs) in eachwound sample. The Shannon–Weaver Index is an ecological
measure of diversity that includes the number of uniquemicrobial taxa and
their relative evenness within each sample. For all comparisons andmodel-
ling, the level of significance was set at P,0.05. Data are given as mean,
median (+SD) and 95%CI.
Results
Antimicrobial efficacies of topical wound solutions
against mature biofilms in vitro
The effects of topical antimicrobial solutions on reductions in log10
cfu/coupon following treatments at 15min and 24h are shown in
Figure 1(a and b). LIVE/DEADV
R
stain with CLSM and the percentage
of red signal (dead/damaged cells) and green signal (viable cells) at
15min exposures are noted in Supplementary data Part S3.
At 15min exposures PVP-I was the only solution to show complete
and efficient killing of both S. aureus and P. aeruginosa biofilms
(6 and 7 log10 reduction, P"0.001). CHX was effective against
S. aureus biofilms showing complete removal of all bacteria (6 log10
reduction, P"0.001), and further demonstrated a 3.96 log10 cfu
reduction against the P. aeruginosa biofilm (P"0.01). In contrast,
SOS demonstrated complete eradication of the P. aeruginosa bio-
film (7 log10 reduction, P"0.001) and a 4 log10 cfu/mL reduction
against S. aureus (4.3 log10 reduction P"0.01). No significant
reduction in S. aureus counts was observed for treatment with
SBPHMB (0.8 log10 reduction); however, it was highly effective
against P. aeruginosa biofilm showing complete eradication (7 log10
reduction, P"0.01). Treatment with SBMO was ineffective against
both S. aureus and P. aeruginosa biofilm. In contrast, treatment
of biofilm with topical antimicrobials for 24h exposure showed
complete and efficient killing of biofilm, except for SBMO, which
failed to eradicate S. aureus (but still achieved a 2.5 log10 cfu/
coupon).
Antimicrobial efficacy of SOS against mature biofilms in
an ex vivo porcine skin explant model
Levels of P. aeruginosa PA01 viable bacteria after 12 cycles of nega-
tive pressure therapy and instillation of saline or SOS are shown in
Figure 2. The total bacterial bioburden (planktonic! biofilm) grow-
ing on the porcine skin explant was 8.0 log10 cfu/mL, of which
7.1 log10 cfu/mLwere biofilm bacteria, as defined by being tolerant
to incubation in 50% MIC gentamicin for 24h at 37 C. When
porcine skin explants withmature P. aeruginosa PA01 biofilmwere
exposed to 12 cycles of negative pressure wound therapy alone
without instillation of any solution (control for negative pressure
wound therapy), which is equivalent to ‘pulsed or intermittent
negative pressure wound therapy’, the level of P. aeruginosa PA01
cfu was reduced to 6.9 log10 cfu/mL. When the porcine skin
explants were treated with negative pressure wound therapy with
12 cycles of instillation with saline with a 10min exposure time,
the level of P. aeruginosa PA01 bacteria was the same (6.9 log10
cfu/mL). Changing the instillation solution to SOS and using the
same 12 cycles of instillation, the level of P. aeruginosa PAO1
bacteria was essentially the same as with saline instillation, with
6.8 log10 cfu/mL surviving the instillation treatment. In contrast,
planktonic and biofilm bacteria were completely eradicated using
the in vitro CDC biofilm reactor laboratory test.
As shown in Supplementary data Part S4, SEM of the wound
area in the porcine skin explants demonstrated very thick continu-
ous biofilm on untreated explants (panel A). SEM of explants
treated with saline instillation (panel C) or explants treated only
with negative pressure and no instillation (panel D) showed a
reduction in biofilm structures, but substantial amounts of
attached bacteria were still present. Explants treated with
SOS instillation (panel B) also showed a reduction in the biofilm
structure but persistence of attached bacteria.
The effect of SBMO against the microbial load and
diversity of DFUs complicated by biofilm in vivo
Ten patients with chronic non-healing DFUs were enrolled. A total
of 1306086 high-quality DNA sequences were generated
(before"623117, after"682969), with a median of 61132 per
sample-level data (range" 5702–168421). The OTUs identified
1976 unique taxa of which low-abundance OTUs were removed
(,0.1%), leaving 124OTUs for further analysis.
Confirmation of the presence or absence of biofilms in
each DFU
Biofilms were visualized and confirmed in all 10 participants using
SEM (Supplementary data Part S5). Biofilm architecture was
graded using an arbitrary sliding scale froma score of 5 (heavy bio-
film) to 0 (no biofilm) as previously reported.17 The median value
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Figure 2. Treatment of porcine skin explants. 108 cfu of P. aeruginosa PA01 was inoculated onto porcine skin explants and after 3 days of growth at
37 C, the average cfu of viable total bacteria or biofilm bacteria present before or after 12 cycles of 10min instillations with saline or SOS solutions or
only NPWT without instillation are shown. NPWT, negative pressure wound therapy.
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Figure 1. Effect of test products on bacterial viability. Bars represent means of logarithms of colony-forming units of viable biofilm cells after
(a) 15min exposure and (b) after 24h exposure. Error bars represent the standard error of the means from three coupons (**P,0.01, ***P,0.001, no
viable cells).
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of DFU biofilm architecture reduced from 4 pre-treatment (large
microcolonies100 cells, and a continuous film/matrix) to 3 post-
treatment (largemicrocolonies100 cells).
Microbial load of chronic non-healing DFUs complicated
by biofilm
The application of SBMO for 15min exposure daily, for 7days,
resulted in no change to the totalmicrobial load (Figure 3) (median
log10 microbial load pre-treatment"4.9 log10 16S copies/mg of
tissue, versus 4.8 log10 16S copies/mg of tissue, P"0.43).
Analysis of community richness and diversity of chronic
non-healing DFUs treated with SBMO
The most abundant OTUs contributing to.1% of the microorgan-
isms within individual DFUs are shown in Figure 4(a); P. aeruginosa,
S. aureus, Anaerococcus spp., Prevotella spp. and Streptococcus
spp. were most commonly identified. The relative abundance of
P. aeruginosa and S. aureus increased in all but one patient post-
treatment with SBMO (Figure 4b), with pooled data from all sam-
ples identifying this to be statistically significant for the amount of
Staphylococcus spp. DNA copies (P"0.04). Only patient 9 seemed
to experience a reduction in S. aureus levels (Supplementary data
Part S6); however, a significant increase in P. aeruginosawas noted
as a result (Figure 4a). Overall, there were increases in both aero-
bes and facultative microorganisms but these were reflected by a
composite reduction in the relative abundance of anaerobicmicro-
organisms (Figure 4d).
Microorganisms contributing to .1% of microbial communities
in individual DFUs and from pooled data were analysed by alpha
and beta diversitymeasures. Chronic DFUs prior to treatment were
rich and diverse, yet there were minimal changes to community
richness (P"0.3), diversity (P"0.1) or community composition of
DFUs post-treatment (P"0.9) (Figure 5a–c).
Discussion
Summary of key findings
We systematically tested the performance of topical antimicrobial
solutions using short exposure times for in vitro and ex vivomodels
and an in vivo human trial. Our results suggest that the perform-
ance of these solutions is poor when challenged against mature
biofilms using short exposure times that mimic real clinical use
(i.e. 15min application). Clinicians using topical antimicrobials to
cleanse chronic wounds as a single therapy under the assumption
of removing biofilm may therefore experience poor clinical out-
comes. Clinicians should consider multifaceted strategies that
include sharp debridement as the gold standard.16
What this study adds to the available evidence and new
recommendations
There are many facets to the management of chronic wounds,
with a large focus onmanaging wounds colonized or infectedwith
either planktonic or biofilm phenotype microorganisms. While
there is a plethora of data pertaining to the effectiveness of topical
antimicrobials in vitro against both planktonic and sessile microor-
ganisms, here we identify the inherent limitations of in vitrometh-
odologies that fail to consider clinically relevant biofilm models
when testing topical antimicrobials for use in wound care.9–11 In
particular, in vitromodels testing topical antimicrobial wound solu-
tions have not considered the clinical applications of the products’
intended use with regards to the time of exposure,11 and out-
comes are often reported after 24h exposure times. This does not
reflect the typical clinical pattern of usage of these products or the
‘instructions for use’ explained in product inserts. Nor does the use
of immature biofilms (early forming biofilm 24h old) that have a
less organized structure, a more active metabolism and a less
pronounced stress response truly depict the complex, mature and
highly tolerant biofilms identified inmany chronicwounds.3,18
This may explain why some of the topical antimicrobials tested
at clinically relevant times in this study performed poorly. Our
in vitromodel utilized two clinically relevant bacteria, P. aeruginosa
and S. aureus, which have been noted as causes of delayedwound
healing and as pathogens of infection.2,19 Testing the efficacy of
solutions over a single 15min exposure time in vitro, we identified
great variability in test performances. In general, surfactant-based
topical antimicrobials performed poorly (except for SBPHMB
against P. aeruginosa) and were no more effective than normal
saline (non-antimicrobial).
Traditional antiseptics such as CHX and PVP-I were highly effec-
tive, while new-generation solutions such as SOS were also highly
efficacious. CHX is a cationic bisbiguanide with a broad-spectrum
biocide that is active against both Gram-positive and -negative
bacteria.20 Its primary action is against the negatively charged
bacterial cell wall, leading to increased cell permeability resulting
in cell death.20 The efficacy of CHX in reducing or eradicating single
or multispecies biofilm has been demonstrated in vitro,21–23
with the combination of cetrimide and CHX producing enhanced
antimicrobial activity (and anti-biofilm activity). One explanation
for the effectiveness of CHX in vitro in this studymay be the cationic
surfactant properties of cetrimide, which has demonstrated the
capacity to decrease themechanical stability of biofilm (in addition
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Figure 3. Effects of SBMO pre- and post-treatment of 10 chronic non-
healing diabetic foot ulcers. Box-and-whisker plots show the median
log10 16S copies/mg of tissue values for all 10 patients.
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to its proven bactericidal activity), but further work is required to
elucidate further these effects inwoundmodels.24
PVP-I also performed well in vitro, and as a broad-spectrum
microbicide is capable of inactivating Gram-positive and -negative
bacteria, bacterial spores, fungi, protozoa and several viruses.25
PVP enables the delivery of free iodine to a target cell membrane,
where it destabilizes the structural components of cell mem-
branes.25 It has demonstrated activity against biofilms in vitro;26,27
moreover, more recent in vitro data on the performance of a
wound care-related PVP-I on multispecies biofilms using the CDC
reactor have corroborated the results of this study.28
More recently, ‘newer generation’ topical solutions with antimi-
crobial properties such as SOS have been utilized as anti-biofilm
therapies in wound care, even in the presence of a low evidence
base. SOS contains as a primary ingredient hyperchlorous acid
(which is not new generation), and only one in vitro study is
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Figure 4. Effects onmicrobial communities following treatment with SBMO. Pairwise comparisons of pre- and post-treatment (A) microbial commun-
ities at the genus level in microorganisms contributing .1% within each wound. Further analysis of pooled data depicts changes across all ten
patients when all DNA copies are pooled and examined. (a) Relative abundance (%) for individual wound-level data pre- and post-treatment. (b)
Pooled data (all DNA copies) from ten patients identifies the relative abundance (%) of microorganisms pre- and post-treatment. (c) Relative abun-
dance of pooled sample data of Staphylococcus spp. DNA copies pre- and post-treatment identifies a statistically significant increase (P"0.04). (d)
Relative abundance (%) of pooled sample data detailing the aerotolerance of microorganisms. This figure appears in colour in the online version of
JAC and in black and white in the print version of JAC.
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available that used the concentrations of SOS found in current
wound care solution formulations.10 Using a continuous flow tube
reactor (tomimic the clinical scenario of a catheter) to growmature
6-day-old P. aeruginosa PA01 biofilms, Sauer and colleagues10 uti-
lized SOS at the same concentration (80ppm) reported in this
study, to achieve a 2.5 log10 reduction after 60min exposure.
Our study identified that SOS could eradicate P. aeruginosa bio-
films in addition to performing well against S. aureus biofilm.
This was in contrast to the porcine skin model, which identified
that SOS achieved only 0.77 log10 reduction against P. aeruginosa
PA01 biofilms. Potential explanations to describe these results
could be the two different strains of P. aeruginosa that were used
for the study. The in vitro model utilized P. aeruginosa (ATCCV
R
25619TM) and the porcine skin explant utilized P. aeruginosa (PA01,
ATCCV
R
BAA-47TM). Sauer and colleagues also utilized P. aeruginosa
(PA01, ATCCV
R
BAA-47TM). Interestingly, the use of the P. aeruginosa
PA01 strain yielded results that identified a reduced effectiveness
of SOS. It is possible that whilst our in vitro P. aeruginosa (ATCCV
R
25619TM) strain readily formed a biofilm with the characteristic
P. aeruginosa architecture, it did not develop a high-level biofilm-
specific resistance,29 whichmayhave arisen in the PA01 strain.
Other explanations for the different results observed for SOS
in vitro versus the porcine skin model may be the surface the bio-
films were formed on (i.e. the soft tissue dermal matrix of porcine
skin, which more closely represented an actual wound bed
compared with an abiotic polycarbonate disc). This may have
contributed to alterations inmicrobial behaviour in response to the
presence of biotic signals or organic material.30,31 Biofilms grown
on biotic substrates or in vivo often do not display themorphologi-
cal or architectural characteristics of those grown in vitro
(e.g. mushroom structures and towers), which are important
parameters that undoubtedly affect bacterial behaviour.32 Lastly
unlike an abiotic surface, porcine skin has a striking similarity to
human skin in terms of its structure and this is important given
thatmicrobial aggregates have been identified as not only forming
on a wound surface, but also penetrating to deeper structures in a
non-random distribution.33 In this scenario, any topical solution
applied to a contact surface would have to penetrate a biofilm
formed on that contact surface in addition to then penetrating
between tissue cells. This in itself presents a greater challenge
(than that already posed by biofilm tolerance mechanisms)
and may contribute to the reduced effectiveness of topical
antimicrobials.
Lastly, the performance of SBMOwas tested on human tissue in
an in vivo study of chronic non-healing DFUs. SBMO was applied
daily for 15min over a 7day treatment period, with the results
identifying no change in the total microbial load from tissue biop-
sies. Interestingly, our in vivo results identified a correlation
between the poor performance of SBMO against P. aeruginosa and
S. aureus thatwas also seen in vitro.
Next generationDNA sequencingwas performed tounderstand
the effects of SBMO on microbial communities in chronic non-
healing DFUs. The relative abundances of both P. aeruginosa and
S. aureus within the majority of DFUs increased post-treatment.
Conversely, an overall reduction in the relative abundance of anae-
robic microorganisms and low frequency taxa (microorganisms
contributing ,1% relative abundance) was noted; however,
the total microbial loads within these wounds did not decrease.
This potentially suggests that more dominant species such as
Staphylococcus spp., or Pseudomonas spp., benefit from the
increasednutrient availability causedbydisruption to themicrobial
community (that resulted from removal of competing microor-
ganisms),34 thus sustaining themicrobial loadwithin tissues.
Treatment with SBMO resulted in a reduction in the relative
abundance of anaerobic microorganisms. Anaerobic microorgan-
isms have been identified as part of polymicrobial communities
cited for their involvement in delayedwoundhealing,35,36 as patho-
gens of infection in the diabetic foot37 and in biofilm production.38
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Figure 5. Alpha and beta diversity analysis pre- and post-treatment with
SBMO. (a) The richness plot is a measure of the number of distinct or unique
OTUs. These were reduced post-treatment but were non-significant. (b)
The Shannon index is a measure of diversity that includes the number of
unique microbial taxa and their relative evenness within each sample.
Diversity of biofilm in diabetic foot ulcers post-treatment is reduced but
non-significantly. (c) Principal coordinates analysis plots with Bray–Curtis
distances between pre- and post-treatment samples identified that micro-
bial communities are similar pre- and pre-treatment (blue triangles, pre-
treatment; red circles, post-treatment). This figure appears in colour in the
online version of JAC and in black andwhite in the print version of JAC.
Wounds solutions as treatments for microbial biofilms JAC
7 of 9
Downloaded from https://academic.oup.com/jac/advance-article-abstract/doi/10.1093/jac/dkx391/4641704
by guest
on 18 November 2017
In this instance reducing their numbers would seem like a positive
step to reducing microorganisms with the potential to negatively
impact the wound environment. Unfortunately, it is likely not this
simple, particularly given the concomitant increases in pyogenic
cocci (Staphylococcus spp.) andGram-negative rods (P. aeruginosa),
which are equal (if not greater) pathogens of infection.
To assess the overall effects of SBMO treatment on DFU micro-
biota (community richness, diversity, structure and composition)
DNA sequence datawere analysed usingQIIME.39
Minimal reductions were seen in the number of OTUs (richness)
and community diversity of chronic DFUs post-treatment. In a
recent study by Loesche et al.,40 the temporal analysis of chronic
DFUs found that patient samples that received systemic antimi-
crobial therapy had no alterations to species richness or diversity,
and that antimicrobial exposure did not drive microbiota variation.
Instead the data indicated that antimicrobial exposure disrupted
the microbiota where antimicrobials were specifically directed to
treat underlying wound infection. We found a similar pattern of
events with our data, in that exposure to SBMO had some effects
when we explored our samples individually. For example, sample
2 experienced a significant disruption to its microbiota whereby
pre-treatment Staphylococcus spp. contributed ,1% relative
abundance; post-treatment this significantly increased to .65%.
Similar patterns are seen across our data but it is not possible to
infer if these changes would result in positive or negative effects to
a wound. This intriguing aspect requires further correlation with
longitudinal sampling that maps microbiota disruption to wound
outcomes.
Our molecular-based data on the 16S gene, whilst informative
in describing ‘who is there’, is unable to truly define ‘who is doing
what’.41 In some wounds in which anaerobic microorganisms are
acting synergistically with aerobic counterparts to increase patho-
genicity or virulence in a chronic wound, their reduction may likely
lead to positive effects. Conversely, and food for thought, any
perturbations to the complex microflora seen within chronic
wounds may lead to microbial dysbiosis. Of particular significance
is the reduction in microbial diversity, which may directly contrib-
ute to pathogen selection and persistence.42 Longitudinal studies
are required to determine whether the alterations to themicrobial
diversity of chronic non-infected wounds seen by using topical
antimicrobials lead to future complications.
Limitations
The CDC biofilm reactor used in vitro was performed under flow
allowing mature biofilms to form on the polycarbonate coupons;
however, this abiotic surface does not reflect the complexity of
human tissue and the absence of the host immune response.
Secondly, most chronic wounds are contaminated with multiple
species of bacteria3 and this study utilized single-species biofilms
in vitro. That aside, our model tested clinically relevant exposure
times against clinically relevant microorganisms involved in both
chronic and infectedwound types in screening the performance of
topical antimicrobial solutions. qPCR was utilized to measure total
microbial load in vivo;15 however, this method has limitations in its
inability to differentiate live or dead bacteria. The log reductions
noted in this study therefore represent the minimal response and
weacknowledge that some of the bacteria detected by qPCR could
bedead, resulting in a lower calculable efficacy.
Overall, the limitations in vitro were circumvented by the addi-
tion of an in vivo study. Costs to perform this study were a limiting
factor in not being able to test a wider range of topical antimicro-
bials in vivo. Further studies incorporating a human in vivo design
may be required to understand the efficacy of single products
tested in the in vitro stage of this study against microbial biofilms.
However, when taking the group of studies performed collectively,
there is a strong correlation between exposure timeand efficacy.
Conclusions
Polymicrobial communities forming biofilms in chronicwoundsmay
have extended time periods to develop complex, highly tolerant
communities that differ greatly from single-species biofilm models
grown on polycarbonate coupons for 24–72h. The discrepancies
between the three different test parameters in this study raise an
important question about in vitro testing for anti-biofilm therapeu-
tics, in which results identifying potential effectiveness against
biofilm differ markedly when the test parameters are changed.
In vitro testing for anti-biofilm strategies could be used as a screen-
ing tool for identifying potential therapeutics thatmay performwell
at the next stage of testing (i.e. when taken to animal models or to
clinical studies). The effectiveness of an anti-biofilm therapeutic at
this in vitro stage is however not absolute, yet for many medical
device companies this is the only data available for use in the pro-
motion of products. This highlights the limitations of clinicians rely-
ing solely on in vitro data. When using porcine explants and human
in vivo tissue samples, our data are highly suggestive that the expo-
sure time of topical antimicrobial wound solutions and irrigation
solutions is too short and that exposure time is critical in determin-
ing the efficacy of these products. Clinicians using these topical anti-
microbial solutions as a sole therapy under the assumption of killing
or eradicating biofilm should consider adopting multifaceted strat-
egies that include sharp debridement as the gold standard.
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ABSTRACT
Introduction: The concept of biofilms in human health and disease is now widely accepted as cause of
chronic infection. Typically, biofilms show remarkable tolerance to many forms of treatments and the
host immune response. This has led to vast increase in research to identify new (and sometimes old)
anti-biofilm strategies that demonstrate effectiveness against these tolerant phenotypes.
Areas covered: Unfortunately, a standardized methodological approach of biofilm models has not
been adopted leading to a large disparity between testing conditions. This has made it almost
impossible to compare data across multiple laboratories, leaving large gaps in the evidence.
Furthermore, many biofilm models testing anti-biofilm strategies aimed at the medical arena have
not considered the matter of relevance to an intended application. This may explain why some in vitro
models based on methodological designs that do not consider relevance to an intended application fail
when applied in vivo at the clinical level.
Expert commentary: This review will explore the issues that need to be considered in developing
performance standards for anti-biofilm therapeutics and provide a rationale for the need to standardize
models/methods that are clinically relevant. We also provide some rational as to why no standards
currently exist.
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1. Introduction
Since the early 1970s, an explosion of research on the concept
of biofilms and their involvement in human health and disease
has appeared in the medical literature [1]. This new wealth of
information, driven largely by advancements in emerging
technologies and techniques applicable to the study of bac-
terial populations in situ, have advanced the understanding of
‘microbial biofilms.’ The concept of biofilms in human health
and disease is now universally accepted in chronic wounds
[2,3] periodontal disease and dental caries [4,5], cystic fibrosis
[6–8], in-dwelling medical device infection [9,10], otitis media
and other upper respiratory infections [11,12], orthopedic
infections [13], and tuberculosis [14].
Current definitions have described biofilms as microbes
attached to surfaces or to each other in aggregates or clumps.
They encapsulate in a self-produced extracellular polymeric
substance (EPS) or matrix that can also contain host-derived
components. As such, biofilms show extreme tolerance to
antimicrobials and host defenses [15–18]. A plethora of in
vitro biofilm models has elucidated that bacterial biofilms are
more tolerant to antiseptics and disinfectants [19] as well as
withstanding antimicrobial concentrations 100–1000 times
higher than that of planktonic counterparts [20–23]. In spite
of the wealth of research undertaken to identify biofilm
tolerance to antimicrobials, no single causative mechanism
has been identified. Instead, it has been suggested that a likely
combination of factors contributes to biofilm tolerance [24,25]
with several areas of interest including but not limited to; slow
or incomplete permeation of antimicrobials through EPS
[20,26], altered microenvironment and niches within biofilms
promoting slow growth rates and adaptive stress response
[27,28], efflux pumps [29], and the role of low frequency
dormant ‘persister’ cells [30].
Regardless of whether researchers fully uncover the
answers to the biofilm riddle of tolerance, the practical impli-
cations are that individual patients suffer with prolonged
chronic infections that often require multiple rounds of anti-
biotics [31]. The current treatment strategy for chronic infec-
tions comes at a high cost to the healthcare system and, more
importantly, to the patient, both economically and in the
potential loss in their quality of life.
2. Exploring the concept of what is a relevant
reduction for medically relevant biofilms?
Antimicrobial therapies for acute infections based on mini-
mum inhibitory concentrations (MIC) (planktonic microorgan-
isms’ susceptibility to antibiotics) target rapidly multiplying
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planktonic microorganisms with high efficacy. Therapies based
on MIC results employed against biofilm phenotype microor-
ganisms that differ markedly in both their physiology and
activity, typically fail to eradicate the problem, leading to a
chronic infection for the patient. For some patients with in-
dwelling medical devices the infection cannot be resolved
until the material is completely removed [32].
Further clarity is required in understanding if this lack of
correlation between conventional susceptibility test results,
and therapeutic success in chronic infections may be reflective
of biofilm presence. A recent Cochrane review on standard
versus biofilm antimicrobial susceptibility testing to guide
antibiotic therapy in cystic fibrosis identified that biofilm sus-
ceptibility testing was not superior to conventional antimicro-
bial susceptibility testing for biofilm [33]. In fact, the Cochrane
review suggests that biofilm antimicrobial susceptibility test-
ing may be more appropriate in the development of newer,
more effective formulations of drugs that can be tested in
clinical trials.
This aside, researchers have been driven to evaluate the
efficacy of anti-biofilm strategies, using susceptibility test
results based on assays that identify the minimum biofilm
eradication concentration (MBEC) assay through in vitro mod-
els such as the Calgary biofilm device [34].
In addition to antibiotics, various alternate agents have also
been explored for anti-biofilm strategies. These have included
peptides, antiseptics, and oral and topical antimicrobials. How
these agents are delivered to the biofilm have also varied
greatly with mechanisms including coatings, drug eluting,
wound gels, nanoparticles, irrigations, and solutions, all
being explored. To further complicate the picture, several
alternate techniques have been developed to quantify out-
come measures of these agents in vitro. Biofilm biomass has
been explored most typically in 96-well microtiter plates and
flow systems using staining methods (crystal violet, Syto9
staining) with optical density (ODnm) or confocal laser scan-
ning microscopy (CLSM) to detect live/dead cells (expressed as
percentages or ODnm) [35,36]. Plate counts to enumerate
viable cells that calculate antimicrobial efficacy expressed as
cfu/ml, cfu/surface area, cfu/mg tissue have also been utilized.
Adding to the conundrum is the absence of a ‘target’
reference value required to ascertain the ‘effectiveness’ of
anti-biofilm strategies in aiding the host immune response to
clear infective microorganisms is profound. This has important
consequences at a treatment level where clinicians often seek
guidance from laboratory-based studies (often due the lack of
in vivo data) in directing them to choose the most relevant
and effective agent to reduce microbial colonization/infection.
Granted, these decisions have historically been based around
managing infections using planktonic paradigms, further high-
lights the requirement for data on the efficacy of anti-biofilm
strategies.
Importantly, when deciphering what may be a ‘target refer-
ence,’ there are two sides of the fence to consider when
posing questions around the performance standards of an
agent that cites claims on ‘effectiveness’ or ‘efficacy.’ First,
there is a regulatory perspective that looks to determine a
‘target reference’ based on standardized approaches using
statistical attributes in determining the repeatability standard
deviation and type I and type II error associated with an agent
[37,38]. Undertaking this enhances statistical confidence in the
outcome that an agent is efficacious. Second, is how well in
vitro or ex vivo results translate to clinical efficacy and if those
target references correlate to improvements in clinical symp-
toms and resolution of chronic infections.
With respect to the consideration of what would be a
potential target value, no suggestions in the literature have
been cited, and there are no data to support what a reason-
able figure would be. This question in itself is complex given
that a target reference value may move depending on the
type of infection, the infecting strain, or the immune status of
the patient. For example, data to support a reasonable target
reference value for in vitro testing, must take into considera-
tion that any changes in infectivity when bacteria are expres-
sing biofilm phenotype in vivo may alter drastically. Until a
clear path exists, then the most conservative approach is that
the drug or device must demonstrate complete eradication of
the biofilm in in vitro testing. The obvious approach to deter-
mine a reference value would be to transition from in vitro
testing to in vivo clinical trials, as this would allow direct
observations of what worked and what did not. In many
cases, however, it may not be possible (an unethical) to obtain
biofilm data directly from patients.
How the US Environmental Protection Agency (EPA)
addressed this concern for human health biofilm disinfection
claims is they are proposing a 6-log reduction in biofilm. The
statistics tells us that if industry wants to be highly confident
that they will achieve this target log reduction, then they need
to formulate the biocide to completely kill the biofilm. What
we are missing is data, and until that data is collected, the
conservative approach would be to kill everything.
3. How should we approach assessing the
‘effectiveness’ of anti-biofilm therapies based on in
vitro models in order to predict clinical results?
Throughout this article, the discussion of biofilm infections in
patients has been purposefully over-simplified, given the com-
plexity and breathes of discussing all concepts relating to how
they contribute to human infection. Biofilms exist in many
niches and vary significantly. This in itself, likely restricts the
ability to develop an assay that closely mimics the exact
architecture of an in vivo biofilm that could be used univer-
sally. Conversely, it is unlikely that an assay for every infection
will be developed, given the large variation in biofilm archi-
tecture from in vitro to in vivo. Whether one is evaluating
biocides for use against biofilm in toilets, or antibiotics to
treat chronic wounds, it is virtually impossible to perfectly
mimic an actual infection or environment in the laboratory.
A potential way forward for performance testing could be
to develop a simplified biofilm assay that allows standardized
adaptations (calibrated) to test parameters allowing the per-
formance of a product to aid in predicting successful in vivo
outcomes. Whilst no in vitro test will provide a direct answer
to this, it does provide confidence to move forward with a
very costly clinical trial.
Furthermore, it is not uncommon for researchers or testing
laboratories to use standard methods beyond its original
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intended use. For instance, a method designed and validated
to test antimicrobial urinary catheters should not be used to
study venous catheters without some significant modifica-
tions. This is similar to using a standard curve developed for
chlorine to determine bromine concentrations – similar but
not quite the same. Sometimes labs use the method because
that is all they have available, this may be exemplified with 96-
well assays or the CDC reactor. Once a laboratory starts using
microtiter plates or CDC reactor, often they will just keep
reapplying the same method to other applications. This raises
questions how relevant the test is anymore. As researchers, we
do our best to model what are thought to be the most
important parameters to gain insights into how the biocide
or antibiotic will perform when actually used. Ideally, there will
be a menu of various methods designed for different applica-
tion areas. This takes time and money, and right now research-
ers are in the foundation stages of model development.
Various publications have stated the need for the standar-
dization of methods for assessing the ‘effectiveness’ of anti-
biofilm therapies. A distinct problem, however, facing anyone
attempting to decipher the literature and or attempting to
replicate biofilm models for new therapies has been the lack
of standardized methods for experimentally studying biofilms.
This has caused much confusion when attempting to compare
results between different research groups, and has led to large
discrepancies when attempting to replicate the same results
between different laboratories. The lack of methods also
means there is no pathway for companies to follow when
attempting to register a new device and/or drug with a reg-
ulatory agency.
In the most applied sense, standard methods development
is the creation of laboratory protocols for the purpose of
comparison, both within a single laboratory and among var-
ious laboratories. Researchers choose to use a standard
method for various reasons. For instance, because every step
of the laboratory process is exactly defined, a standard
method is useful for teaching proper laboratory protocol or
monitoring equipment performance. The impetus for the
development of many microbial standard methods, though,
is efficacy testing for product registration with a regulatory
agency.
Regulatory agencies require efficacy data when a product is
registered to ensure the quality, safety, and efficacy of anti-
microbials (biocides, disinfectants, sterilants) in circulation (in a
particular country). For this purpose, standardized methods
that are repeatable, reproducible, rugged, and responsive are
required [39]. A standard method should also be reasonable,
meaning it should utilize equipment that is ‘typical’ for a
laboratory and it should not require an excessive amount of
time, supplies, or highly specialized training. Many biofilm
research methods can uncover intriguing scientific insights
even though the results are qualitative. However, regulatory
authorities and standard setting organizations mostly prefer
quantitative measures of efficacy.
In this manner, uniform test conditions permit comparison of
results between products and laboratories. For a disinfectant to
make a bactericidal claim for example, efficacy against plank-
tonic P. aeruginosa, Proteus vulgaris, E. coli, and S. aureus is
required by the Australian Therapeutic Goods Administration
(TGO 54) [40], with similar organisms being required by other
regulatory organizations. All these organisms are good biofilm
producers and are associated with clinically relevant biofilm
infections so it seems reasonable to include anti-biofilm testing
for these (or a subset of these) organisms. Unfortunately, stan-
dard methods only exist for biofilms formed by P. aeruginosa
(ASTM Methods E2196, E2562, E2647, and E2799).
Importantly, a relevant laboratory method should ade-
quately emulate ‘real use’ conditions so that a laboratory test
is predictive of how well a device (or test product of interest)
will perform in vivo. Highlighting the decontamination of
equipment and clinical surfaces with disinfectants/sterilants
as an example, it is of importance for users (or clinicians)
responsible for the decontamination of instruments or sur-
faces, to understand that the product they are using has
been tested under conditions that best resemble the purpose
they are to be applied, such as the hospital environment.
Therefore, in terms of relevance, there are two basic strategies
that researchers should strive to answer and that clinicians
should strive to understand.
The first strategy is to engineer a biofilm in a laboratory test
to have specific characteristics that emulates the biofilm in
vivo, matching for example, the architecture, thickness,
strength of attachment, and host factors such as proteins or
immune cells. This is because alterations in any of these para-
meters can lead to alterations in the test outcomes, for exam-
ple the sensitivity of biofilm to disinfectants varies with both
the age of the biofilm and the method of growth [41]. This
was well demonstrated in a paper by Buckingham-Meyer
where kill rate (log reduction) decreased as the amount of
shear on the test biofilm during growth increased.
The ASTM standard biofilm methods were developed based
upon this relevance strategy (Table 1). By employing basic
fluid dynamic concepts with regard to fluid shear and flow
dynamics, the ASTM methods describe how to grow a biofilm
that represents a general biofilm grown under high shear in a
continuous stirred tank reactor (CSTR) (ASTM Method E2562)
[42], in medium shear in a CSTR (ASTM Method E2196) [43],
low shear in a plug flow reactor close to the air liquid interface
(ASTM Method E2647) [44], and minimal shear in a batch
reactor (ASTM Method E 2799) [45]. Others have recently
reviewed the applicability of the biofilm reactors described
in the ASTM methods for various applications [46–48].
The second basic strategy in methods development
involves using reactors that incorporate the most important
physiochemical and biological characteristics in the environ-
ment of interest [54,55]. An effective strategy that was fol-
lowed for the development of the ASTM biofilm methods was
to partition methods into sets of components. For testing the
efficacy of disinfectants or antibiotics, these components
include: growing a repeatable and relevant biofilm, applying
the antimicrobial treatment, harvesting a sample of the trea-
ted biofilm, and analyzing the sample for viable cells. To better
visualize this concept, Figure 1 shows a product testing and
development guidance tree that outlines some of the numer-
ous parameters under consideration for medically relevant
biofilm standard methods.
In spite of the above, many researchers involved in biocide
disinfection of a surface (not for medical devices or antimicrobial
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therapies) may still pose questions such as how well does the
hydrated biofilm formed on a coupon or in the MBEC plate
represent biofilm on a clinical surface which is in a semi-dehy-
drated state and encased in thickened EPS? It is also unlikely
that a biofilm formed on coupons or in an MBEC device will
present the same challenge to biocides as biofilm that has been
subjected to multiple rounds of decontamination, e.g. biofilm
contaminating endoscope channels [56]. Biofilms form on all
material types within the clinical environment, ranging from
fabrics to plastics to stainless steel. Therefore, should research
design questions be directed toward testing on different types
of surfaces? For example, how relevant is a hard surface test as
seen with current standards to killing biofilm on fabric? The CDC
biofilm reactor (used in ASTM E2562) [42] uses removable cou-
pons and thus has the capacity to compare different hard sur-
face carriers with a range in free energy values and
hydrophobicity, e.g. glass, plastic, porcelain, and steel. The pre-
mise of pushing the boundaries of any test condition and
allowing researchers the ‘artistic’ flexibility to mimic ‘real-use’
conditions often increases the test methodologies in complexity.
Typically, methods that try to exactly match every parameter of
interest in this manner are complex and, therefore, when the
method is verified in an inter-laboratory study (or ring trial), they
do not perform well.
4. Expert commentary
Biofilm research as a whole has grown exponentially over the
last two decades, yet there is minimal data correlating in vitro
results to clinical outcomes. In addition, whilst the medical
community has a greater awareness of the role of biofilms in
human health and disease, there are still many areas of con-
fusion for clinicians, who in particular find it difficult to under-
stand how in vitro methods translate to something of clinical
relevance [57]. This begs the question, why are we not further
along in the battle against biofilm-associated infections? What
is holding us back?
In trying to understand why the pursuit of new anti-biofilm
therapies has been lethargic in some areas of medically rele-
vant biofilm research, potential explanations are: (1) A lack of
standardized methods for testing anti-biofilm models that is
clinically applicable (to be discussed in the next section)
Figure 1. Product testing and development guidance. The decision making process begins with understanding the mechanism of action (MOA) of the of the anti-
biofilm technology. The technology then determines the regulatory claim. For instance, an antimicrobial surface would most likely be associated with a ‘prevents
initial attachment’ or ‘reduces biofilm accumulation’ claim, whereas a biocide manufacturer would most likely pursue a ‘kills’ or ‘removes’ biofilm claim. The claim
then determines the necessary test output that will provide the necessary data to support the claim. For instance, a test that measures the log reduction in viable
biofilm bacteria would provide the relevant data for ‘kill’ claim. The next step is to determine which laboratory growth and treatment methods best mimic the real
world application. Various parameters of particular concern for biofilm methods are included in this figure, but it is important to note that the list is not exhaustive.
The growth and treatment will often determine how the laboratory biofilm will be harvested and analysed. For instance, biofilm grown in microtitier plates is often
not harvested, but stained directly and placed into a plate reader. Finally, every standard method must meet the statistical attributes listed in the figure. The text
highlighted in red demonstrates the standardization path taken to measure the efficacy (kill) of biocides against biofilm. In this case, a single species biofilm is
grown under high shear in the CDC reactor. The mature biofilm is removed from the reactor and tested under static conditions for a contact time specified by the
biocide manufacture. Appropriate controls are always included. Sonication and vortexing is used to harvest the biofilm and the viable cells are enumerated using
viable cells counts. Finally, the proposed method has undergone a collaborative study to verify that it meets the required statistical attributes. The text highlighted
in purple demonstrates a potential strategy for testing antimicrobial surfaces engineered to prevent biofilm attachment. Full color available online.
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[58,59]. (2) The lack of regulatory guidance for setting perfor-
mance standards for biofilm-related product claims in the
medical device arena. (3) A poor understanding of what
defines ‘effectiveness’ when applied to anti-biofilm strategies.
(4) The slow response of industry in pursuing new anti-biofilm
therapeutics, perhaps due to the lack of regulatory guidance,
standard methods, the cost of research and development, and
the cost of appropriate human clinical trials. These factors
inadvertently force the industry to test their potential anti-
biofilm therapies using methods that do not correlate to
clinical outcomes. (5) Lack of funding resources to support
the development of standard methods. (6) The slow progres-
sion in translating anti-biofilm research and therapeutics to
clinically relevant information [47].
With the explosion in evidence detailing most aspects of
biofilm involvement in human health and disease, clinicians
and regulatory agencies have been hesitant to accept and
pursue anti-biofilm treatment strategies. In contrast, the che-
mical disinfection world for example, has lobbied hard for
anti-biofilm claims on products and these efforts have led to
the development, validation, and approval of standard meth-
ods for testing of anti-biofilm products. Examples of these are
five ASTM standard test methods (E2196, E2562, E2647, E2799,
and E2871) (Table 1). The culmination of working toward
developing standardized approaches that industry can utilize
has meant that within the next 2 years, we may well see
products with ‘kills biofilm’ claims.
However, the overall lack of advancement in anti-biofilms
strategies from industry that include medical device/biocide
companies maybe explained in their haste to scramble toward
testing their current therapeutics. Historically promoted for
use against planktonic microorganisms in acute infections,
the drive to ascertain if they now have an action against
biofilms may explain why industry are not diversifying away
from traditional antimicrobials that have a high efficacy
against planktonic microorganisms, and move toward new
research and development specifically targeting anti-biofilm
strategies. A major contributor for this is most likely the sig-
nificant investment costs required to develop new therapies
utilizing evidence from in vitro through to in vivo. The experi-
mental designs in human studies for example would likely
need to include a large number of patients for a statistically
relevant conclusion to be reached. An example of this could
be the bioengineering approaches to medical devices such as
catheters and the lengthy processes required to bring a new
device to market.
In tandem with a lack of investment from industry is the
ever-increasing challenge to find funding to support the
development of standard methods. The other point to con-
sider is the time it takes to develop a standard method. Once a
standard operating procedure is written, the method needs to
go through rigorous intra-laboratory testing to accumulate
sufficient data that supports that the method is repeatable,
responsive, and rugged. This process may take 1–2 years,
depending upon how compatible for standardization the
research method is. The method is then taken to a standard
setting organization where each step is critically reviewed and
discussed, which may also take a few years. Finally, the
method goes through a multi-lab collaborative study to deter-
mine the reproducibility of the method. Assuming the method
performs well, the process is complete. But, if the method
does not do well, it goes back to a standard setting organiza-
tion (i.e. ASTM group) and is modified, extending the cost and
time associated with standardizing it.
What is startling is why clinicians have not demanded the
same development of anti-biofilm therapeutics? Or why med-
ical device companies have been slow to pursue new thera-
peutics. One reason to explain this slow progress is when
clinicians come across a new drug and/or device, the regula-
tions on the wording of the claim/documentation is focused
on curing or preventing infection. Biofilm does not become
part of the discussion. This may seem to be a case of seman-
tics, but simply not having biofilm be part of the discussion
means generally it is not included as part of the clinician’s
decision-making in terms of infection management. With
regard to an appropriate outcome, clinicians would also
need to understand what ‘effectiveness’ of a product meant,
whether biofilm was reduced (if so, by how much?) or if a
100% kill was achieved. Importantly, any reductions or killing
of a biofilm would need to be associated with a reduction of
infective symptoms and improved patient outcome.
For a change to happen, clinicians need to start asking if
the patient has a chronic biofilm or an acute infection. In
orthopedic device-, catheter-, or cardiac valve-related infec-
tions, clinicians are fully aware of the presence of biofilms. In
fact, treatment is directed at biofilms with well-documented
anti-biofilm activity such as fluoroquinolones [60,61] or rifam-
pin [62], often in combination with another antibiotic [63],
since resistance to rifampin can occur with a single point
mutation [64]. In surgery, more aggressive debridement is
also being practiced as an anti-biofilm strategy, treating bio-
film infections more like an aggressive cancer which can come
back with devastating consequences unless completely eradi-
cated. However, specific biofilm-targeted treatment options
are limited and if the biofilm is not eradicated there is an
increased probability of generating resistance, leading to
further complications for treating the infection down the
road. This translates into demand for new strategies/treat-
ments to cure biofilm infections.
Aiding in the confusion and lack of association between
biofilm and chronic infection are the huge disparity in diag-
nostics. There are no diagnostic tools or biomarkers to help
identify when biofilm is the driver of infection [65,66]. In the
age of science-based medicine, how can clinicians be
expected to deviate from standard measures of treating plank-
tonic infections based on antimicrobial stewardships and
make decisions to treat the infection as a biofilm infection, if
there is no way to verify it?
When medical devices companies decide to pursue anti-
biofilm strategies, they are faced with the barriers of navigat-
ing the minefield of regulatory standards. In this instance,
regulatory agencies want clinical data that demonstrate a
new drug or device’s ability to decrease infection rates in
patients. Historically, the regulatory tests to make these claims
have been based on the MIC for planktonic microorganisms
(Clinical laboratory standards institute (CLSI), M02-A12,
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M07-A10, M100-S26). This is different than showing that a
device prevents and/or reduces biofilm. Although logically, a
person cannot develop a biofilm-based infection if no biofilm
forms, but this is not the outcome that is being regulated or
monitored by clinicians.
Even though researchers have demonstrated that biofilm is
the root cause of many chronic infections, there is limited
clinical biofilm data because clinicians do not routinely collect
samples for biofilm-specific diagnostics. Granted this would be
extremely challenging, but with advancements in new non-
invasive technologies, the possibility certainly exists that a
mechanism for collecting these samples will exist in the future.
This can be exemplified in chronic non-healing wounds com-
plicated by biofilm, where in general practice the clinician
does not collect a swab or tissue sample of the wound bed
to quantify the biofilm in order to direct antimicrobial therapy
to treat the infection. Based upon data from industrial
research, bacterial counts in the process water do not neces-
sarily correlate to counts on the pipe’s surface. This could also
hold true in the human body. A low count in the urine does
not mean that no biofilm is present; it just means that the
biofilm has not grown to the point where the body is showing
signs of infection. And of course, it would be unethical to do a
study where catheters are removed over time to record the
biofilm that forms, and correlate this number to when the
‘typical’ person begins to show signs of an infection (which
is what occurs in industrial models for biofilm testing).
However, it is only useful to develop biofilm-specific sam-
pling if clinical microbiology has the tools for appropriate
diagnostics. Currently, confocal microscopy is considered the
most direct way of demonstrating biofilms in clinical speci-
mens [67] but these methods are time consuming and require
highly specialized training.
This leads to a very important question. We do not know
what the necessary log reduction in biofilm bacteria is that will
ultimately cure the infection. For testing measures pertaining
to the performance standards of an antimicrobial against
planktonic microorganisms, the necessary reduction in micro-
organism counts has been defined as a greater than 3 log
reduction (if the reproducibility standard deviation is 1 log10
then the antimicrobial must achieve a greater than 4 log10
reduction) [68]. Without knowing what this reference value is
for biofilm-based infections, a conservative approach may be
for regulatory agencies to require that the antibiotic/device
must kill everything.
If this were the case, what does this mean for antimicrobial
therapies currently employed against biofilms that exhibit only
partial reductions against biofilms in vitro? Using the concept
of rifampin, the more commonly employed antimicrobial
against biofilms, evidence has identified it does not entirely
kill the bacterial biofilm in most in vitro models [62,69]. Does
this account to regulatory agencies not validating its future
use against biofilm-associated infections, and/or clinicians not
using it for the same purpose? Presently, the simple answer is
no, clinicians will still likely use this systemic antimicrobial,
evidence or not, because right now that is their only option
and clinicians are committed to trying to help the patient to
the best of their ability. Currently, the FDA would also not
register an antibiotic or new drug based solely upon in vitro
data as they are limited and do not take into account a human
immune response, nor can any statements be made about
preventing or curing infection.
Ideally, the systemic antimicrobial is working in combina-
tion with the person’s immune system to resolve the infection,
but the presence of a biofilm can restrict this response [70].
This may explain why people with chronic biofilm infections
require multiple doses (and combinations) of systemic antimi-
crobials over extended periods of time (sometimes even in the
order of magnitude of months or years). This exemplifies the
main underlying theme of this review paper, which is that
current in vitro biofilm tests are inadequate, and therefore
are not predicting how the antibiotic will perform clinically.
This may explain why there is little correlation between in in
vitro and clinical results. The requirement for better designed
(more clinically relevant) in vitro biofilm tests that have gone
through a standardization process may improve clinical out-
comes and help direct clinicians to using antimicrobials with
proven efficacy against biofilms. Once the standard methods
are in place, then correlation to clinical data and ideally per-
formance standards will follow.
5. Five-year view
Is there a clear path toward the direction of standardized
approaches to biofilm strategies? Many examples outlined in
this review article highlight the biofilm-specific issues that
need to be addressed in order to help provide better guidance
to clinicians managing biofilm-associated infections. When the
performance of an anti-biofilm strategy relates to the clinical
care of patients, there is a need to achieve a standardized
biofilm methods ‘utopia.’ This will provide pharmaceutical/
device manufacturers all the experimental parameters
required so that a collaborative study may be done. From a
regulatory perspective, this would also allow for the method’s
reproducibility standard deviation (SD) to be determined. This
requirement is highly relevant for clinicians to appreciate, who
may read a paper on a new technology that performed fabu-
lously in a one laboratory study, did fine in an animal model,
but failed miserably in a clinical trial. If an appropriate statis-
tical analysis had been performed, the probability of failure
would have been predicted. In general, a large percentage of
experiments may lack the statistical attributes that are
required of a standard method, and without statistics, there
is no statistical confidence in the outcome.
In the same instance, there needs to be delineation
between absolute standard methods and research methods,
with the latter affording the flexibility for researchers to
advance new therapeutic strategies toward biofilm-associated
infections. Roberts and colleagues made reference to this
notion, suggesting that researchers should not be afraid of
undertaking initial in vitro screening (nonstandardized experi-
ments) (Roberts et al. 2016).In doing so, this may provide
greater predictive power for in vivo activity, and also allow
side-by-side comparative studies with established antimicro-
bial agents. This may actually enhance the capability to better
understand biofilm-associated infections.
However, Roberts and colleagues make the same conclu-
sion as we would, which is the most relevant system should be
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used based upon the questions being asked. Although pre-
liminary experiments will allow researchers to make advances
in our basic understanding of these biofilm infections, regula-
tory agencies require data collected with methods that have
been statistically validated, which generally means the
method has gone through a standardization process.
Perhaps, it is the reluctance of medical researchers to use
standard methods that has provided a roadblock and explains
why the medical field lags behind the biocide/industrial field
with regard to biocide claims.
Key issues
● Biofilms show remarkable tolerance to many forms of treat-
ments and the host immune response.
● The lack of correlation between conventional susceptibility
test results and therapeutic success in chronic infections
maybe reflective of biofilm presence.
● The absence of a ‘target’ reference value required to ascer-
tain the ‘effectiveness’ of anti-biofilm strategies to clear
infective microorganisms suggests complete eradication is
required.
● A potential way forward for performance testing could be
to develop a simplified biofilm assay that allows standar-
dized adaptations (calibrated) to test parameters allowing
the performance of a product to aid in predicting successful
in vivo outcomes.
● No in vitro test provides a prediction on how well a product
will work in vivo, but it does provide confidence to move
forward onto animal models or costly clinical in vivo trials.
● Many areas of confusion regarding anti-biofilm strategies
still exist for clinicians who are caught either; 1. Finding it
difficult to understand how in vitro methods translate to
something of clinical relevance or 2. Think successful in vitro
outcomes will provide similar results in vivo.
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